,Article,Date,Symbol,Time,Title,Url
0,"   By Ransdell Pierson  Bristol-Myers Squibb Co (BMY.N) on Friday reported stronger-than-expected quarterly results, but its shares fell because of investors' jitters about the pace at which the company is developing a promising new combination of cancer drugs.The stock dropped as much as 6.7 percent after company officials said on a conference call with investors that they were not yet planning a late-stage trial that would combine two of its high-profile drugs as a treatment for lung cancer.Instead, Bristol-Myers said it would continue a mid-stage study of the drugs - an experimental medicine called nivolumab and an approved melanoma treatment called Yervoy - before moving them into a larger Phase III lung cancer trial. Both drugs enhance the immune system's ability to fight cancer.""Many investors expected Bristol-Myers to rapidly advance the Nivo-Yervoy combo to Phase III, with the plans for such a move perhaps being announced as early as today,"" BMO analyst Alex Arfaei said in a research note.The company's slower timetable might be interpreted as a sign of caution or suggest a lack of ""synergy"" between the two drugs when targeting lung cancer, he said.Results of the mid-stage trial, called Checkmate-012, are expected to be released at a cancer meeting in late May or early June.""We believe today's news is incrementally positive for Merck & Co,"" (MRK.N) Arfaei said, which is developing a rival drug in the same PD-1 inhibitor class as nivolumab.Shares of Bristol were down 3.7 percent at $51.93 in afternoon trading after dropping as low as $50.35. Merck was up 0.2 percent at $51.71 amid a sharp downturn for the broad stock market.ELIQUIS SALES JUMP  In announcing its fourth-quarter results, Bristol-Myers said it had benefited from cost cuts and growing sales of its treatments for cancer, blood clots and diabetes.Sales increased sharply for Eliquis, a closely watched new blood clot preventer, but the product is off to a far slower start than Wall Street had hoped.Eliquis, which is used to prevent strokes among patients with an irregular heartbeat condition called atrial fibrillation, generated sales of $71 million, up from $41 million in the prior quarter.But when the pill was approved in late 2012, analysts had predicted sales would eventually reach $3 billion to $5 billion a year.""We're waiting for Eliquis to hit an inflection point, but it hasn't hit that big pop yet,"" said Morningstar analyst Damien Conover. ""It will still get there, to $5 billion."" Eliquis, which Bristol-Myers markets with Pfizer Inc (PFE.N), proved safer and more effective in clinical trials than the standard oral treatment, warfarin, in preventing strokes among patients with atrial fibrillation.Many patients instead are taking two new blood clot preventers that were approved before Eliquis - Pradaxa from Boehringer Ingelheim and Xarelto from Johnson & Johnson (JNJ.N) and Bayer AG (BAYGn.DE). But many industry analysts and doctors consider Eliquis to be the best of the new crop of oral agents.Other Bristol-Myers drugs that stood out in the quarter include Yervoy, whose sales rose 23 percent to $260 million, and leukemia treatment Sprycel, whose sales jumped 30 percent to $365 million. And sales of HIV treatment Sustiva increased 11 percent to $427 million.COST CUTS DELIVER The company reported quarterly earnings of $726 million, or 44 cents per share. That compares with $925 million, or 56 cents per share, in the year-earlier period, when it took a big write-off for a failed hepatitis C drug. Excluding special items, the profit was 51 cents per share, above the analysts' average estimate of 43 cents, according to Thomson Reuters I/B/E/S.Revenue rose 6 percent to $4.44 billion, topping Wall Street expectations of $4.3 billion.Marketing, selling and administrative expenses fell 7 percent, and research spending shrank 12 percent.""Bristol-Myers' execution on cost structure continues to impress, with lower-than-expected spending"" that helped the company handily beat earnings estimates, Leerink Swann analyst Seamus Fernandez said.Bristol said it still expected 2014 earnings of $1.65 to $1.80 per share, excluding special items. The forecast assumes current foreign exchange rates and the closing of a deal with British drugmaker AstraZeneca Plc (AZN.L) in the first quarter.AstraZeneca last month agreed to buy Bristol-Myers' stake in a longstanding diabetes joint venture between the two drugmakers for an initial $2.7 billion, up to $1.4 billion in additional milestone payments, and royalties on net sales through 2025.The joint venture includes oral medicines Onglyza, Kombiglyze and Forxiga, as well as injectable treatments Bydureon and Byetta.The sale will give Bristol more funds to invest in other areas, such as cancer.(Reporting by Ransdell Pierson; Editing by Stephen Powell and Lisa Von Ahn)",2014-01-24,BMY,"Fri Jan 24, 2014 | 1:57pm EST",Pace of Bristol-Myers' cancer trial spooks investors,http://www.reuters.com//article/us-bristol-myers-sales-idUSBREA0N0TF20140124?type=companyNews
1,"  By Ransdell PiersonJan 24 Bristol-Myers Squibb Co on Friday reported stronger-than-expected quarterly results, but its shares fell because of investors' jitters about the pace at which the company is developing a promising new combination of cancer drugs.The stock dropped as much as 6.7 percent after company officials said on a conference call with investors that they were not yet planning a late-stage trial that would combine two of its high-profile drugs as a treatment for lung cancer.Instead, Bristol-Myers said it would continue a mid-stage study of the drugs - an experimental medicine called nivolumab and an approved melanoma treatment called Yervoy - before moving them into a larger Phase III lung cancer trial. Both drugs enhance the immune system's ability to fight cancer.""Many investors expected Bristol-Myers to rapidly advance the Nivo-Yervoy combo to Phase III, with the plans for such a move perhaps being announced as early as today,"" BMO analyst Alex Arfaei said in a research note.The company's slower timetable might be interpreted as a sign of caution or suggest a lack of ""synergy"" between the two drugs when targeting lung cancer, he said.Results of the mid-stage trial, called Checkmate-012, are expected to be released at a cancer meeting in late May or early June.""We believe today's news is incrementally positive for Merck & Co,"" Arfaei said, which is developing a rival drug in the same PD-1 inhibitor class as nivolumab.Shares of Bristol were down 3.7 percent at $51.93 in afternoon trading after dropping as low as $50.35. Merck was up 0.2 percent at $51.71 amid a sharp downturn for the broad stock market. ELIQUIS SALES JUMP In announcing its fourth-quarter results, Bristol-Myers said it had benefited from cost cuts and growing sales of its treatments for cancer, blood clots and diabetes.Sales increased sharply for Eliquis, a closely watched new blood clot preventer, but the product is off to a far slower start than Wall Street had hoped.Eliquis, which is used to prevent strokes among patients with an irregular heartbeat condition called atrial fibrillation, generated sales of $71 million, up from $41 million in the prior quarter.But when the pill was approved in late 2012, analysts had predicted sales would eventually reach $3 billion to $5 billion a year. ""We're waiting for Eliquis to hit an inflection point, but it hasn't hit that big pop yet,"" said Morningstar analyst Damien Conover. ""It will still get there, to $5 billion.""Eliquis, which Bristol-Myers markets with Pfizer Inc , proved safer and more effective in clinical trials than the standard oral treatment, warfarin, in preventing strokes among patients with atrial fibrillation.Many patients instead are taking two new blood clot preventers that were approved before Eliquis - Pradaxa from Boehringer Ingelheim and Xarelto from Johnson & Johnson  and Bayer AG. But many industry analysts and doctors consider Eliquis to be the best of the new crop of oral agents.Other Bristol-Myers drugs that stood out in the quarter include Yervoy, whose sales rose 23 percent to $260 million, and leukemia treatment Sprycel, whose sales jumped 30 percent to $365 million. And sales of HIV treatment Sustiva increased 11 percent to $427 million.COST CUTS DELIVER  The company reported quarterly earnings of $726 million, or 44 cents per share. That compares with $925 million, or 56 cents per share, in the year-earlier period, when it took a big write-off for a failed hepatitis C drug.Excluding special items, the profit was 51 cents per share, above the analysts' average estimate of 43 cents, according to Thomson Reuters I/B/E/S.Revenue rose 6 percent to $4.44 billion, topping Wall Street expectations of $4.3 billion.Marketing, selling and administrative expenses fell 7 percent, and research spending shrank 12 percent.""Bristol-Myers' execution on cost structure continues to impress, with lower-than-expected spending"" that helped the company handily beat earnings estimates, Leerink Swann analyst Seamus Fernandez said.Bristol said it still expected 2014 earnings of $1.65 to $1.80 per share, excluding special items. The forecast assumes current foreign exchange rates and the closing of a deal with British drugmaker AstraZeneca Plc in the first quarter.AstraZeneca last month agreed to buy Bristol-Myers' stake in a longstanding diabetes joint venture between the two drugmakers for an initial $2.7 billion, up to $1.4 billion in additional milestone payments, and royalties on net sales through 2025.The joint venture includes oral medicines Onglyza, Kombiglyze and Forxiga, as well as injectable treatments Bydureon and Byetta.The sale will give Bristol more funds to invest in other areas, such as cancer.",2014-01-24,BMY,"Fri Jan 24, 2014 | 1:56pm EST",UPDATE 3-Pace of Bristol-Myers' cancer trial spooks investors,http://www.reuters.com//article/bristolmyers-results-idUSL2N0KY0J120140124?type=companyNews
2,"  (For more market insights, including options activity, click on  ; for the Day Ahead newsletter link.reuters.com/mex49s;  for the Morning News Call newsletter, link.reuters.com/nex49s)   U.S. stocks fell on Friday in the wake of a selloff in emerging market assets, as expectations grew that the Federal Reserve will trim its market-friendly stimulus measures further next week. The Dow Jones industrial average was down 0.51 percent at 16,114.13, the S&P 500 was down 0.66 percent at 1,816.45 and the Nasdaq Composite was down 0.82 percent at 4,184.309.** MICROSOFT CORP, $37.1944, +3.16 pctThe company posted a bigger-than-expected quarterly profit on Thursday, boosted by strong sales of its software and services for businesses, a solid holiday season for its new Xbox game console and Surface tablets, and a slightly lower tax bill.** COVIDIEN PLC, $69.88, +4.58 pctThe medical devices maker posted a quarterly profit above analysts' estimates, helped by strong sales of its surgical products, especially vessel sealing and stapling devices.** PTC THERAPEUTICS INC, $23.98, -8.54 pctThe company said a committee of the European Medicines Agency recommended against a conditional approval to its drug for the treatment of a rare muscular disorder, sending its shares down nearly 30 percent in premarket trading.** BIODELIVERY SCIENCES INTERNATIONAL INC, $9.05, +44.80 pctAn experimental painkiller developed by the company and Endo Health Solutions Inc showed a significant improvement in pain relief compared with a placebo.At least two brokerages raised their price target on BioDelivery's stock on Friday.** XEROX CORP, $11.52, -2.04 pctThe company, best known as a maker of printers and copiers, reported weaker-than-expected quarterly revenue as growth in its services business stalled.** EBAY INC, $54.12, -1.49 pctActivist investor Carl Icahn's stake in the e-commerce company is more than previously reported at close to 2 percent, a source familiar with the matter said on Thursday. EBay said this week that Icahn had taken a 0.82 percent interest in the company earlier this month and made a non-binding proposal for eBay to spin off its PayPal payments business.** GENERAL MOTORS, $37.4, -2.65 pctThe company is seeking to cut shifts by half at one of its South Korean factories as it realigns global manufacturing in a move that could affect about 1,100 jobs, a source with direct knowledge of the matter told Reuters on Friday.** STARBUCKS CORP, $75.9104, +3.43 pctThe world's biggest coffee chain's quarterly sales at established restaurants in its U.S.-dominated Americas region cooled more than analysts expected as online shopping kept more consumers at home and reduced their visits to its coffee bars.However, the company boosted its fiscal 2014 earnings per share forecast to a range of $2.59 to $2.67, from $2.55 to $2.65 previously.** INTUITIVE SURGICAL INC, $419.905, -4.35 pctThe company said on Thursday that it expected to sell fewer of its high-priced da Vinci surgical robot systems in 2014 than last year and diverged from past practice by not providing a revenue forecast for the year.** JUNIPER NETWORKS INC, $28.158, +8.26 pctJana Partners LLC has taken a large stake in the network gear maker, a move that comes at a time when Juniper is being urged by one of its prominent investors to increase shareholder returns.** KANSAS CITY SOUTHERN, $96.12, -18.04 pctThe regional railroad operator missed fourth-quarter profit estimates on Friday amid weakness in its energy business, including lower coal shipments.** HONEYWELL INTERNATIONAL INC, $90.55, +0.84 pctThe diversified U.S. manufacturer of aerospace parts and climate control systems backed its 2014 financial targets, set last month, but forecast first-quarter earnings below Wall Street's estimates.** BRISTOL-MYERS SQUIBB CO, $55.19, +2.30 pct The drugmaker's quarterly sales and earnings beat Wall Street expectations, helped by cost cuts and growing sales of its treatments for cancer, blood clots and diabetes.** BOEING CO, $139.2, -1.49 pctThe reliability of Boeing's 787 Dreamliner is slowly improving but it is still not at a satisfactory level and the firm is working to improve the jet's performance, said Mike Fleming, Boeing's vice president for 787 support and services.** PROCTER & GAMBLE CO, $81.59, +4.28 pct** KIMBERLEY CLARK CORP, $110.32, +4.65 pctProcter & Gamble, the world's largest household products maker, said it expected organic sales, which strip out the impact of currency changes as well as acquisitions and divestitures, to rise 3-4 percent, and core earnings to rise 5-7 percent in 2014. However, the company reported lower quarterly profit, hurt by unfavorable currency movements and lower gross profit margin.Rival Kimberley Clark said its organic sales rose 5 percent, and forecast that they would rise 3-5 percent in 2014.** CST BRANDS INC, $31.31, -4.28 pctThe gas station operator and convenience merchandise retailer said on Thursday that its fourth-quarter motor fuel volume in both the United States and Canada was expected to be close to the low-end of its previous estimate.Motor fuel volume is expected to be 4,850-4,950 gallons per site per day in the United States and 3,300-3,400 gallons per site per day in Canada.The company also said it expected North America merchandise sales in the quarter to be at the low end of its prior forecast.** COMPUWARE CORP, $10.3573, -1.83 pctThe business software maker reported lower-than-expected third-quarter revenue on Thursday, hurt by lower fee from its software license business coupled with stagnant maintenance activities fee and professional services revenue.** QUALCOMM INC, $74.92, -1.25 pct** HEWLETT-PACKARD CO, $28.9, -1.60 pctChipmaker Qualcomm acquired a patent portfolio from Hewlett-Packard, including those of its iPaq smartphone, for an undisclosed amount. The portfolio comprises about 1,400 granted patents and pending patent applications from the United States and about 1,000 granted patents and pending patent applications from other countries. ** STANLEY BLACK & DECKER INC, $82.61, +2.74 pctThe power tools maker reported fourth-quarter results that beat analysts' estimates, driven by a 7 percent rise in volumes.The company reported a profit of $1.32 per share on revenue of $2.90 billion. Analysts on average had expected a profit of $1.30 per share on revenue of $2.87 billion, according to Thomson Reuters I/B/E/S.** ARCH COAL INC, $4.17, -1.65 pctAnalysts at Clarkson Capital Markets cut their rating on the coal producer's stock to ""underperform"" from ""market-perform,"" saying they expected the company to generate a negative free cash flow in 2015.Analysts also expressed concerns about declining productivity at Arch Coal's flagship steel-making metallurgical coal mine of Mountain Laurel, West Virginia.** RICE ENERGY INC, $21.13, +0.62 pctThe natural gas producer's shares rose as much as 7 percent in their U.S. market debut, valuing the company at about $2.9 billion. The 44-million-share offering raised about $924 million after being priced at $21 per share, the high end of the expected price range.** MCKESSON CORP, $175.25, +1.67 pctThe U.S. drugs distributor succeeded in its second attempt to win control of German peer Celesio in a deal with Celesio's two largest shareholders, German investment group Haniel and U.S. hedge fund Elliott.** INTERNATIONAL GAME TECHNOLOGY, $15.68, -11.16 pctThe slot-machine maker warned that its full-year profit would more likely be towards the lower end of its previous forecast due to continued weakness in the North American gaming market.** JA SOLAR HOLDINGS CO LTD, $8.88, -4.62 pct** RENESOLA LTD, $3.56, -5.82 pct ** YINGLI GREEN ENERGY HOLDING CO LTD, $5.98, -6.27 pct** TRINA SOLAR LTD, $13.98, -7.42 pct** CANADIAN SOLAR INC, $38.5, -6.28 pctU.S. trade officials opened investigations on Thursday into imports of certain solar power products from China and Taiwan, following a complaint at the end of last year by the U.S. unit of German solar manufacturer SolarWorld AG.The company at the time said it was seeking to close a loophole that enabled Chinese solar panel producers to evade U.S. import duties by using cells manufactured in other countries, mainly Taiwan.** LOCKHEED MARTIN CORP, $148.22, -1.51 pctA new U.S. Defense Department report warned that ongoing software, maintenance and reliability problems with Lockheed Martin's F-35 stealth fighter could delay the Marine Corps' plans to start using its F-35 jets by mid-2015.The company forecast on Thursday higher earnings in 2014 after charges linked to U.S. defense budget cuts and workforce reductions depressed earnings in the fourth quarter.** BANK OF AMERICA CORP, $16.66, -1.19 pctThe lender is looking to win more advisory and stock underwriting business to offset an expected slowdown in the issuance of corporate bonds, a top executive said in an interview on Thursday.** SYNGENTA AG, $74.94, -3.69 pctTwo leading U.S. grain groups have asked the world's largest crop chemicals company to suspend the commercial use in the United States of two genetically modified strains of corn not currently approved in China.** DIGI INTERNATIONAL INC, $10.58, -12.49 pctThe networking device maker forecast current-quarter results below analysts' estimates, after reporting lower-than-expected results for the first quarter on Thursday due to a fall in revenue in its product business.The company said its product revenue was hurt by a delay in orders from some customers.** APPLIED MICRO CIRCUITS CORP, $10.9, -3.96 pctThe chipmaker reported third-quarter revenue slightly below estimates on Thursday, prompting brokerage BMO Capital Markets to lower its price target on the company's stock to $12 from $14.** DISCOVER FINANCIAL SERVICES, $55.08, +5.11 pctThe credit card issuer reported a better-than-expected 11 percent rise in quarterly profit as more consumers used cards to make payments.** OPENTEXT CORP, $101.92, +12.47 pctThe Canadian business software maker's  second-quarter results beat analysts' estimates, driven by higher license sales and customer service revenue.** PROGENICS PHARMACEUTICALS INC, $6.43, -4.46 pctThe company filed a prospectus, called a shelf registration, with the U.S. Securities and Exchange Commission seeking to raise up to $150 million through the potential sale of securities that could include stock, debt securities, or warrants.** KKR & CO, $25.14, -2.44 pct** BLACKROCK INC, $311.22, -1.38 pctKKR & Co and BlackRock are among the investors in talks to buy a stake in China Huarong Asset Management Co Ltd as the bad debt manager seeks to raise more than $2 billion, people familiar with the matter told Reuters.** NOVARTIS, $80.23, -1.91 pctThe European Medicine Agency recommended rejecting an application from the Swiss drugmaker to market its heart failure drug serelaxin.** GOLDMAN SACHS GROUP INC, $168.92, -1.07 pctThe bank may stop traders from using certain chat messaging services to protect internal conversations that are lately being subjected to intense regulatory scrutiny, the Wall Street Journal reported.    (Compiled by Neha Dimri in Bangalore; Edited by Kirti Pandey)",2014-01-24,BMY,"Fri Jan 24, 2014 | 10:11am EST","MARKET PULSE-Rice Energy, Xerox, Covidien, Kansas City Southern",http://www.reuters.com//article/markets-usa-stocks-pulse-idUSL3N0KY45620140124?type=companyNews
3,"  Jan 24 Canada's main stock index looked set to open lower on Friday as emerging market currencies fell on a sell-off accelerated by worries surrounding China and U.S. monetary policy.TOP STORIES * Japanese government calculations indicate that Prime Minister Shinzo Abe cannot meet his budget-balancing promise in coming years on the current course, suggesting he may come under greater pressure from fiscal hawks for future tax increases.* Procter & Gamble Co, the world's largest household products maker, reported lower quarterly profit, hurt by unfavorable currency movements and lower gross profit margin.* Business software maker Open Text Corp's  second-quarter results beat analysts' estimates, driven by higher license sales and customer service revenue.* Bristol-Myers Squibb Co's quarterly sales and earnings beat Wall Street expectations, helped by cost cuts and growing sales of its treatments for cancer, blood clots and diabetes.* Microsoft Corp posted a bigger-than-expected quarterly profit on Thursday, boosted by strong sales of its software and services for businesses, a solid holiday season for its new Xbox game console and Surface tablets, and a slightly lower tax bill.MARKET SNAPSHOT * Canada stock futures traded down 0.5 percent * U.S. stock futures , , were down around 0.54 percent to 0.71 percent* European shares, were downCOMMODITY PRICE MOVES * Thomson Reuters-Jefferies CRB Index : 281.943; rose 0.02 percent* Gold futures : $1,269.3; rose 0.53 percent * US crude : $96.99; fell 0.34 percent* Brent crude : $106.71; fell 0.81 percent* LME 3-month copper : $7,222; rose 0.22 percentCANADIAN STOCKS TO WATCH * Enbridge Inc : CEO Al Monaco said on Thursday that an amendment to the U.S. presidential permit for its Alberta Clipper pipeline, which the company needs to expand the line's capacity, will likely be delayed past a previous target of mid-2014. ANALYSTS' RECOMMENDATIONS Following is a summary of research actions on Canadian companies reported by Reuters.* Avigilon : CIBC raises target price to C$50 from C$32, says introduction of a partner loyalty program will lead to 2014 sales beating consensus* Barrick Gold Corp : RBC raises target price to $23 from $20 says the company's shares should re-rate higher and return to their valuation range prior to the discount created by Pascua-Lama capital escalation and a weak balance sheet* OpenText Corp : CIBC raises target price to $110 from $95 based on the company's quarterly results beating estimates and its acquisition of GXS* Semafo Inc : CIBC raises target price to C$4.25 from C$3 citing the company's continues to deliver steady operational results and its ability to advance development/production of new deposits at ManaON THE CALENDAR * Major Canadian economic data includes inflation* No major U.S. events and data scheduled for release",2014-01-24,BMY,"Fri Jan 24, 2014 | 8:20am EST","CANADA STOCKS-TSX may open lower, emerging market sell-off weighs",http://www.reuters.com//article/markets-canada-stocks-idUSL3N0KY3XL20140124?type=companyNews
4,"  Jan 24 Bristol-Myers Squibb Co's  quarterly sales and earnings beat Wall Street expectations, helped by cost cuts and growing sales of its treatments for cancer, blood clots and diabetes.The company on Friday said it earned $726 million, or 44 cents per share, in the fourth quarter. That compared with $925 million, or 56 cents per share, in the year-earlier period, when Bristol-Myers took a big write-off for a failed hepatitis C drug. Excluding special items, the drugmaker earned 51 cents per share, well above the average analyst estimate of 43 cents, according to Thomson Reuters I/B/E/S.  Global company revenue rose 6 percent to $4.44 billion, topping Wall Street expectations of $4.3 billion.",2014-01-24,BMY,"Fri Jan 24, 2014 | 7:30am EST","Bristol-Myers beats sales, profit forecasts",http://www.reuters.com//article/idUSL2N0KY00G20140124?type=companyNews
5,"  Feb 3 AstraZeneca PLC :  * AstraZeneca completed, on 1 February 2014, the acquisition of the entirety of Bristol-Myers Squibb's interests in the companies' diabetes alliance  * For more news, please click here   ",2014-02-03,BMY,"Mon Feb 3, 2014 | 2:08am EST",BRIEF-AstraZeneca completes Bristol-Myers diabetes acquisition,http://www.reuters.com//article/astrazeneca-brief-idUSWLB006ZT20140203?type=companyNews
6,"  (Corrects throughout to change source to U.S. Food and Drug Administration from Bristol-Myers Squibb. The error also appeared in a previous version of the story)Feb 25 The U.S. Food and Drug Administration said it approved Bristol-Myers Squibb Co's drug to treat rare and potentially fatal disorders involving loss of body fat.The drug has been approved as a replacement therapy to treat complications caused by leptin hormone deficiency in patients with congenital or acquired generalized lipodystrophy. Generalized lipodystrophy patients experience a loss of fat tissue, especially under the skin, leading to low levels of leptin.Leptin deficiency causes serious imbalance in the body, leading to fat accumulation in muscles and organs such as the liver. The deficiency can lead to diabetes, pancreatitis and fatty liver disease. The drug, Myalept (metreleptin), is a form of leptin meant to reduce accumulation of fat in organs to better control blood sugar and high levels of triglycerides - a type of fat in the bloodstream associated with increased risk of heart disease. The FDA said it asked for seven post-marketing studies on Myalept. (r.reuters.com/jam27v)Bristol-Myers had co-developed the drug with AstraZeneca .   (Reporting by Shailesh Kuber; Editing by Ted Kerr and Kirti Pandey)",2014-02-25,BMY,"Tue Feb 25, 2014 | 3:53pm EST",CORRECTED-UPDATE 1-FDA approves Bristol-Myers drug for rare body fat disorder,http://www.reuters.com//article/bristolmyers-fda-idUSL3N0LU3ZA20140225?type=companyNews
7,"  (Corrects source to U.S. Food and Drug Administration from Bristol-Myers Squibb)Feb 25 The U.S. Food and Drug Administration said it approved Bristol-Myers Squibb Co's drug to treat rare and potentially fatal disorders involving loss of body fat. The condition, known as generalized lipodystrophy, involves fat buildup in the blood and organs such as liver and muscle and can lead to diabetes, pancreatitis and fatty liver disease.  The FDA said it required seven post-marketing studies on the drug, Myalept. (r.reuters.com/jam27v)   (Reporting by Shailesh Kuber; Editing by Ted Kerr)",2014-02-25,BMY,"Tue Feb 25, 2014 | 3:51pm EST",CORRECTED-FDA approves Bristol-Myers' drug for rare fat disorder,http://www.reuters.com//article/bristolmyers-fda-idUSL3N0LU3XK20140225?type=companyNews
8,"  Bristol-Myers Squibb Co said the U.S. Food and Drug Administration approved its drug to treat rare and potentially fatal disorders involving loss of body fat.The drug has been approved as a replacement therapy to treat complications caused by leptin hormone deficiency in patients with congenital or acquired generalized lipodystrophy.Generalized lipodystrophy patients experience a loss of fat tissue, especially under the skin, leading to low levels of leptin. Leptin deficiency causes serious imbalance in the body, leading to fat accumulation in muscles and organs such as the liver. The deficiency can lead to diabetes, pancreatitis and fatty liver disease.The drug, Myalept (metreleptin), is a form of leptin meant to reduce accumulation of fat in organs to better control blood sugar and high levels of triglycerides - a type of fat in the bloodstream associated with increased risk of heart disease. Bristol-Myers said the FDA had asked it to conduct seven post-marketing studies on Myalept. (r.reuters.com/jam27v) The drugmaker had co-developed the drug with AstraZeneca.(Reporting by Shailesh Kuber; Editing by Ted Kerr and Kirti Pandey)",2014-02-25,BMY,"Tue Feb 25, 2014 | 10:59am EST",FDA approves Bristol-Myers drug for rare body fat disorder,http://www.reuters.com//article/us-bristolmyers-fda-idUSBREA1O18920140225?type=companyNews
9,"  The U.S. Food and Drug Administration said it approved Bristol-Myers Squibb Co's drug to treat rare and potentially fatal disorders involving loss of body fat.The condition, known as generalized lipodystrophy, involves fat buildup in the blood and organs such as liver and muscle and can lead to diabetes, pancreatitis and fatty liver disease. The FDA said it required seven post-marketing studies on the drug, Myalept. (r.reuters.com/jam27v)  (Reporting by Shailesh Kuber; Editing by Ted Kerr)",2014-02-26,BMY,"Wed Feb 26, 2014 | 11:24am EST",FDA approves Bristol-Myers' drug for rare fat disorder,http://www.reuters.com//article/us-bristolmyers-fda-idUSBREA1O18920140226?type=companyNews
10,"  Bristol-Myers Squibb Co on Tuesday said it plans this year to begin a late-stage trial testing whether a combination of two of its high-profile immunotherapies can effectively treat lung cancer, easing concerns about the company's intentions.Company executives spooked investors in January by saying they were not yet planning a late-stage trial that would combine its experimental medicine, nivolumab, and an approved melanoma treatment called Yervoy as a treatment for lung cancer.The company's cautious timetable suggested to some investors a possible lack of ""synergy"" between the two drugs when targeting lung cancer. The medicines both enhance the immune system's ability to fight cancer.But spirits lifted on Tuesday when Brian Daniels, senior vice president of global development for Bristol-Myers, told investors at the Cowen and Co healthcare conference in Boston that the Phase III trial was indeed on track to begin by the end of 2014. Alex Arfaei, an analyst with BMO Capital Markets, said insights from an ongoing mid-stage trial of the drug combination, presumably durable effectiveness and improved patient survival, had given company officials confidence to move ahead with the costlier larger trial.Nivolumab is a member of an emerging new class of drugs that block a protein called PD-1, thereby allowing the immune system to recognize cancer cells and go after them. Merck & Co and Roche Holding AG are developing similar drugs and all are believed capable of generating annual sales in the billions of dollars, if approved. Researchers believe combining the PD-1 inhibitors with other therapies that harness the immune system or target cancer in other ways could be the future of cancer care, in part because the effectiveness of the new drugs does not quickly fall off as is the case with many standard therapies. ""We remain firmly of the view that Bristol-Myers will retain its position as the leader in immuno-oncology (IO) as IO combinations advance in melanoma, kidney, and lung cancer, and as new IO targeted tumors emerge over the next 12-18 months,"" Leerink Partners analyst Seamus Fernandez said in a research note.Shares of Bristol-Myers rose 5.5 percent to $56.42 on the New York Stock Exchange on Tuesday.(Reporting by Ransdell Pierson and Bill Berkrot; Editing by Jonathan Oatis)",2014-03-04,BMY,"Tue Mar 4, 2014 | 5:52pm EST","Bristol plans big lung cancer study, pairing immunotherapies",http://www.reuters.com//article/us-bristol-cancer-idUSBREA2328A20140304?type=companyNews
11,"  March 4 Bristol-Myers Squibb Co on Tuesday said it plans this year to begin a late-stage trial testing whether a combination of two of its high-profile immunotherapies can effectively treat lung cancer, easing concerns about the company's intentions.Company executives spooked investors in January by saying they were not yet planning a late-stage trial that would combine its experimental medicine, nivolumab, and an approved melanoma treatment called Yervoy as a treatment for lung cancer.The company's cautious timetable suggested to some investors a possible lack of ""synergy"" between the two drugs when targeting lung cancer. The medicines both enhance the immune system's ability to fight cancer.But spirits lifted on Tuesday when Brian Daniels, senior vice president of global development for Bristol-Myers, told investors at the Cowen and Co healthcare conference in Boston that the Phase III trial was indeed on track to begin by the end of 2014. Alex Arfaei, an analyst with BMO Capital Markets, said insights from an ongoing mid-stage trial of the drug combination, presumably durable effectiveness and improved patient survival, had given company officials confidence to move ahead with the costlier larger trial. Nivolumab is a member of an emerging new class of drugs that block a protein called PD-1, thereby allowing the immune system to recognize cancer cells and go after them. Merck & Co  and Roche Holding AG are developing similar drugs and all are believed capable of generating annual sales in the billions of dollars, if approved.Researchers believe combining the PD-1 inhibitors with other therapies that harness the immune system or target cancer in other ways could be the future of cancer care, in part because the effectiveness of the new drugs does not quickly fall off as is the case with many standard therapies. ""We remain firmly of the view that Bristol-Myers will retain its position as the leader in immuno-oncology (IO) as IO combinations advance in melanoma, kidney, and lung cancer, and as new IO targeted tumors emerge over the next 12-18 months,"" Leerink Partners analyst Seamus Fernandez said in a research note.Shares of Bristol-Myers rose 5.5 percent to $56.42 on the New York Stock Exchange on Tuesday.",2014-03-04,BMY,"Tue Mar 4, 2014 | 5:50pm EST","Bristol plans big lung cancer study, pairing immunotherapies",http://www.reuters.com//article/bristol-cancer-idUSL1N0M120Y20140304?type=companyNews
12,"  March 14 U.S. regulators have approved an additional use of Bristol-Myers Squibb Co's blood clot preventer Eliquis, to prevent  blood clots in the legs and lungs of patients who have undergone surgery to receive artificial hips or knees.The drug is already sold in partnership with Pfizer Inc  to prevent blood clots that can cause strokes in patients with atrial fibrillation, an irregular heartbeat that is most common in the elderly.The drugmakers, in a joint release on Friday, said the U.S. Food and Drug Administration had approved the new use, noting that each year in the United States there are about 719,000 total knee replacement surgeries and 332,000 hip replacements. After such surgeries, patients are at greater risk of developing blood clots in the deep veins of the legs, which can break free and travel to the lungs, where they can be fatal.The new approval will help Eliquis to compete with Xarelto, a similar drug from Johnson & Johnson and Bayer AG  that is also approved for use after knee and hip replacements, as well as to prevent strokes among those with atrial fibrillation. Shares of Bristol Myers were down 0.4 percent, while Pfizer shares rose 0.5 percent, both on the New York Stock Exchange. ",2014-03-14,BMY,"Fri Mar 14, 2014 | 1:42pm EDT","UPDATE 1-Bristol's Eliquis approved to prevent clots after hip, knee surgery",http://www.reuters.com//article/bristolmyers-pfizer-idUSL2N0MB15Z20140314?type=companyNews
13,"  March 14 U.S. regulators have approved an additional use of Bristol-Myers Squibb Co's blood clot preventer Eliquis, to prevent  blood clots in the legs and lungs of patients who have undergone surgery to receive artificial hips or knees.The drug is already sold in partnership with Pfizer Inc  to prevent blood clots that can cause strokes in patients with atrial fibrillation, an irregular heartbeat that is most common in the elderly.   ",2014-03-14,BMY,"Fri Mar 14, 2014 | 1:17pm EDT","Bristol's Eliquis approved to prevent clots after hip, knee surgery",http://www.reuters.com//article/bristolmyers-pfizer-idUSL2N0MB14W20140314?type=companyNews
14,"   By Bill Berkrot  A combination of two anti-viral drugs developed by Bristol-Myers Squibb Co cured 90 percent of previously untreated hepatitis C patients and 82 percent of those who failed to respond to prior therapy, according to results from a late stage study presented on Thursday.The Phase III trial of more than 700 patients called Hallmark-Dual tested a combination of Bristol's daclatasvir and asunaprevir over 24 weeks of therapy in patients with genotype 1b of the virus that causes progressive liver disease.The cure rate was also 82 percent among patients unable to tolerate treatment with the older standard drugs interferon and ribavirin and 84 percent in patients who had cirrhosis, which accounted for nearly a third of those in the trial.Patients for whom the virus was undetectable in the blood 12 weeks after completing 24 weeks of treatment were deemed to have achieved sustained virologic response (SVR), which is considered cured.""Not only was the daclatasvir and asunaprevir regimen highly effective among study participants, it was also very well tolerated, even among sicker patients with more advanced liver disease,"" Professor Michael Manns, the study's lead investigator from Hannover Medical School in Germany, said in a statement.The study results were presented at the annual meeting of the European Association for the Study of the Liver (EASL) in London. Genotype 1 is the most prevalent and considered the most difficult to treat form of the virus. Genotype 1b tends to be more common in Europe and 1a is more widely seen in the United States.Several drugmakers, including Gilead Sciences Inc, AbbVie and Merck & Co are developing a new generation of all-oral hepatitis C treatments that do not include interferon or ribavirin, which cause miserable side effects that have led thousands of patients to put off treatment to wait for the highly touted new drugs.In clinical trials, the new drugs have demonstrated cure rates in excess of 90 percent while cutting treatment duration to 12 weeks with few side effects, leading to Wall Street forecasts of multibillion-dollar annual sales in what is shaping up to be a fiercely competitive market. Prior to the recent approval of the first of Gilead's new drugs, standard treatments cured about 75 percent of patients and required either 24 or 48 weeks of therapy.Bristol this week applied for U.S. approval of the two drug combination and said it expects to file for approval of a three-drug combination early next year.Based on earlier studies, Bristol's three-drug combination is likely to further boost cure rates with 12 weeks of treatment, which would be more competitive to results seen so far from rival drugmakers. Patients in the Hallmark-Dual trial received 60 mg of daclatasvir once a day and 100 mg of asunaprevir twice daily. The drugs belong to new classes of medicines that work in different ways to prevent the virus from replicating.The discontinuation rate due to adverse side effects was between 1 and 3 percent, the company said. Headache was the most common side effect, and serious side effects, such as elevations in liver enzymes, were seen in 5 percent to 7 percent of patients.Liver enzyme elevations were reversible and resolved following treatment, the company said.About 170 million people are believed to be infected with hepatitis C worldwide. If left untreated the disease can lead to cirrhosis, liver cancer or need for a liver transplant.(Reporting by Bill Berkrot; Editing by Cynthia Osterman)",2014-04-10,BMY,"Thu Apr 10, 2014 | 7:02am EDT",Bristol-Myers hepatitis C treatment cures up to 90 percent: study,http://www.reuters.com//article/us-hepatitis-bristolmyers-idUSBREA390Q720140410?type=companyNews
15,"   By Bill Berkrot | April 10  April 10 A combination of two anti-viral drugs developed by Bristol-Myers Squibb Co cured 90 percent of previously untreated hepatitis C patients and 82 percent of those who failed to respond to prior therapy, according to results from a late stage study presented on Thursday.The Phase III trial of more than 700 patients called Hallmark-Dual tested a combination of Bristol's daclatasvir and asunaprevir over 24 weeks of therapy in patients with genotype 1b of the virus that causes progressive liver disease.The cure rate was also 82 percent among patients unable to tolerate treatment with the older standard drugs interferon and ribavirin and 84 percent in patients who had cirrhosis, which accounted for nearly a third of those in the trial.Patients for whom the virus was undetectable in the blood 12 weeks after completing 24 weeks of treatment were deemed to have achieved sustained virologic response (SVR), which is considered cured.""Not only was the daclatasvir and asunaprevir regimen highly effective among study participants, it was also very well tolerated, even among sicker patients with more advanced liver disease,"" Professor Michael Manns, the study's lead investigator from Hannover Medical School in Germany, said in a statement. The study results were presented at the annual meeting of the European Association for the Study of the Liver (EASL) in London.Genotype 1 is the most prevalent and considered the most difficult to treat form of the virus. Genotype 1b tends to be more common in Europe and 1a is more widely seen in the United States.Several drugmakers, including Gilead Sciences Inc, AbbVie and Merck & Co are developing a new generation of all-oral hepatitis C treatments that do not include interferon or ribavirin, which cause miserable side effects that have led thousands of patients to put off treatment to wait for the highly touted new drugs. In clinical trials, the new drugs have demonstrated cure rates in excess of 90 percent while cutting treatment duration to 12 weeks with few side effects, leading to Wall Street forecasts of multibillion-dollar annual sales in what is shaping up to be a fiercely competitive market.Prior to the recent approval of the first of Gilead's new drugs, standard treatments cured about 75 percent of patients and required either 24 or 48 weeks of therapy.Bristol this week applied for U.S. approval of the two drug combination and said it expects to file for approval of a three-drug combination early next year. Based on earlier studies, Bristol's three-drug combination is likely to further boost cure rates with 12 weeks of treatment, which would be more competitive to results seen so far from rival drugmakers.Patients in the Hallmark-Dual trial received 60 mg of daclatasvir once a day and 100 mg of asunaprevir twice daily. The drugs belong to new classes of medicines that work in different ways to prevent the virus from replicating.The discontinuation rate due to adverse side effects was between 1 and 3 percent, the company said. Headache was the most common side effect, and serious side effects, such as elevations in liver enzymes, were seen in 5 percent to 7 percent of patients.Liver enzyme elevations were reversible and resolved following treatment, the company said.About 170 million people are believed to be infected with hepatitis C worldwide. If left untreated the disease can lead to cirrhosis, liver cancer or need for a liver transplant.   (Reporting by Bill Berkrot; Editing by Cynthia Osterman)",2014-04-10,BMY,"Thu Apr 10, 2014 | 7:00am EDT",Bristol-Myers hepatitis C treatment cures up to 90 pct -study,http://www.reuters.com//article/health-hepatitis-bristolmyers-idUSL2N0N12BT20140410?type=companyNews
16,"   By Ransdell Pierson  Bristol-Myers Squibb Co (BMY.N) reported higher-than-expected quarterly earnings, helped by cost cuts and lower taxes, but sparked concerns over a possible delay in completing its marketing application for a high-profile cancer drug.Shares of the U.S. drugmaker, whose sales missed Wall Street estimates, were down 3.6 percent at $48.54 in afternoon trading on Tuesday.Bristol-Myers said it had earned $937 million, or 56 cents per share, in the first quarter, compared with $609 million, or 37 cents per share, a year earlier.Excluding gains from the recent sale of its diabetes drug business to longtime partner AstraZeneca Plc (AZN.L) and other special items, Bristol-Myers earned 46 cents per share. Analysts on average were expecting 43 cents, according to Thomson ReutersI/B/E/S. Bristol-Myers said it would begin its U.S. marketing application for lung cancer treatment nivolumab within a few days but would not complete the ""rolling submission"" of clinical trial data until the end of the year.Sanford Bernstein analyst Tim Anderson said the prolonged submission process implied a slight delay and that the U.S. Food and Drug Administration might be requiring more clarity on results from of the study. ""Bristol-Myers would not provide details on what exactly the FDA might want to see,"" Anderson said in a research note. But the company, in a conference call with industry analysts, said trial results suggested there were lasting responses to nivolumab among patients receiving it.Deemed a potential blockbuster, nivolumab is a member of a promising new class of cancer treatments called PD1 inhibitors, which allow the immune system to recognize cancer cells and go after them.Despite the year-end timeline for completing the marketing application, JPMorgan analyst Chris Schott said he remained confident in nivolumab and other immuno-oncology drugs that have become Bristol-Myers' biggest focus. ""In our view, nivolumab development and the broader immuno-oncology opportunity remain the core story for Bristol-Myers shares,"" Schott said.Bristol-Myers raised the lower end of its 2014 profit forecast to $1.70 a share, excluding special items, from $1.65 while keeping the top end at $1.80.First-quarter sales fell 1 percent to $3.81 billion, about $80 million shy of Wall Street expectations.Sales of leukemia treatment Sprycel rose 26 percent to $342 million, while sales of melanoma treatment Yervoy fell 8 percent to $271 million. Rheumatoid arthritis treatment Orencia rose 7 percent to $363 million. AWAY FROM MEGA-DEAL FRAY A kind of merger fever seems to have swept the drug industry in the past week, with Pfizer Inc (PFE.N) on Monday disclosing it had been rebuffed after offering to pay almost $100 billion to acquire AstraZeneca.Last week, Canada's Valeant Pharmaceuticals (VRX.TO) and activist investor Bill Ackman said they had made an unsolicited $47 billion bid to buy Botox maker Allergan Inc (AGN.N).By contrast, Bristol-Myers is known for steadily pursuing smaller deals, which it calls its ""string of pearls"" strategy.In keeping with that pattern, Bristol-Myers on Tuesday said it would spend $175 million to buy privately held iPierian and its early-stage drugs to treat neurodegenerative diseases, including palsy. The purchase price ultimately could include up to $550 million more in milestone payments, plus royalties.(Reporting by Ransdell Pierson, Editing by Franklin Paul and Lisa Von Ahn)",2014-04-29,BMY,"Tue Apr 29, 2014 | 1:38pm EDT",Possible delay for Bristol cancer-drug causes jitters,http://www.reuters.com//article/us-bristol-myers-results-idUSBREA3S0WF20140429?type=companyNews
17,"  (Adds analyst comments, details on nivolumab; updates share movement)By Ransdell PiersonApril 29 Bristol-Myers Squibb Co  reported higher-than-expected quarterly earnings, helped by cost cuts and lower taxes, but sparked concerns over a possible delay in completing its marketing application for a high-profile cancer drug.Shares of the U.S. drugmaker, whose sales missed Wall Street estimates, were down 3.6 percent at $48.54 in afternoon trading on Tuesday.Bristol-Myers said it had earned $937 million, or 56 cents per share, in the first quarter, compared with $609 million, or 37 cents per share, a year earlier.Excluding gains from the recent sale of its diabetes drug business to longtime partner AstraZeneca Plc and other special items, Bristol-Myers earned 46 cents per share. Analysts on average were expecting 43 cents, according to Thomson Reuters I/B/E/S.Bristol-Myers said it would begin its U.S. marketing application for lung cancer treatment nivolumab within a few days but would not complete the ""rolling submission"" of clinical trial data until the end of the year. Sanford Bernstein analyst Tim Anderson said the prolonged submission process implied a slight delay and that the U.S. Food and Drug Administration might be requiring more clarity on results from of the study.""Bristol-Myers would not provide details on what exactly the FDA might want to see,"" Anderson said in a research note. But the company, in a conference call with industry analysts, said trial results suggested there were lasting responses to nivolumab among patients receiving it.Deemed a potential blockbuster, nivolumab is a member of a promising new class of cancer treatments called PD1 inhibitors, which allow the immune system to recognize cancer cells and go after them.Despite the year-end timeline for completing the marketing application, JPMorgan analyst Chris Schott said he remained confident in nivolumab and other immuno-oncology drugs that have become Bristol-Myers' biggest focus. ""In our view, nivolumab development and the broader immuno-oncology opportunity remain the core story for Bristol-Myers shares,"" Schott said.Bristol-Myers raised the lower end of its 2014 profit forecast to $1.70 a share, excluding special items, from $1.65 while keeping the top end at $1.80.First-quarter sales fell 1 percent to $3.81 billion, about $80 million shy of Wall Street expectations. Sales of leukemia treatment Sprycel rose 26 percent to $342 million, while sales of melanoma treatment Yervoy fell 8 percent to $271 million. Rheumatoid arthritis treatment Orencia rose 7 percent to $363 million.AWAY FROM MEGA-DEAL FRAY A kind of merger fever seems to have swept the drug industry in the past week, with Pfizer Inc on Monday disclosing it had been rebuffed after offering to pay almost $100 billion to acquire AstraZeneca.Last week, Canada's Valeant Pharmaceuticals and activist investor Bill Ackman said they had made an unsolicited $47 billion bid to buy Botox maker Allergan Inc.By contrast, Bristol-Myers is known for steadily pursuing smaller deals, which it calls its ""string of pearls"" strategy.In keeping with that pattern, Bristol-Myers on Tuesday said it would spend $175 million to buy privately held iPierian and its early-stage drugs to treat neurodegenerative diseases, including palsy. The purchase price ultimately could include up to $550 million more in milestone payments, plus royalties.   (Reporting by Ransdell Pierson, Editing by Franklin Paul and Lisa Von Ahn)",2014-04-29,BMY,"Tue Apr 29, 2014 | 1:38pm EDT",UPDATE 2-Possible delay for Bristol cancer-drug causes jitters,http://www.reuters.com//article/bristol-myers-results-idUSL2N0NL0H920140429?type=companyNews
18,"   By Ransdell Pierson  Bristol-Myers Squibb Co (BMY.N) reported higher-than-expected quarterly earnings, helped by cost cuts and lower taxes, but sales missed Wall Street estimates, and the U.S. drugmaker's shares fell.The company on Tuesday said it had earned $937 million, or 56 cents per share, in the first quarter, compared with $609 million, or 37 cents per share, a year earlier.Excluding special items, the profit came to 46 cents per share. Analysts on average were expecting 43 cents, according to Thomson Reuters I/B/E/S.The company's effective tax rate was 5 percent, compared with 7.6 percent a year earlier.Bristol-Myers also benefited from the recent sale of its diabetes drugs business to longtime partner AstraZeneca Plc (AZN.L).Bristol-Myers raised the lower end of its 2014 profit forecast to $1.70 a share, excluding special items, from $1.65 while keeping the top end at $1.80.Sales fell 1 percent to $3.81 billion, about $80 million shy of Wall Street expectations. Shares of Bristol-Myers were down 2.2 percent at $49.24 in trading before the market opened.A kind of merger fever seems to have swept the drug industry in the past week, with Pfizer Inc (PFE.N) on Monday disclosing it had been rebuffed after offering to pay almost $100 billion to acquire AstraZeneca. But the biggest U.S. drugmaker vowed to continue its pursuit of its British rival and to domicile the combined company in Britain in order to achieve lower taxes.Last week, Canada's Valeant Pharmaceuticals (VRX.TO) and activist investor Bill Ackman said they had made an unsolicited $47 billion bid to buy Botox maker Allergan Inc (AGN.N). By contrast, Bristol-Myers Squibb has been known for building its drug pipeline by steadily pursuing smaller deals, which it calls its ""string of pearls"" strategy.In keeping with that pattern, Bristol-Myers on Tuesday said it would spend $175 million to acquire privately held iPierian and its early-stage drugs to treat neurodegenerative diseases, including palsy. The purchase price ultimately could include up to $550 million more in milestone payments, plus royalties on sales of iPierian drugs.Sales of Bristol Myers' Sprycel leukemia drug rose 26 percent to $342 million in the first quarter, while sales of melanoma treatment Yervoy fell 8 percent to $271 million. Orencia, used to treat rheumatoid arthritis, rose 7 percent to $363 million.Combined marketing and advertising costs fell by $132 million in the quarter, while research spending rose only slightly.(Reporting by Ransdell Pierson, Editing by Franklin Paul and Lisa Von Ahn)",2014-04-29,BMY,"Tue Apr 29, 2014 | 9:28am EDT","Bristol-Myers profit beats forecasts, but sales lag",http://www.reuters.com//article/us-bristol-myers-results-idUSBREA3S0KN20140429?type=companyNews
19,"  U.S. drugmaker Bristol-Myers Squibb Co (BMY.N) reported higher-than-expected quarterly earnings, helped by cost cuts, but sales fell short of Wall Street expectations.The company on Tuesday said it earned $937 million, or 56 cents per share in the first quarter ending March 31, helped by gains from the recent sale of its diabetes drugs to longtime partner AstraZeneca Plc (AZN.L). That compared with $609 million, or 37 cents per share, in the year earlier period. Excluding special items, Bristol-Myers earned 46 cents per share. Analysts, on average, were expecting 43 cents per share, according to Thomson Reuters I/B/E/S.  (Reporting by Ransdell Pierson, Editing by Franklin Paul)",2014-04-29,BMY,"Tue Apr 29, 2014 | 7:52am EDT",Bristol-Myers quarterly profit beats expectations as costs cut,http://www.reuters.com//article/us-bristol-myers-results-idUSBREA3S0FN20140429?type=companyNews
20,"  April 29 U.S. drugmaker Bristol-Myers Squibb Co  reported higher-than-expected quarterly earnings, helped by cost cuts, but sales fell short of Wall Street expectations.The company on Tuesday said it earned $937 million, or 56 cents per share in the first quarter ending March 31, helped by gains from the recent sale of its diabetes drugs to longtime partner AstraZeneca Plc. That compared with $609 million, or 37 cents per share, in the year earlier period. Excluding special items, Bristol-Myers earned 46 cents per share. Analysts, on average, were expecting 43 cents per share, according to Thomson Reuters I/B/E/S.  (Reporting by Ransdell Pierson, Editing by Franklin Paul)",2014-04-29,BMY,"Tue Apr 29, 2014 | 7:51am EDT",Bristol-Myers quarterly profit beats expectations as costs cut,http://www.reuters.com//article/bristol-myers-results-idUSL2N0NL0CS20140429?type=companyNews
21,"   By Bill Berkrot  When the world's leading cancer doctors meet in Chicago next month, new treatments from Merck & Co, Bristol-Myers Squibb Co and Roche Holding AG that help the immune system fight disease are expected to capture much of the spotlight. The drugs, known as anti-PD-1 or anti-PDL1 therapies, are biotech medicines that work by blocking a tumor's ability to camouflage itself, thereby allowing T cells in the immune system to recognize and attack the cancer.They have shown great promise against advanced melanoma - the deadliest of skin cancers - as well as advanced lung and kidney cancers, with relatively mild side effects, generating  excitement among researchers and investors. At the American Society of Clinical Oncology meeting in Chicago beginning May 30, researchers will for the first time present data on Roche's anti-PDL1 drug in advanced bladder cancer for which there have been few advances in decades. Merck will have no less than 16 studies involving its highly touted anti PD-1 drug, MK-3475, including a first look at the drug as an initial lung cancer treatment. Early data released on Wednesday showed 36 percent of 45 patients had an initial immune response to the treatment. Merck will also provide results from the first trial of the drug in head and neck cancer.Brief summaries, or abstracts, of thousands of studies to be presented at the ASCO meeting were released on Wednesday. ""This area should represent a major advance in cancer therapy and patient survivability,"" said Len Yaffe, portfolio manager for the healthcare fund StockDoc Partners. ""Wall Street is increasingly recognizing the multibillion-dollar potential for cancer immunotherapies."" The potential for lasting effects of these drugs will be on display in a pair of studies involving the Bristol-Myers anti PD-1 drug nivolumab.Researchers will present follow-up data from a 107-patient nivolumab study in metastatic melanoma showing that 41 percent were still alive after three years, an apparent leveling off from the 48 percent survival rate after two years.Three-year survival with advanced melanoma was virtually unheard of prior to the advent of cancer immunotherapy.In a trial of patients whose advanced kidney cancer had progressed following prior treatments, the mean overall survival was 25.5 months for the 2 milligram nivolumab dose. Past kidney cancer studies of drugs currently in use have demonstrated a mean survival of about 14 months, said Fouad Namouni, Bristol's head of global development for nivolumab.MOST LIKELY TO BENEFIT  As drugmakers face greater scrutiny over how they price new therapies - with immuno-oncology expected to be among the most expensive - several studies will aim to identify which patients are most likely to benefit from the new treatments.Researchers can now perform a test to determine the degree to which the PD-L1 protein is expressed on the surface of cancer cells. On a 0 to 3 scale, a score of 0 or 1 is considered PD-L1 negative, while 2 or 3 is deemed PD-L1 positive.If early data is confirmed in larger trials, this class of immunotherapies could become standalone treatments for some patients, while PD-L1 negative patients may require combination or alternative therapies, according to some researchers.In a small, Phase I study of Bristol's nivolumab in previously untreated patients with advanced lung cancer, five out of 10 PD-L1 positive patients saw their tumors shrink by at least 30 percent. No such responses were seen among 7 PD-L1 negative patients. Roche also saw half of the 20 PD-L1 positive patients in its bladder cancer trial respond to its drug.Namouni said Bristol would focus on PD-L1 positive patients only in a large Phase III lung cancer trial of previously untreated subjects. Its Phase III studies of those who had received prior treatments will include PD-L1 negative patients.   (Reporting by Bill Berkrot; Editing by Michele Gershberg and Andre Grenon)",2014-05-14,BMY,"Wed May 14, 2014 | 6:14pm EDT","Bristol, Merck, Roche immune therapies are cancer meeting focus",http://www.reuters.com//article/us-health-cancer-immunotherapy-idUSKBN0DU20C20140514?type=companyNews
22,"  (Adds more information on Bristol-Myers Phase III plan in final paragraph)By Bill BerkrotMay 14 When the world's leading cancer doctors meet in Chicago next month, new treatments from Merck & Co, Bristol-Myers Squibb Co and Roche Holding AG that help the immune system fight disease are expected to capture much of the spotlight.The drugs, known as anti-PD-1 or anti-PDL1 therapies, are biotech medicines that work by blocking a tumor's ability to camouflage itself, thereby allowing T cells in the immune system to recognize and attack the cancer.They have shown great promise against advanced melanoma - the deadliest of skin cancers - as well as advanced lung and kidney cancers, with relatively mild side effects, generating  excitement among researchers and investors.At the American Society of Clinical Oncology meeting in Chicago beginning May 30, researchers will for the first time present data on Roche's anti-PDL1 drug in advanced bladder cancer for which there have been few advances in decades.Merck will have no less than 16 studies involving its highly touted anti PD-1 drug, MK-3475, including a first look at the drug as an initial lung cancer treatment. Early data released on Wednesday showed 36 percent of 45 patients had an initial immune response to the treatment. Merck will also provide results from the first trial of the drug in head and neck cancer.Brief summaries, or abstracts, of thousands of studies to be presented at the ASCO meeting were released on Wednesday. ""This area should represent a major advance in cancer therapy and patient survivability,"" said Len Yaffe, portfolio manager for the healthcare fund StockDoc Partners. ""Wall Street is increasingly recognizing the multibillion-dollar potential for cancer immunotherapies.""The potential for lasting effects of these drugs will be on display in a pair of studies involving the Bristol-Myers  anti PD-1 drug nivolumab.Researchers will present follow-up data from a 107-patient nivolumab study in metastatic melanoma showing that 41 percent were still alive after three years, an apparent leveling off from the 48 percent survival rate after two years. Three-year survival with advanced melanoma was virtually unheard of prior to the advent of cancer immunotherapy.In a trial of patients whose advanced kidney cancer had progressed following prior treatments, the mean overall survival was 25.5 months for the 2 milligram nivolumab dose.Past kidney cancer studies of drugs currently in use have demonstrated a mean survival of about 14 months, said Fouad Namouni, Bristol's head of global development for nivolumab. MOST LIKELY TO BENEFIT As drugmakers face greater scrutiny over how they price new therapies - with immuno-oncology expected to be among the most expensive - several studies will aim to identify which patients are most likely to benefit from the new treatments.Researchers can now perform a test to determine the degree to which the PD-L1 protein is expressed on the surface of cancer cells. On a 0 to 3 scale, a score of 0 or 1 is considered PD-L1 negative, while 2 or 3 is deemed PD-L1 positive.If early data is confirmed in larger trials, this class of immunotherapies could become standalone treatments for some patients, while PD-L1 negative patients may require combination or alternative therapies, according to some researchers.In a small, Phase I study of Bristol's nivolumab in previously untreated patients with advanced lung cancer, five out of 10 PD-L1 positive patients saw their tumors shrink by at least 30 percent. No such responses were seen among 7 PD-L1 negative patients. Roche also saw half of the 20 PD-L1 positive patients in its bladder cancer trial respond to its drug.Namouni said Bristol would focus on PD-L1 positive patients only in a large Phase III lung cancer trial of previously untreated subjects. Its Phase III studies of those who had received prior treatments will include PD-L1 negative patients.    (Reporting by Bill Berkrot; Editing by Michele Gershberg and Andre Grenon)",2014-05-14,BMY,"Wed May 14, 2014 | 5:54pm EDT","UPDATE 1-Bristol, Merck, Roche immune therapies are cancer meeting focus",http://www.reuters.com//article/health-cancer-immunotherapy-idUSL1N0O024O20140514?type=companyNews
23,"   By Bill Berkrot  May 14 When the world's leading cancer doctors meet in Chicago next month, new treatments from Merck & Co, Bristol-Myers Squibb Co and Roche Holding AG that help the immune system fight disease are expected to capture much of the spotlight.The drugs, known as anti-PD-1 or anti-PDL1 therapies, are biotech medicines that work by blocking a tumor's ability to camouflage itself, thereby allowing T cells in the immune system to recognize and attack the cancer.They have shown great promise against advanced melanoma - the deadliest of skin cancers - as well as advanced lung and kidney cancers, with relatively mild side effects, generating  excitement among researchers and investors.At the American Society of Clinical Oncology meeting in Chicago beginning May 30, researchers will for the first time present data on Roche's anti-PDL1 drug in advanced bladder cancer for which there have been few advances in decades.Merck will have no less than 16 studies involving its highly touted anti PD-1 drug, MK-3475, including a first look at the drug as an initial lung cancer treatment. Early data released on Wednesday showed 36 percent of 45 patients had an initial immune response to the treatment. Merck will also provide results from the first trial of the drug in head and neck cancer.Brief summaries, or abstracts, of hundreds of studies to be presented at the ASCO meeting were released on Wednesday. ""This area should represent a major advance in cancer therapy and patient survivability,"" said Len Yaffe, portfolio manager for the healthcare fund StockDoc Partners. ""Wall Street is increasingly recognizing the multibillion-dollar potential for cancer immunotherapies.""The potential for lasting effects of these drugs will be on display in a pair of studies involving the Bristol-Myers  anti PD-1 drug nivolumab.Researchers will present follow-up data from a 107-patient nivolumab study in metastatic melanoma showing that 41 percent were still alive after three years, an apparent leveling off from the 48 percent survival rate after two years.Three-year survival with advanced melanoma was virtually unheard of prior to the advent of cancer immunotherapy. In a trial of patients whose advanced kidney cancer had progressed following prior treatments, the mean overall survival was 25.5 months for the 2 milligram nivolumab dose.Past kidney cancer studies of drugs currently in use have demonstrated a mean survival of about 14 months, said Fouad Namouni, Bristol's head of global development for nivolumab. MOST LIKELY TO BENEFIT As drugmakers face greater scrutiny over how they price new therapies - with immuno-oncology expected to be among the most expensive - several studies will aim to identify which patients are most likely to benefit from the new treatments.Researchers can now perform a test to determine the degree to which the PD-L1 protein is expressed on the surface of cancer cells. On a 0 to 3 scale, a score of 0 or 1 is considered PD-L1 negative, while 2 or 3 is deemed PD-L1 positive.If early data is confirmed in larger trials, this class of immunotherapies could become standalone treatments for some patients, while PD-L1 negative patients may require combination or alternative therapies, according to some researchers.In a small, Phase I study of Bristol's nivolumab in previously untreated patients with advanced lung cancer, five out of 10 PD-L1 positive patients saw their tumors shrink by at least 30 percent. No such responses were seen among 7 PD-L1 negative patients. Roche also saw half of the 20 PD-L1 positive patients in its bladder cancer trial respond to its drug.Namouni said Bristol would focus on PD-L1 positive patients in planning its large Phase III trials.   (Reporting by Bill Berkrot; Editing by Michele Gershberg and Andre Grenon)",2014-05-14,BMY,"Wed May 14, 2014 | 5:00pm EDT","Bristol, Merck, Roche immune therapies are cancer meeting darlings",http://www.reuters.com//article/health-cancer-immunotherapy-idUSL1N0NZ1K320140514?type=companyNews
24,"  (Corrects to Reimbursement Intelligence from Intelligence Reimbursement, to Whang as co-president from president, to Steve Miller from Stuart Miller)By Caroline Humer and Deena BeasleyNEW YORK/LOS ANGELES May 28 Shocked by the rapid adoption of a new $84,000 hepatitis C treatment, U.S. health insurers are trying to make sure they aren't blindsided by other drugs being developed and are looking for ways to limit their use from the day they are launched.Manufacturer Gilead Sciences Inc says 30,000 people have received hepatitis drug Sovaldi so far, and that sales hit a record-breaking $2.3 billion within a few months. The treatment, typically 84 pills taken over 12 weeks, completely cures the disease in more than 90 percent of patients.As many as 3.2 million Americans are infected by hepatitis C, and the cost of giving most of them Sovaldi would surpass $200 billion. Some insurers have already put conditions on who can get the drug, and states including California and Texas have slowed or put treatment on hold while they study what to do.Insurers warned that these unforeseen costs will cut 2014 earnings and require rate hikes. Now, at industry conferences, in conversations with investors, and in private, they are pushing Gilead's rivals, a group that includes AbbVie Inc , Merck & Co and Bristol-Myers Squibb Co , to discount their own new hepatitis C treatments when they come to market starting this fall. Such a high-profile campaign by insurers before drugs are even approved is new.They are also signaling they will restrict who can get coverage for new cholesterol drugs being developed by Amgen Inc , Pfizer Inc and a partnership of Regeneron Pharmaceuticals Inc and Sanofi SA.By law, insurers cannot deny access to new drugs if they represent a real improvement for patients, leaving drug companies with the upper hand in most price discussions. When comparable competitors, or a generic version is on the market about a decade later, insurers have room to steer patients away from the new drugs, and pharmaceutical companies cut prices steeply and give big discounts.But insurers have not faced such a highly effective drug aimed at a widespread disease that is so expensive and so quickly adopted. The previous record for a drug reaching blockbuster status was set in 2011, when hepatitis C therapy Incivek from Vertex Pharmaceuticals raked in $1.56 billion for the entire year. Sovaldi has sold more in a quarter of the time.As a result, insurers are taking a harder line on which patients should get Sovaldi, based on the drug's clinical data.Sovaldi is ""game-changing"" for insurers' thinking, said John Whang, co-president of Reimbursement Intelligence, a consulting firm that helps pharmaceutical companies set prices. The only way for them to respond is to control the volume of treatment used, he said.PUBLIC SHAMING  In a sign of how serious the industry has become, the largest insurer lobby group last week took Gilead to task at a public conference.""The company in this case is asking for a blank check and you can't give anyone anymore a blank check because it will blow up family budgets, state Medicaid budgets, employer costs and wreak havoc on the federal debt,"" said Karen Ignagni, president of America's Health Insurance Plans.Gilead argues that Sovaldi's price is worth it, since it will replace even costlier spending on hospital visits and treatments for cirrhosis or liver failure. It has not budged on price for the hepatitis C drug, although Gregg Alton, Gilead's executive vice president for corporate and medical affairs, acknowledged that insurers are going to start negotiating.U.S. drug spending reached a record $329 billion in 2013, driven by a double-digit increase in prices for new cancer, HIV and hepatitis C therapies. Express Scripts, the nation's largest pharmacy benefit manager, expects spending on such specialty drugs to rise an additional 63 percent from 2014 to 2016, driven by an 1,800 percent increase in hepatitis C drug costs.Successful drugs can cost $1 billion to bring to market, including spending on research, development and marketing. Supporters of drug companies say big advances necessitate high prices.""We are the only country in the world that pays exorbitant prices to provide innovation first here, but that's what we need and that's what the American people have come to expect,"" said Richard Burr, a Republican Senator from North Carolina who has spent decades working on bipartisan health bills.LIMITING USE  Hepatitis C complications can take years to develop, which gives insurers and government health agencies leeway to determine when treatment should start.Many insurers, which manage most of the 150 million people covered by employer-based plans as well as some government Medicare and Medicaid plans, require patients to get authorization before using Sovaldi. Some limit the drug to patients with a certain genetic type of the disease.Express Scripts has been pushing for all but the sickest patients to wait for new therapies that are expected to compete head-to-head with Sovaldi late this year. It is also pressing rival manufacturers for low prices, hoping to avoid the shock of Sovaldi, which sped through trials and regulatory approval and caught insurers by surprise.""In this particular case there was very little discussion pre-launch. But other companies are now already discussing potential future price points in response,"" said Steve Miller, Express Scripts Chief Medical Officer.AbbVie and Merck both declined to comment on whether discussions with insurers about their new drugs were underway.Gilead, which says it discussed the Sovaldi launch with insurers, is in talks over which patients should be treated with its next hepatitis C pill. That will be a two-drug combination that will eliminate the need for a companion drug that nearly doubles Sovaldi's current total cost. Industry analysts expect the company will price it closer to Sovaldi's $84,000 than to the $150,000 cost of a combination of Sovaldi and a Johnson & Johnson drug that some doctors prescribe.Mick Kolassa, chairman of pricing consultancy Medical Marketing Economics, in Oxford, Mississippi, who advises pharma companies, says insurers are being aggressive. ""We are seeing some of them step up and flex their muscles,"" he said.CHOLESTEROL DRUGS IN SIGHT More scrutiny of new pricing is likely ahead as the country comes to terms with how it should pay for expensive drugs, according to John Castellani, Chief Executive Officer of leading drug industry lobby group Pharmaceutical Research and Manufacturers of America or PhRMA.Sovaldi has shown that patients are bearing too much of the drug's costs because of rising co-payments, co-insurance and deductibles, he told Reuters, laying the blame on factors controlled by insurance companies.But patient advocates are not choosing sides yet, which may have the effect of giving insurers room for action.""I think the fault lies with both the for-profit insurers and the drug companies,"" said Anne Donnelly, director of healthcare policy at the San Francisco-based Project Inform, which advocates for hepatitis C patients. The system has not changed to reflect the impact of new effective, expensive drugs, she said.The next big price battle centers on a new class of cholesterol drugs known as PCSK9 inhibitors, which help the liver to clear ""bad"" LDL cholesterol from the blood.Large-scale studies show the new drugs can help patients who cannot tolerate, or get enough benefit from, the most widely-used cholesterol drugs, statins. The PCSK9 therapies are expected to cost thousands of dollars a year, far above the price of statins sold as generics.Drugmakers are expected to push for the new medicines to be used by 7 million to 20 million people, or up to 30 percent of the 71 million Americans with high cholesterol. Insurers already are questioning whether the estimates of use are legitimate.""There is really no need to take these new medications and spread them out across a larger community of people who will respond to existing treatments, many of which are generic,"" Aetna Inc's National Medical Director for Pharmacy Policy Ed Pezalla said in an interview.   (Editing by Michele Gershberg and Peter Henderson)",2014-05-28,BMY,"Wed May 28, 2014 | 4:28pm EDT","CORRECTED-INSIGHT-RPT-Insurers scrutinize drug costs after $84,000 Sovaldi surprise",http://www.reuters.com//article/usa-healthcare-hepatitisc-insight-graphi-idUSL1N0OE00T20140528?type=companyNews
25,"  (Corrects to Reimbursement Intelligence from Intelligence Reimbursement, to Whang as co-president from president, to Steve Miller from Stuart Miller)By Caroline Humer and Deena BeasleyNEW YORK/LOS ANGELES May 28 Shocked by the rapid adoption of a new $84,000 hepatitis C treatment, U.S. health insurers are trying to make sure they aren't blindsided by other drugs being developed and are looking for ways to limit their use from the day they are launched.Manufacturer Gilead Sciences Inc says 30,000 people have received hepatitis drug Sovaldi so far, and that sales hit a record-breaking $2.3 billion within a few months. The treatment, typically 84 pills taken over 12 weeks, completely cures the disease in more than 90 percent of patients.As many as 3.2 million Americans are infected by hepatitis C, and the cost of giving most of them Sovaldi would surpass $200 billion. Some insurers have already put conditions on who can get the drug, and states including California and Texas have slowed or put treatment on hold while they study what to do.Insurers warned that these unforeseen costs will cut 2014 earnings and require rate hikes. Now, at industry conferences, in conversations with investors, and in private, they are pushing Gilead's rivals, a group that includes AbbVie Inc , Merck & Co and Bristol-Myers Squibb Co , to discount their own new hepatitis C treatments when they come to market starting this fall. Such a high-profile campaign by insurers before drugs are even approved is new.They are also signaling they will restrict who can get coverage for new cholesterol drugs being developed by Amgen Inc , Pfizer Inc and a partnership of Regeneron Pharmaceuticals Inc and Sanofi SA.By law, insurers cannot deny access to new drugs if they represent a real improvement for patients, leaving drug companies with the upper hand in most price discussions. When comparable competitors, or a generic version is on the market about a decade later, insurers have room to steer patients away from the new drugs, and pharmaceutical companies cut prices steeply and give big discounts.But insurers have not faced such a highly effective drug aimed at a widespread disease that is so expensive and so quickly adopted. The previous record for a drug reaching blockbuster status was set in 2011, when hepatitis C therapy Incivek from Vertex Pharmaceuticals raked in $1.56 billion for the entire year. Sovaldi has sold more in a quarter of the time.As a result, insurers are taking a harder line on which patients should get Sovaldi, based on the drug's clinical data.Sovaldi is ""game-changing"" for insurers' thinking, said John Whang, co-president of Reimbursement Intelligence, a consulting firm that helps pharmaceutical companies set prices. The only way for them to respond is to control the volume of treatment used, he said.PUBLIC SHAMING  In a sign of how serious the industry has become, the largest insurer lobby group last week took Gilead to task at a public conference.""The company in this case is asking for a blank check and you can't give anyone anymore a blank check because it will blow up family budgets, state Medicaid budgets, employer costs and wreak havoc on the federal debt,"" said Karen Ignagni, president of America's Health Insurance Plans.Gilead argues that Sovaldi's price is worth it, since it will replace even costlier spending on hospital visits and treatments for cirrhosis or liver failure. It has not budged on price for the hepatitis C drug, although Gregg Alton, Gilead's executive vice president for corporate and medical affairs, acknowledged that insurers are going to start negotiating.U.S. drug spending reached a record $329 billion in 2013, driven by a double-digit increase in prices for new cancer, HIV and hepatitis C therapies. Express Scripts, the nation's largest pharmacy benefit manager, expects spending on such specialty drugs to rise an additional 63 percent from 2014 to 2016, driven by an 1,800 percent increase in hepatitis C drug costs.Successful drugs can cost $1 billion to bring to market, including spending on research, development and marketing. Supporters of drug companies say big advances necessitate high prices.""We are the only country in the world that pays exorbitant prices to provide innovation first here, but that's what we need and that's what the American people have come to expect,"" said Richard Burr, a Republican Senator from North Carolina who has spent decades working on bipartisan health bills.LIMITING USE  Hepatitis C complications can take years to develop, which gives insurers and government health agencies leeway to determine when treatment should start.Many insurers, which manage most of the 150 million people covered by employer-based plans as well as some government Medicare and Medicaid plans, require patients to get authorization before using Sovaldi. Some limit the drug to patients with a certain genetic type of the disease.Express Scripts has been pushing for all but the sickest patients to wait for new therapies that are expected to compete head-to-head with Sovaldi late this year. It is also pressing rival manufacturers for low prices, hoping to avoid the shock of Sovaldi, which sped through trials and regulatory approval and caught insurers by surprise.""In this particular case there was very little discussion pre-launch. But other companies are now already discussing potential future price points in response,"" said Steve Miller, Express Scripts Chief Medical Officer.AbbVie and Merck both declined to comment on whether discussions with insurers about their new drugs were underway.Gilead, which says it discussed the Sovaldi launch with insurers, is in talks over which patients should be treated with its next hepatitis C pill. That will be a two-drug combination that will eliminate the need for a companion drug that nearly doubles Sovaldi's current total cost. Industry analysts expect the company will price it closer to Sovaldi's $84,000 than to the $150,000 cost of a combination of Sovaldi and a Johnson & Johnson drug that some doctors prescribe.Mick Kolassa, chairman of pricing consultancy Medical Marketing Economics, in Oxford, Mississippi, who advises pharma companies, says insurers are being aggressive. ""We are seeing some of them step up and flex their muscles,"" he said.CHOLESTEROL DRUGS IN SIGHT More scrutiny of new pricing is likely ahead as the country comes to terms with how it should pay for expensive drugs, according to John Castellani, Chief Executive Officer of leading drug industry lobby group Pharmaceutical Research and Manufacturers of America or PhRMA.Sovaldi has shown that patients are bearing too much of the drug's costs because of rising co-payments, co-insurance and deductibles, he told Reuters, laying the blame on factors controlled by insurance companies.But patient advocates are not choosing sides yet, which may have the effect of giving insurers room for action.""I think the fault lies with both the for-profit insurers and the drug companies,"" said Anne Donnelly, director of healthcare policy at the San Francisco-based Project Inform, which advocates for hepatitis C patients. The system has not changed to reflect the impact of new effective, expensive drugs, she said.The next big price battle centers on a new class of cholesterol drugs known as PCSK9 inhibitors, which help the liver to clear ""bad"" LDL cholesterol from the blood.Large-scale studies show the new drugs can help patients who cannot tolerate, or get enough benefit from, the most widely-used cholesterol drugs, statins. The PCSK9 therapies are expected to cost thousands of dollars a year, far above the price of statins sold as generics.Drugmakers are expected to push for the new medicines to be used by 7 million to 20 million people, or up to 30 percent of the 71 million Americans with high cholesterol. Insurers already are questioning whether the estimates of use are legitimate.""There is really no need to take these new medications and spread them out across a larger community of people who will respond to existing treatments, many of which are generic,"" Aetna Inc's National Medical Director for Pharmacy Policy Ed Pezalla said in an interview.   (Editing by Michele Gershberg and Peter Henderson)",2014-05-28,BMY,"Wed May 28, 2014 | 4:27pm EDT","CORRECTED-INSIGHT-Insurers scrutinize drug costs after $84,000 Sovaldi surprise",http://www.reuters.com//article/usa-healthcare-hepatitisc-insight-graphi-idUSL1N0OD1F820140528?type=companyNews
26,"   By Julie Steenhuysen | CHICAGO  CHICAGO U.S. researchers are finalizing plans to test two immunotherapy drugs made by Bristol-Myers Squibb Co on patients newly diagnosed with the most common form of deadly brain tumors in adults.Dr. Mark Gilbert, a leading brain tumor researcher at University of Texas MD Anderson Cancer Center in Houston, said he got approval last Tuesday from the National Cancer Institute (NCI) to start designing the trial, likely to begin this fall, with the melanoma drug Yervoy and an experimental drug called nivolumab.The trial will be run through the nonprofit NRG Oncology, an NCI sponsored cooperative group of cancer researchers. ""We're really excited about them,"" said Gilbert, who spoke in an interview at the American Society of Clinical Oncology  meeting in Chicago.The hope, he said, is that the drugs, which ramp up the immune system to fight cancer, will prove effective in treating the brain tumors known as glioblastomas.Researchers are already testing Bristol's nivolumab in patients with a glioblastoma that has come back after standard treatment, which involves surgery followed by radiation and chemotherapy. Michael Giordano, head of development for oncology and immunology at Bristol-Myers, said the company's trial in recurrent glioblastoma is part of its push to test the potential of immunotherpies in a broad range of cancers.Gilbert said he has met with company officials, who still need to give written approval for their drugs to be used in the government-backed study.Initially, the trial in newly diagnosed patients will test the safety of the drugs in some 42 patients, Gilbert said. One concern is that bolstering the immune system in the brain could trigger an autoimmune reaction known as encephalitis, causing swelling and worsening patients' symptoms.  But so far, the studies in patients with recurrent tumors have not shown that to be a major issue, Gilbert said.""We have to take it slow. We want to understand what we're doing,"" he said. What is challenging about brain tumors is getting active treatments through a protective membrane called the blood-brain barrier. A major study led by Gilbert, reported at last year's American Society of Clinical Oncology meeting, showed Roche's antibody drug Avastin failed to prolong life in patients with newly diagnosed disease. But early studies of immunotherapy in melanoma showed the treatments did shrink tumors in patients whose cancer has spread to the brain, suggesting that immune system cells were reaching their target in the brain and raising hope for immunotherapy treatments.Gilbert acknowledged that research on brain tumors has lagged some other fields, especially with new immune system therapies, but he sees that changing.Glioblastomas are the most common and most deadly form of brain and nervous system tumors, which affect an estimated 240,000 adults globally per year. With standard treatments,  average survival is 15 to 17 months. (Reporting by Julie Steenhuysen; Editing by Tom Brown)",2014-06-01,BMY,"Sun Jun 1, 2014 | 5:31pm EDT",U.S. to test immunotherapy drugs on newly diagnosed brain tumors,http://www.reuters.com//article/us-health-cancer-brain-idUSKBN0EC1XY20140601?type=companyNews
27,"   By Julie Steenhuysen | CHICAGO, June 1  CHICAGO, June 1 U.S. researchers are finalizing plans to test two immunotherapy drugs made by Bristol-Myers Squibb Co on patients newly diagnosed with the most common form of deadly brain tumors in adults.Dr. Mark Gilbert, a leading brain tumor researcher at University of Texas MD Anderson Cancer Center in Houston, said he got approval last Tuesday from the National Cancer Institute (NCI) to start designing the trial, likely to begin this fall, with the melanoma drug Yervoy and an experimental drug called nivolumab.The trial will be run through the nonprofit NRG Oncology, an NCI sponsored cooperative group of cancer researchers.""We're really excited about them,"" said Gilbert, who spoke in an interview at the American Society of Clinical Oncology  meeting in Chicago.The hope, he said, is that the drugs, which ramp up the immune system to fight cancer, will prove effective in treating the brain tumors known as glioblastomas. Researchers are already testing Bristol's nivolumab in patients with a glioblastoma that has come back after standard treatment, which involves surgery followed by radiation and chemotherapy.Michael Giordano, head of development for oncology and immunology at Bristol-Myers, said the company's trial in recurrent glioblastoma is part of its push to test the potential of immunotherpies in a broad range of cancers.Gilbert said he has met with company officials, who still need to give written approval for their drugs to be used in the government-backed study. Initially, the trial in newly diagnosed patients will test the safety of the drugs in some 42 patients, Gilbert said. One concern is that bolstering the immune system in the brain could trigger an autoimmune reaction known as encephalitis, causing swelling and worsening patients' symptoms.But so far, the studies in patients with recurrent tumors have not shown that to be a major issue, Gilbert said. ""We have to take it slow. We want to understand what we're doing,"" he said.What is challenging about brain tumors is getting active treatments through a protective membrane called the blood-brain barrier. A major study led by Gilbert, reported at last year's American Society of Clinical Oncology meeting, showed Roche's  antibody drug Avastin failed to prolong life in patients with newly diagnosed disease.But early studies of immunotherapy in melanoma showed the treatments did shrink tumors in patients whose cancer has spread to the brain, suggesting that immune system cells were reaching their target in the brain and raising hope for immunotherapy treatments.Gilbert acknowledged that research on brain tumors has lagged some other fields, especially with new immune system therapies, but he sees that changing.Glioblastomas are the most common and most deadly form of brain and nervous system tumors, which affect an estimated 240,000 adults globally per year. With standard treatments,  average survival is 15 to 17 months.      (Reporting by Julie Steenhuysen; Editing by Tom Brown)",2014-06-01,BMY,"Sun Jun 1, 2014 | 4:52pm EDT",U.S. to test immunotherapy drugs on newly diagnosed brain tumors,http://www.reuters.com//article/health-cancer-brain-idUSL1N0OI07G20140601?type=companyNews
28,"   By Bill Berkrot  New data on Bristol-Myers Squibb Co's melanoma drug Yervoy, including updated results from an effort to combine it with another promising cancer immunotherapy, suggest it can improve treatment for patients with both advanced and slightly earlier stage disease, according to findings released on Monday.Yervoy, which takes natural brakes off the immune system to help it more effectively attack cancer, is approved to treat metastatic, or stage 4, melanoma - the deadliest form of skin cancer. Cowen and Co expects the drug to capture annual sales of $1.95 billion by 2020, as it is approved in new indications and combinations with other treatments. During the annual American Society of Clinical Oncology meeting in Chicago, Bristol-Myers presented several studies on Yervoy and nivolumab, its experimental cancer immunotherapy from a highly promising class called PD-1 inhibitors, both as standalone treatments and in combination. In one late-stage study on Yervoy alone, the drug reduced the risk of melanoma recurrence by 25 percent following surgery compared with a placebo. The median recurrence-free survival (RFS), or average time to disease return, following successful surgery to remove cancerous tumors was 26.1 months for Yervoy compared with 17.1 months for the placebo group. The result was deemed to be statistically significant.Patients in this study had stage 3 disease in which the cancer had spread to regional lymph nodes but not yet to other parts of the body.""This benefit was observed across all patient sub-groups, including those who were at highest risk of recurrence,"" Alexander Eggermont, the study's lead investigator, said in a statement.The result could pave the way for the drug's use earlier in the disease and boost future sales. Current treatment options to reduce the risk of recurrence following surgery are very limited, Eggermont said. The 951-patient Phase III study was the first large trial to look at Yervoy's effect following complete resection surgery.Overall survival data was not yet available. But three years after beginning treatment, an estimated 46.5 percent of Yervoy patients were free of disease recurrence compared with 34.8 percent in the placebo group. Nearly half of the Yervoy patients stopped treatment due to side effects, which are common with the drug, and there were five drug-related deaths, or 1.1 percent, researchers reported.Bristol shares were down 2 percent to $48.65 with some experts expressing concern about side effects.""There is a delay in recurrence, however I would argue that the delay  is comparable to interferon. And there was toxicity,"" said Dr Steven O'Day, director of the Los Angeles Skin Cancer Institute, noting the five deaths.Ron Peck, Bristol's global development leader for Yervoy, said a high 10 milligram dose was used in the study and may have contributed to the side effect rate. A 3 mg dose is being used in later studies. LONG-TERM SURVIVAL FOR COMBINATION Data from a separate, early-stage study of advanced melanoma patients demonstrated compelling survival data for Yervoy combined with nivolumab.At two years, the overall survival rate for the first 53 patients in the study was estimated to be 79 percent, down only a bit from the 85 percent survival rate reported after one year.""If this survival data is confirmed in Phase III trials, it's unprecedented. This is really exciting data,"" said Dr. Mario Sznol, a professor of medicine at Yale Cancer Center in New Haven, Connecticut, and the study's lead investigator. Among the 17 patients who received the two drug doses that Bristol chose to test in its larger, later stage trials the two-year survival rate was 88 percent. Seventeen percent of patients in the study had a complete response, or no detectable cancer. Sznol expects that number to rise. Immunotherapy results often improve over time as the immune system learns to fight the disease.The results were consistent whether or not a patient's tumors expressed the PD-L1 protein, which helps camouflage them against the immune system. Patients who are deemed negative for PD-L1 tend to get little benefit from drugs like nivolumab alone, suggesting the addition of Yervoy may also help them.The incidence of serious side effects among the first 53 patients in the study was about 53 percent and rose to 62 percent with an additional group of 41 more patients.There was a 23 percent discontinuation rate due to side effects and one drug-related death, researchers reported.""These toxicities really are manageable in the clinic,"" Sznol said. ""If you're getting 79 percent overall survival at two years, the side effects are clearly worth it.""BMO Capital Markets analyst Alex Arfaei expressed disappointment about separate kidney cancer data for the combination that could be contributing to the Bristol stock downturn. ""We remain uncertain that the incremental benefit of adding Yervoy to nivo is worth the additional toxicity,"" he said.  (Reporting by Bill Berkrot, additional reporting by Deena Beasley in Chicago; Editing by Michele Gershberg, Eric Walsh and Cynthia Osterman)",2014-06-02,BMY,"Mon Jun 2, 2014 | 1:38pm EDT","Bristol's Yervoy, alone or in combo, improves melanoma results: studies",http://www.reuters.com//article/us-health-cancer-melanoma-bristolmyers-idUSKBN0ED1TU20140602?type=companyNews
29,"  (Adds analyst, outside doctor comment, share price)By Bill BerkrotJune 2 New data on Bristol-Myers Squibb Co's  melanoma drug Yervoy, including updated results from an effort to combine it with another promising cancer immunotherapy, suggest it can improve treatment for patients with both advanced and slightly earlier stage disease, according to findings released on Monday.Yervoy, which takes natural brakes off the immune system to help it more effectively attack cancer, is approved to treat metastatic, or stage 4, melanoma - the deadliest form of skin cancer. Cowen and Co expects the drug to capture annual sales of $1.95 billion by 2020, as it is approved in new indications and combinations with other treatments.During the annual American Society of Clinical Oncology meeting in Chicago, Bristol-Myers presented several studies on Yervoy and nivolumab, its experimental cancer immunotherapy from a highly promising class called PD-1 inhibitors, both as standalone treatments and in combination.In one late-stage study on Yervoy alone, the drug reduced the risk of melanoma recurrence by 25 percent following surgery compared with a placebo. The median recurrence-free survival (RFS), or average time to disease return, following successful surgery to remove cancerous tumors was 26.1 months for Yervoy compared with 17.1 months for the placebo group. The result was deemed to be statistically significant.Patients in this study had stage 3 disease in which the cancer had spread to regional lymph nodes but not yet to other parts of the body.""This benefit was observed across all patient sub-groups, including those who were at highest risk of recurrence,"" Alexander Eggermont, the study's lead investigator, said in a statement.The result could pave the way for the drug's use earlier in the disease and boost future sales. Current treatment options to reduce the risk of recurrence following surgery are very limited, Eggermont said.The 951-patient Phase III study was the first large trial to look at Yervoy's effect following complete resection surgery. Overall survival data was not yet available. But three years after beginning treatment, an estimated 46.5 percent of Yervoy patients were free of disease recurrence compared with 34.8 percent in the placebo group.Nearly half of the Yervoy patients stopped treatment due to side effects, which are common with the drug, and there were five drug-related deaths, or 1.1 percent, researchers reported.Bristol shares were down 2 percent to $48.65 with some experts expressing concern about side effects.""There is a delay in recurrence, however I would argue that the delay  is comparable to interferon. And there was toxicity,"" said Dr Steven O'Day, director of the Los Angeles Skin Cancer Institute, noting the five deaths. Ron Peck, Bristol's global development leader for Yervoy, said a high 10 milligram dose was used in the study and may have contributed to the side effect rate. A 3 mg dose is being used in later studies.LONG-TERM SURVIVAL FOR COMBINATION Data from a separate, early-stage study of advanced melanoma patients demonstrated compelling survival data for Yervoy combined with nivolumab.At two years, the overall survival rate for the first 53 patients in the study was estimated to be 79 percent, down only a bit from the 85 percent survival rate reported after one year. ""If this survival data is confirmed in Phase III trials, it's unprecedented. This is really exciting data,"" said Dr. Mario Sznol, a professor of medicine at Yale Cancer Center in New Haven, Connecticut, and the study's lead investigator.Among the 17 patients who received the two drug doses that Bristol chose to test in its larger, later stage trials the two-year survival rate was 88 percent.Seventeen percent of patients in the study had a complete response, or no detectable cancer. Sznol expects that number to rise. Immunotherapy results often improve over time as the immune system learns to fight the disease.The results were consistent whether or not a patient's tumors expressed the PD-L1 protein, which helps camouflage them against the immune system. Patients who are deemed negative for PD-L1 tend to get little benefit from drugs like nivolumab alone, suggesting the addition of Yervoy may also help them.The incidence of serious side effects among the first 53 patients in the study was about 53 percent and rose to 62 percent with an additional group of 41 more patients.There was a 23 percent discontinuation rate due to side effects and one drug-related death, researchers reported.""These toxicities really are manageable in the clinic,"" Sznol said. ""If you're getting 79 percent overall survival at two years, the side effects are clearly worth it.""BMO Capital Markets analyst Alex Arfaei expressed disappointment about separate kidney cancer data for the combination that could be contributing to the Bristol stock downturn. ""We remain uncertain that the incremental benefit of adding Yervoy to nivo is worth the additional toxicity,"" he said.    (Reporting by Bill Berkrot, additional reporting by Deena Beasley in Chicago; Editing by Michele Gershberg, Eric Walsh and Cynthia Osterman)",2014-06-02,BMY,"Mon Jun 2, 2014 | 1:07pm EDT","UPDATE 1-Bristol's Yervoy, alone or in combo, improves melanoma results-studies",http://www.reuters.com//article/health-cancer-melanoma-bristolmyers-idUSL1N0OJ0YM20140602?type=companyNews
30,"   By Bill Berkrot  New data on Bristol-Myers Squibb Co's melanoma drug Yervoy, including fresh results from an effort to combine it with another promising cancer immunotherapy, suggest it can improve treatment for patients with both advanced and slightly earlier stage disease, according to findings released on Monday.Yervoy, which takes natural brakes off the immune system to help it more effectively attack cancer, is approved to treat metastatic, or stage 4, melanoma - the deadliest form of skin cancer. Cowen and Co expects the drug to capture annual sales of $1.95 billion by 2020, as it is approved in new indications and combinations with other treatments. During the annual American Society of Clinical Oncology meeting in Chicago, Bristol-Myers presented several studies on Yervoy and nivolumab, its experimental cancer immunotherapy from a highly promising class called PD-1 inhibitors, both as standalone treatments and in combination. In one late-stage study on Yervoy alone, the drug reduced the risk of melanoma recurrence by 25 percent following surgery compared with a placebo. The median recurrence-free survival (RFS), or average time to disease return, following successful surgery to remove cancerous tumors was 26.1 months for Yervoy compared with 17.1 months for the placebo group. The result was deemed to be statistically significant.Patients in this study had stage 3 disease in which the cancer had spread to regional lymph nodes but not yet to other parts of the body.""This benefit was observed across all patient sub-groups, including those who were at highest risk of recurrence,"" Alexander Eggermont, the study's lead investigator, said in a statement.The result could pave the way for the drug's use earlier in the disease and boost future sales. Current treatment options to reduce the risk of recurrence following surgery are very limited, Eggermont said. The 951-patient Phase III study was the first large trial to look at Yervoy's effect following complete resection surgery. Overall survival data was not yet available. But three years after beginning treatment, an estimated 46.5 percent of Yervoy patients were free of disease recurrence compared with 34.8 percent in the placebo group.Nearly half of the Yervoy patients stopped treatment due to side effects, which are common with the drug, and there were five drug-related deaths, or 1.1 percent, researchers reported.Ron Peck, Bristol's global development leader for Yervoy, said a high 10 milligram dose was used in the study and may have contributed to the side effect rate. A 3 mg dose is being used in later studies. LONG-TERM SURVIVAL FOR COMBINATION Data from a separate, early-stage study of advanced melanoma patients showed results for Yervoy combined with nivolumab that researchers found very encouraging.At two years, the overall survival rate for the first 53 patients in the study was estimated to be 79 percent, down only a bit from the 85 percent survival rate reported after one year.""If this survival data is confirmed in Phase III trials, it's unprecedented. This is really exciting data,"" said Dr. Mario Sznol, a professor of medicine at Yale Cancer Center in New Haven, Connecticut, and the study's lead investigator. Having 80 percent of advanced melanoma patients alive at two years ""is almost unheard of,"" Sznol said in a telephone interview.Among the 17 patients in the study who received the two drug doses that Bristol chose to test in its larger, later stage trials the two-year survival rate was 88 percent. Seventeen percent of patients in the study had a complete response, or no detectable cancer. Sznol expects that number to rise. Immunotherapy results often improve over time as the immune system learns to fight the disease.The results were consistent whether or not a patient's tumors expressed the PD-L1 protein, which helps camouflage them against the immune system. Patients who are deemed negative for PD-L1 tend to get little benefit from drugs like nivolumab alone, suggesting the addition of Yervoy may also help them.The incidence of serious side effects among the first 53 patients in the study was about 53 percent and rose to 62 percent with an additional group of 41 more patients. There was a 23 percent discontinuation rate due to side effects and one drug-related death, researchers reported.""These toxicities really are manageable in the clinic,"" Sznol said. ""If you're getting 79 percent overall survival at two years, the side effects are clearly worth it."" (Reporting by Bill Berkrot; Editing by Michele Gershberg and Eric Walsh)",2014-06-02,BMY,"Mon Jun 2, 2014 | 7:32am EDT","Bristol's Yervoy, alone or in combo, improves melanoma results: studies",http://www.reuters.com//article/us-health-cancer-melanoma-bristolmyers-idUSKBN0ED11P20140602?type=companyNews
31,"   By Bill Berkrot | June 2  June 2 New data on Bristol-Myers Squibb Co's  melanoma drug Yervoy, including fresh results from an effort to combine it with another promising cancer immunotherapy, suggest it can improve treatment for patients with both advanced and slightly earlier stage disease, according to findings released on Monday.Yervoy, which takes natural brakes off the immune system to help it more effectively attack cancer, is approved to treat metastatic, or stage 4, melanoma - the deadliest form of skin cancer. Cowen and Co expects the drug to capture annual sales of $1.95 billion by 2020, as it is approved in new indications and combinations with other treatments.During the annual American Society of Clinical Oncology meeting in Chicago, Bristol-Myers presented several studies on Yervoy and nivolumab, its experimental cancer immunotherapy from a highly promising class called PD-1 inhibitors, both as standalone treatments and in combination.In one late-stage study on Yervoy alone, the drug reduced the risk of melanoma recurrence by 25 percent following surgery compared with a placebo. The median recurrence-free survival (RFS), or average time to disease return, following successful surgery to remove cancerous tumors was 26.1 months for Yervoy compared with 17.1 months for the placebo group. The result was deemed to be statistically significant.Patients in this study had stage 3 disease in which the cancer had spread to regional lymph nodes but not yet to other parts of the body.""This benefit was observed across all patient sub-groups, including those who were at highest risk of recurrence,"" Alexander Eggermont, the study's lead investigator, said in a statement.The result could pave the way for the drug's use earlier in the disease and boost future sales. Current treatment options to reduce the risk of recurrence following surgery are very limited, Eggermont said. The 951-patient Phase III study was the first large trial to look at Yervoy's effect following complete resection surgery.Overall survival data was not yet available. But three years after beginning treatment, an estimated 46.5 percent of Yervoy patients were free of disease recurrence compared with 34.8 percent in the placebo group.Nearly half of the Yervoy patients stopped treatment due to side effects, which are common with the drug, and there were five drug-related deaths, or 1.1 percent, researchers reported.Ron Peck, Bristol's global development leader for Yervoy, said a high 10 milligram dose was used in the study and may have contributed to the side effect rate. A 3 mg dose is being used in later studies. LONG-TERM SURVIVAL FOR COMBINATION Data from a separate, early-stage study of advanced melanoma patients showed results for Yervoy combined with nivolumab that researchers found very encouraging.At two years, the overall survival rate for the first 53 patients in the study was estimated to be 79 percent, down only a bit from the 85 percent survival rate reported after one year. ""If this survival data is confirmed in Phase III trials, it's unprecedented. This is really exciting data,"" said Dr. Mario Sznol, a professor of medicine at Yale Cancer Center in New Haven, Connecticut, and the study's lead investigator.Having 80 percent of advanced melanoma patients alive at two years ""is almost unheard of,"" Sznol said in a telephone interview.Among the 17 patients in the study who received the two drug doses that Bristol chose to test in its larger, later stage trials the two-year survival rate was 88 percent.Seventeen percent of patients in the study had a complete response, or no detectable cancer. Sznol expects that number to rise. Immunotherapy results often improve over time as the immune system learns to fight the disease.The results were consistent whether or not a patient's tumors expressed the PD-L1 protein, which helps camouflage them against the immune system. Patients who are deemed negative for PD-L1 tend to get little benefit from drugs like nivolumab alone, suggesting the addition of Yervoy may also help them.The incidence of serious side effects among the first 53 patients in the study was about 53 percent and rose to 62 percent with an additional group of 41 more patients. There was a 23 percent discontinuation rate due to side effects and one drug-related death, researchers reported.""These toxicities really are manageable in the clinic,"" Sznol said. ""If you're getting 79 percent overall survival at two years, the side effects are clearly worth it.""   (Reporting by Bill Berkrot; Editing by Michele Gershberg and Eric Walsh)",2014-06-02,BMY,"Mon Jun 2, 2014 | 7:30am EDT","Bristol's Yervoy, alone or in combo, improves melanoma results-studies",http://www.reuters.com//article/health-cancer-melanoma-bristolmyers-idUSL1N0OF27E20140602?type=companyNews
32,"   By Bill Berkrot | NEW YORK  NEW YORK In the race to find a faster cure for hepatitis C, Bristol-Myers Squibb Co said it will test its experimental antiviral drug combination with Gilead Sciences Inc's blockbuster drug Sovaldi, hoping to cut treatment time to four weeks.Bristol-Myers disclosed plans for the exploratory 30-patient trial testing its three-drug combination with Sovaldi in an interview with Reuters. Eric Hughes, the leader of Bristol's global hepatitis program, said the details were due to be posted on the clinicaltrials.gov website next week. Sovaldi's $84,000 price tag for a 12-week treatment has spurred outrage among insurers, state health officials and lawmakers who fear the cost of treating millions of Americans with the progressive liver disease will top $250 billion. Insurers are pushing Gilead's rivals to offer lower prices when their hepatitis C medicines reach the market. Using the drug for a shorter course of treatment could, in theory, lower the cost, even when combined with Bristol's therapies. Rivals Merck & Co and AbbVie are also racing to develop next-generation hepatitis C treatments that cure most people of the virus in a shorter time frame.But drug pricing experts expect Gilead and its rivals may still argue that the quicker cure represents a value to patients, buffering any steep price reductions.""The position and concept of pharma is not ingredient costs or duration of treatment cost. Pharma is looking at it as cost per cure,"" said John Whang, co-president of Reimbursement Intelligence, which works with pharmaceutical companies and payers to help determine prices for medicines.The cost could come down, he said, ""but it's not going to be proportionate to the degree that the duration of treatment shortens."" The new generation of oral drugs being developed by several companies has raised hepatitis C cure rates to well above 90 percent from about 75 percent without the need for interferon or ribavirin, which caused miserable side effects that led many patients to delay or drop treatment. The drugs in clinical trials have already cut treatment time to 12 weeks from 24 to 48 weeks.  ""We got rid of the tolerability problem. We got rid of the efficacy problem. Now there is a tremendous drive to get down to shorter treatment durations,"" Bristol-Myers' Hughes said in a telephone interview.REVIVING A SOVALDI COMBO  Bristol's plan essentially revives an effort to test its drugs in combination with Sovaldi. It previously tested a single compound with Sovaldi, achieving cure rates close to 100 percent in 12 weeks. But Gilead scrapped further testing in 2012, as it  preferred to develop its own combination without a partner. Gilead's pill that combines Sovaldi with its ledipasvir is expected to gain U.S. approval this year for therapies of eight or 12 weeks, depending on the patient. The company is also testing the combination as a six-week treatment.The go-it-alone strategy has already paid off as Gilead was first to market with Sovaldi, breaking pharmaceutical industry sales records with $2.3 billion in sales within a few months. The new study, set to begin in late July, will test a trio of Bristol drugs with Sovaldi in previously untreated patients with the most common Genotype 1 form of the virus. It will involve two groups of 15 patients each - one getting four weeks of treatment and the other six. If Bristol can demonstrate cure rates in excess of 90 percent in four weeks, it plans to conduct larger trials with a more diverse patient population. ""We'll see what the data says,"" Hughes said. ""Taking this forward will be a very exciting thing.""       With Gilead not involved in the effort, Bristol will pay full price for Sovaldi to conduct the trial.Bristol would not discuss potential pricing of its regimen, since its drugs are not approved. But if treatment can be cut to four weeks from 12, the Sovaldi portion would be closer to $28,000. Other rivals are also advancing efforts to compete in what is expected to be a huge market.Merck this month agreed to pay $3.85 billion to acquire Idenix Pharmaceuticals Inc with the hope that combining the two companies' most promising drugs will produce cures in four to six weeks across the full spectrum of genotypes.U.S. and European health regulators in the last week said they would accelerate their reviews of AbbVie's four-drug regimen, meaning it could be vying for market share by early next year. (Reporting by Bill Berkrot; Editing by Michele Gershberg and Douglas Royalty)",2014-06-20,BMY,"Fri Jun 20, 2014 | 9:07am EDT",A 4-week hep C cure? Bristol to test drugs with Gilead's Sovaldi,http://www.reuters.com//article/us-health-hepatitis-bristol-idUSKBN0EV0BL20140620?type=companyNews
33,"   By Bill Berkrot | NEW YORK  NEW YORK In the race to find a faster cure for hepatitis C, Bristol-Myers Squibb Co said it will test its experimental antiviral drug combination with Gilead Sciences Inc's blockbuster drug Sovaldi, hoping to cut treatment time to four weeks.Bristol-Myers disclosed plans for the exploratory 30-patient trial testing its three-drug combination with Sovaldi in an interview with Reuters. Eric Hughes, the leader of Bristol's global hepatitis program, said the details were due to be posted on the clinicaltrials.gov website next week. Sovaldi's $84,000 price tag for a 12-week treatment has spurred outrage among insurers, state health officials and lawmakers who fear the cost of treating millions of Americans with the progressive liver disease will top $250 billion. Insurers are pushing Gilead's rivals to offer lower prices when their hepatitis C medicines reach the market. Using the drug for a shorter course of treatment could, in theory, lower the cost, even when combined with Bristol's therapies. Rivals Merck & Co and AbbVie are also racing to develop next-generation hepatitis C treatments that cure most people of the virus in a shorter time frame.But drug pricing experts expect Gilead and its rivals may still argue that the quicker cure represents a value to patients, buffering any steep price reductions.""The position and concept of pharma is not ingredient costs or duration of treatment cost. Pharma is looking at it as cost per cure,"" said John Whang, co-president of Reimbursement Intelligence, which works with pharmaceutical companies and payers to help determine prices for medicines.The cost could come down, he said, ""but it's not going to be proportionate to the degree that the duration of treatment shortens."" The new generation of oral drugs being developed by several companies has raised hepatitis C cure rates to well above 90 percent from about 75 percent without the need for interferon or ribavirin, which caused miserable side effects that led many patients to delay or drop treatment. The drugs in clinical trials have already cut treatment time to 12 weeks from 24 to 48 weeks.  ""We got rid of the tolerability problem. We got rid of the efficacy problem. Now there is a tremendous drive to get down to shorter treatment durations,"" Bristol-Myers' Hughes said in a telephone interview.REVIVING A SOVALDI COMBO  Bristol's plan essentially revives an effort to test its drugs in combination with Sovaldi. It previously tested a single compound with Sovaldi, achieving cure rates close to 100 percent in 12 weeks. But Gilead scrapped further testing in 2012, as it  preferred to develop its own combination without a partner. Gilead's pill that combines Sovaldi with its ledipasvir is expected to gain U.S. approval this year for therapies of eight or 12 weeks, depending on the patient. The company is also testing the combination as a six-week treatment.The go-it-alone strategy has already paid off as Gilead was first to market with Sovaldi, breaking pharmaceutical industry sales records with $2.3 billion in sales within a few months. The new study, set to begin in late July, will test a trio of Bristol drugs with Sovaldi in previously untreated patients with the most common Genotype 1 form of the virus. It will involve two groups of 15 patients each - one getting four weeks of treatment and the other six. If Bristol can demonstrate cure rates in excess of 90 percent in four weeks, it plans to conduct larger trials with a more diverse patient population. ""We'll see what the data says,"" Hughes said. ""Taking this forward will be a very exciting thing.""       With Gilead not involved in the effort, Bristol will pay full price for Sovaldi to conduct the trial.Bristol would not discuss potential pricing of its regimen, since its drugs are not approved. But if treatment can be cut to four weeks from 12, the Sovaldi portion would be closer to $28,000. Other rivals are also advancing efforts to compete in what is expected to be a huge market.Merck this month agreed to pay $3.85 billion to acquire Idenix Pharmaceuticals Inc with the hope that combining the two companies' most promising drugs will produce cures in four to six weeks across the full spectrum of genotypes.U.S. and European health regulators in the last week said they would accelerate their reviews of AbbVie's four-drug regimen, meaning it could be vying for market share by early next year. (Reporting by Bill Berkrot; Editing by Michele Gershberg and Douglas Royalty)",2014-06-20,BMY,"Fri Jun 20, 2014 | 7:06am EDT",Exclusive: A 4-week hep C cure? Bristol to test drugs with Gilead's Sovaldi,http://www.reuters.com//article/us-health-hepatitis-bristol-idUSKBN0EV11V20140620?type=companyNews
34,"  (Add share price move, background)June 24 A late-stage trial testing Bristol-Myers Squibb Co's  cancer immunotherapy nivolumab in advanced melanoma patients was halted early after it was determined that the drug was likely to prolong survival, the company said on Tuesday.Bristol-Myers shares rose nearly 3 percent after the company announced the survival benefit finding.The 418-patient Phase III study, called CheckMate -066, was testing nivolumab as an initial, or first line, therapy for patients with advanced melanoma, the deadliest form of skin cancer.An interim analysis performed by an independent data-monitoring committee found evidence of superior overall survival in patients receiving nivolumab compared with those who received the chemotherapy dacarbazine, Bristol said. The committee stopped the study early to allow the dacarbazine patients to switch to the Bristol drug. Nivolumab belongs to a new class of medicines called PD-1 inhibitors that have generated great excitement for their ability to help the immune system recognize and attack cancer.Analysts have forecast multibillion-dollar sales for the drugs being developed by several companies once they gain regulatory approval. Merck & Co Inc, AstraZeneca Plc and Roche Holding AG have similar drugs in development that have shown great promise in treating melanoma and are also being tested against lung, kidney, bladder and other cancers.""The outcome of CheckMate -066 ... represents the first well-controlled, randomized Phase III trial of an investigational PD-1 checkpoint inhibitor to demonstrate an overall survival benefit,"" Michael Giordano, Bristol's head of oncology development, said in a statement. Independent monitors routinely analyze data from blinded trials at various points and can stop a study if a safety problem arises or if the study drug is seen as likely to prove clearly superior to the control medicine.The duration of the survival benefit was not yet available. Bristol said it plans to complete a full evaluation of the trial data and work with researchers on a future presentation of the results.Bristol-Myers shares rose to $49.58 in after-hours trading, a 2.7 percent increase over their New York Stock Exchange close at $48.30.    (Reporting by Bill Berkrot; Editing by Steve Orlofsky and Lisa Shumaker)",2014-06-24,BMY,"Tue Jun 24, 2014 | 5:55pm EDT",UPDATE 1-Bristol immunotherapy prolongs survival in melanoma trial,http://www.reuters.com//article/bristolmyers-melanoma-idUSL2N0P51VV20140624?type=companyNews
35,"  A late stage trial testing Bristol-Myers Squibb Co's  cancer immunotherapy nivolumab in advanced melanoma patients was halted early after it was determined that the drug was likely to prolong survival, the company said on Tuesday.The 418-patient Phase III study, called CheckMate -066, was testing nivolumab as an initial, or first line, therapy for patients with advanced melanoma, the deadliest form of skin cancer.An interim analysis performed by an independent data monitoring committee found evidence of superior overall survival in patients receiving nivolumab compared with those who received the chemotherapy dacarbazine, Bristol said. The committee stopped the study early to allow the dacarbazine patients to switch to the Bristol drug.Nivolumab belongs to a new class of medicines called PD-1 inhibitors that have generated great excitement for their ability to help the immune system recognize and attack cancer. Analysts have forecast multibillion-dollar sales for the drugs being developed by several companies once they gain regulatory approval. ""The outcome of CheckMate -066 ... represents the first well-controlled, randomized Phase III trial of an investigational PD-1 checkpoint inhibitor to demonstrate an overall survival benefit,"" Michael Giordano, Bristol's head of oncology development, said in a statement.Independent monitors routinely analyze data from blinded trials at various points and can stop a study if a safety problem arises or if the study drug is seen as likely to prove clearly superior to the control medicine.  (Reporting by Bill Berkrot; Editing by Steve Orlofsky)",2014-06-24,BMY,"Tue Jun 24, 2014 | 5:42pm EDT",Bristol immunotherapy prolongs survival in melanoma trial,http://www.reuters.com//article/us-bristolmyers-melanoma-idUSKBN0EZ2RO20140624?type=companyNews
36,"  June 24 A late stage trial testing Bristol-Myers Squibb Co's  cancer immunotherapy nivolumab in advanced melanoma patients was halted early after it was determined that the drug was likely to prolong survival, the company said on Tuesday.The 418-patient Phase III study, called CheckMate -066, was testing nivolumab as an initial, or first line, therapy for patients with advanced melanoma, the deadliest form of skin cancer.An interim analysis performed by an independent data monitoring committee found evidence of superior overall survival in patients receiving nivolumab compared with those who received the chemotherapy dacarbazine, Bristol said. The committee stopped the study early to allow the dacarbazine patients to switch to the Bristol drug. Nivolumab belongs to a new class of medicines called PD-1 inhibitors that have generated great excitement for their ability to help the immune system recognize and attack cancer. Analysts have forecast multibillion-dollar sales for the drugs being developed by several companies once they gain regulatory approval. ""The outcome of CheckMate -066 ... represents the first well-controlled, randomized Phase III trial of an investigational PD-1 checkpoint inhibitor to demonstrate an overall survival benefit,"" Michael Giordano, Bristol's head of oncology development, said in a statement.Independent monitors routinely analyze data from blinded trials at various points and can stop a study if a safety problem arises or if the study drug is seen as likely to prove clearly superior to the control medicine.   (Reporting by Bill Berkrot; Editing by Steve Orlofsky)",2014-06-24,BMY,"Tue Jun 24, 2014 | 5:27pm EDT",Bristol immunotherapy prolongs survival in melanoma trial,http://www.reuters.com//article/bristolmyers-melanoma-idUSL2N0P51TZ20140624?type=companyNews
37,"  * Final read on first-quarter GDP on tap, contraction expected* Investors watching Iraq tension, crude oil rises early* Bristol immunotherapy prolongs survival in melanoma trial* Futures up: Dow 9 pts, S&P 500 2 pts, Nasdaq 0.5 ptBy Ryan VlastelicaNEW YORK, June 25 U.S. stock index futures were flat on Wednesday, following a sharp decline in the previous session, as investors looked ahead to a read on GDP expected to show the economy shrank in the first quarter. * The final read on first-quarter gross domestic product is due at 8:30 a.m. (1230 GMT) and is seen showing a contraction of 1.7 percent, wider than the previous read of minus 1 percent.* A negative read, which largely reflects the impact of harsh winter weather throughout the early months of the year, is likely priced into markets, but other economic indicators could drive trading. Durable goods orders, also due at 8:30 a.m., are seen as flat in May, while a June read on service sector business activity from financial data firm Markit is seen as essentially unchanged from May.* The S&P 500 hit an intraday record in early trading on Tuesday, boosted by some positive economic data, but enthusiasm waned in the final hours of trading as concerns over Iraq returned to the forefront. The Dow posted its biggest daily decline in over a month. * S&P 500 e-mini futures rose 2 points and were above fair value, a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract. Dow Jones industrial average e-mini futures  rose 9 points and Nasdaq 100 e-mini futures rose 0.5 point.* Geopolitical tensions will remain in view. In a mounting Sunni insurgency, militants in Iraq attacked one of the country's largest air bases. Separately, the first U.S. teams arrived to assess Iraqi security forces and decide how to help counter the violence. * Investors are concerned about the impact prolonged turmoil in Iraq could have on oil prices, which are already up 3.8 percent this month. U.S. crude futures rose 0.6 percent to $106.64 per barrel in early trading. Many analysts have speculated that prices above $115 per barrel for an extended period will weigh on economic activity.* The CBOE Volatility index spiked more than 10 percent on Tuesday, coinciding with the market's pivot lower, the biggest one-day pop for the ""fear index"" since April. Still, at 12.13 the VIX remains at very low levels from an historical basis.* Bristol-Myers Squibb Co late Tuesday said a late-stage trial testing its immunotherapy nivolumab in advanced melanoma patients was halted early after it was determined that the drug was likely to prolong survival.* The U.S. Air Force late Tuesday said it had awarded Lockheed Martin Corp a fixed-price contract valued at $1.9 billion to complete work on two missile-warning satellites as part of the Space-Based Infrared System.* Golar LNG Ltd was one of the Nasdaq's most active premarket movers, falling 3 percent to $53.65 a day after it priced an offering of 11 million shares at a discount to its Tuesday close.    (Editing by Chizu Nomiyama)",2014-06-25,BMY,"Wed Jun 25, 2014 | 7:39am EDT","US STOCKS-Futures flat after decline, GDP data awaited",http://www.reuters.com//article/markets-usa-stocks-idUSL2N0P60AV20140625?type=companyNews
38,"  LONDON Pfizer and Bristol-Myers Squibb's oral anticoagulant Eliquis has been recommended for wider use in Europe, boosting prospects for an important drug to both U.S. companies.European Medicines Agency (EMA) experts recommended that Eliquis, also known as apixaban, should be approved for treating deep vein thrombosis and pulmonary embolism, as well as for preventing recurrent cases, the drugmakers said on Friday.The two conditions occur when a clot blocks the flow of blood in a deep vein - usually in the lower leg, thigh or pelvis - or in blood vessels in the lungs. Eliquis is already approved for reducing the risk of stroke in patients with atrial fibrillation, a form of irregular heartbeat common among the elderly.The new approval will help Eliquis to compete with Xarelto, a similar drug from Bayer and Johnson & Johnson, as well as other rivals in the nascent field. Industry analysts believe the new generation of blood thinners could eventually generate sales of more than $10 billion a year. Recommendations for marketing approval by the EMA's Committee for Medicinal Products for Human Use, or CHMP, are normally endorsed by the European Commission within a couple of months.  (Reporting by Ben Hirschler; editing by Kate Kelland)",2014-06-27,BMY,"Fri Jun 27, 2014 | 7:26am EDT","Pfizer, Bristol clot drug wins EU green light for wider use",http://www.reuters.com//article/us-europe-medicine-pfizer-bristol-myers-idUSKBN0F212720140627?type=companyNews
39,"  LONDON, June 27 Pfizer and Bristol-Myers Squibb's oral anticoagulant Eliquis has been recommended for wider use in Europe, boosting prospects for an important drug to both U.S. companies.European Medicines Agency (EMA) experts recommended that Eliquis, also known as apixaban, should be approved for treating deep vein thrombosis and pulmonary embolism, as well as for preventing recurrent cases, the drugmakers said on Friday.The two conditions occur when a clot blocks the flow of blood in a deep vein - usually in the lower leg, thigh or pelvis - or in blood vessels in the lungs. Eliquis is already approved for reducing the risk of stroke in patients with atrial fibrillation, a form of irregular heartbeat common among the elderly. The new approval will help Eliquis to compete with Xarelto, a similar drug from Bayer and Johnson & Johnson , as well as other rivals in the nascent field. Industry analysts believe the new generation of blood thinners could eventually generate sales of more than $10 billion a year. Recommendations for marketing approval by the EMA's Committee for Medicinal Products for Human Use, or CHMP, are normally endorsed by the European Commission within a couple of months.   (Reporting by Ben Hirschler; editing by Kate Kelland)",2014-06-27,BMY,"Fri Jun 27, 2014 | 7:01am EDT","Pfizer, Bristol clot drug wins EU green light for wider use",http://www.reuters.com//article/europe-medicine-pfizer-bristol-myers-idUSL6N0P828W20140627?type=companyNews
40,"  July 1 Bristol-Myers Squibb Co said it was voluntarily recalling six lots of the injectable version of its blood thinner, Coumadin, in the United States, after particulate matter was found in some unreleased samples.The recall is a ""precautionary measure"" and no complaints or adverse events related to the drug have been reported so far, the company said in a statement published on the U.S. Food and Drug Administration website on Tuesday. (1.usa.gov/1qNGUdg)Coumadin tablets are not impacted by the recall, the company said. Bristol-Myers discontinued Coumadin injection in early April. The recall involves lots distributed between November 2011 and January 2014. The company said it initiated the recall after investigations found some contaminated 5 mg single-use vials of the injection. The New York-based company's shares were largely unchanged at $48.06 on the New York Stock Exchange on Tuesday.   (Reporting by Natalie Grover in Bangalore; Editing by Kirti Pandey)",2014-07-01,BMY,"Tue Jul 1, 2014 | 12:34pm EDT",Bristol-Myers recalls six lots of blood thinner injection,http://www.reuters.com//article/bristol-myers-recall-idUSL4N0PC3WU20140701?type=companyNews
41,"  July 7 Bristol-Myers Squibb and Co said its combination drug for the treatment of hepatitis C was approved in Japan. The treatment, which comprises Daklinza and Sunvepra drugs, is meant for patients who are intolerant or have failed to respond to standard medication.    (Reporting By Penumudi Amrutha in Bangalore; Editing by Don Sebastian)  ",2014-07-07,BMY,"Mon Jul 7, 2014 | 7:41am EDT",Bristol-Myers hepatitis C drug gets approval in Japan,http://www.reuters.com//article/bristol-myers-japan-idUSL4N0PI2ZN20140707?type=companyNews
42,"  July 10 Bristol-Myers Squibb Co said on Thursday it plans to seek U.S. marketing approval in the third quarter for its experimental cancer immunotherapy Opdivo as a treatment for advanced melanoma, which would be months sooner than Wall Street expected.The company said it would seek approval to market the drug to patients who had previously been treated with Bristol-Myers' already approved melanoma drug Yervoy, which works through a different mechanism than Opdivo.Mark Schoenebaum, an analyst with ISI Group, said many analysts had not expected Bristol-Myers to submit the marketing application until mid-2015, although he and some others had speculated an earlier filing was possible. The U.S. drugmaker in April, in a so-called rolling submission that will be completed by the year end, asked the U.S. Food and Drug Administration to approve Opdivo (nivolumab) to treat patients with another type of cancer, squamous cell lung cancer. Opdivo works by blocking a protein called PD-1, thereby enabling the immune system to recognize cancer cells and then attack them. It is considered one of Bristol-Myers' most important experimental drugs, with potential to generate multibillion-dollar annual sales, if approved. Bristol-Myers shares were little changed in premarket trading.   (Reporting by Ransdell Pierson; Editing by Meredith Mazzilli)",2014-07-10,BMY,"Thu Jul 10, 2014 | 9:22am EDT",Bristol to seek melanoma approval for Opdivo ahead of expectations,http://www.reuters.com//article/bristol-myers-opdivo-melanoma-idUSL2N0PL0S320140710?type=companyNews
43,"   By Ransdell Pierson  Bristol-Myers Squibb Co reported better-than-expected quarterly results, helped by cost controls and strong sales of its Eliquis blood clot preventer and Yervoy treatment for melanoma.Sales of Eliquis, which Bristol-Myers co-markets with Pfizer Inc, rose to $171 million. The pill, used to prevent strokes in patients with an irregular heartbeat called atrial fibrillation, has had disappointing sales since it was approved in late 2012, but has picked up steam in recent months.    Yervoy sales jumped 38 percent to $321 million. Company revenue slipped 4 percent to $3.90 billion, but topped Wall Street expectations of $3.85 billion. Revenue would have risen 7 percent if Bristol-Meyers had not earlier this year sold its global diabetes business to longtime partner AstraZeneca.    Bristol-Myers is counting on an array of experimental immuno-oncology drugs to succeed in clinical trials and propel sales growth in coming years. The company, along with Merck & Co and Roche Holding AG, is racing to develop such treatments, which train the immune system to recognize cancer cells and to attack them.Yervoy, one of the first immuno-oncology drugs, was approved in 2011 to treat patients with late-stage melanoma. But most excitement is centered around a drug called Opdivo (nivolumab), which Bristol-Myers is testing against melanoma, lung cancer and blood cancers. It is a so-called PD-1 inhibitor, considered the most promising new class of cancer treatments. In a conference call with investors on Thursday, Bristol-Myers executives said they expect data from those trials to begin rolling out this year and next year.""Overall, we continue to see Bristol-Myers' immuno-oncology portfolio as an $8 billion to $10 billion (annual sales) opportunity for the company"" that is not fully reflected in Bristol-Myers' share price, JP Morgan analyst Chris Schott said Thursday in a research note. The U.S. drugmaker said it earned $333 million, or 20 cents per share, in the second quarter. That compared with $536 million, or 32 cents per share, in the year-earlier period.Excluding special items, including $458 million in merger-related charges, Bristol-Myers earned 48 cents per share. Analysts on average expected 44 cents per share.  Bristol-Myers stuck to its prior full-year earnings view of $1.70 to $1.80 per share.Company shares were up 0.7 percent to $49.67 in afternoon trading on the New York Stock Exchange. (Reporting by Ransdell Pierson, Editing by Franklin Paul, Chizu Nomiyama and Diane Craft)",2014-07-24,BMY,"Thu Jul 24, 2014 | 2:28pm EDT","Bristol-Myers profit tops forecasts, helped by newer drugs",http://www.reuters.com//article/us-bristol-myers-results-idUSKBN0FT2G820140724?type=companyNews
44,"  (Adds analyst comment, shares, details on immuno-oncology drugs)By Ransdell PiersonJuly 24 Bristol-Myers Squibb Co reported better-than-expected quarterly results, helped by cost controls and strong sales of its Eliquis blood clot preventer and Yervoy treatment for melanoma.Sales of Eliquis, which Bristol-Myers co-markets with Pfizer Inc, rose to $171 million. The pill, used to prevent strokes in patients with an irregular heartbeat called atrial fibrillation, has had disappointing sales since it was approved in late 2012, but has picked up steam in recent months.Yervoy sales jumped 38 percent to $321 million.Company revenue slipped 4 percent to $3.90 billion, but topped Wall Street expectations of $3.85 billion. Revenue would have risen 7 percent if Bristol-Meyers had not earlier this year sold its global diabetes business to longtime partner AstraZeneca. Bristol-Myers is counting on an array of experimental immuno-oncology drugs to succeed in clinical trials and propel sales growth in coming years. The company, along with Merck & Co  and Roche Holding AG, is racing to develop such treatments, which train the immune system to recognize cancer cells and to attack them.Yervoy, one of the first immuno-oncology drugs, was approved in 2011 to treat patients with late-stage melanoma. But most excitement is centered around a drug called Opdivo (nivolumab), which Bristol-Myers is testing against melanoma, lung cancer and blood cancers. It is a so-called PD-1 inhibitor, considered the most promising new class of cancer treatments. In a conference call with investors on Thursday, Bristol-Myers executives said they expect data from those trials to begin rolling out this year and next year.""Overall, we continue to see Bristol-Myers' immuno-oncology portfolio as an $8 billion to $10 billion (annual sales) opportunity for the company"" that is not fully reflected in Bristol-Myers' share price, JP Morgan analyst Chris Schott said Thursday in a research note.The U.S. drugmaker said it earned $333 million, or 20 cents per share, in the second quarter. That compared with $536 million, or 32 cents per share, in the year-earlier period. Excluding special items, including $458 million in merger-related charges, Bristol-Myers earned 48 cents per share. Analysts on average expected 44 cents per share.Bristol-Myers stuck to its prior full-year earnings view of $1.70 to $1.80 per share.Company shares were up 0.7 percent to $49.67 in afternoon trading on the New York Stock Exchange.(Reporting by Ransdell Pierson, Editing by Franklin Paul, Chizu Nomiyama and Diane Craft)",2014-07-24,BMY,"Thu Jul 24, 2014 | 2:19pm EDT","UPDATE 2-Bristol-Myers profit tops forecasts, helped by newer drugs",http://www.reuters.com//article/bristol-myers-results-idUSL2N0PZ0OF20140724?type=companyNews
45,"  July 24 Bristol-Myers Squibb Co reported better-than-expected quarterly results, helped by cost controls and strong sales of its Eliquis blood clot preventer and Yervoy treatment for melanoma.The U.S. drugmaker on Thursday said it earned $333 million, or 20 cents per share, in the second quarter. That compared with $536 million, or 32 cents per share, in the year-earlier period.  Excluding special items, including $458 million in merger-related charges, Bristol-Myers earned 48 cents per share. Analysts, on average expected 44 cents per share.       (Reporting by Ransdell Pierson, Editing by Franklin Paul) ",2014-07-24,BMY,"Thu Jul 24, 2014 | 7:39am EDT","Bristol-Myers profit tops forecasts, helped by newer drugs",http://www.reuters.com//article/bristol-myers-results-idUSL2N0PY37K20140724?type=companyNews
46,"   By Olivia Oran, Soyoung Kim and Greg Roumeliotis | NEW YORK  NEW YORK Aug 18 ConvaTec's private equity owners plan to explore a sale of the medical device maker next year, even as interest from several healthcare companies in a potential $10 billion acquisition intensifies, according to people familiar with the matter.Amid a wave of mergers in the healthcare sector aimed at reducing corporate tax rates, Luxembourg-based ConvaTec has emerged as a target for U.S. companies looking to move their tax domiciles abroad in a practice known as inversion.Diversified U.S. manufacturer 3M Co and medical equipment makers CareFusion Corp and C.R. Bard Inc  are among the companies exploring a potential deal for ConvaTec, the people said.CareFusion, with a market capitalization of $9 billion, and C.R. Bard, with $11.2 billion, would both be able to achieve an inversion if they use their own stock to pay for ConvaTec. While ConvaTec would review any compelling offer that would come before 2015, the company for now wants to boost its value further before launching an auction or an initial public offering next year, the people said.Still, calls from some U.S. politicians to crack down on inversions could prompt a potential buyer to act sooner rather than later, for fear missing the window of opportunity, one of the people added. ConvaTec reported earnings before interest, tax, depreciation and amortization (EBITDA) of $502.5 million in 2013, up 15 percent year-on-year. It is hoping to exceed $600 million in EBITDA this year, the people said.The people asked not to be identified discussing private deliberations. ConvaTec, Avista Capital, Nordic Capital, 3M, CareFusion and C.R. Bard could not be reached for comment. ConvaTec makes wound care and ostomy care products at 11 manufacturing sites in eight countries, and sells them in more than 100 countries. It is scheduled to report its second-quarter earnings on Tuesday.Private equity firms Avista Capital Partners and Nordic Capital acquired ConvaTec from Bristol-Myers Squibb Co  in 2011 for $4.1 billion. 3M was one of the contenders for ConvaTec at the time, according to people familiar with the matter.Inversion deals so far this year include medical device maker Medtronic Inc's acquisition of peer Covidien Plc  for $42.9 billion, and drugmaker AbbVie Inc's  $54.7 billion merger with pharmaceutical company Shire Plc .   (Reporting by Olivia Oran, Soyoung Kim and Greg Roumeliotis in New York; Editing by Tom Brown)",2014-08-18,BMY,"Mon Aug 18, 2014 | 3:07pm EDT",ConvaTec owners eye 2015 sale as buyout interest builds-sources,http://www.reuters.com//article/convatec-sale-idUSL2N0QO0TQ20140818?type=companyNews
47,"  Bristol-Myers Squibb Co and Pfizer Inc on Thursday said U.S. regulators have approved an expanded use for their Eliquis blood clot preventer, to treat blood clots in the legs and lungs.The drugmakers said the U.S. Food and Drug Administration also approved use of the pill to reduce risk of recurrent blood clots in the deep veins of the leg, called deep vein thrombosis, and in the lung, called pulmonary embolism, following initial therapy.Leg clots, if untreated, can travel to the heart, lungs and brain, and cause heart attacks and stroke. Lung clots, which can choke off blood flow, are linked to high mortality rates and require immediate treatment. Eliquis, which works by blocking a protein called Factor Xa that is involved in the clotting process, is already approved to prevent strokes in patients who have an irregular heartbeat called atrial fibrillation. It is meant to be an alternative to warfarin, an older oral drug that can cause serious bleeding episodes and comes with strict dietary restrictions and the need for frequent blood checks.  In large clinical trials involving patients with leg and lung clots, Eliquis was shown to cause far fewer cases of major bleeding than standard treatment with blood clot preventer enoxaparin for five days, overlapped by treatment with warfarin. Eliquis was shown to be similarly effective as standard care.Bristol-Myers and Pfizer are hoping the new approved use for Eliquis will significantly boost demand for Eliquis, whose sales have been very disappointing since it was introduced in late 2012. It garnered $171 million in sales in the second quarter. That pales with blockbuster sales of a similar drug from Johnson & Johnson called Xarelto, and a different but new type of blood clot preventer called Pradaxa, sold by privately held German drugmaker Boehringer Ingelheim.  (Reporting by Ransdell Pierson; Editing by James Dalgleish and Steve Orlofsky)",2014-08-21,BMY,"Thu Aug 21, 2014 | 2:49pm EDT","FDA approves use of Eliquis to treat leg, lung clots",http://www.reuters.com//article/us-bristol-myers-pfizer-eliquis-idUSKBN0GL1V920140821?type=companyNews
48,"  (Adds details on Eliquis, rival blood clot drugs)Aug 21 Bristol-Myers Squibb Co and Pfizer Inc on Thursday said U.S. regulators have approved an expanded use for their Eliquis blood clot preventer, to treat blood clots in the legs and lungs.The drugmakers said the U.S. Food and Drug Administration also approved use of the pill to reduce risk of recurrent blood clots in the deep veins of the leg, called deep vein thrombosis, and in the lung, called pulmonary embolism, following initial therapy.Leg clots, if untreated, can travel to the heart, lungs and brain, and cause heart attacks and stroke. Lung clots, which can choke off blood flow, are linked to high mortality rates and require immediate treatment. Eliquis, which works by blocking a protein called Factor Xa that is involved in the clotting process, is already approved to prevent strokes in patients who have an irregular heartbeat called atrial fibrillation. It is meant to be an alternative to warfarin, an older oral drug that can cause serious bleeding episodes and comes with strict dietary restrictions and the need for frequent blood checks.In large clinical trials involving patients with leg and lung clots, Eliquis was shown to cause far fewer cases of major bleeding than standard treatment with blood clot preventer enoxaparin for five days, overlapped by treatment with warfarin. Eliquis was shown to be similarly effective as standard care. Bristol-Myers and Pfizer are hoping the new approved use for Eliquis will significantly boost demand for Eliquis, whose sales have been very disappointing since it was introduced in late 2012. It garnered $171 million in sales in the second quarter. That pales with blockbuster sales of a similar drug from Johnson & Johnson called Xarelto, and a different but new type of blood clot preventer called Pradaxa, sold by privately held German drugmaker Boehringer Ingelheim.(Reporting by Ransdell Pierson; Editing by James Dalgleish and Steve Orlofsky)",2014-08-21,BMY,"Thu Aug 21, 2014 | 2:44pm EDT","UPDATE 1-FDA approves use of Eliquis to treat leg, lung clots",http://www.reuters.com//article/bristol-myers-pfizer-eliquis-idUSL2N0QR1MW20140821?type=companyNews
49,"  Aug 21 Bristol-Myers Squibb Co and Pfizer Inc on Thursday said U.S. regulators have approved an expanded use for their Eliquis blood clot preventer, to treat dangerous blood clots in the legs and lungs.The drugmakers said the U.S. Food and Drug Administration had also approved use of the pill to reduce risk of recurrent blood clots in the deep veins of the leg, called deep vein thrombosis, and in the lung, called pulmonary embolism. The clots, if untreated, can travel to the heart and brain and cause heart attacks and stroke.  Eliquis, which works by blocking a protein called Factor Xa that is involved in the clotting process, is already approved to prevent strokes in patients who have an irregular heartbeat called atrial fibrillation. It is meant to be an alternative to warfarin, an older oral drug which comes with strict dietary restrictions and the need for frequent blood checks.    (Reporting by Ransdell Pierson; Editing by James Dalgleish) ",2014-08-21,BMY,"Thu Aug 21, 2014 | 1:56pm EDT","FDA OKs use of Eliquis to treat leg, lung clots",http://www.reuters.com//article/bristol-myers-pfizer-eliquis-idUSL2N0QR1ME20140821?type=companyNews
50,"  FRANKFURT Germany's Bayer unveiled plans to launch three new studies to expand the uses of its anti-clotting drug Xarelto, one of its top five new medicines.Xarelto, which competes with the Eliquis pill developed by Bristol-Myers Squibb and Pfizer in stroke prevention, reached sales of $1.7 billion in the 12 months to June. Analysts estimate annual sales could rise to more than $9.5 billion by 2020.The drug, jointly developed with U.S. firm Johnson & Johnson, is currently approved for uses including the prevention of strokes caused by atrial fibrillation, a type of arrhythmia.Bayer said on Friday that a Phase III trial involving about 7,000 patients would examine whether Xarelto can help prevent the recurrence of strokes in patients who have suffered strokes of undetermined cause.""We really have just as many strokes due to undetermined causes as to atrial fibrillation,"" Frank Misselwitz, head of the Therapeutic Area Cardiovascular and Coagulation at Bayer HealthCare, told Reuters. A second Phase III trial announced on Friday will examine the potential benefits of Xarelto in reducing thrombotic vascular complications in more than 5,000 patients with peripheral artery disease.The third new study is a Phase II trial designed to evaluate Xarelto for long-term prevention of acute coronary syndrome in patients who have suffered from the illness. If the study involving between 2,000 and 3,000 patients is successful, a Phase III study will follow, Bayer said.Misselwitz declined to say whether expanding the uses of Xarelto would prompt Bayer to raise its estimate of the drug's peak sales potential, which Chief Executive Marijn Dekkers has so far put at about 3.5 billion euros a year. ""But these are major illnesses,"" Misselwitz said with reference to the planned trials. Bayer shares were flat at 1441 GMT, against a 0.8 percent lower Dax index. Xarelto is also currently used to treat and prevent deep vein thrombosis and pulmonary embolisms and to reduce the risk of strokes and blood clots in patients with an irregular heart beat that is not caused by heart problems. (Reporting by Frank Siebelt; Writing by Maria Sheahan; Editing by Jonathan Gould and Pravin Char)",2014-08-29,BMY,"Fri Aug 29, 2014 | 11:32am EDT",Germany's Bayer to launch three new Xarelto trials,http://www.reuters.com//article/us-bayer-xarelto-idUSKBN0GT1UI20140829?type=companyNews
51,"  Bristol-Myers Squibb Co on Thursday filed a lawsuit against Merck & Co Inc for allegedly infringing its immunotherapy patent. The company is seeking unspecified damages.Immunotherapy is a mechanism that uses the body's own immune system to eliminate cancer cells.In its lawsuit filed in the U.S. District Court of Delaware, Bristol-Myers said Merck was planning to exploit its invention with a later-developed treatment, pembrolizumab, violating the company's May 20 patent. U.S. regulators on Thursday approved the use pembrolizumab, as a treatment for patients with advanced melanoma who are no longer responding to other therapies.Bristol-Myers is using its patented technology to develop its own drug, nivolumab, which is being tested in different areas of cancer including melanoma. The company also plans to file an application with the U.S. Food and Drug Administration by the end of this month for use of the drug, which is approved in Japan, for patients with advanced melanoma.Other pharmaceutical companies including Roche Holding AG and Novartis AG are also in the process of developing similar drugs.According to the American Cancer Society, about 76,100 new melanomas will be diagnosed this year. The disease is the most dangerous kind of skin cancer and can originate in any part of the body that contains pigment-containing cells. Both Bristol-Myers and Merck could not be reached for a comment outside regular working hours.The case is Bristol-Myers Squibb Co and Ono Pharmaceutical co ltd v. Merck & Co Inc, U.S. District Court, for the district of Delaware, Wilmington No. 14-CV-01131  (Reporting by Amrutha Penumudi in Bangalore; Editing by Lisa Shumaker)",2014-09-06,BMY,"Fri Sep 5, 2014 | 9:46pm EDT",Bristol-Myers sues Merck over U.S. immunotherapy patent,http://www.reuters.com//article/us-bristol-myers-merck-co-lawsuit-idUSKBN0H102X20140906?type=companyNews
52,"  Sept 5 Bristol-Myers Squibb Co on Thursday filed a lawsuit against Merck & Co Inc for allegedly infringing its immunotherapy patent. The company is seeking unspecified damages.Immunotherapy is a mechanism that uses the body's own immune system to eliminate cancer cells.In its lawsuit filed in the U.S. District Court of Delaware, Bristol-Myers said Merck was planning to exploit its invention with a later-developed treatment, pembrolizumab, violating the company's May 20 patent.U.S. regulators on Thursday approved the use pembrolizumab, as a treatment for patients with advanced melanoma who are no longer responding to other therapies.Bristol-Myers is using its patented technology to develop its own drug, nivolumab, which is being tested in different areas of cancer including melanoma. The company also plans to file an application with the U.S. Food and Drug Administration by the end of this month for use of the drug, which is approved in Japan, for patients with advanced melanoma.Other pharmaceutical companies including Roche Holding AG  and Novartis AG are also in the process of developing similar drugs. According to the American Cancer Society, about 76,100 new melanomas will be diagnosed this year. The disease is the most dangerous kind of skin cancer and can originate in any part of the body that contains pigment-containing cells.Both Bristol-Myers and Merck could not be reached for a comment outside regular working hours. The case is Bristol-Myers Squibb Co and Ono Pharmaceutical co ltd v. Merck & Co Inc, U.S. District Court, for the district of Delaware, Wilmington No. 14-CV-01131(Reporting by Amrutha Penumudi in Bangalore; Editing by Lisa Shumaker)",2014-09-06,BMY,"Fri Sep 5, 2014 | 9:25pm EDT",Bristol-Myers sues Merck over U.S. immunotherapy patent,http://www.reuters.com//article/bristol-myers-merck-co-lawsuit-idUSL1N0R703L20140906?type=companyNews
53,"  The U.S. Food and Drug Administration has granted a six-month, priority review to Bristol-Myers Squibb Co's application for immuno-oncology drug Opdivo as a treatment for previously treated melanoma, the company said on Friday.The FDA decision is due by March 30, 2015.Bristol said European regulators have also agreed to an accelerated review of the drug as a treatment for advanced melanoma.Opdivo, or nivolumab, is part of a promising new class of drugs designed to help the body's own immune system fend off cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target known as PD-L1, used by tumors to evade disease-fighting cells. Merck & Co Inc's Keytruda, or pembrolizumab, became the first PD-1 drug available in the United States, when the FDA earlier this month approved its use for patients with advanced melanoma who are no longer responding to other therapies.Companies including Roche Holding AG and AstraZeneca Plc are also developing PD-1 pathway drugs for a variety of cancers, including lung cancer. Some analysts expect the new class could generate more than $30 billion in annual sales worldwide by 2025. Bristol said Opdivo was also designated by the FDA as a ""breakthrough"" melanoma therapy. The agency earlier this year designated the drug as a breakthrough therapy for patients with Hodgkin lymphoma who had failed other treatments. In April, Bristol initiated a ""rolling"" submission with the FDA for Opdivo use in certain patients with a type of non-small cell lung cancer. The company said it expects to complete that application by the end of the year. (Reporting By Deena Beasley. Editing by Andre Grenon)",2014-09-26,BMY,"Fri Sep 26, 2014 | 5:17pm EDT",Bristol immunotherapy gets six month U.S. FDA review for melanoma,http://www.reuters.com//article/us-bristol-myers-fda-idUSKCN0HL2EH20140926?type=companyNews
54,"  Sept 26 The U.S. Food and Drug Administration has granted a six-month, priority review to Bristol-Myers Squibb Co's application for immuno-oncology drug Opdivo as a treatment for previously treated melanoma, the company said on Friday.The FDA decision is due by March 30, 2015.Bristol said European regulators have also agreed to an accelerated review of the drug as a treatment for advanced melanoma. Opdivo, or nivolumab, is part of a promising new class of drugs designed to help the body's own immune system fend off cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target known as PD-L1, used by tumors to evade disease-fighting cells.Merck & Co Inc's Keytruda, or pembrolizumab, became the first PD-1 drug available in the United States, when the FDA earlier this month approved its use for patients with advanced melanoma who are no longer responding to other therapies. Companies including Roche Holding AG and AstraZeneca Plc are also developing PD-1 pathway drugs for a variety of cancers, including lung cancer. Some analysts expect the new class could generate more than $30 billion in annual sales worldwide by 2025. Bristol said Opdivo was also designated by the FDA as a ""breakthrough"" melanoma therapy. The agency earlier this year designated the drug as a breakthrough therapy for patients with Hodgkin lymphoma who had failed other treatments.In April, Bristol initiated a ""rolling"" submission with the FDA for Opdivo use in certain patients with a type of non-small cell lung cancer. The company said it expects to complete that application by the end of the year.   (Reporting By Deena Beasley. Editing by Andre Grenon)",2014-09-26,BMY,"Fri Sep 26, 2014 | 5:08pm EDT",Bristol immunotherapy gets 6-month U.S. FDA review for melanoma,http://www.reuters.com//article/bristol-myers-fda-idUSL2N0RR2EI20140926?type=companyNews
55,"   By Ben Hirschler | MADRID  MADRID Bristol-Myers Squibb's immunotherapy drug Opdivo produced markedly improved response rates with fewer toxic side effects compared to chemotherapy in a major melanoma study, underscoring its potential as a new treatment option.The data has been keenly awaited since this is the first presentation of results from a pivotal Phase III clinical trial of a promising new class of drugs designed to help the body's own immune system fight cancer.In the study, involving people with advanced melanoma, 32 percent of patients saw their tumors shrink when given Opdivo against 11 percent of those treated with conventional chemotherapy drugs.Importantly, the duration of response was also much longer. Patients on chemotherapy typically responded for 3.6 months, whereas 95 percent of those who responded to Opdivo were still benefiting after six months and the median duration of response was not reached.Patients in the study had previously been treated with the company's Yervoy immunotherapy, which works in a different way to take natural brakes off the immune system. I was very nicely surprised,"" said Jeffrey Weber of the Moffitt Cancer Center in Florida, who presented the results at the European Society of Medical Oncology annual congress on Monday.A 32 percent response rate with the majority staying in remission past six months is probably going to turn into a very impressive level of survival, he said. ""I hope this is the death knell for chemotherapy in melanoma.""Opdivo, or nivolumab, is part of a promising new class of drugs designed to block a protein known as Programmed Death receptor (PD-1), or a related target known as PD-L1, used by tumors to evade the immune system's disease-fighting cells. Industry analysts are waiting next to see how Opdivo performs in another Phase III trial in lung cancer, for which they expect results in the fourth quarter of 2014. Since non-small lung cancer is a much bigger market than melanoma, that trial is viewed as critical to the drug's commercial outlook.Some investors are nervous about Opdivo's lung cancer prospects but Weber, for one, is upbeat. It is highly likely that the lung data will be positive, he told Reuters.  Opdivo became the first PD-1 inhibitor to receive regulatory approval anywhere in the world in July when Japanese regulators gave it a green light, although it has been beaten to market in the United States by Merck & Co's rival Keytruda, which was approved earlier this month.On Friday, Bristol-Myers said the U.S. Food and Drug Administration had granted Opdivo a priority review and a decision on approval was due by the end of March.Companies such as Roche and AstraZeneca are also developing PD-1 pathway drugs for a variety of cancers, including lung cancer. Some analysts expect the new class could generate more than $30 billion in annual sales worldwide by 2025.  (Editing by Michael Urquhart, editing by Louise Heavens)",2014-09-29,BMY,"Mon Sep 29, 2014 | 5:25am EDT",Bristol immune drug shows strong effect in melanoma study,http://www.reuters.com//article/us-health-cancer-bristol-myers-idUSKCN0HO0HM20140929?type=companyNews
56,"  * 32 percent response rate in patients treated with Opdivo* 95 percent of responders still benefiting after 6 months* Lung cancer results with Opdivo expected later in year   (Adds detail on forthcoming lung cancer study findings)By Ben HirschlerMADRID, Sept 29 Bristol-Myers Squibb's  immunotherapy drug Opdivo produced markedly improved response rates with fewer toxic side effects compared to chemotherapy in a major melanoma study, underscoring its potential as a new treatment option.The data has been keenly awaited since this is the first presentation of results from a pivotal Phase III clinical trial of a promising new class of drugs designed to help the body's own immune system fight cancer. In the study, involving people with advanced melanoma, 32 percent of patients saw their tumours shrink when given Opdivo against 11 percent of those treated with conventional chemotherapy drugs.Importantly, the duration of response was also much longer. Patients on chemotherapy typically responded for 3.6 months, whereas 95 percent of those who responded to Opdivo were still benefiting after six months and the median duration of response was not reached.Patients in the study had previously been treated with the company's Yervoy immunotherapy, which works in a different way to take natural brakes off the immune system. ""I was very nicely surprised,"" said Jeffrey Weber of the Moffitt Cancer Center in Florida, who presented the results at the European Society of Medical Oncology annual congress on Monday.""A 32 percent response rate with the majority staying in remission past six months is probably going to turn into a very impressive level of survival,"" he said. ""I hope this is the death knell for chemotherapy in melanoma.""Opdivo, or nivolumab, is part of a promising new class of drugs designed to block a protein known as Programmed Death receptor (PD-1), or a related target known as PD-L1, used by tumours to evade the immune system's disease-fighting cells. Industry analysts are waiting next to see how Opdivo performs in another Phase III trial in lung cancer, for which they expect results in the fourth quarter of 2014. Since non-small lung cancer is a much bigger market than melanoma, that trial is viewed as critical to the drug's commercial outlook.Some investors are nervous about Opdivo's lung cancer prospects but Weber, for one, is upbeat. ""It is highly likely that the lung data will be positive,"" he told Reuters.Opdivo became the first PD-1 inhibitor to receive regulatory approval anywhere in the world in July when Japanese regulators gave it a green light, although it has been beaten to market in the United States by Merck & Co's rival Keytruda, which was approved earlier this month.On Friday, Bristol-Myers said the U.S. Food and Drug Administration had granted Opdivo a priority review and a decision on approval was due by the end of March.Companies such as Roche and AstraZeneca are also developing PD-1 pathway drugs for a variety of cancers, including lung cancer. Some analysts expect the new class could generate more than $30 billion in annual sales worldwide by 2025.    (Editing by Michael Urquhart, editing by Louise Heavens)",2014-09-29,BMY,"Mon Sep 29, 2014 | 4:47am EDT",UPDATE 1-Bristol immune drug shows strong effect in melanoma study,http://www.reuters.com//article/health-cancer-bristol-myers-idUSL6N0RU16F20140929?type=companyNews
57,"   By Ben Hirschler | MADRID, Sept 29  MADRID, Sept 29 Bristol-Myers Squibb's  immunotherapy drug Opdivo produced markedly improved response rates with fewer toxic side effects compared to chemotherapy in a major melanoma study, underscoring its potential as a new treatment option.The data has been keenly awaited since this is the first presentation of results from a pivotal Phase III clinical trial of a promising new class of drugs designed to help the body's own immune system fight cancer.In the study, involving people with advanced melanoma, 32 percent of patients saw their tumours shrink when given Opdivo against 11 percent of those treated with conventional chemotherapy drugs. Importantly, the duration of response was also much longer. Patients on chemotherapy typically responded for 3.6 months, whereas 95 percent of those who responded to Opdivo were still benefiting after six months and the median duration of response was not reached.""I was very nicely surprised,"" said Jeffrey Weber of the Moffitt Cancer Center in Florida, who presented the results at the European Society of Medical Oncology annual congress on Monday. ""A 32 percent response rate with the majority staying in remission past six months is probably going to turn into a very impressive level of survival,"" he added.Opdivo, or nivolumab, is part of a promising new class of drugs designed to block a protein known as Programmed Death receptor (PD-1), or a related target known as PD-L1, used by tumours to evade the immune system's disease-fighting cells. The drug became the first PD-1 inhibitor to receive regulatory approval anywhere in the world in July when Japanese regulators gave it a green light, although it has been beaten to market in the United States by Merck & Co's rival Keytruda, which was approved earlier this month.On Friday, Bristol-Myers said the U.S. Food and Drug Administration had granted Opdivo a priority review and a decision on approval was due by the end of March.Companies such as Roche and AstraZeneca are also developing PD-1 pathway drugs for a variety of cancers, including lung cancer. Some analysts expect the new class could generate more than $30 billion in annual sales worldwide by 2025.         (Editing by Michael Urquhart)",2014-09-29,BMY,"Mon Sep 29, 2014 | 3:00am EDT",Bristol immune drug shows strong effect in melanoma study,http://www.reuters.com//article/health-cancer-bristol-myers-idUSL6N0RT0SA20140929?type=companyNews
58,"  (Adds details)ZURICH Oct 6 Swiss pharma group Novartis AG  said on Monday it would work with Bristol-Myers Squibb Co to test the U.S. drugmaker's immuno-oncology drug Opdivo in combination with three of its own experimental lung cancer drugs.The clinical collaboration will help Novartis advance its efforts in the field of immunotherapy, one of the hottest areas in biotech right now, following the acquisition of CoStim Pharmaceuticals Inc this year, the drugmaker said.Novartis currently lags rivals such as Roche, Merck , AstraZeneca and Bristol-Myers in the race to develop immunotherapies - drugs that fight cancer by harnessing the body's immune system. The two companies will test the combination of three molecularly targeted compounds with Bristol-Myers' investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab) in phase I and II studies, Novartis said, adding it would conduct both studies.""Preclinical data suggests that combining molecularly targeted agents with immunotherapies such as nivolumab may have synergistic effects and lead to better outcomes for patients,"" Alessandro Riva, global head of Novartis oncology development and medical affairs, said in the statement. Opdivo is part of a closely watched class of drugs known as anti-PD-1 therapies, which block a tumour's ability to camouflage itself from attack by the immune system's cells.The drug is approved in Japan for the treatment of unresectable melanoma and is under review by the U.S and European health regulators. It is also being tested as a treatment for a range of other cancers. One of the Novartis studies will evaluate Opdivo with Novartis' Zykadia, which was approved by the U.S. Food and Drug Administration (FDA) in April as a treatment for late-stage non-small cell lung cancer.The second study will test Opdivo with two investigational drugs, INC280 and EGF816.Novartis is also developing Chimeric Antigen Receptor T-cell, or CAR-T, immunotherapies, which involves engineering a patient's own T-cells to identify proteins on cancer cells.       (Reporting by Silke Koltrowitz and Caroline Copley; ediing by Ryan Woo and Susan Thomas)",2014-10-06,BMY,"Mon Oct 6, 2014 | 3:17am EDT",UPDATE 1-Novartis works with Bristol-Myers Squibb to test lung cancer drugs,http://www.reuters.com//article/novartis-bristol-myers-collaboration-idUSL6N0S10GR20141006?type=companyNews
59,"  ZURICH Oct 6 Swiss pharma group Novartis AG  said on Monday it had entered into a clinical collaboration with Bristol-Myers Squibb Co to evaluate the safety and efficacy of combination treatments for patients with non-small cell lung cancer.The collaboration will help Novartis further advance its efforts in the field of immunotherapy, following the acquisition of CoStim Pharmaceuticals Inc this year, Novartis said in a statement. The two companies will test the combination of three molecularly targeted compounds with Bristol-Myers' investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab) in phase I and II studies, Novartis said, adding it would conduct both studies.  ""Preclinical data suggests that combining molecularly targeted agents with immunotherapies such as nivolumab may have synergistic effects and lead to better outcomes for patients,"" Alessandro Riva, global head of Novartis oncology development and medical affairs, said in the statement.       (Reporting by Silke Koltrowitz; Editing by Ryan Woo)",2014-10-06,BMY,"Mon Oct 6, 2014 | 1:47am EDT",Novartis works with Bristol-Myers for lung cancer studies,http://www.reuters.com//article/novartis-bristol-myers-collaboration-idUSL6N0S109J20141006?type=companyNews
60,"   By Bill Berkrot | NEW YORK  NEW YORK Bristol-Myers Squibb Co on Tuesday said it is no longer seeking U.S. approval for an oral two-drug combination to treat hepatitis C because of competition from rival drugs that require treatment for half as long and have shown higher cure rates.The drugmaker's shares fell more than 2 percent.Bristol-Myers' combination of experimental antiviral drugs daclatasvir and asunaprevir was intended for patients with the genotype 1b form of the liver-destroying virus, which is far less prevalent in the United States than the 1a form.In addition, Bristol-Myers' drug faced stiff competition from products being developed by rival drugmakers, including Gilead Sciences <GILD, AbbVie and Merck & Co.In late-stage clinical trials, Bristol's two-drug combination cured about 85 percent of patients with 24 weeks of therapy. The combinations being developed by rival drugmakers have demonstrated cure rates well in excess of 90 percent with just 12 weeks of therapy, and they are pursuing even shorter treatment durations. ""We believe revenue expectations for this two-drug combination in the U.S. were reasonably low given the lower efficacy relative to other regimens from Gilead and AbbVie that are awaiting approval later this year,"" ISI Group analyst Mark Schoenebaum said in a research note. Gilead's once-a-day, two-drugs-in-one pill combination for hepatitis C is expected to gain U.S. approval as soon as this week. Its already-approved Sovaldi - half of that regimen - has shattered sales records for a new medicine, racking up $3.5 billion in the second quarter alone.Bristol said it will continue to pursue U.S. approval of daclatasvir, a potent drug from a new class called NS5A inhibitors, which could then be combined with other medicines. It is testing that drug in combination with Gilead's Sovaldi. The company also has a three-drug regimen that, based on earlier studies, is expected to cure more people in 12 weeks and would compete more favorably with rival treatments.A U.S. marketing application for Bristol's three-drug combination is expected to be filed next year.Bristol's two-drug combination was approved in July for use in Japan, which it long considered a prime market for the treatment. Genotype 1b is prevalent in Japan, where intolerance to the older medicine interferon is particularly high, creating a big need for new treatment options. ""We believe this treatment has the potential to play a major role in curing HCV patients in Japan, as well as in other markets where the HCV patient population is similar to Japan,"" Bristol-Myers said in a statement. Bristol-Myers shares were down $1.12, or 2.2 percent, at  $49.98 in midday trading on the New York Stock Exchange. (Reporting by Bill Berkrot; Additional reporting by Vidya L Nathan in Bangalore; Editing by Savio D'Souza and Leslie Adler)",2014-10-07,BMY,"Tue Oct 7, 2014 | 12:21pm EDT",Bristol-Myers pulls U.S. marketing application for hep C treatment,http://www.reuters.com//article/us-bristolmyers-fda-hepatitisc-idUSKCN0HW1N120141007?type=companyNews
61,"  (Adds comment from Bristol-Myers and analyst, adds background, updates shares)By Bill BerkrotNEW YORK Oct 7 Bristol-Myers Squibb Co  on Tuesday said it is no longer seeking U.S. approval for an oral two-drug combination to treat hepatitis C because of competition from rival drugs that require treatment for half as long and have shown higher cure rates.The drugmaker's shares fell more than 2 percent.Bristol-Myers' combination of experimental antiviral drugs daclatasvir and asunaprevir was intended for patients with the genotype 1b form of the liver-destroying virus, which is far less prevalent in the United States than the 1a form.In addition, Bristol-Myers' drug faced stiff competition from products being developed by rival drugmakers, including Gilead Sciences <GILD, AbbVie and Merck & Co. In late-stage clinical trials, Bristol's two-drug combination cured about 85 percent of patients with 24 weeks of therapy. The combinations being developed by rival drugmakers have demonstrated cure rates well in excess of 90 percent with just 12 weeks of therapy, and they are pursuing even shorter treatment durations.""We believe revenue expectations for this two-drug combination in the U.S. were reasonably low given the lower efficacy relative to other regimens from Gilead and AbbVie that are awaiting approval later this year,"" ISI Group analyst Mark Schoenebaum said in a research note. Gilead's once-a-day, two-drugs-in-one pill combination for hepatitis C is expected to gain U.S. approval as soon as this week. Its already-approved Sovaldi - half of that regimen - has shattered sales records for a new medicine, racking up $3.5 billion in the second quarter alone.Bristol said it will continue to pursue U.S. approval of daclatasvir, a potent drug from a new class called NS5A inhibitors, which could then be combined with other medicines. It is testing that drug in combination with Gilead's Sovaldi.The company also has a three-drug regimen that, based on earlier studies, is expected to cure more people in 12 weeks and would compete more favorably with rival treatments. A U.S. marketing application for Bristol's three-drug combination is expected to be filed next year.Bristol's two-drug combination was approved in July for use in Japan, which it long considered a prime market for the treatment. Genotype 1b is prevalent in Japan, where intolerance to the older medicine interferon is particularly high, creating a big need for new treatment options.""We believe this treatment has the potential to play a major role in curing HCV patients in Japan, as well as in other markets where the HCV patient population is similar to Japan,"" Bristol-Myers said in a statement.Bristol-Myers shares were down $1.12, or 2.2 percent, at  $49.98 in midday trading on the New York Stock Exchange.    (Reporting by Bill Berkrot; Additional reporting by Vidya L Nathan in Bangalore; Editing by Savio D'Souza and Leslie Adler)",2014-10-07,BMY,"Tue Oct 7, 2014 | 12:07pm EDT",UPDATE 2-Bristol-Myers pulls U.S. marketing application for hep C treatment,http://www.reuters.com//article/bristolmyers-fda-hepatitisc-idUSL3N0S23JE20141007?type=companyNews
62,"  Bristol-Myers Squibb said it withdrew its U.S. marketing application for an oral drug combination to treat hepatitis C, citing a ""rapidly evolving"" treatment landscape in the country.The drugmaker's shares fell nearly 2 percent in early trading.Bristol-Myers is racing against Merck & Co and AbbVie to try and cut the treatment time by half and avoid side effects from older standard drugs interferon and ribavirin.Interferon and ribavirin treat hepatitis C (HCV) in about 24 weeks, but their side effects have led to thousands of patients putting off the treatment to wait for new drugs.Bristol-Myers' two-drug combination treatment, in a late-stage study in April, showed that it could cure HCV infections in 24 weeks in 82 percent of patients who were unable to tolerate interferon and ribavirin. The company also has a three-drug combination that, based on earlier studies, is expected to cure more people in the same 12 weeks, an efficacy rate that would compete favorably with that of rival treatments.A U.S. marketing application for this three-drug combination is expected early next year.The drugmaker's now-shelved two-drug combination was approved in July for use in Japan. Bristol-Myers said on Tuesday it would continue to pursue a U.S. marketing approval for daclatasvir, one component of the two-drug combination.The company said it plans to submit additional data on daclatasvir from an ongoing program to the U.S. Food and Drug Administration. Bristol-Myers' shares were down 1.9 percent to $50.13. Through Monday's close, the stock had gained 3.7 percent since the company reported late-stage results from the two-drug combination on April 10.(The story corrects paragraph 5 to say Bristol-Myers' two-drug combination treated hepatitis in 24 weeks, not 12 weeks) (Reporting by Vidya L Nathan in Bangalore; Editing by Savio D'Souza)",2014-10-07,BMY,"Tue Oct 7, 2014 | 11:15am EDT",Bristol-Myers pulls U.S. marketing application for hepatitis C treatment,http://www.reuters.com//article/us-bristolmyers-fda-hepatitisc-idUSKCN0HW15A20141007?type=companyNews
63,"  Oct 7 Bristol-Myers Squibb said it withdrew its U.S. marketing application for a drug combination to treat hepatitis C.The drugmaker will continue to pursue marketing approval of daclatasvir, one part of the combination, the company said in a statement. Bristol-Myers said the combination treatment of daclatasvir and asunaprevir was approved in July for use in Japan.  The company plans to submit additional data on daclatasvir from an ongoing study to the U.S. Food and Drug Administration.   (Reporting by Vidya L Nathan in Bangalore; Editing by Savio D'Souza)",2014-10-07,BMY,"Tue Oct 7, 2014 | 8:51am EDT",Bristol-Myers pulls U.S. marketing application for hepatitis C treatment,http://www.reuters.com//article/bristolmyers-fda-hepatitisc-idUSL3N0S23GJ20141007?type=companyNews
64,"   By Sophie Sassard and Anjuli Davies | LONDON  LONDON Oct 15 ConvaTec's owners have appointed Morgan Stanley and Goldman Sachs to explore a sale of the medical device maker which could be worth up to $10 billion, sources familiar with the matter said.Private equity firms Avista Capital Partners and Nordic Capital are preparing the groundwork for a possible sale or initial public offering (IPO) in 2015 for the Luxembourg-based company, said the sources who spoke on condition of anonymity because the process is private.Mergers and acquisitions in the healthcare space have hit a record pace so far this year, in part driven by U.S. companies seeking to redomicile in countries that have a lower corporate tax rate, in a practice known as inversion.Kimberley-Clark and 3M are considered likely bidders for ConvaTec, said the sources, adding that the U.S. firms' interest was not motivated by tax inversion issues. ConvaTec, Nordic Capital, 3M, Goldman Sachs and Morgan Stanley declined to comment. Kimberley Clark and Avista Capital did not immediately respond to requests for comment.Reuters reported in August that some U.S. companies including diversified manufacturer 3M and medical equipment makers CareFusion Corp and C.R. Bard Inc were potentially exploring a deal, but that ConvaTec wanted to boost its value further before launching an auction or IPO. CareFusion has since been swallowed by medical equipment supplier Becton Dickinson & Co for $12.2 billion, taking them out of the field. Also, in recent weeks equity markets have stumbled and the market for IPOs has stalled.Avista Capital Partners and Nordic Capital acquired ConvaTec from Bristol-Myers Squibb Co in 2011 for $4.1 billion. 3M and Kimberley-Clark were among the contenders for ConvaTec at the time, according to people familiar with the matter.ConvaTec reported earnings before interest, tax, depreciation and amortization (EBITDA) of $502.5 million in 2013, up 15 percent year-on-year. It is hoping to exceed $600 million in EBITDA this year, sources have said.The company makes wound care and ostomy care products at 11 manufacturing sites in eight countries, and sells them in more than 100 countries.       (Editing by Pravin Char)",2014-10-15,BMY,"Wed Oct 15, 2014 | 6:17am EDT",ConvaTec owners appoint banks to explore sale - sources,http://www.reuters.com//article/convatec-sale-idUSL6N0SA11020141015?type=companyNews
65,"  Oct 24 Bristol-Myers Squibb Co :  * Company says interested in deals of different sizes, geared primarily toward products and technologies, rather than toward inversions  * Company, in conference call with analysts, says ""encouraged"" by clincal trial data from ""069"" melanoma trial involving combo of its Yervoy and Opdivo immuno-oncology drugs  * Company says has in-house data from ""069"" study, premature to disclose regulatory strategy for use of data   ",2014-10-24,BMY,"Fri Oct 24, 2014 | 11:42am EDT",BRIEF-Bristol Myers says keen on deals of different sizes,http://www.reuters.com//article/bristolmyerssquibb-brief-idUSWEN00E6U20141024?type=companyNews
66,"   By Ransdell Pierson  Bristol-Myers Squibb Co (BMY.N) reported better-than-expected third-quarter results, as sizzling sales of its treatments for blood clots, cancer and arthritis helped offset sharply higher taxes, sending the stock up 2.6 percent.The U.S. drugmaker said on Friday it earned $721 million, or 43 cents per share, in the quarter. That compared with $692 million, or 42 cents per share, in the year-earlier period.Excluding special items, the company earned 45 cents per share, beating the average analyst estimate of 42 cents, according to a poll by Thomson Reuters I/B/E/S. The effective tax rate was 27.4 percent, compared with 15.4 percent a year ago.Sanford Bernstein analyst Tim Anderson, who expected a 13 percent tax rate, saw few other material updates on its finances or products in the earnings report.Later Friday, investors will pay close attention to any updates from executives about how Bristol-Myers' high-profile immuno-oncology drugs are faring in clinical trials and in an ongoing review by regulators. The medicines include Opdivo (nivolumab), a so-called PD-1 inhibitor that takes the brakes off immune system cells to allow them to recognize and attack cancer cells. Bristol-Myers, along with Merck & Co Inc (MRK.N), Roche Holding AG ROG.VX and AstraZeneca Plc (AZN.L)(AZN.N) are leaders in PD-1 inhibitors, and analysts say the new class could generate more than $30 billion in annual global sales by 2025. Opdivo was approved in Japan in July to treat melanoma, and Bristol-Myers has begun the process of seeking U.S. marketing approval for the drug to treat the less common ""squamous"" form of lung cancer as well as melanoma. Bristol-Myers is expected on Oct. 31 at a meeting in Chicago to present clinical trial data on the use of Opdivo as a treatment for squamous lung cancer, after two earlier courses of treatment failed. ""Overall, we believe the Street is significantly underestimating (Opdivo's) potential in lung cancer,"" BMO Capital Markets analyst Alex Arfaei said on Friday. He predicted the stock could jump to the $55 to $65 range, if favorable data are seen at the meeting, the Chicago Multidisciplinary Symposium on Thoracic Oncology.Arfaei noted other Opdivo lung cancer data are expected in coming months and could help support U.S. approval of the drug.Shares were up $1.38 to $53.88. Merck's Keytruda, or pembrolizumab, last month became the first PD-1 inhibitor available in the United States. It was approved for patients with advanced melanoma.Bristol-Myers' quarterly revenue fell 4 percent to $3.92 billion, largely due to the recent sale of its diabetes products to longtime partner AstraZeneca, but were above Wall Street estimates of $3.8 billion. Excluding the divested diabetes drugs, revenue rose 7 percent.Despite the third-quarter profit beat, Bristol-Myers stuck to its earlier full-year profit forecast of $1.70 to $1.80 per share.     (Reporting by Ransdell Pierson in New York; Editing by Jeffrey Benkoe)",2014-10-24,BMY,"Fri Oct 24, 2014 | 10:34am EDT",Bristol-Myers tops third-quarter estimates as sales of top drugs sizzle,http://www.reuters.com//article/us-bristolmyers-results-idUSKCN0ID14J20141024?type=companyNews
67,"  (Adds analyst comment, details on Opdivo cancer drug, shares)By Ransdell PiersonOct 24 Bristol-Myers Squibb Co reported better-than-expected third-quarter results, as sizzling sales of its treatments for blood clots, cancer and arthritis helped offset sharply higher taxes, sending the stock up 2.6 percent.The U.S. drugmaker said on Friday it earned $721 million, or 43 cents per share, in the quarter. That compared with $692 million, or 42 cents per share, in the year-earlier period.Excluding special items, the company earned 45 cents per share, beating the average analyst estimate of 42 cents, according to a poll by Thomson Reuters I/B/E/S. The effective tax rate was 27.4 percent, compared with 15.4 percent a year ago.Sanford Bernstein analyst Tim Anderson, who expected a 13 percent tax rate, saw few other material updates on its finances or products in the earnings report. Later Friday, investors will pay close attention to any updates from executives about how Bristol-Myers' high-profile immuno-oncology drugs are faring in clinical trials and in an ongoing review by regulators.The medicines include Opdivo (nivolumab), a so-called PD-1 inhibitor that takes the brakes off immune system cells to allow them to recognize and attack cancer cells. Bristol-Myers, along with Merck & Co Inc, Roche Holding AG and AstraZeneca Plc  are leaders in PD-1 inhibitors, and analysts say the new class could generate more than $30 billion in annual global sales by 2025.Opdivo was approved in Japan in July to treat melanoma, and Bristol-Myers has begun the process of seeking U.S. marketing approval for the drug to treat the less common ""squamous"" form of lung cancer as well as melanoma. Bristol-Myers is expected on Oct. 31 at a meeting in Chicago to present clinical trial data on the use of Opdivo as a treatment for squamous lung cancer, after two earlier courses of treatment failed.""Overall, we believe the Street is significantly underestimating (Opdivo's) potential in lung cancer,"" BMO Capital Markets analyst Alex Arfaei said on Friday.He predicted the stock could jump to the $55 to $65 range, if favorable data are seen at the meeting, the Chicago Multidisciplinary Symposium on Thoracic Oncology. Arfaei noted other Opdivo lung cancer data are expected in coming months and could help support U.S. approval of the drug.Shares were up $1.38 to $53.88.Merck's Keytruda, or pembrolizumab, last month became the first PD-1 inhibitor available in the United States. It was approved for patients with advanced melanoma.Bristol-Myers' quarterly revenue fell 4 percent to $3.92 billion, largely due to the recent sale of its diabetes products to longtime partner AstraZeneca, but were above Wall Street estimates of $3.8 billion. Excluding the divested diabetes drugs, revenue rose 7 percent.Despite the third-quarter profit beat, Bristol-Myers stuck to its earlier full-year profit forecast of $1.70 to $1.80 per share.       (Reporting by Ransdell Pierson in New York; Editing by Jeffrey Benkoe)",2014-10-24,BMY,"Fri Oct 24, 2014 | 10:25am EDT",UPDATE 2-Bristol-Myers tops 3rd-qtr estimates as sales of top drugs sizzle,http://www.reuters.com//article/bristolmyers-results-idUSL2N0SJ0N220141024?type=companyNews
68,"  Oct 24 Bristol-Myers Squibb Co reported better-than-expected third-quarter results, fueled by strong sales of its treatments for blood clots, cancer and arthritis.The U.S. drugmaker said on Friday it earned $721 million, or 43 cents per share, in the quarter. That compared with $692 million, or 42 cents per share, in the year-earlier period. Excluding special items, the company earned 45 cents per share. Analysts, on average, expected 42 cents, according to Thomson Reuters I/B/E/S.  Revenue fell 4 percent to $3.92 billion, largely due to the company's earlier divestiture of diabetes products, but were above Wall Street estimates of $3.8 billion.   (Reporting by Ransdell Pierson; Editing by Jeffrey Benkoe)",2014-10-24,BMY,"Fri Oct 24, 2014 | 7:41am EDT",Bristol-Myers beats 3rd-qtr forecasts as top drugs deliver,http://www.reuters.com//article/bristolmyers-results-idUSL2N0SJ0MD20141024?type=companyNews
69,"   By Bill Berkrot  Treatment of a common form of advanced lung cancer with Bristol-Myers Squibb Co's experimental immunotherapy nivolumab  led to a one-year survival rate of 41 percent in a midstage clinical trial, according to data to be presented at a medical meeting, sending the drugmaker's shares up 8.8 percent.While the study, called CheckMate-063, did not compare nivolumab with another drug or placebo, the historical one-year survival rate for patients like those in the trial, whose  squamous non-small cell lung cancer (NSCLC) had progressed after treatment with two or more prior therapies, is between 5.5 percent and 18 percent, the company said on Thursday. Squamous cell cancer tends to be found in the middle of the lung.""The data today look very, very good,"" ISI Group analyst Mark Schoenebaum said, adding that it bodes well for an ongoing  Phase III trial in NSCLC patients following just one prior therapy.He had estimated a 1-year survival rate of about 20 percent as the number to beat.Nivolumab belongs to a new class of drugs called PD-1 inhibitors that have generated great excitement in the medical community. They work by blocking a tumor's ability to camouflage itself, allowing the body's immune system to recognize and attack the cancer.Merck & Co Inc last month received the first U.S. approval of a drug from the class to treat advanced melanoma - the deadliest form of skin cancer. ""The Phase II findings from CheckMate-063 are encouraging as there are no effective treatment options for patients with refractory squamous cell lung cancer after their disease has progressed through two prior therapies,"" Dr. Suresh Ramalingam, director of medical oncology at Winship Cancer Institute of Emory University, said in a statement.Bristol-Myers, which has proposed the brand name Opdivo for nivolumab, plans to use the data as part of its rolling submissions seeking U.S. and European approvals.Sanford Bernstein analyst Tim Anderson sees Opdivo sales reaching $4.6 billion in 2020. Median overall survival was 8.2 months in the 117-patient trial. The median duration of response had not yet been reached.The objective response rate (ORR), which was the primary goal of the trial, was 15 percent as assessed by an independent review committee. That compares with historical expectations in the single digits, the company said. ORR was defined as reduction of the target lesion of at least 30 percent with no new lesions.The results were scheduled to be reported on Friday at a thoracic oncology meeting in Chicago. Fatigue, lung tissue inflammation and diarrhea were among the most common adverse side effects reported. The discontinuation rate due to drug-related side effects was 12 percent, and there were two drug-related deaths, the company reported.  Lung is the leading cause of cancer deaths globally, with about 1.5 million each year, according to the World Health Organization. NSCLC accounts for about 85 percent of lung cancer cases.Bristol-Myers shares were up $4.71 at $58.87 on the New York Stock Exchange. (Additional reporting by Ransdell Pierson in New York; Editing by Matthew Lewis and Jeffrey Benkoe)",2014-10-30,BMY,"Thu Oct 30, 2014 | 11:37am EDT",Bristol immunotherapy shows encouraging survival in lung cancer trial,http://www.reuters.com//article/us-bristol-myers-cancer-study-idUSKBN0IJ1KT20141030?type=companyNews
70,"   By Bill Berkrot  Oct 30 Treatment of advanced squamous cell non-small cell lung cancer (NSCLC) with Bristol-Myers Squibb Co's experimental immunotherapy nivolumab led to a one-year survival rate of 41 percent in a midstage clinical trial, according to data being presented at a medical meeting.While the study called CheckMate-063 did not compare nivolumab with another drug or placebo, the historical one-year survival rate for patients like those in the trial, whose cancer had progressed after treatment with two or more prior therapies, is between 5.5 percent and 18 percent, the company said.Nivolumab belongs to a highly promising new class of drugs called PD-1 inhibitors that block a tumor's ability to camouflage itself, allowing the body's immune system to recognize and attack the cancer. Merck & Co last month received the first U.S. approval of a drug from the class to treat advanced melanoma - the deadliest form of skin cancer. ""The Phase II findings from CheckMate-063 are encouraging as there are no effective treatment options for patients with refractory squamous cell lung cancer after their disease has progressed through two prior therapies,"" Dr Suresh Ramalingam, director of Medical Oncology at Winship Cancer Institute of Emory University, said in a statement.Bristol-Myers, which has proposed the brand name Opdivo for nivolumab, plans to use the data as part of its rolling submissions seeking U.S. and European approvals. The median overall survival in the 117-patient trial was 8.2 months. The median duration of response had not yet been reached.The objective response rate (ORR), which was the primary goal of the trial, was 15 percent as assessed by an independent review committee. That compares with historical expectations in the single digits, the company said. ORR was defined as reduction of the target lesion of at least 30 percent with no new lesions. The results were scheduled to be reported on Friday at a thoracic oncology meeting in Chicago.Fatigue, lung tissue inflammation and diarrhea were among the most common adverse side effects reported. The discontinuations rate due to drug-related side effects was 12 percent, and there were two drug-related deaths, the company reported.Lung cancer is the leading cause of cancer deaths globally, with about 1.5 million each year, according to the World Health Organization. NSCLC accounts for about 85 percent of lung cancer cases.   (Reporting by Bill Berkrot in New York; editing by Matthew Lewis)",2014-10-30,BMY,"Thu Oct 30, 2014 | 9:00am EDT",Bristol immunotherapy shows promise in lung cancer trial,http://www.reuters.com//article/bristol-myers-cancer-study-idUSL1N0SO2NN20141030?type=companyNews
71,"   By Ransdell Pierson  Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results.The impressive results, compared with chemo, were seen in a late-stage study of the Bristol-Myers drug Opdivo, which helps take the brakes off the immune system by blocking the protein PD-1.The 418-patient-study involved previously untreated patients with advanced melanoma, the most deadly form of skin cancer. Among those taking Opdivo, 73 percent were alive one year later, compared with 42 percent of those receiving standard chemo treatment dacarbazine. Moreover, 40 percent of those taking Opdivo had tumor shrinkage, versus 14 percent for the chemo group. The treatment was associated with mild side effects, including fatigue and nausea.""The results were incredibly good and show there will no longer be a role for chemotherapy in advanced melanoma,"" said Dr. Georgina Long, an associate professor at the Melanoma Institute Australia who helped lead the study. Findings were presented at a medical meeting in Zurich.Long, reached by phone there, said the findings bode well not only for Opdivo, but for an emerging crop of other PD-1 inhibitors being developed by other companies. They include products being tested by Merck & Co, Roche Holding AG and AstraZeneca Plc.Merck's Keytruda in September received the first U.S. approval of a drug from the class, to treat advanced melanoma.   Opdivo had also shown strong results in a different Phase III trial that involved advanced melanoma patients who had previously been treated with Yervoy, another immuno-oncology drug from Bristol-Myers. Those results, released in September, showed tumors shrank in 32 percent of patients given Opdivo, compared with 11 percent of those receiving chemo.Bristol-Myers is testing Opdivo for many other cancers, with early glimpses of success. Treatment of a common form of advanced lung cancer with the drug led to a one-year survival rate of 41 percent in a midstage clinical trial, according to data presented two weeks ago.The historical one-year survival rate for such patients, who previously failed on other drugs, is between 5.5 percent and 18 percent. (Reporting by Ransdell Pierson; Editing by Leslie Adler)",2014-11-16,BMY,"Sun Nov 16, 2014 | 4:21am EST",Bristol-Myers immunotherapy shows promise to replace chemo for melanoma,http://www.reuters.com//article/us-bristol-myers-melanoma-idUSKCN0J008B20141116?type=companyNews
72,"   By Ransdell Pierson  Nov 16 Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results.The impressive results, compared with chemo, were seen in a late-stage study of the Bristol-Myers drug Opdivo, which helps take the brakes off the immune system by blocking the protein PD-1.The 418-patient-study involved previously untreated patients with advanced melanoma, the most deadly form of skin cancer. Among those taking Opdivo, 73 percent were alive one year later, compared with 42 percent of those receiving standard chemo treatment dacarbazine.Moreover, 40 percent of those taking Opdivo had tumor shrinkage, versus 14 percent for the chemo group. The treatment was associated with mild side effects, including fatigue and nausea. ""The results were incredibly good and show there will no longer be a role for chemotherapy in advanced melanoma,"" said Dr. Georgina Long, an associate professor at the Melanoma Institute Australia who helped lead the study.Findings were presented at a medical meeting in Zurich. Long, reached by phone there, said the findings bode well not only for Opdivo, but for an emerging crop of other PD-1 inhibitors being developed by other companies. They include products being tested by Merck & Co, Roche Holding AG  and AstraZeneca Plc.Merck's Keytruda in September received the first U.S. approval of a drug from the class, to treat advanced melanoma. Opdivo had also shown strong results in a different Phase III trial that involved advanced melanoma patients who had previously been treated with Yervoy, another immuno-oncology drug from Bristol-Myers. Those results, released in September, showed tumors shrank in 32 percent of patients given Opdivo, compared with 11 percent of those receiving chemo.Bristol-Myers is testing Opdivo for many other cancers, with early glimpses of success.Treatment of a common form of advanced lung cancer with the drug led to a one-year survival rate of 41 percent in a midstage clinical trial, according to data presented two weeks ago.The historical one-year survival rate for such patients, who previously failed on other drugs, is between 5.5 percent and 18 percent.     (Reporting by Ransdell Pierson; Editing by Leslie Adler)",2014-11-16,BMY,"Sun Nov 16, 2014 | 3:45am EST",Bristol-Myers immunotherapy shows promise to replace chemo for melanoma,http://www.reuters.com//article/bristol-myers-melanoma-idUSL2N0T501H20141116?type=companyNews
73,"   By Ransdell Pierson  Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results.The impressive results, compared with chemo, were seen in a late-stage study of the Bristol-Myers drug Opdivo, which helps take the brakes off the immune system by blocking the protein PD-1.The 418-patient-study involved previously untreated patients with advanced melanoma, the most deadly form of skin cancer. Among those taking Opdivo, 73 percent were alive one year later, compared with 42 percent of those receiving standard chemo treatment dacarbazine. Moreover, 40 percent of those taking Opdivo had tumor shrinkage, versus 14 percent for the chemo group. The treatment was associated with mild side effects, including fatigue and nausea.""The results were incredibly good and show there will no longer be a role for chemotherapy in advanced melanoma,"" said Dr. Georgina Long, an associate professor at the Melanoma Institute Australia who helped lead the study. Findings were presented at a medical meeting in Zurich.Long, reached by phone there, said the findings bode well not only for Opdivo, but for an emerging crop of other PD-1 inhibitors being developed by other companies. They include products being tested by Merck & Co, Roche Holding AG and AstraZeneca Plc.Merck's Keytruda in September received the first U.S. approval of a drug from the class, to treat advanced melanoma.   Opdivo had also shown strong results in a different Phase III trial that involved advanced melanoma patients who had previously been treated with Yervoy, another immuno-oncology drug from Bristol-Myers. Those results, released in September, showed tumors shrank in 32 percent of patients given Opdivo, compared with 11 percent of those receiving chemo.Bristol-Myers is testing Opdivo for many other cancers, with early glimpses of success. Treatment of a common form of advanced lung cancer with the drug led to a one-year survival rate of 41 percent in a midstage clinical trial, according to data presented two weeks ago.The historical one-year survival rate for such patients, who previously failed on other drugs, is between 5.5 percent and 18 percent. (Reporting by Ransdell Pierson; Editing by Leslie Adler)",2014-11-17,BMY,"Mon Nov 17, 2014 | 7:22am EST",Bristol-Myers immunotherapy shows promise to replace chemo for melanoma,http://www.reuters.com//article/us-bristol-myers-melanoma-idUSKCN0J117Z20141117?type=companyNews
74,"   By Ransdell Pierson  Nov 16 Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results.The impressive results, compared with chemo, were seen in a late-stage study of the Bristol-Myers drug Opdivo, which helps take the brakes off the immune system by blocking the protein PD-1.The 418-patient-study involved previously untreated patients with advanced melanoma, the most deadly form of skin cancer. Among those taking Opdivo, 73 percent were alive one year later, compared with 42 percent of those receiving standard chemo treatment dacarbazine.Moreover, 40 percent of those taking Opdivo had tumor shrinkage, versus 14 percent for the chemo group. The treatment was associated with mild side effects, including fatigue and nausea. ""The results were incredibly good and show there will no longer be a role for chemotherapy in advanced melanoma,"" said Dr. Georgina Long, an associate professor at the Melanoma Institute Australia who helped lead the study.Findings were presented at a medical meeting in Zurich. Long, reached by phone there, said the findings bode well not only for Opdivo, but for an emerging crop of other PD-1 inhibitors being developed by other companies. They include products being tested by Merck & Co, Roche Holding AG  and AstraZeneca Plc.Merck's Keytruda in September received the first U.S. approval of a drug from the class, to treat advanced melanoma. Opdivo had also shown strong results in a different Phase III trial that involved advanced melanoma patients who had previously been treated with Yervoy, another immuno-oncology drug from Bristol-Myers. Those results, released in September, showed tumors shrank in 32 percent of patients given Opdivo, compared with 11 percent of those receiving chemo.Bristol-Myers is testing Opdivo for many other cancers, with early glimpses of success.Treatment of a common form of advanced lung cancer with the drug led to a one-year survival rate of 41 percent in a midstage clinical trial, according to data presented two weeks ago.The historical one-year survival rate for such patients, who previously failed on other drugs, is between 5.5 percent and 18 percent.     (Reporting by Ransdell Pierson; Editing by Leslie Adler)",2014-11-17,BMY,"Mon Nov 17, 2014 | 7:00am EST",RPT-Bristol-Myers immunotherapy shows promise to replace chemo for melanoma,http://www.reuters.com//article/bristol-myers-melanoma-idUSL2N0T503D20141117?type=companyNews
75,"  Bristol-Myers Squibb Co on Wednesday said U.S. regulators had declined to approve the use of its experimental treatment for hepatitis C, daclatasvir, in combination with other antiviral drugs.Bristol-Myers said it had initially sought permission from the U.S. Food and Drug Administration to market the drug, a so-called NS5A inhibitor, in combination with asunaprevir, one of the New York-based company's experimental medicines.But Bristol-Myers abandoned its U.S. marketing application for asunaprevir in October because of potential competition from more potent drugs, leaving the FDA without data to gauge the effectiveness of daclatasvir as part of a combination regimen. Bristol-Myers said the FDA has asked it for data involving use of daclatasvir with other drugs, and that the company is in discussions with the agency about the scope of the required information. Most notably, it is testing daclatasvir in combination with Gilead Sciences Inc's Sovaldi, a blockbuster treatment that is used on its own or as a component of a combination treatment called Harvoni that was recently introduced by Gilead and is expected to quickly become the market leader.Bristol-Myers' combination of daclatasvir and asunaprevir,  however, was approved in July for use in Japan, which it long considered a prime market for the treatment. One strain of the hepatitis C virus, Genotype 1b, is prevalent in Japan, where intolerance to interferon, an older medicine, is particularly high. In late-stage clinical trials, the combination treatment cured about 85 percent of patients with 24 weeks of therapy. The combinations being developed by rival drugmakers have demonstrated cure rates well in excess of 90 percent with just 12 weeks of therapy, and they are pursuing even shorter treatment durations.Bristol-Myers, meanwhile, is studying a three-drug regimen that, based on earlier studies, is expected to cure more people in 12 weeks and would compete more favorably with rival treatments. The U.S. marketing application for the company's three-drug combination is expected to be filed next year. Shares of Bristol-Myers were little changed in afternoon trading on Wednesday. (Reporting by Ransdell Pierson; Editing by Paul Simao)",2014-11-26,BMY,"Wed Nov 26, 2014 | 1:06pm EST",FDA declines to approve Bristol-Myers hepatitis drug,http://www.reuters.com//article/us-bristol-myers-hepatitis-idUSKCN0JA1QL20141126?type=companyNews
76,"  (Adds details on drug, other Bristol-Myers, rival treatments)Nov 26 Bristol-Myers Squibb Co on Wednesday said U.S. regulators had declined to approve the use of its experimental treatment for hepatitis C, daclatasvir, in combination with other antiviral drugs.Bristol-Myers said it had initially sought permission from the U.S. Food and Drug Administration to market the drug, a so-called NS5A inhibitor, in combination with asunaprevir, one of the New York-based company's experimental medicines.But Bristol-Myers abandoned its U.S. marketing application for asunaprevir in October because of potential competition from more potent drugs, leaving the FDA without data to gauge the effectiveness of daclatasvir as part of a combination regimen. Bristol-Myers said the FDA has asked it for data involving use of daclatasvir with other drugs, and that the company is in discussions with the agency about the scope of the required information.Most notably, it is testing daclatasvir in combination with Gilead Sciences Inc's Sovaldi, a blockbuster treatment that is used on its own or as a component of a combination treatment called Harvoni that was recently introduced by Gilead and is expected to quickly become the market leader. Bristol-Myers' combination of daclatasvir and asunaprevir,  however, was approved in July for use in Japan, which it long considered a prime market for the treatment. One strain of the hepatitis C virus, Genotype 1b, is prevalent in Japan, where intolerance to interferon, an older medicine, is particularly high. In late-stage clinical trials, the combination treatment cured about 85 percent of patients with 24 weeks of therapy. The combinations being developed by rival drugmakers have demonstrated cure rates well in excess of 90 percent with just 12 weeks of therapy, and they are pursuing even shorter treatment durations.Bristol-Myers, meanwhile, is studying a three-drug regimen that, based on earlier studies, is expected to cure more people in 12 weeks and would compete more favorably with rival treatments. The U.S. marketing application for the company's three-drug combination is expected to be filed next year.Shares of Bristol-Myers were little changed in afternoon trading on Wednesday.       (Reporting by Ransdell Pierson; Editing by Paul Simao)",2014-11-26,BMY,"Wed Nov 26, 2014 | 1:05pm EST",UPDATE 1-FDA declines to approve Bristol-Myers hepatitis drug,http://www.reuters.com//article/bristol-myers-hepatitis-idUSL2N0TG1C720141126?type=companyNews
77,"  Nov 26 Bristol-Myers Squibb Co on Wednesday said U.S. regulators had declined to approve use of its experimental daclatasvir drug for hepatitis C, in combination with other antiviral drugs.Bristol-Myers said it had initially sought permission from the U.S. Food and Drug Administration to market the drug, a so-called NS5A inhibitor, in combination with another experimental company medicine called asunaprevir that Bristol-Myers abandoned in October because of competition from more potent rival drugs.  (Reporting by Ransdell Pierson) ",2014-11-26,BMY,"Wed Nov 26, 2014 | 11:56am EST",FDA declines to approve Bristol-Myers hepatitis drug,http://www.reuters.com//article/bristol-myers-hepatitis-idUSL2N0TG1AK20141126?type=companyNews
78,"   By Bill Berkrot  Eighty-seven percent of Hodgkin lymphoma patients responded to a  Bristol-Myers Squibb drug that helps the immune system fight the blood cancer, according to data from a small, early stage trial released on Saturday.The study of Bristol-Myers' immunotherapy drug nivolumab involved 23 patients whose lymphoma had progressed after numerous prior treatments, including chemotherapy, stem cell transplants and the Seattle Genetics drug Adcetris.Of the 23, 16 saw their tumors shrink by at least half and four had a complete response, meaning no detectable sign of the cancer, generating excitement among researchers. The remaining three patients had stable disease.""What makes these results especially encouraging is that they were achieved in patients who had exhausted other treatment options,"" said Dr. Margaret Shipp, co-lead investigator of the  Checkmate-039 study from Dana-Farber Cancer Institute in Boston.""We're also excited by the duration of responses to the drug,"" she said. ""The majority of patients who had a response are still doing well more than a year after their treatment."" The results were being presented at the American Society of Hematology meeting in San Francisco.A larger Phase II study is underway, the company said, one that will be used to confirm the results and to seek approval. Nivolumab belongs to a new class of drugs called PD-1 inhibitors that work by blocking cancer cells' ability to camouflage themselves from the immune system, allowing it to recognize and attack the cancer.The drug received a breakthrough designation for Hodgkin lymphoma from U.S. health regulators, given to medicines seen as a potentially important advance. It is awaiting U.S. and European approval decisions for melanoma and lung cancer.Merck & Co this year became the first company to receive U.S. approval for a PD-1 drug. It was for advanced melanoma, the deadliest form of skin cancer. Bristol's drug is approved in Japan for melanoma under the brand name Opdivo. Hodgkin lymphoma is one of the most frequent cancers in children and young adults. More than 9,000 cases are estimated to be diagnosed in the United States this year, according to the Leukemia and Lymphoma Society. About a quarter of all patients eventually relapse, creating a need for new treatments.The most common side effects reported in the nivolumab study were rash and decreased blood platelet count. (Reporting by Bill Berkrot in New York; Editing by David Gregorio)",2014-12-06,BMY,"Sat Dec 6, 2014 | 1:04pm EST",High rate of lymphoma patients respond to Bristol-Myers drug: study,http://www.reuters.com//article/us-bristol-myers-lymphoma-idUSKBN0JK0OZ20141206?type=companyNews
79,"   By Bill Berkrot  Dec 6 Eighty-seven percent of Hodgkin lymphoma patients responded to a  Bristol-Myers Squibb drug that helps the immune system fight the blood cancer, according to data from a small, early stage trial released on Saturday.The study of Bristol-Myers' immunotherapy drug nivolumab involved 23 patients whose lymphoma had progressed after numerous prior treatments, including chemotherapy, stem cell transplants and the Seattle Genetics drug Adcetris.Of the 23, 16 saw their tumors shrink by at least half and four had a complete response, meaning no detectable sign of the cancer, generating excitement among researchers. The remaining three patients had stable disease.""What makes these results especially encouraging is that they were achieved in patients who had exhausted other treatment options,"" said Dr. Margaret Shipp, co-lead investigator of the  Checkmate-039 study from Dana-Farber Cancer Institute in Boston. ""We're also excited by the duration of responses to the drug,"" she said. ""The majority of patients who had a response are still doing well more than a year after their treatment.""The results were being presented at the American Society of Hematology meeting in San Francisco. A larger Phase II study is underway, the company said, one that will be used to confirm the results and to seek approval.Nivolumab belongs to a new class of drugs called PD-1 inhibitors that work by blocking cancer cells' ability to camouflage themselves from the immune system, allowing it to recognize and attack the cancer. The drug received a breakthrough designation for Hodgkin lymphoma from U.S. health regulators, given to medicines seen as a potentially important advance. It is awaiting U.S. and European approval decisions for melanoma and lung cancer.Merck & Co this year became the first company to receive U.S. approval for a PD-1 drug. It was for advanced melanoma, the deadliest form of skin cancer. Bristol's drug is approved in Japan for melanoma under the brand name Opdivo.Hodgkin lymphoma is one of the most frequent cancers in children and young adults. More than 9,000 cases are estimated to be diagnosed in the United States this year, according to the Leukemia and Lymphoma Society. About a quarter of all patients eventually relapse, creating a need for new treatments.The most common side effects reported in the nivolumab study were rash and decreased blood platelet count.   (Reporting by Bill Berkrot in New York; Editing by David Gregorio)",2014-12-06,BMY,"Sat Dec 6, 2014 | 1:00pm EST",High rate of lymphoma patients respond to Bristol-Myers drug-study,http://www.reuters.com//article/bristol-myers-lymphoma-idUSL2N0TO2FD20141206?type=companyNews
80,"  The U.S. Food and Drug Administration approved Bristol-Myers Squibb Co's skin cancer drug, more than three months before the scheduled review date.Opdivo, or nivolumab, belongs to a promising new class of drugs designed to help the body's own immune system fight cancer by blocking a protein called Programmed Death receptor (PD-1). The drug is the second PD-1 inhibitor to be approved by the FDA, the first being Merck & Co Inc's Keytruda in September.Opdivo is intended for melanoma patients who have received prior treatment, including those who have been administered Bristol-Myers' cancer drug, Yervoy.The National Cancer Institute estimates that 76,100 Americans will be diagnosed with melanoma, the deadliest form of skin cancer, this year and 9,710 will die from the disease. The approval is based on trial data that showed 32 percent of patients receiving Opdivo saw their tumors shrink, compared with 11 percent of those given conventional chemotherapy.The FDA was scheduled to review the drug on March 30. Roche Holding AG and AstraZeneca Plc are also developing PD-1 inhibitors for different kinds of cancers. Opdivo became the world's first approved PD-1 inhibitor in July when it received an approval in Japan. The drug is also being evaluated for use in other cancers, including lymphoma and lung cancer. Bristol-Myers shares were little changed at $61.10 in late afternoon trading on the New York Stock Exchange. (Reporting by Anjali Rao Koppala in Bengaluru; Editing by Kirti Pandey)",2014-12-22,BMY,"Mon Dec 22, 2014 | 3:35pm EST",FDA approves Bristol-Myers' immunotherapy for skin cancer,http://www.reuters.com//article/us-bristol-myers-fda-idUSKBN0K01R020141222?type=companyNews
81,"  (Adds details, background, shares)Dec 22 The U.S. Food and Drug Administration approved Bristol-Myers Squibb Co's skin cancer drug, more than three months before the scheduled review date.Opdivo, or nivolumab, belongs to a promising new class of drugs designed to help the body's own immune system fight cancer by blocking a protein called Programmed Death receptor (PD-1). (1.usa.gov/1zWChn5)The drug is the second PD-1 inhibitor to be approved by the FDA, the first being Merck & Co Inc's Keytruda in September. Opdivo is intended for melanoma patients who have received prior treatment, including those who have been administered Bristol-Myers' cancer drug, Yervoy.The National Cancer Institute estimates that 76,100 Americans will be diagnosed with melanoma, the deadliest form of skin cancer, this year and 9,710 will die from the disease. The approval is based on trial data that showed 32 percent of patients receiving Opdivo saw their tumors shrink, compared with 11 percent of those given conventional chemotherapy.The FDA was scheduled to review the drug on March 30. Roche Holding AG and AstraZeneca Plc   are also developing PD-1 inhibitors for different kinds of cancers.Opdivo became the world's first approved PD-1 inhibitor in July when it received an approval in Japan. The drug is also being evaluated for use in other cancers, including lymphoma and lung cancer.Bristol-Myers shares were little changed at $61.10 in late afternoon trading on the New York Stock Exchange.   (Reporting by Anjali Rao Koppala in Bengaluru; Editing by Kirti Pandey)",2014-12-22,BMY,"Mon Dec 22, 2014 | 3:31pm EST",UPDATE 1-FDA approves Bristol-Myers' immunotherapy for skin cancer,http://www.reuters.com//article/bristol-myers-fda-idUSL3N0U643W20141222?type=companyNews
82,"  Dec 22 The U.S. Food and Drug Administration granted an accelerated approval to Bristol-Myers Squibb Co's  drug for an advanced form of skin cancer.The drug, Opdivo, inhibits the action of the protein PD-1, which prevents the body's immune system from attacking melanoma tumors. (1.usa.gov/1zWChn5)  The FDA's approval comes well before its scheduled review date of March 30.   (Reporting by Anjali Rao Koppala in Bengaluru; Editing by Kirti Pandey) ",2014-12-22,BMY,"Mon Dec 22, 2014 | 2:32pm EST",FDA approves Bristol-Myer's skin cancer drug,http://www.reuters.com//article/bristol-myers-fda-idUSL3N0U643G20141222?type=companyNews
83,"  (Adds comments from Birmingham Airport CEO, Bristol deal)LONDON Dec 29 Canada's Ontario Teachers' Pension Plan said it had bought a 19.25 percent stake in Birmingham Airport from Australia's Victorian Funds Management Corporation, taking its investment in the British airport to 48.25 percent.The investment was led by Ontario Teachers' Infrastructure Group, which manages a global portfolio of $11.7 billion of investments. Its other airport investments include UK's Bristol, Copenhagen and Brussels.The Canadian pension fund wants to strengthen Birmingham Airport's position as a regional hub in the UK by tapping into its capacity of around 9.5 million passengers per year.The airport, which hosts a number of low cost airlines such as Ryanair, Flybe, Monarch and Thomas Cook, offers domestic and international flights to destinations in Europe, North America and the Middle East. It ranks as the UK's seventh busiest airport after Edinburgh and Luton, according to the UK Civil Aviation Authority, while London's Heathrow and Gatwick are in the top two spots with more than 110 million combined passengers, followed by Manchester Airport with more than 21 million annual passengers.Ontario Teachers first invested in Birmingham Airport in 2001. It then acquired a joint 48.25 percent stake with Victorian Funds Management (VFM) for 420 million pounds in 2007 when Macquarie Airports Group and Aer Rianta made a full exit. The pension fund gave no financial details of their latest buyout.The Canadian pension fund became the sole owner of the UK's ninth busiest airport, Bristol, after buying out its co-shareholder Macquarie Group in September. Seven West Midlands district councils have kept a significant ownership of Birmingham Airport and will continue investing alongside Ontario Teachers.""The shared goal is to develop Birmingham Airport's connectivity to benefit both the region and the UK as a whole,"" said Birmingham Airport Chief Executive, Paul Kehoe.Ontario Teachers' is the largest single-profession pension plan in Canada. It pays pensions and invests on behalf of 307,000 working and retired teachers in Ontario.    (Reporting by Pamela Barbaglia; editing by Jason Neely and Louise Heavens)",2014-12-29,BMY,"Mon Dec 29, 2014 | 5:51am EST",UPDATE 1-Ontario Teachers raises stake in UK's Birmingham Airport,http://www.reuters.com//article/birmingham-airport-ma-ontario-teachers-idUSL6N0UD0MO20141229?type=companyNews
84,"   By Bill Berkrot  Bristol-Myers Squibb and Merck & Co broke further away from rival drugmakers in the race to treat lung cancer with a new generation of immune system therapies, adding pressure on the likes of Roche and AstraZeneca to play catch-up.Merck said it would file an application with U.S. regulators in the middle of this year seeking expanded use of its new Keytruda treatment for non-small cell lung cancer, the most common form of the deadly disease. That followed a late Sunday announcement by Bristol-Myers that independent monitors halted a trial of its Opdivo treatment for lung cancer when it became clear the drug extended survival compared with standard chemotherapy.  While the magnitude of the benefit was not yet known, it marked the first time the new class of immunotherapy demonstrated an overall survival benefit in lung cancer.       Some industry analysts expect this class, known as PD-1 or PD-L1 inhibitors, to generate more than $30 billion in worldwide annual sales by 2025, with lung cancer seen as the most lucrative use.Keytruda and Opdivo are already approved to treat advanced melanoma, the most deadly form of skin cancer. They work by blocking a mechanism used by tumors to hide from disease fighting immune system cells. Sanford Bernstein analyst Tim Anderson sees Merck closing a perceived gap with Bristol-Myers in using their drugs for lung cancer.""The review time for Merck's application could be on the order of a few months,"" implying approval in the second half of 2015, nearly a year earlier than Wall Street had expected, Anderson said in a note.As a result, ""Merck may only be about six months behind Bristol-Myers in bringing its product to market.""Bristol has not said when it expects an approval decision for Opdivo as a treatment for lung cancer. Leerink Partners analyst Seamus Fernandez said in a research note that Merck's rapid advancement may pose a setback to similar programs from Roche and AstraZeneca. Roche's timeline for seeking regulatory approval remains unclear, Fernandez noted. AstraZeneca, meanwhile, may not be able to secure an accelerated review in lung cancer if the Bristol-Myers or Merck drug is already on the market, potentially adding several months to a decision on its contender.Roche said it expects pivotal data for its PD-L1 drug in lung and bladder cancer in the first half of this year, with potential filings seeking approval in the second half if the trials are successful.  Bahija Jallal of AstraZeneca's MedImmune oncology unit, speaking at the JP Morgan healthcare conference in San Francisco, said the company's focus was on testing combinations of its immunotherapy with its own traditional drugs.""I think we're in a great position because we have biologics on one side and small molecules on the other side,"" Jallal said.Lung cancer is the leading cause of cancer deaths globally, killing more than 1.5 million people each year, according the World Health Organization.Bristol-Myers shares were up 3 percent at $62.17, while Merck shares were off 0.4 percent at $62.27. (Reporting by Bill Berkrot in New York; Additional reporting by Caroline Humer in San Francisco; Editing by Leslie Adler)",2015-01-12,BMY,"Mon Jan 12, 2015 | 3:36pm EST","Merck, Bristol heat up immunotherapy race in lung cancer",http://www.reuters.com//article/us-bristol-myers-merck-co-lung-idUSKBN0KL26320150112?type=companyNews
85,"   By Bill Berkrot  Jan 12 Bristol-Myers Squibb and Merck & Co broke further away from rival drugmakers in the race to treat lung cancer with a new generation of immune system therapies, adding pressure on the likes of Roche and AstraZeneca to play catch-up.Merck said it would file an application with U.S. regulators in the middle of this year seeking expanded use of its new Keytruda treatment for non-small cell lung cancer, the most common form of the deadly disease.That followed a late Sunday announcement by Bristol-Myers that independent monitors halted a trial of its Opdivo treatment for lung cancer when it became clear the drug extended survival compared with standard chemotherapy.While the magnitude of the benefit was not yet known, it marked the first time the new class of immunotherapy demonstrated an overall survival benefit in lung cancer.Some industry analysts expect this class, known as PD-1 or PD-L1 inhibitors, to generate more than $30 billion in worldwide annual sales by 2025, with lung cancer seen as the most lucrative use. Keytruda and Opdivo are already approved to treat advanced melanoma, the most deadly form of skin cancer. They work by blocking a mechanism used by tumors to hide from disease fighting immune system cells.Sanford Bernstein analyst Tim Anderson sees Merck closing a perceived gap with Bristol-Myers in using their drugs for lung cancer.""The review time for Merck's application could be on the order of a few months,"" implying approval in the second half of 2015, nearly a year earlier than Wall Street had expected, Anderson said in a note. As a result, ""Merck may only be about six months behind Bristol-Myers in bringing its product to market."" Bristol has not said when it expects an approval decision for Opdivo as a treatment for lung cancer.Leerink Partners analyst Seamus Fernandez said in a research note that Merck's rapid advancement may pose a setback to similar programs from Roche and AstraZeneca.Roche's timeline for seeking regulatory approval remains unclear, Fernandez noted. AstraZeneca, meanwhile, may not be able to secure an accelerated review in lung cancer if the Bristol-Myers or Merck drug is already on the market, potentially adding several months to a decision on its contender. Roche said it expects pivotal data for its PD-L1 drug in lung and bladder cancer in the first half of this year, with potential filings seeking approval in the second half if the trials are successful.Bahija Jallal of AstraZeneca's MedImmune oncology unit, speaking at the JP Morgan healthcare conference in San Francisco, said the company's focus was on testing combinations of its immunotherapy with its own traditional drugs.""I think we're in a great position because we have biologics on one side and small molecules on the other side,"" Jallal said.Lung cancer is the leading cause of cancer deaths globally, killing more than 1.5 million people each year, according the World Health Organization.Bristol-Myers shares were up 3 percent at $62.17, while Merck shares were off 0.4 percent at $62.27.   (Reporting by Bill Berkrot in New York; Additional reporting by Caroline Humer in San Francisco; Editing by Leslie Adler)",2015-01-12,BMY,"Mon Jan 12, 2015 | 3:34pm EST","Merck, Bristol heat up immunotherapy race in lung cancer",http://www.reuters.com//article/bristol-myers-merck-co-lung-idUSL1N0UR1ZB20150112?type=companyNews
86,"  Bristol-Myers Squibb Co said the independent data monitoring committee concluded that a late stage study evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer met its endpoint.The company said the data demonstrates superior overall survival in patients receiving Opdivo compared to the control arm, indicating a survival advantage with an anti-PD1 immune checkpoint inhibitor in lung cancer.Bristol-Myers stopped the comparative portion of the trial and said it will share the data with health authorities. Last month, the U.S. Food and Drug Administration approved Opdivo for skin cancer, more than three months before the scheduled review date. Opdivo, or nivolumab, belongs to a promising new class of drugs designed to help the body's own immune system fight cancer by blocking a protein called Programmed Death receptor (PD-1).  (Reporting by Supriya Kurane in Bengaluru; Editing by Gopakumar Warrier)",2015-01-12,BMY,"Sun Jan 11, 2015 | 10:36pm EST",Bristol-Myers says panel finds Opdivo lung cancer study meets endpoint,http://www.reuters.com//article/us-bristol-myers-cancer-idUSKBN0KL05S20150112?type=companyNews
87,"  Jan 11 Bristol-Myers Squibb Co said the independent data monitoring committee concluded that a late stage study evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer met its endpoint.The company said the data demonstrates superior overall survival in patients receiving Opdivo compared to the control arm, indicating a survival advantage with an anti-PD1 immune checkpoint inhibitor in lung cancer. Bristol-Myers stopped the comparative portion of the trial and said it will share the data with health authorities. Last month, the U.S. Food and Drug Administration approved Opdivo for skin cancer, more than three months before the scheduled review date. Opdivo, or nivolumab, belongs to a promising new class of drugs designed to help the body's own immune system fight cancer by blocking a protein called Programmed Death receptor (PD-1).   (Reporting by Supriya Kurane in Bengaluru; Editing by Gopakumar Warrier)",2015-01-12,BMY,"Sun Jan 11, 2015 | 10:33pm EST",Bristol-Myers says panel finds Opdivo lung cancer study meets endpoint,http://www.reuters.com//article/bristol-myers-cancer-idUSL3N0UR1DD20150112?type=companyNews
88,"  Eli Lilly & Co signed two separate deals with Merck & Co Inc and Bristol-Myers Squibb Co to test combinations of its cancer treatments with two recently approved therapies that belong to a promising new class of drugs.Lilly will test its treatments - approved and experimental - in combination with PD-1 inhibitors Keytruda and Opdivo. The treatments are designed to help the body's own immune system fight cancer by blocking a protein called Programmed Death receptor (PD-1).Bristol-Myers' Opdivo was approved by the U.S. Food and Drugs Administration on Dec. 22. Merck's Keytruda was approved by the FDA on Sept. 4. It is also being tested as a treatment for a form of lung cancer.The deal signed with Merck will cover three studies of Keytruda with Lilly's two approved cancer drugs and one experimental treatment, the companies said. Lilly will conduct two out of the three studies planned with Keytruda. Lilly will test a combination of its experimental drug, galunisertib, and Bristol-Myers' Opdivo. (Reporting by Vidya L Nathan in Bengaluru; Editing by Maju Samuel)",2015-01-13,BMY,"Tue Jan 13, 2015 | 9:05am EST","Lilly to test combinations with Merck, Bristol-Myers' cancer drugs",http://www.reuters.com//article/us-lilly-study-idUSKBN0KM1HC20150113?type=companyNews
89,"  Jan 13 Eli Lilly & Co signed two separate deals with Merck & Co Inc and Bristol-Myers Squibb Co to test combinations of its cancer treatments with two recently approved therapies that belong to a promising new class of drugs.Lilly will test its treatments - approved and experimental - in combination with PD-1 inhibitors Keytruda and Opdivo.The treatments are designed to help the body's own immune system fight cancer by blocking a protein called Programmed Death receptor (PD-1). Bristol-Myers' Opdivo was approved by the U.S. Food and Drugs Administration on Dec. 22.Merck's Keytruda was approved by the FDA on Sept. 4. It is also being tested as a treatment for a form of lung cancer. The deal signed with Merck will cover three studies of Keytruda with Lilly's two approved cancer drugs and one experimental treatment, the companies said. Lilly will conduct two out of the three studies planned with Keytruda.Lilly will test a combination of its experimental drug, galunisertib, and Bristol-Myers' Opdivo.    (Reporting by Vidya L Nathan in Bengaluru; Editing by Maju Samuel)",2015-01-13,BMY,"Tue Jan 13, 2015 | 9:02am EST","Lilly to test combinations with Merck, Bristol-Myers' cancer drugs",http://www.reuters.com//article/lilly-study-idUSL3N0US4IG20150113?type=companyNews
90,"   By Bill Berkrot | NEW YORK  NEW YORK U.S. drugmaker Bristol-Myers Squibb Co on Tuesday said Chief Operating Officer Giovanni Caforio will replace Lamberto Andreotti as chief executive on May 5, in another selection of a long-time insider to lead the company.Caforio, 50, who has a medical background and led the company's global oncology operations, will take over Bristol-Myers at a time when it is riding high on its new high-profile cancer drugs that help the immune system fight the disease.Late last year, U.S. regulators approved Bristol's Opdivo, from a highly promising new class of immunotherapies called PD-1 inhibitors, to treat advanced melanoma.Opdivo is also being tested against lung cancer, with ambitious plans to test it in combination with several other medicines, both from in-house and from other companies, against a variety of cancers.Prior to Opdivo, Bristol's Yervoy, which uses another mechanism to take the brakes off the immune system, became the first drug to improve overall survival in patients with advanced melanoma - the deadliest of skin cancers. The company has several other immunotherapies in its developmental pipeline, as well as drugs for hepatitis C, fibrotic diseases and cardiovascular medicines. Andreotti, 64, who has been CEO since May 2010 after a long career with the company, will become executive chairman of the board on May 5 and continue as chairman after his Aug. 3 retirement, the company said.""I have a high level of confidence in Giovanni that is shared by everyone who has seen him consistently and successfully drive performance,"" Andreotti said in a statement. Caforio has been on the Bristol-Myers board since last year. He joined the company in 2000 as an executive in Italy following a medical affairs role at Abbott Laboratories.John Boris, an analyst with Suntrust Robinson Humphrey, said Caforio has a highly desirable combination of global commercial operations expertise and background as a medical doctor that will serve Bristol-Myers well as it launches new cancer medicines and other drugs.  ""He is a logicalsuccession and someone who will do a good job,"" Boris said. ""It will be a very smooth passing of the torch.""Former Chairman and Chief Executive James Cornelius, who helped restore luster to the drugmaker after an inventory scandal involving his predecessor, has chosen not to stand for re-election as non-executive chairman and will retire from the board, the company said. (Reporting by Bill Berkrot and Ransdell Pierson; Editing by James Dalgleish)",2015-01-20,BMY,"Tue Jan 20, 2015 | 6:34pm EST",Bristol-Myers taps insider Caforio as next CEO,http://www.reuters.com//article/us-bristolmyers-ceo-idUSKBN0KT2J420150120?type=companyNews
91,"  (Adds background on Bristol-Myers drugs)By Bill BerkrotNEW YORK Jan 20 U.S. drugmaker Bristol-Myers Squibb Co on Tuesday said Chief Operating Officer Giovanni Caforio will replace Lamberto Andreotti as chief executive on May 5, in another selection of a long-time insider to lead the company.Caforio, 50, who has a medical background and led the company's global oncology operations, will take over Bristol-Myers at a time when it is riding high on its new high-profile cancer drugs that help the immune system fight the disease.Late last year, U.S. regulators approved Bristol's Opdivo, from a highly promising new class of immunotherapies called PD-1 inhibitors, to treat advanced melanoma.Opdivo is also being tested against lung cancer, with ambitious plans to test it in combination with several other medicines, both from in-house and from other companies, against a variety of cancers. Prior to Opdivo, Bristol's Yervoy, which uses another mechanism to take the brakes off the immune system, became the first drug to improve overall survival in patients with advanced melanoma - the deadliest of skin cancers.The company has several other immunotherapies in its developmental pipeline, as well as drugs for hepatitis C, fibrotic diseases and cardiovascular medicines. Andreotti, 64, who has been CEO since May 2010 after a long career with the company, will become executive chairman of the board on May 5 and continue as chairman after his Aug. 3 retirement, the company said.""I have a high level of confidence in Giovanni that is shared by everyone who has seen him consistently and successfully drive performance,"" Andreotti said in a statement.Caforio has been on the Bristol-Myers board since last year. He joined the company in 2000 as an executive in Italy following a medical affairs role at Abbott Laboratories. John Boris, an analyst with Suntrust Robinson Humphrey, said Caforio has a highly desirable combination of global commercial operations expertise and background as a medical doctor that will serve Bristol-Myers well as it launches new cancer medicines and other drugs.""He is a logical succession and someone who will do a good job,"" Boris said. ""It will be a very smooth passing of the torch.""Former Chairman and Chief Executive James Cornelius, who helped restore luster to the drugmaker after an inventory scandal involving his predecessor, has chosen not to stand for re-election as non-executive chairman and will retire from the board, the company said.(Reporting by Bill Berkrot and Ransdell Pierson; Editing by James Dalgleish)",2015-01-20,BMY,"Tue Jan 20, 2015 | 6:33pm EST",UPDATE 1-Bristol-Myers taps insider Caforio as next CEO,http://www.reuters.com//article/bristolmyers-ceo-idUSL1N0UZ2JY20150120?type=companyNews
92,"  Jan 20 U.S. drugmaker Bristol-Myers Squibb Co  on Tuesday said Chief Operating Officer Giovanni Caforio will replace Lamberto Andreotti as chief executive on May 5, as the company again tapped a long-time insider to lead it.The 50-year-old Caforio, who has a medical background and led the company's global oncology operations, will take over Bristol-Myers at a time when it is riding high behind its new high-profile cancer drugs that help the immune system fight the disease.Andreotti, 64, who has been CEO since May 2010 after a long career with the company, will become executive chairman of the board on May 5 and continue as chairman after his Aug. 3 retirement, the company said. ""I have a high level of confidence in Giovanni that is shared by everyone who has seen him consistently and successfully drive performance,"" Andreotti said in a statement.Caforio has been on the Bristol-Myers board since last year. He joined the company in 2000 as an executive in Italy following a medical affairs role at Abbott Laboratories. John Boris, an analyst with Suntrust Robinson Humphrey, said Caforio has a highly desirable combination of global commercial operations expertise and background as a medical doctor that will serve Bristol-Myers well as it launches highly promising cancer medicines and other drugs. ""He is a logical succession and someone who will do a good job,"" Boris said. ""It will be a very smooth passing of the torch.""Former Chairman and Chief Executive James Cornelius, who helped restore luster to the drugmaker after an inventory scandal involving his predecessor, has chosen not to stand for re-election as non-executive chairman and will retire from the board, the company said.   (Reporting by Bill Berkrot and Ransdell Pierson; Editing by James Dalgleish)",2015-01-20,BMY,"Tue Jan 20, 2015 | 5:22pm EST",Bristol-Myers taps insider Caforio as next CEO,http://www.reuters.com//article/bristolmyers-ceo-idUSL1N0UZ2GX20150120?type=companyNews
93,     ,2015-01-27,BMY,"Tue Jan 27, 2015 | 5:42pm EST","UPDATE 2-U.S. multinationals hit hard by strong dollar, to bleed further into 2015",http://www.reuters.com//article/usa-earnings-dollar-idUSL1N0V61CU20150127?type=companyNews
94,"  (Repeats to fix formatting)* Strong dollar may cut up to $12 bln from Q4 U.S. revenue -FireApps* Dupont sees 2015 $0.60/share impact, Bristol-Myers $0.12-$0.14/share* Apple, P&G, Stryker also see headwindsBy Chuck Mikolajczak and Sinead CarewNEW YORK, Jan 27 A slew of U.S. multinational companies, from DuPont to Procter & Gamble, showed that a strong U.S. dollar hurt their earnings, and several blue-chip exporters said the situation will get worse if the greenback holds its strength.All told, the resurgent U.S. currency could shave up to $12 billion off U.S. companies' fourth-quarter 2014 revenue alone, according to currency expert Wolfgang Koester, chief executive of FireApps, a data analytics company in Phoenix, Arizona, that examines quarterly reports for currency-related losses.The pain is hitting multiple sectors, including industrial companies such as 3M Co, technology companies like Microsoft Corp and Apple Inc, airlines such as American Airlines Group Inc, healthcare companies, including Bristol-Myers Squibb Co and Pfizer Inc , and consumer firms like Procter & Gamble - which all garner a large portion of their sales from outside the United States.""This is a slow-motion crash,"" said Kim Forrest, senior equity research analyst at Fort Pitt Capital Group in Pittsburgh. It could take a couple of quarters for currency conversion losses to show up, she said.After hitting a 6-1/2 month low in May, the dollar  has surged nearly 20 percent against a basket of major currencies, making overseas sales denominated in other currencies less valuable in dollar terms. The stronger dollar can also make U.S.-made products more expensive for consumers in other currencies and thus cut demand.The Dow Jones industrial average, composed of large and well-known companies, was hit especially hard on Tuesday as six of seven companies in the index that reported results since Monday evening declined, with only United Technologies gaining.""You have companies who don't normally complain about (the dollar) who are starting to harp on it and it does make sense from an economic perspective that this would be a drag,"" said James Liu, global market strategist at JPMorgan Funds in Chicago. ""It's really the pace that matters - not just whether it is strengthening or weakening."" HEDGING HELP LIMITED WITH SHARP MOVES The choice for multinationals is stark. They can keep customers loyal by maintaining overseas prices and take a revenue hit from a tough conversion to dollars, or raise prices and risk the loss of customers to cheaper local competitors.While many companies successfully use currency hedging to at least partly protect against foreign exchange-related losses, the speed and extent of recent fluctuations have made it more difficult to hedge. This has also hurt Wall Street analysts' ability to estimate losses.One of the worst-hit companies appears to be chemicals giant DuPont, which derives roughly 60 percent of its revenue from overseas. DuPont said the strong dollar cut 7 cents per share off fourth-quarter earnings and will shave 60 cents off 2015 earnings per share based on recent currency rates. Procter & Gamble said foreign exchange will reduce its fiscal 2015 sales by 5 percent and its net earnings by 12 percent in what it described as its most significant currency impact ever. Bristol-Myers said it expects foreign exchange rates to cut its 2015 revenue by $800 million and 12 to 14 cents in terms of earnings per share.The impact looks even more abysmal when compared with the 1 cent per share currency impact target that multinationals set for their foreign exchange managers, according to FireApps.American icon Apple Inc is also at risk as it brings in roughly 62 percent of its revenue from overseas. It had to close its online store in Russia temporarily in December due to dramatic currency fluctuations.Currency could shave as much as $3 billion off Apple's 2015 revenue even if its hedging strategy succeeds in halving the impact, technology analyst Shannon Cross at Cross Research in Millburn, New Jersey, said ahead of its report.Apple's Chief Financial Officer said on Tuesday that foreign exchange is a ""clear headwind"" included in the company's guidance for the year ahead.Shares in Microsoft, which gets nearly three-quarters of its revenue from overseas, finished off 9.2 percent on Tuesday after it said it was hurt by the strong dollar but gave no specifics.Medical device maker Stryker Corp said that if exchange rates stay around current levels, it expects first- quarter and 2015 sales to be hurt by 3 percent to 4 percent.Other notables names citing currency headwinds so far in the earnings season include Johnson & Johnson and IBM .Dollar strength already shaved at least $4 billion off U.S. corporate revenue in the third quarter, according to FireApps. But actual losses may be much higher as many firms citing currency impacts did not disclose the amount, it noted.   (Additional reporting by Caroline Humer and Ransdell Pierson; Editing by Linda Stern, Dan Grebler and Christian Plumb)",2015-01-27,BMY,"Tue Jan 27, 2015 | 5:39pm EST","RPT-UPDATE 2-U.S. multinationals hit hard by strong dollar, to bleed further into 2015",http://www.reuters.com//article/usa-earnings-dollar-idUSL1N0V62PS20150127?type=companyNews
95,"  (Adds details on 2015 forecast, shares)By Ransdell PiersonJan 27 Bristol-Myers Squibb Co on Tuesday said profits could fall as much as 16 percent in 2015, a worse forecast than Wall Street had expected, as the stronger dollar takes a toll on U.S.  drugmakers.Bristol-Myers, whose shares fell almost 2 percent in premarket trading, said it earned $13 million, or 1 cent per share, in the fourth quarter. That compared with $726 million, or 44 cents per share, a year earlier.Excluding special items, including an after-tax charge of 28 cents per share resulting from the transfer of U.S. pension obligations, Bristol-Myers earned 46 cents per share. Analysts on average expected 41 cents. Revenue fell 4 percent to $4.26 billion, coming in above Wall Street expectations of $4.03 billion. Sales would have fallen only 1 percent if not for the stronger dollar, which reduces the value of sales abroad.Bristol-Myers said it expects 2015 earnings of $1.55 to $1.70 per share, assuming current foreign exchange rates. The entire range is below the average analyst forecast of $1.71 per share and reflects earnings as much as 16 percent below those seen in 2014. Many investors expect Bristol-Myers earnings to vault higher in following years thanks to development of potentially lucrative immuno-oncology treatments, drugs that treat cancer by harnessing the immune system.U.S. regulators last month approved its Opdivo medicine to treat patients with advanced melanoma. It competes with Keytruda, a melanoma treatment from Merck and Co that also works by blocking a protein called PD-1 that allows tumor cells to conceal themselves. Rival U.S. drugmaker Pfizer Inc on Tuesday also provided a 2015 view below Wall Street expectations. It cited competition with cheaper generic drugs and the impact of the stronger dollar.Bristol-Myers shares were trading at $61.30 before the market opened, from their closing price Monday of $62.46 on the New York Stock Exchange.(Reporting by Ransdell Pierson; Editing by Lisa Von Ahn and Alden Bentley)",2015-01-27,BMY,"Tue Jan 27, 2015 | 9:11am EST",UPDATE 1-Bristol-Myers issues cautious 2015 forecast due to strong dollar,http://www.reuters.com//article/bristol-myers-results-idUSL1N0V60TI20150127?type=companyNews
96,"  Jan 27 Bristol-Myers Squibb Co reported higher-than-expected quarterly earnings, helped by surprisingly strong sales of its hepatitis C drugs and its Eliquis blood clot preventer.The U.S. drugmaker on Tuesday said it earned $13 million, or 1 cent per share, in the fourth quarter. That compared with $726 million, or 44 cents per share, a year earlier. Excluding special items, including an after-tax charge of 28 cents per share resulting from the transfer of U.S. pension obligations, Bristol-Myers earned 46 cents per share. Analysts on average expected 41 cents.  Revenue fell 4 percent to $4.26 billion, coming in above Wall Street expectations of $4.03 billion. Sales would have fallen only 1 percent if not for the stronger dollar, which reduces the value of sales abroad.    (Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)",2015-01-27,BMY,"Tue Jan 27, 2015 | 7:56am EST",Bristol-Myers quarterly profit beats forecasts,http://www.reuters.com//article/bristol-myers-results-idUSL1N0V60RO20150127?type=companyNews
97,"  The U.S. Food and Drug Administration on Thursday approved two fixed-dose HIV pills that combine protease inhibitors - one made by Bristol-Myers Squibb Co and the other by Johnson & Johnson - both with a boosting agent produced by Gilead Sciences Inc.Bristol-Myers said its drug, Evotaz, is a once-daily pill containing Reyataz, also known as atazanavir, a protease inhibitor, with the booster cobicistat. J&J's once-daily Prezcobix, combines protease inhibitor darunavir, or Prezista, with cobicistat. The FDA approved both drugs for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. Because patients infected with human immunodeficiency virus, which can cause AIDS, may over time become resistant to treatments, there is a need for a broad range of antiretroviral therapies.  (Reporting By Deena Beasley. Editing by Andre Grenon)",2015-01-29,BMY,"Thu Jan 29, 2015 | 6:37pm EST","FDA approves Bristol-Myers, J&J HIV pills",http://www.reuters.com//article/us-bristol-myers-hiv-fda-idUSKBN0L22W120150129?type=companyNews
98,"  Jan 29 The U.S. Food and Drug Administration has approved the sale of Evotaz, a once-daily combination pill to treat HIV made by Bristol-Myers Squibb Co, the company said on Thursday.The new drug combines Reyataz, also known as atazanavir, a Bristol-Myers' protease inhibitor, with cobicistat, a boosting agent produced by Gilead Sciences Inc.  The FDA approval is for use of Evotaz in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.   (Reporting By Deena Beasley. Editing by Andre Grenon) ",2015-01-29,BMY,"Thu Jan 29, 2015 | 5:44pm EST",U.S. FDA approves Bristol-Myers' HIV drug,http://www.reuters.com//article/bristol-myers-hiv-fda-idUSL1N0V83US20150129?type=companyNews
99,"  (Adds PTC Therapeutics, Keurig Green Mountain, Finmeecanica, Bristol-Myers, AAR, Globe Specialty, Armstrong World)Feb 23 The following bids, mergers, acquisitions and disposals were reported by 2115 GMT on Monday:** Rare disease drugmaker PTC Therapeutics Inc is exploring a potential sale amid takeover interest from several pharmaceutical companies including Shire PLC and BioMarin Pharmaceutical Inc, according to people familiar with the matter.** EU antitrust regulators launched an extensive investigation into General Electric's proposed takeover of Alstom's power equipment business, concerned that the 12.4-billion-euro ($14.06 billion) deal may reduce competition.** The European Commission said it had opened an in-depth investigation into Cargill Inc's planned acquisition of the industrial chocolate business of rival Archer Daniels Midland Co.** Keurig Green Mountain Inc, the maker of the K-Cup single-serve coffee pod, will buy back more than half of Italian coffee maker Luigi Lavazza SpA's stake in the company for about $624 million.**  Italian aerospace and defense group Finmeccanica  is set to announce the sale of its shares in rail and signaling units AnsaldoBreda and Ansaldo STS to Japan's Hitachi as soon as Tuesday, a source close to the matter said.** German holding company Primondo GmbH is looking to sell mail-order group TriStyle and plans to approach private equity groups with an interest in fashion, such as Permira Beteiligungsberatung, two people with knowledge of the offering said.** Canada's Valeant Pharmaceuticals International Inc   agreed to acquire gastrointestinal drug maker Salix Pharmaceuticals Ltd in an all-cash deal valued at about $10.1 billion, the two companies said.** Japanese chemical maker Asahi Kasei Corp said on Monday it would buy Polypore International Inc's Energy Storage segment for $2.2 billion as it seeks to expand in the energy and environment business.** Bristol-Myers Squibb Co said it would buy privately held drugmaker Flexus Biosciences Inc for up to $1.25 billion to add an emerging class of cancer-fighting drugs to its pipeline. ** U.S. silicon-alloy producer Globe Specialty Metals Inc  and Spain's Grupo FerroAtlntica SA said they would merge to form a company with an enterprise value of $3.1 billion and controlled by FerroAtlntica shareholders.** Britain's finance ministry has raised 500 million pounds ($769 million) through the sale of a further 1 percent stake in Lloyds Banking Group Plc, cutting its holding to below 24 percent.** Aviation services provider AAR Corp said it would sell its cargo handling business, Telair Cargo Group, to TransDigm Group Inc for $725 million in cash.** South Africa's Bidvest Group Ltd has offered to buy shares it doesn't already own in drugmaker Adcock Ingram Holdings Ltd, in a deal worth a potential 6 billion rand ($515 million). ** Japan's Sosei Group Corp is to buy privately owned British biotechnology business Heptares for up to $400 million, the companies said, continuing the feverish pace of dealmaking in the sector.** Germany's Aareal Bank AG said it had agreed to buy property lender Westdeutsche Immobilienbank for 350 million euros ($398 million) from Erste Abwicklungsanstalt.** DS Smith Plc, a British maker of corrugated cardboard, recycled paper and plastic packaging, said it agreed to buy Vienna-based packaging business Duropack for about 300 million euros ($341 million) from a subsidiary of One Equity Partners.** A trade union group representing Aer Lingus Group Plc  workers has reversed its position and said it would now back a takeover approach by International Airlines Group SA  after the British Airways' owner laid out its growth plans for the Irish airline.** British holiday company Thomas Cook Group Plc is seeking to sell its airline business as part of a cost-saving plan, the Sunday Times newspaper reported. ** Rupert Murdoch's Twenty-First Century Fox Inc  held preliminary takeover talks with Discovery Communications Inc with a view to creating a $100 billion entertainment giant, the Australian Financial Review reported. Fox, which like other broadcasters is battling a shift to on-demand TV, denied there had been any talks with Discovery, which owns Animal Planet and the Discovery Channel.** South Korea's Samsung SDI Co said it had agreed to buy the battery pack business of Canadian car parts maker Magna International Inc, marking a further push by the Samsung Electronics affiliate into a key automotive parts business.** Japan's biggest airline, ANA Holdings Inc, confirmed that it offered to help bail out bankrupt airline Skymark Airlines Inc.** Private equity firm Abraaj Group has bought a minority stake in Hepsiburada.com, one of the largest online retailers in Turkey, from the Dogan family, the Dubai-based firm said.** British American Tobacco Plc is considering a buyout of the 24.7 percent stake it does not already own in Souza Cruz SA, Brazil's largest cigarette company, in a deal that could cost about 2.3 billion pounds ($3.53 billion).** The private equity owners of Parques Reunidos have put on ice plans to sell the Spanish zoo, marine and water park operator that could have valued the business at about 2 billion euros, six sources familiar with the matter said on Monday.** Construction materials maker Armstrong World Industries Inc said it would spin off its flooring business to concentrate on its ceilings unit.** Austrian property group Buwog AG has no plans to buy competitor conwert Immobilien Invest SE but would be interested in its German real estate portfolio should this be put up for sale, Buwog Chief Executive Daniel Riedl said.** Russia's Sberbank Rossii OAO is preparing to sell its Slovak and Hungarian operations, Czech newspaper Lidove Noviny reported, citing unnamed sources.   ($1 = 0.88 euros) ($1 = 0.65 pounds) ($1 = 2.86 Brazilian reais)   (Compiled by Amrutha Gayathri and Kshitiz Goliya in Bengaluru)",2015-02-23,BMY,"Mon Feb 23, 2015 | 4:19pm EST",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL4N0VX26B20150223?type=companyNews
100,"  Bristol-Myers Squibb Co (BMY.N) said it would buy privately held drugmaker Flexus Biosciences Inc for up to $1.25 billion to add an emerging class of cancer-fighting drugs to its pipeline.The deal value includes $800 million in an upfront payment and up to $450 million of milestone payments, Bristol-Myers said in a statement on Monday.Separately, Bristol-Myers also signed a deal with Rigel Pharmaceuticals Inc (RIGL.O) to develop a line of cancer therapies that can be used with Bristol-Myers's immunotherapy cancer drugs Opdivo and Yervoy.Bristol-Myers will pay Rigel $339 million, including milestones, bringing the drugmaker's investment in cancer treatments on Monday to $1.59 billion. Buying Flexus will give Bristol-Myers rights to an experimental cancer compound belonging to a class of drugs called IDO1-inhibitors, which work by disrupting mechanisms through which cancer cells hide from the body's immune cells.Bristol-Myers currently has eight cancer compounds in various stages of development, four of which are designed to make the body fight cancer on its own. None of them are IDO-inhibitors. Flexus's remaining assets, which are also cancer related, will be part of a newly formed company, Bristol-Myers said. Bristol-Myers shares closed at $60.52 on Friday. They were untraded on Monday before the bell. Rigel's shares shot up 43 percent to $3.65 in premarket trading. (Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D'Souza)",2015-02-23,BMY,"Mon Feb 23, 2015 | 8:46am EST",Bristol-Myers to buy private cancer drugmaker for up to $1.25 billion,http://www.reuters.com//article/us-flexus-bioscience-m-a-bristol-myers-idUSKBN0LR16720150223?type=companyNews
101,"  (Adds details on Flexus deal; adds Rigel deal, shares)Feb 23 Bristol-Myers Squibb Co said it would buy privately held drugmaker Flexus Biosciences Inc for up to $1.25 billion to add an emerging class of cancer-fighting drugs to its pipeline.The deal value includes $800 million in an upfront payment and up to $450 million of milestone payments, Bristol-Myers said in a statement on Monday.Separately, Bristol-Myers also signed a deal with Rigel Pharmaceuticals Inc to develop a line of cancer therapies that can be used with Bristol-Myers's immunotherapy cancer drugs Opdivo and Yervoy. Bristol-Myers will pay Rigel $339 million, including milestones, bringing the drugmaker's investment in cancer treatments on Monday to $1.59 billion. Buying Flexus will give Bristol-Myers rights to an experimental cancer compound belonging to a class of drugs called IDO1-inhibitors, which work by disrupting mechanisms through which cancer cells hide from the body's immune cells.Bristol-Myers currently has eight cancer compounds in various stages of development, four of which are designed to make the body fight cancer on its own. None of them are IDO-inhibitors. Flexus's remaining assets, which are also cancer related, will be part of a newly formed company, Bristol-Myers said.Bristol-Myers shares closed at $60.52 on Friday. They were untraded on Monday before the bell. Rigel's shares shot up 43 percent to $3.65 in premarket trading.   (Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D'Souza)",2015-02-23,BMY,"Mon Feb 23, 2015 | 8:45am EST",UPDATE 1-Bristol-Myers to buy private cancer drugmaker for up to $1.25 bln,http://www.reuters.com//article/flexus-bioscience-ma-bristol-myers-idUSL4N0VX2SG20150223?type=companyNews
102,"  Feb 23 Bristol-Myers Squibb Co said it would buy privately held drugmaker Flexus Biosciences Inc for up to $1.25 billion to expand its pipeline of cancer drugs. The deal value includes $800 million in an upfront payment and up to $450 million of milestone payments, Bristol-Myers said in a statement on Monday.    (Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D'Souza)  ",2015-02-23,BMY,"Mon Feb 23, 2015 | 8:10am EST",Bristol-Myers to buy private cancer drugmaker for up to $1.25 bln,http://www.reuters.com//article/flexus-bioscience-ma-bristol-myers-idUSL4N0VX2RJ20150223?type=companyNews
103,"   By Bill Berkrot  Ninety-seven percent of hepatitis C patients also infected with HIV were cured of the liver-destroying virus after 12 weeks of treatment with Bristol-Myers Squibb's daclatasvir and Gilead Sciences' Sovaldi, according to data from a study presented on Thursday.The results could help put Bristol's hepatitis C program back on track in the United States, following a setback last year.In the Ally-2 study, including new patients and those not helped by prior treatment, 149 of 153 were deemed cured of hepatitis C regardless of what other anti-viral regimens they were on for HIV, the virus that causes AIDS.""The results of Ally-2 signaled that nearly all HIV-HCV coinfected patients in the study could be cured of hepatitis C with a 12-week regimen on daclatasvir and sofosbuvir,"" Dr. David Wyles, the study's lead investigator, said in a statement, using the chemical name for Sovaldi.There were no reported serious side effects related to the hepatitis drugs, and patients did not require any alteration of HIV medications over potential drug-drug interactions. ""This is a paramount consideration for clinicians treating this patient population,"" added Wyles, who presented the data at the Conference on Retroviruses and Opportunistic Infections (CROI) meeting in Seattle.About 300,000 Americans with HIV also suffer from hepatitis C, according to the Centers for Disease Control and Prevention, making them prone to more rapid progression to liver damage. Daclatasvir is approved in Europe, Brazil and Japan as part of combination therapy, but has fallen behind rivals in the world's most lucrative market. In November, the U.S. Food and Drug Administration declined to approve daclatasvir in combination with other antiviral drugs.The company had sought FDA permission to market daclatasvir in combination with another Bristol drug, asunaprevir. But Bristol abandoned its U.S. marketing application for asunaprevir due to potential competition from more potent drugs, leaving the FDA without data to gauge the effectiveness of daclatasvir as part of a combination regimen.The FDA asked for new data on daclatasvir with other drugs, which the Ally results could help satisfy. Sovaldi is part of Gilead's market-leading hepatitis C franchise and half of its own one-pill-per-day combination treatment Harvoni.All 26 patients in the Ally-2 study with the less common genotypes 2, 3 and 4 of the virus were cured by the combination. A shorter eight-week regimen tested among 50 patients led to a 75 percent cure rate. (Reporting by Bill Berkrot; Editing by James Dalgleish)",2015-02-26,BMY,"Thu Feb 26, 2015 | 3:20pm EST",Bristol hep C drug helps cure 97 percent of HIV coinfected patients: study,http://www.reuters.com//article/us-bristolmyers-hepatitis-idUSKBN0LU2E720150226?type=companyNews
104,"   By Bill Berkrot  Feb 26 Ninety-seven percent of hepatitis C patients also infected with HIV were cured of the liver-destroying virus after 12 weeks of treatment with Bristol-Myers Squibb's daclatasvir and Gilead Sciences'  Sovaldi, according to data from a study presented on Thursday.The results could help put Bristol's hepatitis C program back on track in the United States, following a setback last year.In the Ally-2 study, including new patients and those not helped by prior treatment, 149 of 153 were deemed cured of hepatitis C regardless of what other anti-viral regimens they were on for HIV, the virus that causes AIDS.""The results of Ally-2 signaled that nearly all HIV-HCV coinfected patients in the study could be cured of hepatitis C with a 12-week regimen on daclatasvir and sofosbuvir,"" Dr. David Wyles, the study's lead investigator, said in a statement, using the chemical name for Sovaldi. There were no reported serious side effects related to the hepatitis drugs, and patients did not require any alteration of HIV medications over potential drug-drug interactions.""This is a paramount consideration for clinicians treating this patient population,"" added Wyles, who presented the data at the Conference on Retroviruses and Opportunistic Infections (CROI) meeting in Seattle. About 300,000 Americans with HIV also suffer from hepatitis C, according to the Centers for Disease Control and Prevention, making them prone to more rapid progression to liver damage.Daclatasvir is approved in Europe, Brazil and Japan as part of combination therapy, but has fallen behind rivals in the world's most lucrative market. In November, the U.S. Food and Drug Administration declined to approve daclatasvir in combination with other antiviral drugs. The company had sought FDA permission to market daclatasvir in combination with another Bristol drug, asunaprevir. But Bristol abandoned its U.S. marketing application for asunaprevir due to potential competition from more potent drugs, leaving the FDA without data to gauge the effectiveness of daclatasvir as part of a combination regimen.The FDA asked for new data on daclatasvir with other drugs, which the Ally results could help satisfy.Sovaldi is part of Gilead's market-leading hepatitis C franchise and half of its own one-pill-per-day combination treatment Harvoni.All 26 patients in the Ally-2 study with the less common genotypes 2, 3 and 4 of the virus were cured by the combination. A shorter eight-week regimen tested among 50 patients led to a 75 percent cure rate.   (Reporting by Bill Berkrot; Editing by James Dalgleish)",2015-02-26,BMY,"Thu Feb 26, 2015 | 3:15pm EST",Bristol hep C drug helps cure 97 pct of HIV coinfected patients-study,http://www.reuters.com//article/bristolmyers-hepatitis-idUSL1N0W02MF20150226?type=companyNews
105,"   By Bill Berkrot  U.S. health regulators on Wednesday swiftly approved a Bristol-Myers Squibb Co drug that helps the immune system fight the most common form of lung cancer, sending the company's shares up more than 5 percent to a multi-year high.The eagerly anticipated Food and Drug Administration approval of the drug known as Opdivo came only about three months after Bristol provided trial results showing that the medicine extended survival in non-small cell lung cancer (NSCLC), one of the biggest markets in oncology. The decision also came more than three months ahead of an expected action date by the agency.""This approval will provide patients and health care providers knowledge of the survival advantage associated with Opdivo and will help guide patient care and future lung cancer trials,"" Richard Pazdur, the FDA's head of hematology and oncology product evaluation, said in a statement.Opdivo, known chemically as nivolumab, was approved to  treat non-small cell lung cancer after the disease has progressed following platinum-based chemotherapy, typically the first-line treatment against the disease. It was previously approved to treat advanced melanoma, the deadliest form of skin cancer. Opdivo belongs to a highly promising new class of medicines called PD-1 inhibitors that work by blocking a mechanism tumors use to hide from the immune system, allowing it to recognize and attack cancer cells.Opdivo was reviewed under the FDA's priority review program, which provides for an expedited review of drugs the agency believes would provide significant improvement in treating a serious condition. Analysts believe lung cancer could add billions of dollars in annual sales for Opdivo.  Lung cancer is the leading cause of cancer death in the United States, with an estimated 224,210 new cases and 159,260 deaths in 2014. Non-small cell lung cancer is by far the most common type of the disease. Bristol-Myers shares were up 5.3 percent at $65.22 on the New York Stock Exchange, a level last reached in 2001. (Additional reporting by Michele Gershberg; editing by Chris Reese and Christian Plumb)",2015-03-04,BMY,"Wed Mar 4, 2015 | 3:06pm EST",U.S. FDA approves Bristol-Myers immunotherapy for lung cancer,http://www.reuters.com//article/us-bristol-myers-fda-lung-idUSKBN0M028Q20150304?type=companyNews
106,"  (Adds FDA comment, background, share price)By Bill BerkrotMarch 4 U.S. health regulators on Wednesday swiftly approved a Bristol-Myers Squibb Co drug that helps the immune system fight the most common form of lung cancer, sending the company's shares up more than 5 percent to a multi-year high.The eagerly anticipated Food and Drug Administration approval of the drug known as Opdivo came only about three months after Bristol provided trial results showing that the medicine extended survival in non-small cell lung cancer (NSCLC), one of the biggest markets in oncology. The decision also came more than three months ahead of an expected action date by the agency. ""This approval will provide patients and health care providers knowledge of the survival advantage associated with Opdivo and will help guide patient care and future lung cancer trials,"" Richard Pazdur, the FDA's head of hematology and oncology product evaluation, said in a statement.Opdivo, known chemically as nivolumab, was approved to  treat non-small cell lung cancer after the disease has progressed following platinum-based chemotherapy, typically the first-line treatment against the disease. It was previously approved to treat advanced melanoma, the deadliest form of skin cancer. Opdivo belongs to a highly promising new class of medicines called PD-1 inhibitors that work by blocking a mechanism tumors use to hide from the immune system, allowing it to recognize and attack cancer cells.Opdivo was reviewed under the FDA's priority review program, which provides for an expedited review of drugs the agency believes would provide significant improvement in treating a serious condition. Analysts believe lung cancer could add billions of dollars in annual sales for Opdivo.Lung cancer is the leading cause of cancer death in the United States, with an estimated 224,210 new cases and 159,260 deaths in 2014. Non-small cell lung cancer is by far the most common type of the disease.Bristol-Myers shares were up 5.3 percent at $65.22 on the New York Stock Exchange, a level last reached in 2001.   (Additional reporting by Michele Gershberg; editing by Chris Reese and Christian Plumb)",2015-03-04,BMY,"Wed Mar 4, 2015 | 2:57pm EST",UPDATE 1-U.S. FDA approves Bristol-Myers immunotherapy for lung cancer,http://www.reuters.com//article/bristol-myers-fda-lung-idUSL1N0W621A20150304?type=companyNews
107,"   By Ben Hirschler | LONDON  LONDON The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic.The agreement gives the U.S. drugmaker an exclusive option to the Danish biotech firm's therapeutic prostate cancer vaccine Prostvac and signals that such shots may have a bright future when combined with so-called checkpoint inhibitor drugs.Shares in Bavarian Nordic surged 35 percent on Wednesday on news of the Bristol-Myers tie-up, under which it could receive up to $975 million, including an upfront payment of $60 million.Unlike traditional preventative vaccines, therapeutic ones are designed for people with established disease and the aim is to boost the patient's immune system to keep tumors at bay.Unfortunately, they have run into problems in practice, leading to a series of failures with experimental products such as Merck KGaA's Stimuvax and GlaxoSmithKline's MAGE-A3. The one vaccine to make it to market, Dendreon's Provenge, has not been a commercial success.But Bristol-Myers thinks vaccines, which trigger a response from the immune system's ""foot soldiers"", can play an important role when given in combination with checkpoint inhibitors, like its drug Yervoy, which take the brakes off other immune cells.A week ago, the U.S. company and its Danish partner released early data from a study involving 30 patients showing that 20 percent of men with advanced prostate cancer remained alive 80 months after starting treatment with the most promising dose of Prostvac and Yervoy. The idea of combining therapeutic cancer vaccines with checkpoint inhibitors has gained traction among researchers in recent months and was a talking-point at the European Society of Medical Oncology annual congress in Madrid in September.Roche Chief Executive Severin Schwan also told Reuters last year that the Swiss group, which is the world's largest maker of cancer drugs, was exploring ways of combining its checkpoint inhibitors with cancer vaccines. Companies including Roche, Bristol-Myers, Merck & Co and AstraZeneca are investing heavily in ways to harness the immune system against cancer as they chase an immunotherapy market that some analysts predict will eventually generate annual sales of more than $30 billion. (Editing by Jane Merriman)",2015-03-04,BMY,"Wed Mar 4, 2015 | 10:45am EST",Bristol's $1 billion Bavarian deal may signal cancer vaccine revival,http://www.reuters.com//article/us-bavarian-nordic-bristol-myers-cancer-idUSKBN0M01RZ20150304?type=companyNews
108,"   By Ben Hirschler | LONDON, March 4  LONDON, March 4 The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic .The agreement gives the U.S. drugmaker an exclusive option to the Danish biotech firm's therapeutic prostate cancer vaccine Prostvac and signals that such shots may have a bright future when combined with so-called checkpoint inhibitor drugs.Shares in Bavarian Nordic surged 35 percent on Wednesday on news of the Bristol-Myers tie-up, under which it could receive up to $975 million, including an upfront payment of $60 million.Unlike traditional preventative vaccines, therapeutic ones are designed for people with established disease and the aim is to boost the patient's immune system to keep tumours at bay. Unfortunately, they have run into problems in practice, leading to a series of failures with experimental products such as Merck KGaA's Stimuvax and GlaxoSmithKline's  MAGE-A3.The one vaccine to make it to market, Dendreon's  Provenge, has not been a commercial success. But Bristol-Myers thinks vaccines, which trigger a response from the immune system's ""foot soldiers"", can play an important role when given in combination with checkpoint inhibitors, like its drug Yervoy, which take the brakes off other immune cells.A week ago, the U.S. company and its Danish partner released early data from a study involving 30 patients showing that 20 percent of men with advanced prostate cancer remained alive 80 months after starting treatment with the most promising dose of Prostvac and Yervoy. The idea of combining therapeutic cancer vaccines with checkpoint inhibitors has gained traction among researchers in recent months and was a talking-point at the European Society of Medical Oncology annual congress in Madrid in September.Roche Chief Executive Severin Schwan also told Reuters last year that the Swiss group, which is the world's largest maker of cancer drugs, was exploring ways of combining its checkpoint inhibitors with cancer vaccines.Companies including Roche, Bristol-Myers, Merck & Co  and AstraZeneca are investing heavily in ways to harness the immune system against cancer as they chase an immunotherapy market that some analysts predict will eventually generate annual sales of more than $30 billion.(Editing by Jane Merriman)",2015-03-04,BMY,"Wed Mar 4, 2015 | 10:37am EST",Bristol's $1 bln Bavarian deal may signal cancer vaccine revival,http://www.reuters.com//article/bavarian-nordic-bristol-myers-cancer-vac-idUSL5N0W63L720150304?type=companyNews
109,"   By Sabina Zawadzki | COPENHAGEN  COPENHAGEN Bavarian Nordic (BAVA.CO) has struck a prostate cancer drug deal with Bristol-Myers Squibb (BMY.N) that could be worth $1 billion should its trials, part of a new field in cancer treatment, be successful.Shares in the Danish company soared and by 0950 GMT (0450 ET) they were trading at 282 Danish crowns ($42), up 33 percent. The jump added over $260 million to its market value of $880 million.The agreement gives the U.S. company an exclusive option to license Bavarian's Prostvac drug, an immunotherapy treatment that helps the body's own immune cells fight tumors.Immunotherapy for cancer is a rapidly evolving field which promises better and longer-lasting treatments, although oncology experts warn financial costs are high. Under the deal, Bavarian Nordic stands to receive up to $975 million, including $60 million it will get upfront, if it passes trials and sales milestones, and could also receive royalties.Prostvac is currently undergoing Phase III trials -- the last set of tests before it can be sold on global markets. ""A significant Phase II survival benefit suggests Prostvac immunotherapy has the potential to revolutionize prostate cancer treatment,"" analysts at Jefferies said in a note.Last week Bavarian said results from a small early-stage trial conducted by the U.S. National Cancer Institute, showed Prostvac helped extend survival in patients with advanced prostate cancer significantly. In that trial, patients were treated with Prostvac in addition to escalating doses of Bristol-Myers Squibb's Yervoy, an injectable treatment for advanced melanoma that works by taking the brakes off the body's immune system.Bavarian Chief Executive Paul Chaplin said full results of the Phase III trial are expected by early 2017 but that the company is looking to improve the potential sales position of the drug by combining it with other treatments. ""We will be approved as a monotherapy but what our colleagues at NCI have already shown is that there are synergistic benefits of combining Prostvac,"" he told Reuters.   ""That is where the treatment will be moving."" The two companies said on Wednesday they were preparing for Phase II trials of Prostvac together with Yervoy.""Scientific rationale exists to evaluate Prostvac in combination with Yervoy and other agents from Bristol-Myers Squibb's immuno-oncology portfolio,"" they said in a statement. The deal follows Bavarian's agreement last year with a unit of Johnson & Johnson (JNJ.N) to trial an Ebola vaccine, as an outbreak spread across West Africa.Chaplin said the two deals would allow Bavarian to invest more aggressively in its pipeline of drugs that cover infectious diseases including smallpox and cancer because a Phase III trial for such a small company is very costly.""Fortunately we had the sales of the smallpox vaccine, which was driving our ability to invest in this space, but it was limiting our ability to do other things,"" he said. ""We're spoilt for choice as to where to invest."" (Additional reporting by Teis Jensen; Editing by Mark Potter and Jason Neely)",2015-03-04,BMY,"Wed Mar 4, 2015 | 8:27am EST",Bavarian Nordic shares leap on $1 billion Bristol-Myers deal,http://www.reuters.com//article/us-bavarian-nordic-bristol-myers-idUSKBN0M00R520150304?type=companyNews
110,"  (Adds comments from Bavarian CEO, updates share price)By Sabina ZawadzkiCOPENHAGEN, March 4 Bavarian Nordic  has struck a prostate cancer drug deal with Bristol-Myers Squibb  that could be worth $1 billion should its trials, part of a new field in cancer treatment, be successful.Shares in the Danish company soared and by 0950 GMT they were trading at 282 Danish crowns ($42), up 33 percent. The jump added over $260 million to its market value of $880 million.The agreement gives the U.S. company an exclusive option to license Bavarian's Prostvac drug, an immunotherapy treatment that helps the body's own immune cells fight tumours.Immunotherapy for cancer is a rapidly evolving field which promises better and longer-lasting treatments, although oncology experts warn financial costs are high.Under the deal, Bavarian Nordic stands to receive up to $975 million, including $60 million it will get upfront, if it passes trials and sales milestones, and could also receive royalties. Prostvac is currently undergoing Phase III trials -- the last set of tests before it can be sold on global markets.""A significant Phase II survival benefit suggests Prostvac immunotherapy has the potential to revolutionise prostate cancer treatment,"" analysts at Jefferies said in a note.Last week Bavarian said results from a small early-stage trial conducted by the U.S. National Cancer Institute, showed Prostvac helped extend survival in patients with advanced prostate cancer significantly. In that trial, patients were treated with Prostvac in addition to escalating doses of Bristol-Myers Squibb's Yervoy, an injectable treatment for advanced melanoma that works by taking the brakes off the body's immune system.Bavarian Chief Executive Paul Chaplin said full results of the Phase III trial are expected by early 2017 but that the company is looking to improve the potential sales position of the drug by combining it with other treatments.""We will be approved as a monotherapy but what our colleagues at NCI have already shown is that there are synergistic benefits of combining Prostvac,"" he told Reuters.   ""That is where the treatment will be moving."" The two companies said on Wednesday they were preparing for Phase II trials of Prostvac together with Yervoy.""Scientific rationale exists to evaluate Prostvac in combination with Yervoy and other agents from Bristol-Myers Squibb's immuno-oncology portfolio,"" they said in a statement.The deal follows Bavarian's agreement last year with a unit of Johnson & Johnson to trial an Ebola vaccine, as an outbreak spread across West Africa.Chaplin said the two deals would allow Bavarian to invest more aggressively in its pipeline of drugs that cover infectious diseases including smallpox and cancer because a Phase III trial for such a small company is very costly.""Fortunately we had the sales of the smallpox vaccine, which was driving our ability to invest in this space, but it was limiting our ability to do other things,"" he said. ""We're spoilt for choice as to where to invest.""($1 = 6.6991 Danish crowns)   (Additional reporting by Teis Jensen; Editing by Mark Potter and Jason Neely)",2015-03-04,BMY,"Wed Mar 4, 2015 | 8:23am EST",UPDATE 2-Bavarian Nordic shares leap on $1 bln Bristol-Myers deal,http://www.reuters.com//article/bavarian-nordic-bristol-myers-idUSL5N0W61MY20150304?type=companyNews
111,"  COPENHAGEN Bavarian Nordic expects the full results of its Phase III trials for prostate cancer drug Prostvac by early 2017, Chief Executive Paul Chaplin said after the Danish firm struck a $1 billion supply deal with Bristol-Myers Squibb.""We're looking at late 2016, early 2017 based on potential full data readout,"" he said when asked when the results could come.  ""There are pre-interim analyses that have been agreed with the FDA (U.S. Food and Drugs Administration). That could, of course, trigger earlier data, but we're not really guiding when they will occur,"" Chaplin told Reuters.   (Reporting by Sabina Zawadzki, editing by Terje Solsvik)",2015-03-04,BMY,"Wed Mar 4, 2015 | 7:53am EST",Bavarian sees results of Phase III Prostvac trial by early 2017,http://www.reuters.com//article/us-bavarian-nordic-bristol-myers-idUSKBN0M01BG20150304?type=companyNews
112,"  COPENHAGEN, March 4 Bavarian Nordic  expects the full results of its Phase III trials for prostate cancer drug Prostvac by early 2017, Chief Executive Paul Chaplin said after the Danish firm struck a $1 billion supply deal with Bristol-Myers Squibb.""We're looking at late 2016, early 2017 based on potential full data readout,"" he said when asked when the results could come.  ""There are pre-interim analyses that have been agreed with the FDA (U.S. Food and Drugs Administration). That could, of course, trigger earlier data, but we're not really guiding when they will occur,"" Chaplin told Reuters.   (Reporting by Sabina Zawadzki, editing by Terje Solsvik) ",2015-03-04,BMY,"Wed Mar 4, 2015 | 7:38am EST",Bavarian sees results of Phase III Prostvac trial by early 2017,http://www.reuters.com//article/bavarian-nordic-bristol-myers-idUSL5N0W62V920150304?type=companyNews
113,"  COPENHAGEN, March 4 Shares in Bavarian Nordic  leapt as much as 39 percent on Wednesday after the Danish biotech company announced a prostate cancer drug deal with Bristol-Myers Squibb that could be worth at least $1 billion.The agreement gives the U.S. company an exclusive option to license and commercialise Bavarian's prostate cancer drug candidate Prostvac.Under the deal, Bavarian Nordic could receive up to $975 million, including $60 million upfront, if it passes trials and sales milestones, and could also receive royalties from sales. Prostvac is currently undergoing Phase III trials -- the last set of tests under U.S. regulations before it can be sold on the market.""It's a super deal for Bavarian,"" analyst Frank Horning Andersen from Jyske Bank said. ""Bristol-Myers is the right partner as the company has reorganised recently with cancer as one of its focus areas."" Last week Bavarian said that according to results of a small early-stage trial conducted by the U.S. National Cancer Institute, Prostvac helped extend survival in patients with advanced prostate cancer significantly. Bavarian Nordic shares were up 30.5 percent to 275.50 Danish crowns ($41) at 0840 GMT.($1 = 6.6766 Danish crowns)   (Reporting by Teis Jensen; Editing by Mark Potter)",2015-03-04,BMY,"Wed Mar 4, 2015 | 3:45am EST",Bavarian Nordic shares leap on $1 bln Bristol-Myers deal,http://www.reuters.com//article/bavarian-nordic-bristol-myers-idUSL5N0W61DE20150304?type=companyNews
114,"  March 4 Bavarian Nordic A/S :* Bristol-Myers Squibb signs exclusive agreement with Bavarian Nordic for PROSTVAC, a prostate-specific antigen-targeting cancer immunotherapy * Under terms of agreement, Bavarian Nordic will receive an upfront payment of $60 million  * Bavarian Nordic to receive up to $975 million, inclusive of $60 million upfront and potential exercise payment; potential development, regulatory and commercialization milestone payments; additional tiered double-digit royalties on future sales  Source text for Eikon:  Further company coverage:    (Gdynia Newsroom)",2015-03-04,BMY,"Wed Mar 4, 2015 | 1:39am EST",BRIEF-Bristol-Myers Squibb signs exclusive agreement with Bavarian Nordic for PROSTVAC,http://www.reuters.com//article/idUSFWN0W508X20150304?type=companyNews
115,"  U.S. regulators have accepted Bristol-Myers Squibb Co's re-submitted marketing application for an experimental hepatitis C treatment after the drugmaker was forced last year to withdraw its initial request.Bristol-Myers on Thursday said the U.S. Food and Drug Administration will review daclatasvir, its so-called NS5A inhibitor, for use in combination with Gilead Sciences Inc's potent and widely used Sovaldi treatment. It said the FDA is expected to make its decision within six months.Bristol-Myers originally had sought FDA permission to market daclatasvir in combination with another Bristol drug, asunaprevir. But it abandoned that application due to potential competition from more potent drugs, leaving the FDA without data to gauge the effectiveness of daclatasvir as part of a combination regimen.  Bristol-Myers then went back to the drawing board, collecting data from a separate large trial in which daclatasvir was tested with Sovaldi in patients with a different and less-common strain of hepatitis C, called genotype 3. In that late-stage trial, 90 percent of previously untreated patients had no trace of the virus after 12 weeks of treatment. Daclatasvir is already approved in Europe, Brazil and Japan as part of a combination therapy.  (Reporting by Ransdell Pierson; Editing by Chris Reese and Christian Plumb)",2015-03-12,BMY,"Thu Mar 12, 2015 | 4:44pm EDT",FDA to review re-submitted Bristol-Myers hepatitis C drug,http://www.reuters.com//article/us-bristol-myers-gilead-sciences-idUSKBN0M82HC20150312?type=companyNews
116,"  (Adds details on Bristol-Myers drugs, trial with Sovaldi)March 12 U.S. regulators have accepted Bristol-Myers Squibb Co's re-submitted marketing application for an experimental hepatitis C treatment after the drugmaker was forced last year to withdraw its initial request.Bristol-Myers on Thursday said the U.S. Food and Drug Administration will review daclatasvir, its so-called NS5A inhibitor, for use in combination with Gilead Sciences Inc's  potent and widely used Sovaldi treatment. It said the FDA is expected to make its decision within six months. Bristol-Myers originally had sought FDA permission to market daclatasvir in combination with another Bristol drug, asunaprevir. But it abandoned that application due to potential competition from more potent drugs, leaving the FDA without data to gauge the effectiveness of daclatasvir as part of a combination regimen. Bristol-Myers then went back to the drawing board, collecting data from a separate large trial in which daclatasvir was tested with Sovaldi in patients with a different and less-common strain of hepatitis C, called genotype 3. In that late-stage trial, 90 percent of previously untreated patients had no trace of the virus after 12 weeks of treatment.Daclatasvir is already approved in Europe, Brazil and Japan as part of a combination therapy.   (Reporting by Ransdell Pierson; Editing by Chris Reese and Christian Plumb)",2015-03-12,BMY,"Thu Mar 12, 2015 | 4:34pm EDT",UPDATE 1-FDA to review re-submitted Bristol-Myers hepatitis C drug,http://www.reuters.com//article/bristol-myers-gilead-sciences-idUSL1N0WE2EI20150312?type=companyNews
117,"  March 12 Bristol-Myers Squibb Co said U.S. regulators have accepted the company's re-submitted marketing application for an experimental treatment for hepatitis C, following the drugmaker's decision last year to pull back its initial marketing request.Bristol-Myers on Thursday said the U.S. Food and Drug Administration will review daclatasvir, its so-called NS5A inhibitor, for use in combination with Gilead Sciences Inc's  potent and widely used Sovaldi treatment. It said the FDA is expected to make its decision within six months.  (Reporting by Ransdell Pierson; Editing by Chris Reese) ",2015-03-12,BMY,"Thu Mar 12, 2015 | 3:21pm EDT",FDA to review re-submitted Bristol-Myers hepatitis C drug,http://www.reuters.com//article/bristol-myers-gilead-sciences-idUSL1N0WE2DX20150312?type=companyNews
118,"  Bristol Palin, a reality TV personality and daughter of 2008 Republican vice presidential candidate Sarah Palin, is engaged to marry Medal of Honor winner Dakota Meyer, the couple said on Saturday.""Last night, Sgt Dakota Meyer proposed and I said yes!""  Palin, 24, said on her blog.Meyer, 26, was awarded the Medal of Honor, the highest U.S. award for bravery, in 2011 for saving 36 of his comrades' lives during an ambush in Afghanistan in 2009. Bristol Palin said she met Meyer in 2014 when he came to Alaska to film the reality TV show ""Amazing America"" with her mother, the former governor of Alaska and election running mate of Republican presidential nominee John McCain.Meyer said on Facebook, ""I can't wait to spend the rest of my life with her and Tripp,"" Bristol Palin's son fathered by a high school boyfriend. On her Facebook page, Sarah Palin said, ""Our families couldnt be happier for Bristol and Dakota! Were honored to welcome Dakota into our family.""  (Reporting by Ian Simpson; Editing by Grant McCool)",2015-03-15,BMY,"Sun Mar 15, 2015 | 4:38am EDT",Bristol Palin to marry U.S. Medal of Honor winner Dakota Meyer,http://www.reuters.com//article/us-people-palin-idUSKBN0MB00N20150315?type=companyNews
119,"   By Ben Hirschler | LONDON  LONDON Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion-plus sales potential, according to a Thomson Reuters analysis.More potential blockbusters are expected to be launched this year than last, in an encouraging sign for the pharmaceutical industry, which relies on new products to replenish sales as older medicines go off patent.Regulators have been approving more new drugs in recent years but there remains a debate as to how far this will translate into bigger overall sales and profits, since many modern medicines are for rare diseases.The three biggest potential blockbusters launching this year, however, offer new ways of fighting cancer, high cholesterol and heart failure -- all markets targeting relatively large numbers of patients. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-plus annual sales within five years, up from three in 2014, Thomson Reuters Cortellis said in its latest ""Drugs to Watch"" report on Monday. Bristol-Myers' cancer medicine Opdivo tops the list, with projected 2019 sales of $5.7 billion, according to consensus forecasts compiled by Cortellis.Opdivo belongs to a new class of medicines called PD-1 inhibitors that work by blocking a mechanism tumors use to hide from the immune system, allowing it to recognize and attack cancer cells. The drug went on sale in Japan in September 2014 but was only approved for melanoma in the United States at the end of December, since when it has also received a green light for lung cancer, underlying the potential that healthcare authorities see in such so-called immunotherapies.Sanofi's cholesterol drug Praluent, which is being developed with Regeneron Pharmaceuticals, is expected to generate annual sales in 2019 of $4.4 billion -- twice that seen for Amgen's rival Repatha. The U.S. Food and Drug Administration is due to decide this summer whether to approve the two drugs, which both tackle difficult-to-treat cases of high cholesterol by targeting a protein known as PCSK9.Novartis' new first-in-class heart failure drug LCZ-696, meanwhile, is forecast to sell $3.7 billion by 2019, following impressive clinical trial results. The drug could win U.S. approval in August. (Editing by Keith Weir)",2015-03-23,BMY,"Mon Mar 23, 2015 | 9:50am EDT","Bristol, Sanofi and Novartis drugs to shine among 2015 launches",http://www.reuters.com//article/us-pharmaceuticals-blockbusters-idUSKBN0MJ1F620150323?type=companyNews
120,"  * Opdivo, Praluent, LCZ-696 top 2015 drug hopes - report* 11 potential blockbusters seen among 2015 drug launches* Up from three potential $1 billion-plus drugs in 2014   (Updates with link to report, paragraph 5)By Ben HirschlerLONDON, March 23 Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion-plus sales potential, according to a Thomson Reuters analysis.More potential blockbusters are expected to be launched this year than last, in an encouraging sign for the pharmaceutical industry, which relies on new products to replenish sales as older medicines go off patent. Regulators have been approving more new drugs in recent years but there remains a debate as to how far this will translate into bigger overall sales and profits, since many modern medicines are for rare diseases.The three biggest potential blockbusters launching this year, however, offer new ways of fighting cancer, high cholesterol and heart failure -- all markets targeting relatively large numbers of patients.In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-plus annual sales within five years, up from three in 2014, Thomson Reuters Cortellis said in its latest ""Drugs to Watch"" report on Monday. (bit.ly/1EClfJv) Bristol-Myers' cancer medicine Opdivo tops the list, with projected 2019 sales of $5.7 billion, according to consensus forecasts compiled by Cortellis.Opdivo belongs to a new class of medicines called PD-1 inhibitors that work by blocking a mechanism tumours use to hide from the immune system, allowing it to recognise and attack cancer cells. The drug went on sale in Japan in September 2014 but was only approved for melanoma in the United States at the end of December, since when it has also received a green light for lung cancer, underlying the potential that healthcare authorities see in such so-called immunotherapies.Sanofi's cholesterol drug Praluent, which is being developed with Regeneron Pharmaceuticals, is expected to generate annual sales in 2019 of $4.4 billion -- twice that seen for Amgen's rival Repatha.The U.S. Food and Drug Administration is due to decide this summer whether to approve the two drugs, which both tackle difficult-to-treat cases of high cholesterol by targeting a protein known as PCSK9.Novartis' new first-in-class heart failure drug LCZ-696, meanwhile, is forecast to sell $3.7 billion by 2019, following impressive clinical trial results. The drug could win U.S. approval in August.(Editing by Keith Weir)",2015-03-23,BMY,"Mon Mar 23, 2015 | 9:40am EDT","UPDATE 1-Bristol, Sanofi and Novartis drugs to shine among 2015 launches",http://www.reuters.com//article/pharmaceuticals-blockbusters-idUSL6N0WP2QL20150323?type=companyNews
121,"  * Opdivo, Praluent, LCZ-696 top 2015 drug hopes - report* 11 potential blockbusters seen among 2015 drug launches* Up from three potential $1 billion-plus drugs in 2014By Ben HirschlerLONDON, March 23 Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion-plus sales potential, according to a Thomson Reuters analysis.More potential blockbusters are expected to be launched this year than last, in an encouraging sign for the pharmaceutical industry, which relies on new products to replenish sales as older medicines go off patent. Regulators have been approving more new drugs in recent years but there remains a debate as to how far this will translate into bigger overall sales and profits, since many modern medicines are for rare diseases.The three biggest potential blockbusters launching this year, however, offer new ways of fighting cancer, high cholesterol and heart failure -- all markets targeting relatively large numbers of patients.In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-plus annual sales within five years, up from three in 2014, Thomson Reuters Cortellis said in its latest ""Drugs to Watch"" report on Monday. Bristol-Myers' cancer medicine Opdivo tops the list, with projected 2019 sales of $5.7 billion, according to consensus forecasts compiled by Cortellis.Opdivo belongs to a new class of medicines called PD-1 inhibitors that work by blocking a mechanism tumours use to hide from the immune system, allowing it to recognise and attack cancer cells. The drug went on sale in Japan in September 2014 but was only approved for melanoma in the United States at the end of December, since when it has also received a green light for lung cancer, underlying the potential that healthcare authorities see in such so-called immunotherapies.Sanofi's cholesterol drug Praluent, which is being developed with Regeneron Pharmaceuticals, is expected to generate annual sales in 2019 of $4.4 billion -- twice that seen for Amgen's rival Repatha.The U.S. Food and Drug Administration is due to decide this summer whether to approve the two drugs, which both tackle difficult-to-treat cases of high cholesterol by targeting a protein known as PCSK9.Novartis' new first-in-class heart failure drug LCZ-696, meanwhile, is forecast to sell $3.7 billion by 2019, following impressive clinical trial results. The drug could win U.S. approval in August.(Editing by Keith Weir)",2015-03-23,BMY,"Mon Mar 23, 2015 | 12:00am EDT","Bristol, Sanofi and Novartis drugs to shine among 2015 launches",http://www.reuters.com//article/pharmaceuticals-blockbusters-idUSL6N0WM10G20150323?type=companyNews
122,"  (Adds details on Keytruda, melanoma, rival Bristol-Myers drug)By Ransdell PiersonMarch 24 Merck & Co Inc said on Tuesday that it would stop a large study of its Keytruda melanoma treatment early because an independent monitoring committee determined the drug succeeded in its goal of prolonging survival in previously untreated patients at advanced stage of the disease.The medicine, a PD-1 inhibitor that works by taking the brakes off the immune system, is already approved to treat patients who have failed to benefit from standard treatments, including Bristol-Myers Squibb Co's Yervoy.Patients taking Keytruda showed meaningful improvement in overall survival and in delayed progression of disease, compared with those taking Yervoy, Merck said. The data, if regulators agree, could allow Merck to widen its marketing of Keytruda to people being treated for the first time for the dangerous skin disease.Shares of Merck were up 1 percent at $59.30 in early trading.""Keytruda is the first anti-PD-1 therapy to demonstrate a survival advantage compared to the standard of care for the first-line treatment of advanced melanoma,"" Merck said in a release. It noted that data from the study will be presented at a medical meeting next month in Philadelphia. About 76,000 Americans are diagnosed every year with melanoma, which is highly linked to sun exposure, and more than 9,700 die from the disease, according to the National Cancer Institute.Merck said safety of Keytruda in the halted study was similar to that seen in earlier trials, where the most common side effects were fatigue, coughing, nausea and other mostly mild reactions. Keytruda in September became the first PD-1 inhibitor approved by U.S. regulators. Three months later, the U.S. Food and Drug Administration approved Bristol-Myers' Opdivo, also for patients with advanced melanoma who no longer respond to other drugs. It also works by blocking the PD-1 protein.AstraZeneca Plc, Pfizer Inc and other drugmakers are also developing PD-1 inhibitors, or similar drugs known as PD-L1 inhibitors. Wall Street expects the products to generate combined annual sales of more than $30 billion by 2025, with lung cancer seen as the most lucrative potential use.Merck aims by midyear to seek U.S. approval of Keytruda for non small cell lung cancer, the most common form of the disease.Bristol-Myers in January said it was halting a trial of Opdivo for lung cancer, also at the advice of independent monitors, when it became clear the drug extended survival compared with standard chemotherapy.   (Reporting by Ransdell Pierson; Editing by Jeffrey Benkoe and Lisa Von Ahn)",2015-03-24,BMY,"Tue Mar 24, 2015 | 10:00am EDT",UPDATE 1-Merck says melanoma drug meets goal; study halted,http://www.reuters.com//article/merck-melanoma-idUSL2N0WQ0MS20150324?type=companyNews
123,"  Bristol-Myers Squibb said on Tuesday it had agreed to acquire rights to a Novo Nordisk immune system research program, which the Danish company is divesting as it focuses further on diabetes care.The project aims to modulate the innate immune system as a therapy for autoimmune diseases and the U.S. drugmaker said it fitted with its long-standing commitment to immunoscience. Financial terms of the licensing agreement were not disclosed.Novo, the world's No. 1 insulin maker, expects sales from  diabetes will become an even bigger part of its business in the coming decade, deputy chief executive Kaare Schultz told Reuters last week.    (Reporting by Ben Hirschler; Editing by Pravin Char)",2015-03-24,BMY,"Tue Mar 24, 2015 | 8:28am EDT",Bristol-Myers buys rights to Novo Nordisk immune system project,http://www.reuters.com//article/us-novo-nordisk-bristol-myers-idUSKBN0MK1CY20150324?type=companyNews
124,"  March 24 Bristol-Myers Squibb said on Tuesday it had agreed to acquire rights to a Novo Nordisk  immune system research programme, which the Danish company is divesting as it focuses further on diabetes care.The project aims to modulate the innate immune system as a therapy for autoimmune diseases and the U.S. drugmaker said it fitted with its long-standing commitment to immunoscience. Financial terms of the licensing agreement were not disclosed. Novo, the world's No. 1 insulin maker, expects sales from  diabetes will become an even bigger part of its business in the coming decade, deputy chief executive Kaare Schultz told Reuters last week.  (Reporting by Ben Hirschler; Editing by Pravin Char)",2015-03-24,BMY,"Tue Mar 24, 2015 | 8:27am EDT",Bristol-Myers buys rights to Novo Nordisk immune system project,http://www.reuters.com//article/novo-nordisk-bristol-myers-idUSL6N0WQ2KC20150324?type=companyNews
125,"  (Adds Vivendi, Informatica, Bristol-Myers Squibb, PCCW, Gazprom)April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:** Japan's Canon Inc is unlikely to raise its offer for Swedish surveillance camera maker Axis AB for now but won't back out of the deal either, despite pressure from hedge fund Elliott Management, sources said.** Ventas Inc, a healthcare real estate investment trust (REIT), said it would buy privately held hospital chain Ardent Medical Services Inc for $1.75 billion in cash.** French media group Vivendi has made a 250 million euro ($275 million) indicative offer for most of Dailymotion, the video-sharing website owned by French telecoms group Orange, a source said. ** Enterprise software company Informatica Corp has received offers from two private equity consortia and is negotiating a sale that could value it at between $5 billion and $6 billion, according to people familiar with the matter.** Bristol-Myers Squibb Co said it would invest in Dutch biotech uniQure NV, joining other big drugmakers who have moved to gain a foothold in the promising gene therapy market.** Gazprom said it plans to sell its 10.52 percent stake in Germany's natural gas supplier Verbundnetz Gas (VNG), in line with the Russian company's strategy to pull back from operations in Europe. ** The Philippines' Ayala Land Inc said it bought a minority stake in Malaysian property developer GW Plastics Holdings Bhd, expanding its footprint in Southeast Asia in line with its diversification goals.** Japanese regional lender Tomony Holdings Inc  said it is in talks to merge with Osaka-based Taisho Bank, owned 26 percent by Mitsubishi UFJ Financial Group Inc (MUFG) , helping to keep up momentum for consolidation in the crowded sector. ** Loss-making Japanese electronics maker Sharp Corp  may spin off its LCD panel business and seek funding for it from the government-backed Innovation Network Corporation of Japan (INCJ), a source familiar with the plan said on Sunday.** The board of Egypt's Commercial International Bank (CIB)  said on Sunday it has asked its management to decide whether to submit a binding offer for Citigroup's retail portfolio in Egypt after a due diligence process.** Total's rubber and insulation unit Hutchinson aims to expand in Germany and could make acquisitions to do so, the unit's chief executive told a German magazine.** Chinese online game developer Shanda Games Ltd  said it has agreed to be taken private by Capitalhold Ltd and its unit Capitalcorp Ltd in a deal valued at $1.9 billion.    (Compiled by Kshitiz Goliya and Lehar Maan in Bengaluru)",2015-04-06,BMY,"Mon Apr 6, 2015 | 4:04pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N0X327720150406?type=companyNews
126,"  Bristol-Myers Squibb Co said it would invest in Dutch biotech uniQure NV, joining other big drugmakers who have moved to gain a foothold in the promising gene therapy market.UniQure's shares jumped more than 55 percent on Monday after Bristol-Myers said it would pick up a 4.9 percent stake in the company.UniQure's gene therapy drug, Glybera, went on sale last year priced at 1.1 million euros.Glybera fights the ultra-rare genetic disease lipoprotein lipase deficiency, which clogs the blood with fat.Investor interest in the field of gene therapy has grown in the past 18 months, with Bluebird Bio Inc, uniQure NV and Spark Therapeutics Inc all staging successful floats on the Nasdaq.Bayer AG struck a gene therapy deal with Dimension Therapeutics in June, while France's Sanofi SA has a long-standing tie-up with Oxford BioMedica.Bristol-Myers will invest about $100 million in uniQure, including $33.84 per share, or at least $32 million in total,  for a 4.9 percent stake, the companies said. The purchase price per share is at a 48 percent premium to uniQure's Thursday close and values the company at about $595.4 million, based on its outstanding shares as of Feb. 9, according to Thomson Reuters calculations.Bristol-Myers will acquire an additional 5 percent stake in the Amsterdam-based company before Dec. 31 at a 10 percent premium. [ID:nBw8xgwS2a]The companies will collaborate on 10 targets, including uniQure's proprietary gene therapy program for congestive heart failure, S100A1. UniQure will be responsible for the manufacture of clinical and commercial supplies, while Bristol-Myers will lead development and regulatory activities and bear all research and development costs.Bristol-Myers will also be responsible for the commercialization of all products from the collaboration.UniQure will be eligible for a number of milestone payments, including up to $254 million for its lead S100A1 therapeutic and up to $217 million for each other gene therapy product potentially developed under the deal. UniQure's shares were up 45.8 percent at $33.34 in morning trading on the Nasdaq.(This story has been refiled to correct the spelling to 'Glybera' from 'Glyberan' in paragraphs 3 and 4) (Reporting by Ankur Banerjee and Samantha Kareen Nair in Bengaluru; Editing by Maju Samuel and Simon Jennings)",2015-04-06,BMY,"Mon Apr 6, 2015 | 1:44pm EDT",Bristol-Myers to invest in Dutch gene therapy company uniQure,http://www.reuters.com//article/us-uniqure-deal-bristol-myers-idUSKBN0MX0SY20150406?type=companyNews
127,"  (Refiles to correct spelling to 'Glybera' from 'Glyberan' in paragraphs 3 and 4)April 6 Bristol-Myers Squibb Co said it would invest in Dutch biotech uniQure NV, joining other big drugmakers who have moved to gain a foothold in the promising gene therapy market.UniQure's shares jumped more than 55 percent on Monday after Bristol-Myers said it would pick up a 4.9 percent stake in the company.UniQure's gene therapy drug, Glybera, went on sale last year priced at 1.1 million euros.Glybera fights the ultra-rare genetic disease lipoprotein lipase deficiency, which clogs the blood with fat.Investor interest in the field of gene therapy has grown in the past 18 months, with Bluebird Bio Inc, uniQure NV and Spark Therapeutics Inc all staging successful floats on the Nasdaq. Bayer AG struck a gene therapy deal with Dimension Therapeutics in June, while France's Sanofi SA  has a long-standing tie-up with Oxford BioMedica .Bristol-Myers will invest about $100 million in uniQure, including $33.84 per share, or at least $32 million in total,  for a 4.9 percent stake, the companies said. The purchase price per share is at a 48 percent premium to uniQure's Thursday close and values the company at about $595.4 million, based on its outstanding shares as of Feb. 9, according to Thomson Reuters calculations.Bristol-Myers will acquire an additional 5 percent stake in the Amsterdam-based company before Dec. 31 at a 10 percent premium.The companies will collaborate on 10 targets, including uniQure's proprietary gene therapy program for congestive heart failure, S100A1. UniQure will be responsible for the manufacture of clinical and commercial supplies, while Bristol-Myers will lead development and regulatory activities and bear all research and development costs.Bristol-Myers will also be responsible for the commercialization of all products from the collaboration.UniQure will be eligible for a number of milestone payments, including up to $254 million for its lead S100A1 therapeutic and up to $217 million for each other gene therapy product potentially developed under the deal.UniQure's shares were up 45.8 percent at $33.34 in morning trading on the Nasdaq.   (Reporting by Ankur Banerjee and Samantha Kareen Nair in Bengaluru; Editing by Maju Samuel and Simon Jennings)",2015-04-06,BMY,"Mon Apr 6, 2015 | 12:34pm EDT",REFILE-UPDATE 1-Bristol-Myers to invest in Dutch gene therapy company uniQure,http://www.reuters.com//article/uniqure-deal-bristol-myers-idUSL3N0X32OH20150406?type=companyNews
128,"  April 6 Bristol-Myers Squibb Co said it would invest in Dutch biotech uniQure NV to get access to uniQure's gene therapy technology platform for cardiovascular diseases.UniQure's shares rose more than 52 percent to $34.42 in early trading. Bristol-Myers will pay at least $32 million to take a 4.9 percent stake in uniQure. Bristol-Myers will acquire an additional 5 percent before Dec. 31 at a 10 percent premium. UniQure will be eligible to receive milestone payments, including up to $254 million for the lead S100A1 therapeutic and up to $217 million for each other gene therapy product potentially developed under the deal.   (Reporting by Ankur Banerjee in Bengaluru; Editing by Maju Samuel)",2015-04-06,BMY,"Mon Apr 6, 2015 | 9:38am EDT",Bristol-Myers buys into Dutch gene therapy company uniQure,http://www.reuters.com//article/uniqure-deal-bristol-myers-idUSL3N0X32MC20150406?type=companyNews
129,"   By Ransdell Pierson  A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against the most common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved lung cancer and melanoma indications.The U.S. drugmaker on Friday said the study, called Checkmate-057, was stopped early after an independent data monitoring committee concluded that Opdivo provided a survival advantage over docetaxel, a standard chemotherapy, among patients with previously treated non-squamous non-small cell lung cancer (NSCLC).The so-called PD-1 inhibitor, which works by taking the brakes off the immune system, was approved by U.S. regulators last month to treat the less-common ""squamous"" form of NSCLC that had spread following treatment with chemotherapy. Opdivo is also approved for use against metastatic melanoma following treatment with Yervoy, another Bristol-Myers immuno-therapy. Opdivo, whose chemical name is nivolumab, competes with Merck & Co's Keytruda, a PD-1 inhibitor that is approved to treat melanoma and which is also being tested against NSCLC. Merck, which aims by midyear to seek U.S. approval of Keytruda for both squamous and non-squamous NSCLC, must now contemplate the likelihood of Bristol-Myers eventually competing in both arenas.     The rival drugs are also in trials against a variety of other cancers. AstraZeneca Plc, Pfizer Inc and other drugmakers are developing their own PD-1 inhibitors, or similar drugs known as PD-L1 inhibitors. Wall Street expects the products to generate combined annual sales of more than $30 billion by 2025, with lung cancer seen as the most lucrative potential use.Data from several trials of the promising new family of cancer drugs is slated to be released over the coming week at the annual meeting of the American Association for Cancer Research (AACR) in Philadelphia. Sanford Bernstein analyst Tim Anderson on Friday said Wall Street is expecting Opdivo to be the market leader among the PD-1 inhibitors, with peak annual sales of $7 billion by 2020. But he recommended that investors buy shares in ""multiple players in the immuno-oncology category.""He said in a research note, ""Because of the size of the I/O opportunity, in our view there will be more than one way to win.""Bristol-Myers shares rose 2.9 percent to $65.55 in midday trading, while Merck shares retreated 1.3 percent to $57.07, also on the New York Stock Exchange. (This version of the story adds analyst comment, details on rival drugs, updates shares) (Editing by Chizu Nomiyama and Ted Botha)",2015-04-17,BMY,"Fri Apr 17, 2015 | 12:13pm EDT",Bristol's Opdivo proves effective against second type of lung cancer,http://www.reuters.com//article/us-bristolmyers-cancer-idUSKBN0N81DX20150417?type=companyNews
130,"  (Adds analyst comment, details on rival drugs, updates shares)By Ransdell PiersonApril 17 A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against the most common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved lung cancer and melanoma indications.The U.S. drugmaker on Friday said the study, called Checkmate-057, was stopped early after an independent data monitoring committee concluded that Opdivo provided a survival advantage over docetaxel, a standard chemotherapy, among patients with previously treated non-squamous non-small cell lung cancer (NSCLC).The so-called PD-1 inhibitor, which works by taking the brakes off the immune system, was approved by U.S. regulators last month to treat the less-common ""squamous"" form of NSCLC that had spread following treatment with chemotherapy. Opdivo is also approved for use against metastatic melanoma following treatment with Yervoy, another Bristol-Myers immuno-therapy.Opdivo, whose chemical name is nivolumab, competes with Merck & Co's Keytruda, a PD-1 inhibitor that is approved to treat melanoma and which is also being tested against NSCLC. Merck, which aims by midyear to seek U.S. approval of Keytruda for both squamous and non-squamous NSCLC, must now contemplate the likelihood of Bristol-Myers eventually competing in both arenas.The rival drugs are also in trials against a variety of other cancers. AstraZeneca Plc, Pfizer Inc and other drugmakers are developing their own PD-1 inhibitors, or similar drugs known as PD-L1 inhibitors. Wall Street expects the products to generate combined annual sales of more than $30 billion by 2025, with lung cancer seen as the most lucrative potential use.Data from several trials of the promising new family of cancer drugs is slated to be released over the coming week at the annual meeting of the American Association for Cancer Research (AACR) in Philadelphia. Sanford Bernstein analyst Tim Anderson on Friday said Wall Street is expecting Opdivo to be the market leader among the PD-1 inhibitors, with peak annual sales of $7 billion by 2020. But he recommended that investors buy shares in ""multiple players in the immuno-oncology category.""He said in a research note, ""Because of the size of the I/O opportunity, in our view there will be more than one way to win.""Bristol-Myers shares rose 2.9 percent to $65.55 in midday trading, while Merck shares retreated 1.3 percent to $57.07, also on the New York Stock Exchange.(Editing by Chizu Nomiyama and Ted Botha)",2015-04-17,BMY,"Fri Apr 17, 2015 | 12:11pm EDT",UPDATE 2-Bristol's Opdivo proves effective against second type of lung cancer,http://www.reuters.com//article/bristolmyers-cancer-idUSL2N0XE0S320150417?type=companyNews
131,"  April 17 A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against a common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved lung cancer and melanoma indications.The U.S. drugmaker on Friday said the study was stopped early after an independent data monitoring committee concluded that Opdivo provided a survival advantage over docetaxel, a standard chemotherapy, among patients with advanced non-squamous non-small lung cancer.  (Reporting by Ransdell Pierson; Editing by Chizu Nomiyama) ",2015-04-17,BMY,"Fri Apr 17, 2015 | 9:19am EDT",Bristol's Opdivo proves effective against second type of lung cancer,http://www.reuters.com//article/bristolmyers-cancer-idUSL2N0XE0RL20150417?type=companyNews
132,"   By Ben Hirschler | LONDON  LONDON European regulators have recommended approval of Bristol-Myers Squibb's Opdivo, paving the way for it to become the first of a closely watched group of immune system-boosting cancer medicines to go on sale in Europe.The drug, also known as nivolumab, was given a green light on Friday by the European Medicines Agency (EMA) for the treatment of melanoma. It is already approved in the United States for melanoma and lung cancer.The EMA said Opdivo was recommended for use on its own for the treatment of advanced melanoma, the most aggressive type of skin cancer, in both first-line and previously treated patients.The agency also recommended approval of Daiichi Sankyo's Lixiana, or edoxaban, for stroke prevention and Vanda Pharma's Hetlioz, or tasimelteon, to treat a sleep-wake disorder in blind people.Bristol's Opdivo belongs to a highly promising new class of medicines called PD-1 inhibitors that block a mechanism tumours use to hide from the immune system. It is expected to be one of the most commercially successful new drugs to reach major markets this year. It competes with Merck & Co's Keytruda, which is also on the market in the United States but not in Europe.Although Keytruda is still waiting for regulatory approval in Europe, some patients in Britain will soon receive it through a new early-access scheme, under which highly promising new drugs are made available free of charge ahead of formal licensing. Friday's positive European opinion on Opdivo is an intermediary step on the drug's path to market, since it now has to be sent to the European Commission for formal adoption. After that, decisions on price and reimbursement will taken by individual governments around Europe.The EMA's Committee for Medicinal Products for Human Use (CHMP) had initially looked at Opdivo last month but it postponed a decision at that time. (This version of the story adds detail on PD-1 drugs, other EMA recommendations) (Reporting by Ben Hirschler; Editing by Jane Merriman and Pravin Char)",2015-04-24,BMY,"Fri Apr 24, 2015 | 8:00am EDT",Bristol wins EU green light for immune system cancer drug,http://www.reuters.com//article/us-health-cancer-bristol-myers-europe-idUSKBN0NF14R20150424?type=companyNews
133,"  (Adds detail on PD-1 drugs, other EMA recommendations)By Ben HirschlerLONDON, April 24 European regulators have recommended approval of Bristol-Myers Squibb's Opdivo, paving the way for it to become the first of a closely watched group of immune system-boosting cancer medicines to go on sale in Europe.The drug, also known as nivolumab, was given a green light on Friday by the European Medicines Agency (EMA) for the treatment of melanoma. It is already approved in the United States for melanoma and lung cancer.The EMA said Opdivo was recommended for use on its own for the treatment of advanced melanoma, the most aggressive type of skin cancer, in both first-line and previously treated patients. The agency also recommended approval of Daiichi Sankyo's  Lixiana, or edoxaban, for stroke prevention and Vanda Pharma's Hetlioz, or tasimelteon, to treat a sleep-wake disorder in blind people.Bristol's Opdivo belongs to a highly promising new class of medicines called PD-1 inhibitors that block a mechanism tumours use to hide from the immune system. It is expected to be one of the most commercially successful new drugs to reach major markets this year. It competes with Merck & Co's Keytruda, which is also on the market in the United States but not in Europe.Although Keytruda is still waiting for regulatory approval in Europe, some patients in Britain will soon receive it through a new early-access scheme, under which highly promising new drugs are made available free of charge ahead of formal licensing. Friday's positive European opinion on Opdivo is an intermediary step on the drug's path to market, since it now has to be sent to the European Commission for formal adoption. After that, decisions on price and reimbursement will taken by individual governments around Europe.The EMA's Committee for Medicinal Products for Human Use (CHMP) had initially looked at Opdivo last month but it postponed a decision at that time.(Reporting by Ben Hirschler; Editing by Jane Merriman and Pravin Char)",2015-04-24,BMY,"Fri Apr 24, 2015 | 7:58am EDT",UPDATE 1-Bristol wins EU green light for immune system cancer drug,http://www.reuters.com//article/health-cancer-bristol-myers-europe-idUSL5N0XL2MJ20150424?type=companyNews
134,  April 24 EU Medicines Agency:* Recommendations for April 2015 * Recommends approval of melanoma drug nivolumab from Bristol-Myers Squibb Co  * Recommends approval of tasimelteon for non 24-hour sleep-wake disorder from Vanda Pharmaceuticals   Link to press release: (bit.ly/1HvQg8n) Further company coverage:     (Bengaluru Newsroom),2015-04-24,BMY,"Fri Apr 24, 2015 | 7:26am EDT",BRIEF-EU medicines agency backs Bristol Myers Squibb's melanoma drug,http://www.reuters.com//article/idUSL5N0XL2I320150424?type=companyNews
135,"   By Ransdell Pierson and Bill Berkrot | April 28  April 28 Investors betting that Bristol-Myers Squibb will emerge as the leading player in a hot new class of cancer drugs hit the pause button on Tuesday as a rival therapy from Merck & Co showed much higher sales.Bristol shares fell as much as 2.7 percent and closed off 1 percent after reporting sales of Opdivo, a therapy that helps the immune system fight cancer, totaled $40 million in the first quarter of the year. That was below Wall Street forecasts of $50 million.Merck said its Keytruda treatment had quarterly sales of $83 million, topping Wall Street estimates of about $70 million, helped by early compassionate use patients converting to paying customers following approval.""When investors saw Opdivo's number was below Keytruda's, that caused concern,"" said John Boris, an analyst with Suntrust Robinson Humphrey. Merck shares closed up 5 percent, though the gains were mostly attributed to positive new safety data on its top-selling Januvia diabetes treatment.Boris and other industry analysts said the early sales data represent only the first skirmish in a long battle for market share between Bristol-Myers and Merck. Some expect both drugs will eventually generate billions of dollars in annual sales, particularly if proven effective against other forms of cancer.In addition, excitement over Bristol-Myers' cancer treatments have pushed shares to trade at 28.5 times expected 2016 per share earnings, Boris said. That compares with a multiple of 15.1 for Merck and 17.6 for the pharmaceutical sector.""Based on price per fundamentals, we like the value of Merck versus Bristol at the moment,"" said Les Funtleyder, healthcare portfolio manager for ESquared Asset Management, which currently holds Merck but not Bristol shares. Ori Hershkovitz, a managing partner at Nexthera Capital in New York, said Bristol-Myers is trading more like a high-flying biotech.""The minute biotech gets pummeled, Bristol bears the brunt,"" he said, noting biotech stocks have retreated sharply in recent weeks on fears they were overly inflated.EARLY ADVANTAGE  Opdivo was approved in December to treat advanced melanoma. In March, it received clearance to treat a common form of lung cancer, giving Bristol an early-mover advantage in a much larger market.Keytruda has been approved for advanced melanoma since September and awaits regulatory approval in lung cancer.Both drugs work by blocking a protein called PD-1, helping the immune system recognize and destroy cancer cells. Roche Holding AG, AstraZeneca Plc and Pfizer Inc  are also developing similar treatments. Boris forecast Opdivo annual sales reaching $7 billion by 2020 and said Tuesday's weakness in Bristol shares represents a buying opportunity. Opdivo has been shown to prolong survival in melanoma and lung cancer, according to clinical trial data.Keytruda has not yet demonstrated a survival benefit but is expected to do so in coming trials. Boris predicted it will capture annual sales of $3.7 billion by 2020.Bristol Chief Scientific Officer Francis Cuss told analysts on Tuesday that strong data on Opdivo along with the U.S. approvals in lung cancer and melanoma and expected European approval ""really puts us in a very strong competitive position.""The company recently reported strong results from a combination of Opdivo and its older immunotherapy Yervoy in advanced melanoma. It plans to apply for approval of the combination therapy by mid-year.Merck head of global human health, Adam Schechter, told analysts that the market will be big enough to handle several competitors, ""so I don't think it should be looked at as one company versus the other.""Pfizer is racing to catch up with Merck and Bristol-Myers, by beginning late-stage trials this year of its PD-1 inhibitor and conducting trials of four other immuno-oncology drugs.PD-1 treatments ""will be the workhorses for the foreseeable future, but they will need to be added to standard therapies or to (other) immuno-oncology treatments,"" Pfizer Chief Executive Ian Read said in an interview. ""That's where the market will be, and we will be well positioned with those combination agents.""     (Reporting by Ransdell Pierson and Bill Berkrot, editing by Michele Gershberg and Andrew Hay)",2015-04-28,BMY,"Tue Apr 28, 2015 | 6:49pm EDT",Strong Merck cancer drug sales upstage rival Bristol-Myers,http://www.reuters.com//article/bristolmyers-merck-cancer-idUSL1N0XP34H20150428?type=companyNews
136,"   By Ransdell Pierson and Bill Berkrot  Investors betting that Bristol-Myers Squibb will emerge as the leading player in a hot new class of cancer drugs hit the pause button on Tuesday as a rival therapy from Merck & Co showed much higher sales.Bristol shares fell as much as 2.7 percent and closed off 1 percent after reporting sales of Opdivo, a therapy that helps the immune system fight cancer, totaled $40 million in the first quarter of the year. That was below Wall Street forecasts of $50 million.Merck said its Keytruda treatment had quarterly sales of $83 million, topping Wall Street estimates of about $70 million, helped by early compassionate use patients converting to paying customers following approval.""When investors saw Opdivo's number was below Keytruda's, that caused concern,"" said John Boris, an analyst with Suntrust Robinson Humphrey. Merck shares closed up 5 percent, though the gains were mostly attributed to positive new safety data on its top-selling Januvia diabetes treatment.       Boris and other industry analysts said the early sales data represent only the first skirmish in a long battle for market share between Bristol-Myers and Merck. Some expect both drugs will eventually generate billions of dollars in annual sales, particularly if proven effective against other forms of cancer.In addition, excitement over Bristol-Myers' cancer treatments have pushed shares to trade at 28.5 times expected 2016 per share earnings, Boris said. That compares with a multiple of 15.1 for Merck and 17.6 for the pharmaceutical sector. ""Based on price per fundamentals, we like the value of Merck versus Bristol at the moment,"" said Les Funtleyder, healthcare portfolio manager for ESquared Asset Management, which currently holds Merck but not Bristol shares.Ori Hershkovitz, a managing partner at Nexthera Capital in New York, said Bristol-Myers is trading more like a high-flying biotech. ""The minute biotech gets pummeled, Bristol bears the brunt,"" he said, noting biotech stocks have retreated sharply in recent weeks on fears they were overly inflated.EARLY ADVANTAGE Opdivo was approved in December to treat advanced melanoma. In March, it received clearance to treat a common form of lung cancer, giving Bristol an early-mover advantage in a much larger market.  Keytruda has been approved for advanced melanoma since September and awaits regulatory approval in lung cancer. Both drugs work by blocking a protein called PD-1, helping the immune system recognize and destroy cancer cells. Roche Holding AG, AstraZeneca Plc and Pfizer Inc are also developing similar treatments.Boris forecast Opdivo annual sales reaching $7 billion by 2020 and said Tuesday's weakness in Bristol shares represents a buying opportunity. Opdivo has been shown to prolong survival in melanoma and lung cancer, according to clinical trial data.Keytruda has not yet demonstrated a survival benefit but is expected to do so in coming trials. Boris predicted it will capture annual sales of $3.7 billion by 2020. Bristol Chief Scientific Officer Francis Cuss told analysts on Tuesday that strong data on Opdivo along with the U.S. approvals in lung cancer and melanoma and expected European approval ""really puts us in a very strong competitive position.""The company recently reported strong results from a combination of Opdivo and its older immunotherapy Yervoy in advanced melanoma. It plans to apply for approval of the combination therapy by mid-year.Merck head of global human health, Adam Schecter, told analysts that the market will be big enough to handle several competitors, ""so I don't think it should be looked at as one company versus the other.""Pfizer is racing to catch up with Merck and Bristol-Myers, by beginning late-stage trials this year of its PD-1 inhibitor and conducting trials of four other immuno-oncology drugs.PD-1 treatments ""will be the workhorses for the foreseeable future, but they will need to be added to standard therapies or to (other) immuno-oncology treatments,"" Pfizer Chief Executive Ian Read said in an interview. ""That's where the market will be, and we will be well positioned with those combination agents.""   (Reporting by Ransdell Pierson and Bill Berkrot, editing by Michele Gershberg and Andrew Hay)",2015-04-28,BMY,"Tue Apr 28, 2015 | 6:43pm EDT",Strong Merck cancer drug sales upstage rival Bristol-Myers,http://www.reuters.com//article/us-bristolmyers-merck-cancer-idUSKBN0NJ2PG20150428?type=companyNews
137,"  (Adds details)April 28 The U.S. Food and Drug Administration said it approved the first copycat versions of Otsuka Pharmaceutical Co Ltd's antipsychotic drug, Abilify.The FDA said on Tuesday that it had granted approval for generic versions of Abilify from four companies, including Teva Pharmaceutical Industries Ltd, to treat mental illnesses such as bipolar disorder and schizophrenia. (1.usa.gov/1EO2DvW) Abilify has an orphan drug designation for the treatment of Tourette's syndrome, a nervous system disorder, in children. The drug, which is also approved to treat schizophrenia and bipolar disorder, went off patent protection for these indications this month. Japanese drugmaker Otsuka bought Avanir Pharmaceuticals Inc  in December for $3.5 billion to expand its offering of neurological products before Abilify went off patent protection.Abilify, which is sold by Bristol-Myers Squibb Co in the United States, brought in sales of $554 million in the first quarter.    (Reporting by Vidya L Nathan in Bengaluru; Editing by Saumyadeb Chakrabarty and Kirti Pandey)",2015-04-28,BMY,"Tue Apr 28, 2015 | 4:00pm EDT",UPDATE 1-FDA approves generic versions of antipsychotic drug Abilify,http://www.reuters.com//article/teva-pharmaceuticals-fda-idUSL4N0XP6TQ20150428?type=companyNews
138,"   By Ransdell Pierson and Bill Berkrot  Bristol-Myers Squibb Co (BMY.N) on Tuesday reported first-quarter sales of its new cancer immunotherapy Opdivo that were about half of those for a rival medicine from Merck & Co (MRK.N), and its shares fell 2 percent.Opdivo, which is used to treat advanced melanoma and was more recently approved to treat a common form of lung cancer, had sales of $40 million in the quarter. Merck on Tuesday said it Keytruda, a similar new drug that helps the immune system to fight cancer, had first quarter sales of $83 million.""Opdivo sales of $40 million is a little disappointing. We expected $54 million,"" BMO Capital Markets analyst Alex Arfaei said in a note. Arfaei said he expects a strong Opdivo launch in the much larger lung cancer market as the year progresses.Bristol is counting on potential multibillion-dollar sales of its immunotherapy cancer drugs to help drive future growth. Yervoy, an older immunotherapy for melanoma, saw sales rise 20 percent to $325 million.Bristol-Myers posted better-than-expected quarterly results for the quarter, helped by cost cuts and a higher estimate of royalties owed the company from sales of its Abilify schizophrenia treatment.  The U.S. drugmaker said it earned $1.19 billion, or 71 cents per share, in the first quarter. That compared with $937 million, or 56 cents per share, in the year-earlier period.Excluding special items, Bristol-Myers earned 71 cents per share, well above the average forecast of 51 cents per share, according to Thomson Reuters I/B/E/S. Results were helped by lower spending on marketing and advertising. Company sales rose 6 percent to $4.04 billion, about $200 million above Wall Street expectations. They would have risen 13 percent if not for the stronger dollar, which lowers the value of sales abroad.Bristol-Myers raised the lower end of its full-year 2015 profit forecast by five cents, to $1.60 per share, while keeping the higher end at $1.70. Sales of Abilify rose 3 percent to $554 million, but would have been far lower if not for a recalculation of royalties Bristol-Myers receives from partner Otsuka Holdings Co (4578.T). Under a marketing agreement that ended April 20, Bristol-Myers last year recorded sales of Abilify that reflected an estimated 33 percent royalty rate. But in the recent first quarter, Bristol-Myers recorded sales that reflected an actual 50 percent royalty.Bristol-Myers shares were off $1.25, or 1.9 percent, at $63.91 on the New York Stock Exchange. (Reporting by Ransdell Pierson and Bill Berkrot; Editing by W Simon and Ted Botha)",2015-04-28,BMY,"Tue Apr 28, 2015 | 11:05am EDT","High-profile Bristol cancer drug disappoints, shares off",http://www.reuters.com//article/us-bristolmyers-results-idUSKBN0NJ1C220150428?type=companyNews
139,"  (Adds shares down, analyst comment)By Ransdell Pierson and Bill BerkrotApril 28 Bristol-Myers Squibb Co on Tuesday reported first-quarter sales of its new cancer immunotherapy Opdivo that were about half of those for a rival medicine from Merck & Co, and its shares fell 2 percent.Opdivo, which is used to treat advanced melanoma and was more recently approved to treat a common form of lung cancer, had sales of $40 million in the quarter. Merck on Tuesday said it Keytruda, a similar new drug that helps the immune system to fight cancer, had first quarter sales of $83 million.""Opdivo sales of $40 million is a little disappointing. We expected $54 million,"" BMO Capital Markets analyst Alex Arfaei said in a note. Arfaei said he expects a strong Opdivo launch in the much larger lung cancer market as the year progresses. Bristol is counting on potential multibillion-dollar sales of its immunotherapy cancer drugs to help drive future growth. Yervoy, an older immunotherapy for melanoma, saw sales rise 20 percent to $325 million.Bristol-Myers posted better-than-expected quarterly results for the quarter, helped by cost cuts and a higher estimate of royalties owed the company from sales of its Abilify schizophrenia treatment.The U.S. drugmaker said it earned $1.19 billion, or 71 cents per share, in the first quarter. That compared with $937 million, or 56 cents per share, in the year-earlier period. Excluding special items, Bristol-Myers earned 71 cents per share, well above the average forecast of 51 cents per share, according to Thomson Reuters I/B/E/S. Results were helped by lower spending on marketing and advertising.Company sales rose 6 percent to $4.04 billion, about $200 million above Wall Street expectations. They would have risen 13 percent if not for the stronger dollar, which lowers the value of sales abroad. Bristol-Myers raised the lower end of its full-year 2015 profit forecast by five cents, to $1.60 per share, while keeping the higher end at $1.70.Sales of Abilify rose 3 percent to $554 million, but would have been far lower if not for a recalculation of royalties Bristol-Myers receives from partner Otsuka Holdings Co.Under a marketing agreement that ended April 20, Bristol-Myers last year recorded sales of Abilify that reflected an estimated 33 percent royalty rate. But in the recent first quarter, Bristol-Myers recorded sales that reflected an actual 50 percent royalty.Bristol-Myers shares were off $1.25, or 1.9 percent, at $63.91 on the New York Stock Exchange.   (Reporting by Ransdell Pierson and Bill Berkrot; Editing by W Simon and Ted Botha)",2015-04-28,BMY,"Tue Apr 28, 2015 | 11:02am EDT","UPDATE 2-High-profile Bristol cancer drug disappoints, shares off",http://www.reuters.com//article/bristolmyers-results-idUSL1N0XP0RG20150428?type=companyNews
140,"  Thomson Reuters April 28, 2015 - Corporate Meetings for US companies for Week ahead.         S&P 500 Earnings - MONTH AHEAD     Dividends                            Non S&P 500 - Weekly             Federal Reserve events               ConferenceCall/Webcast - Weekly  Meetings - Weekly                                Xtra users can see more details on conference calls & webcasts by hovering your mouse  over the RIC, right click, no click on Related Co Data, now click on Co Events.                      - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - DATE       GMT      SYMBOL       EVENT TITLE  28 Apr     13:00           Apollo Commercial Real Estate Annual Shareholders Meeting 28 Apr     13:00             CitiAnnual Shareholders Meeting 28 Apr     13:00        Fiesta Restaurant Annual Shareholders Meeting 28 Apr     13:00          Fortune Brands Home & Security Annual Shareholders Meeting 28 Apr     13:00           Home Properties Annual Shareholders Meeting 28 Apr     13:00          Vantiv Annual Shareholders Meeting 28 Apr     13:30           Federal Signal Corp Annual Shareholders Meeting 28 Apr     13:30        National Penn Bancshares Annual Shareholders Meeting 28 Apr     13:30           SunTrust Banks Annual Shareholders Meeting 28 Apr     13:30           Wells Fargo & Co Annual Shareholders Meeting 28 Apr     23:00           Bio Rad Laboratories Annual Shareholders Meeting 28 Apr     00:00           Principal Financial at Milken Institute Global Conf 28 Apr     12:00            Chubb Corp Annual Shareholders Meeting 28 Apr     12:00           Coca-Cola Enterprises Annual Shareholders Meeting 28 Apr     12:00           PerkinElmer Annual Shareholders Meeting 28 Apr     12:00           Teradata Corp Annual Shareholders Meeting 28 Apr     12:30           HanesBrands Annual Shareholders Meeting 28 Apr     14:00           AGL Resources Annual Shareholders Meeting 28 Apr     14:00        Capital City Bank Annual Shareholders Meeting 28 Apr     14:00           Exelon Corp Annual Shareholders Meeting 28 Apr     14:00           Hershey Co Annual Shareholders Meeting 28 Apr     14:00           Stepan Co Annual Shareholders Meeting 28 Apr     14:00           TAL International Annual Shareholders Meeting 28 Apr     14:00           Total System Services Annual Shareholders Meeting 28 Apr     14:00        UMB Financial Corp Annual Shareholders Meeting 28 Apr     14:00             United States Steel Corp Annual Shareholders Meeting 28 Apr     14:00           Weingarten Realty Investors Annual Shareholders Meeting 28 Apr     14:30           Apartment Investment and Management Annual Shareholders Meeting 28 Apr     14:30        Charter Communications Annual Shareholders Meeting 28 Apr     14:30           Comerica Annual Shareholders Meeting 28 Apr     14:30        Cumberland Pharmaceuticals Annual Shareholders Meeting 28 Apr     14:30           Exterran Holdings Annual Shareholders Meeting 28 Apr     14:30           Noble Energy Annual Shareholders Meeting 28 Apr     15:00           AMC Entertainment Holdings Annual Shareholders Meeting 28 Apr     15:00           BB&T Corp Annual Shareholders Meeting 28 Apr     15:00           Centene Corp Annual Shareholders Meeting 28 Apr     15:00        Control4 Corp Annual Shareholders Meeting 28 Apr     15:00           First Horizon National Corp Annual Shareholders Meeting 28 Apr     15:00        Hancock Holding Co Annual Shareholders Meeting 28 Apr     15:00           International Business Machines Annual Shareholders Meeting 28 Apr     15:00           Kirby Corp Annual Shareholders Meeting 28 Apr     15:00           ManpowerAnnual Shareholders Meeting 28 Apr     15:00           PNC Financial Services Annual Shareholders Meeting 28 Apr     15:00            Praxair Annual Shareholders Meeting 28 Apr     15:00            Spectra Energy Corp Annual Shareholders Meeting 28 Apr     15:00        Washington Trust Bancorp Annual Shareholders Meeting 28 Apr     15:00        YRC Worldwide Annual Shareholders Meeting 28 Apr     15:30        First Financial Bankshares Annual Shareholders Meeting 28 Apr     15:30           Metlife Annual Shareholders Meeting 28 Apr     16:00           MDU Resources Annual Shareholders Meeting 28 Apr     16:15           Rollins Annual Shareholders Meeting 28 Apr     16:30           Principal Financial at Milken Institute Global Conf 28 Apr     17:00           PS Business Parks Annual Shareholders Meeting 28 Apr     18:00          Alexander & Baldwin Annual Shareholders Meeting 28 Apr     18:00        First Community Bancshares Annual Shareholders Meeting 28 Apr     18:00           FMC Corp Annual Shareholders Meeting 28 Apr     18:00         South State Corp Annual Shareholders Meeting 28 Apr     18:30        Renasant Corp Annual Shareholders Meeting 28 Apr     19:00        BOK Financial Corp Annual Shareholders Meeting 28 Apr     19:00           First Commonwealth Financial Corp Annual Shareholders Meeting 28 Apr     19:00        Trustmark Corp Annual Shareholders Meeting 28 Apr     19:00           Valmont Industries Annual Shareholders Meeting 28 Apr     07:30        Aquabounty Technologies Annual Shareholders Meeting 28 Apr     19:30           RPC Annual Shareholders Meeting 28 Apr     20:00        Cepheid Annual Shareholders Meeting 28 Apr     20:00        Earthlink Holdings Corp Annual Shareholders Meeting 28 Apr     20:00           Nautilus Annual Shareholders Meeting 28 Apr     21:00          Corelogic Annual Shareholders Meeting 28 Apr     21:30           Principal Financial at Milken Institute Global Conf 29 Apr     13:00           BorgWarner Annual Shareholders Meeting 29 Apr     13:00           CNA Financial Corp Annual Shareholders Meeting 29 Apr     13:00           Geo Annual Shareholders Meeting 29 Apr     13:00           Harsco Corp Annual Shareholders Meeting 29 Apr     13:00        Inficon Holding AG Annual Shareholders Meeting 29 Apr     13:00         SciQuest Annual Shareholders Meeting 29 Apr     13:00        Tecumseh Products Company Annual Shareholders Meeting 29 Apr     00:00           Ryland Annual Shareholders Meeting 29 Apr     12:00        Bloomin' Brands Annual Shareholders Meeting 29 Apr     14:00         Advanced Micro Devices Annual Shareholders Meeting 29 Apr     14:00           Ball Corp Annual Shareholders Meeting 29 Apr     14:00           Discover Financial Services Annual Shareholders Meeting 29 Apr     14:00        First Niagara Financial Annual Shareholders Meeting 29 Apr     14:00           Gannett Co Annual Shareholders Meeting 29 Apr     14:00           Marathon Petroleum Corp Annual Shareholders Meeting 29 Apr     14:30            Eversource Energy Annual Shareholders Meeting 29 Apr     15:00        Glacier Bancorp Annual Shareholders Meeting 29 Apr     15:00           Marathon Oil Corp Annual Shareholders Meeting 29 Apr     15:00          McGraw Hill Financial Annual Shareholders Meeting 29 Apr     15:00           MRC Global Annual Shareholders Meeting 29 Apr     15:00        Papa John's International Annual Shareholders Meeting 29 Apr     15:00            TECO Energy Annual Shareholders Meeting 29 Apr     15:00            The Coca-Cola Co Annual Shareholders Meeting 29 Apr     15:00            Under Armour Annual Shareholders Meeting 29 Apr     15:00           W W Grainger Annual Shareholders Meeting 29 Apr     15:00           Westwood Holdings Annual Shareholders Meeting 29 Apr     15:30           Fresh Del Monte Produce Annual Shareholders Meeting 29 Apr     15:30           Principal Financial at Milken Institute Global Conf 29 Apr     15:30           Tennant Co Annual Shareholders Meeting 29 Apr     16:00           Ameriprise Financial Annual Shareholders Meeting 29 Apr     16:00           DCT Industrial Trust Annual Shareholders Meeting 29 Apr     16:00        ReachLocal Annual Shareholders Meeting 29 Apr     17:00           Cambrex Corp Annual Shareholders Meeting 29 Apr     18:00        Retail Opportunity Investments Corp Annual Shareholders Meeting 29 Apr     18:00           Stryker Corp Annual Shareholders Meeting 29 Apr     19:00        Ares Capital Corp Annual Shareholders Meeting 29 Apr     19:00           Deluxe Corp Annual Shareholders Meeting 29 Apr     19:00          Douglas Dynamics Annual Shareholders Meeting 29 Apr     19:00           Duke Realty Corp Annual Shareholders Meeting 29 Apr     19:00        Selective Insurance Annual Shareholders Meeting 29 Apr     20:30           Prologis Annual Shareholders Meeting 30 Apr     13:00        Altra Industrial Motion Corp Annual Shareholders Meeting 30 Apr     13:00        BroadSoft Annual Shareholders Meeting 30 Apr     13:00           Cobalt International Energy Annual Shareholders Meeting 30 Apr     13:00           SCANA Corp Annual Shareholders Meeting 30 Apr     13:30           Energen Corp Annual Shareholders Meeting 30 Apr     13:30        RetailMeNot Annual Shareholders Meeting 30 Apr     22:00        Enterprise Financial Services Corp Annual Shareholders Meeting 30 Apr     12:00           American Axle & Manufacturing Annual Shareholders Meeting 30 Apr     12:00           Unisys Corp Annual Shareholders Meeting 30 Apr     12:30           Dana Holding Corp Annual Shareholders Meeting 30 Apr     14:00           Capital One Financial Corp Annual Shareholders Meeting 30 Apr     14:00        CenterState Banks Annual Shareholders Meeting 30 Apr     14:00           EMC Corp Annual Shareholders Meeting 30 Apr     14:00        Entegris Annual Shareholders Meeting 30 Apr     14:00           Fluor Corp Annual Shareholders Meeting 30 Apr     14:00           Mead Johnson Nutrition Co Annual Shareholders Meeting 30 Apr     14:00        MYR Annual Shareholders Meeting 30 Apr     14:00           Owens & Minor Annual Shareholders Meeting 30 Apr     14:00           Polaris Industries Annual Shareholders Meeting 30 Apr     14:00           South Jersey Industries Annual Shareholders Meeting 30 Apr     14:00       Southern Peru Copper Peru Branch Annual Shareholders Meeting 30 Apr     14:00           Vector Ltd Annual Shareholders Meeting 30 Apr     15:00        Bryn Mawr Bank Corp Annual Shareholders Meeting 30 Apr     15:00           Cincinnati Bell Annual Shareholders Meeting 30 Apr     15:00           Corning Annual Shareholders Meeting 30 Apr     15:00           Huntington Ingalls Industries Annual Shareholders Meeting 30 Apr     15:00           Kimberly-Clark Corp Annual Shareholders Meeting 30 Apr     15:00           Snap-On Annual Shareholders Meeting 30 Apr     15:00          Southern Copper Corp Annual Shareholders Meeting 30 Apr     15:00           Torchmark Corp Annual Shareholders Meeting 30 Apr     15:00           Valero Energy Corp Annual Shareholders Meeting 30 Apr     15:30           Hudson Valley Holding Corp Annual Shareholders Meeting 30 Apr     16:00        Enphase Energy Annual Shareholders Meeting 30 Apr     16:00        Kona Grill Annual Shareholders Meeting 30 Apr     16:30           HCP Annual Shareholders Meeting 30 Apr     17:00        EchoStar Corp Annual Shareholders Meeting 30 Apr     17:00        Entropic Special Meeting of Stockholders 30 Apr     17:00        Entropic Communications Annual Shareholders Meeting 30 Apr     17:00        Mobile Mini Annual Shareholders Meeting 30 Apr     17:30           Sunstone Hotel Investors Annual Shareholders Meeting 30 Apr     18:00      Itausa Investimentos Itau SA Annual Shareholders Meeting 30 Apr     18:00        Tessera Technologies Annual Shareholders Meeting 30 Apr     18:30          MSCI Annual Shareholders Meeting 30 Apr     19:00        Endurance International Holdings Annual Shareholders Meeting 30 Apr     19:00           HCA Holdings Annual Shareholders Meeting 30 Apr     20:00           EOG Resources Annual Shareholders Meeting 30 Apr     20:00           Public Storage Annual Shareholders Meeting 30 Apr     20:00        WSFS Financial Corp Annual Shareholders Meeting 01 May     13:00        ArcBest Corp Annual Shareholders Meeting 01 May     13:00           CMS Energy Corp Annual Shareholders Meeting 01 May     13:00          Realogy Holdings Corp Annual Shareholders Meeting 01 May     13:00           Yum! Brands Annual Shareholders Meeting 01 May     13:30            Alcoa Annual Shareholders Meeting 01 May     13:30           Babcock & Wilcox Co Annual Shareholders Meeting 01 May     22:00        FormFactor Annual Shareholders Meeting 01 May                     Lindsay Corp at Gabelli Omaha Research Trip 01 May                  Rentrak Corp at Gabelli Omaha Research Trip 01 May                     Safeguard Scientifics at Gabelli Omaha Research Trip 01 May                    TD Ameritrade Holding Corp at Gabelli Omaha Research Trip 01 May                     Union Pacific Corp at Gabelli Omaha Research Trip 01 May                     Valmont Industries at Gabelli Omaha Research Trip 01 May                  Werner Enterprises at Gabelli Omaha Research Trip 01 May     12:30        Alnylam Pharmaceuticals Annual Shareholders Meeting 01 May     14:00        Lincoln Educational Services Corp Annual Shareholders Meeting 01 May     14:00        Olympic Steel Annual Shareholders Meeting 01 May     14:00         Pilgrims Pride Corp Annual Shareholders Meeting 01 May     14:00        Primoris Services Corp Annual Shareholders Meeting 01 May     14:00             Ryder System Annual Shareholders Meeting 01 May     14:00         Sprouts Farmers Market Annual Shareholders Meeting 01 May     14:00           Zoetis Annual Shareholders Meeting 01 May     14:30           Louisiana-Pacific Corp Annual Shareholders Meeting 01 May     15:00           Allegheny Technologies Annual Shareholders Meeting 01 May     15:00        eBay Annual Shareholders Meeting 01 May     15:00         Magnetek Annual Shareholder Meeting 01 May     15:00           Teleflex Annual Shareholders Meeting 01 May     15:30           Occidental Petroleum Corp Annual Shareholders Meeting 01 May     15:30           RLJ Lodging Trust Annual Shareholders Meeting 01 May     16:00        Huron Consulting Annual Shareholders Meeting 01 May     17:30        CommScope Holding Company Annual Shareholders Meeting 01 May     18:00        Hawaiian Telcom Holdco Annual Shareholders Meeting 01 May     07:00           Rowan Companies PLC Annual Shareholders Meeting 01 May     19:00        Overstock.com Annual Shareholders Meeting 02 May     13:30        Cincinnati Financial Corp Annual Shareholders Meeting 02 May     20:45          Berkshire Hathaway Annual Shareholders Meeting 04 May     13:00          Tumi Holdings Annual Shareholders Meeting 04 May     13:30          Textura Corp Annual Shareholders Meeting 04 May     14:00           Aflac Annual Shareholders Meeting 04 May     14:00           Agree Realty Corp Annual Shareholders Meeting 04 May     14:00        Consolidated Communications Annual Shareholders Meeting 04 May     14:00        Exone Co Annual Shareholders Meeting 04 May     14:00           Masco Corp Annual Shareholders Meeting 04 May     14:00        MKS Instruments Annual Shareholders Meeting 04 May     14:00           Oasis Petroleum Annual Shareholders Meeting 04 May     14:00          STAG Industrial Annual Shareholders Meeting 04 May     14:30        Dot Hill Systems Corp Annual Shareholders Meeting 04 May     15:00        CyrusOne Annual Shareholders Meeting 04 May     15:00           Eli Lilly and Co Annual Shareholders Meeting 04 May     16:00           Clearwater Paper Corp Annual Shareholders Meeting 04 May     16:00         Potlatch Corp Annual Shareholders Meeting 04 May     17:00           Excel Trust Annual Shareholders Meeting 04 May     17:00           PG&E Corp. and Pacific Gas & Electric Co Shareholder Meeting 04 May     18:00           QTS Realty Trust Annual Shareholders Meeting 04 May     18:05           Noble Energy at Credit Suisse Offshore Technology Conf Tour 04 May     18:30         LKQ Corp Annual Shareholders Meeting 04 May     18:30           Peabody Energy Corp Annual Shareholders Meeting 04 May     19:30        First Merchants Corp Annual Shareholders Meeting 04 May     20:00           CBL & Associates Properties Annual Shareholders Meeting 04 May     20:00           E. W. Scripps Co Annual Shareholders Meeting 04 May     20:00           Stillwater Mining Co Annual Shareholders Meeting 04 May     20:05           Chevron Corp at Credit Suisse Offshore Technology Conf Tour 04 May     20:40           Halliburton Co at Credit Suisse Offshore Technology Conf Tour 05 May     13:00        Bravo Brio Restaurant Annual Shareholders Meeting 05 May     13:00           Citizens Financial Annual Shareholders Meeting 05 May     13:00           DiamondRock Hospitality Co Annual Shareholders Meeting 05 May     13:00           FMC Technologies at Credit Suisse Offshore Technology Conf Tour 05 May     13:00          Hubbell Annual Shareholders Meeting 05 May     13:00        Lumos Networks Corp Annual Shareholders Meeting 05 May     13:00           M/I Homes Annual Shareholders Meeting 05 May     13:00          NRG Yield Annual Shareholders Meeting 05 May     13:00           Ramco-Gershenson Properties Trust Annual Shareholders Meeting 05 May     13:00           Sturm Ruger & Co Annual Shareholders Meeting 05 May     13:15           Brady Corp at Wells Fargo Conf 05 May     13:15            Curtiss-Wright Corp at Wells Fargo Conf 05 May     13:15           Pulteat Wells Fargo Conf 05 May     13:30            Franklin Covey Co at Robert W. Baird Conf 05 May     13:30        Habit Restaurants at Robert W. Baird Conf 05 May     13:30        Houston Wire & Cable Co Annual Shareholders Meeting 05 May     13:30        Kraft Foods Annual Shareholders Meeting 05 May     13:30        Meridian Bioscience at Robert W. Baird Conf 05 May     13:30        PostRock Energy Corp Annual Shareholders Meeting 05 May     13:30           Superior Industries International Annual Shareholders Meeting 05 May     13:30           West Pharmaceutical Services Annual Shareholders Meeting 05 May     13:55           Caterpillar at Wells Fargo Conf 05 May     13:55           Dow Chemical Co at Wells Fargo Conf 05 May     13:55        Stock Building Supply Holdings at Wells Fargo Conf 05 May     22:00          LifeLock Annual Shareholders Meeting 05 May                  Adobe Systems at Robert W. Baird Conf 05 May     12:00           Albemarle Corp Annual Shareholders Meeting 05 May                     Ashford Hospitality Trust at Robert W. Baird Conf 05 May                  Asure Software at Credit Suisse Mexico Investment Ideas Conf 05 May                  First Cash Financial Services at Credit Suisse Conf 05 May                     Gap at Credit Suisse Mexico Investment Ideas Conf 05 May                     Monsanto Co at Wells Fargo Conf 05 May                  Nordson Corp at Wells Fargo Conf 05 May                     Pebblebrook Hotel Trust at Robert W. Baird Conf 05 May     12:00           Penske Automotive Annual Shareholders Meeting 05 May     12:00        Strayer Education Annual Shareholders Meeting 05 May                  TESARO at Citi Midwest Healthcare Access Day 05 May     12:00           Zimmer Holdings Annual Shareholders Meeting 05 May     12:30           Charles River Laboratories Annual Shareholders Meeting 05 May     12:30           Entercom Communications Corp Annual Shareholders Meeting 05 May     12:30           Gamco Investors Annual Shareholders Meeting 05 May     12:35           Ametek at Wells Fargo Conf 05 May     12:35           Harman International at Wells Fargo Conf 05 May     12:35           Rockwell Collins at Wells Fargo Conf 05 May     12:35           Tenneco at Wells Fargo Conf 05 May     14:00        Abraxas Petroleum Corp Annual Shareholders Meeting 05 May     14:00           Alon USA Energy Annual Shareholders Meeting 05 May     14:00        Argo International Holdings Ltd Annual Shareholders Meeting 05 May     14:00           Baxter International Annual Shareholders Meeting 05 May     14:00           Bristol-Myers Squibb Co Annual Shareholders Meeting 05 May     14:00        Capella Education Co Annual Shareholders Meeting 05 May     14:00        Fulton Financial Corp Annual Shareholders Meeting 05 May     14:00           Kimco Realty Corp Annual Shareholders Meeting 05 May     14:00           Manitowoc Company Annual Shareholders Meeting 05 May     14:00        NBT Bancorp Annual Shareholders Meeting 05 May     14:00        Progress Software Corp Annual Shareholders Meeting 05 May     14:00        Varonis Systems Annual Shareholders Meeting 05 May     14:00        VSE Corp. Annual Meeting of Stockholders 05 May     14:00           ZAIS Financial Corp Annual Shareholders Meeting 05 May     14:10        Blackbaud at Robert W. Baird Conf 05 May     14:10        Littelfuse at Robert W. Baird Conf 05 May     14:10        Paychex at Robert W. Baird Conf 05 May     14:10           United Parcel Service at Robert W. Baird Conf 05 May     14:30        Horsehead Holding Corp Annual Shareholders Meeting 05 May     14:35           Ball Corp at Wells Fargo Conf 05 May     14:35           Eastman Chemical Co at Wells Fargo Conf 05 May     14:35           Hovnanian Enterprises at Wells Fargo Conf 05 May     14:35        PACCAR at Wells Fargo Conf 05 May     14:45        Exlservice Holdings at Robert W. Baird Conf 05 May     14:45        Gentex Corp at Robert W. Baird Conf 05 May     14:45          Store Capital Corp at Robert W. Baird Conf 05 May     14:45          Zoe's Kitchen at Robert W. Baird Conf 05 May     15:00           Boston Scientific Corp Annual Shareholders Meeting 05 May     15:00           Cousins Properties Annual Shareholders Meeting 05 May     15:00           Great Plains Energy Annual Shareholders Meeting 05 May     15:00           Leggett & Platt Annual Shareholders Meeting 05 May     15:00        NIC Annual Shareholders Meeting 05 May     15:00           Oceaneering International at Credit Suisse Conf Tour 05 May     15:00        O'Reilly Automotive Annual Shareholders Meeting 05 May     15:00        Raptor Pharmaceutical Corp Annual Shareholders Meeting 05 May     15:00        Sigma-Aldrich Corp Annual Shareholders Meeting 05 May     15:00        Thoratec Corp Annual Shareholders Meeting 05 May     15:00        Tractor Supply Co Annual Shareholders Meeting 05 May     15:15           AAR Corp at Wells Fargo Conf 05 May     15:15           FLY Leasing Ltd at Wells Fargo Conf 05 May     15:15           Huntsman Corp at Wells Fargo Conf 05 May     15:15            Owens Corning at Wells Fargo Conf 05 May     15:20        Broadcom Corp at Robert W. Baird Conf 05 May     15:20           Chipotle Mexican Grill at Robert W. Baird Conf 05 May     15:20        EnerNOC at Robert W. Baird Conf 05 May     15:20        Forward Air Corp at Robert W. Baird Conf 05 May     15:30           HNI Corp Annual Shareholders Meeting 05 May     15:30           NVR Annual Shareholders Meeting 05 May     15:30        Quidel Corp Annual Shareholders Meeting 05 May     15:35           Helix Energy Solutions at Credit Suisse Conf Tour 05 May     15:55        Buffalo Wild Wings at Robert W. Baird Conf 05 May     15:55            DeVry Education at Robert W. Baird Conf 05 May     15:55         Silicon Graphics International Corp at Robert W. Baird Conf 05 May     16:00           Goodrich Petroleum Corp Annual Shareholders Meeting 05 May     16:00           Nuverra Environmental Solutions Annual Shareholders Meeting 05 May     16:00          Paycom Software Annual Shareholders Meeting 05 May     16:00           TETRA Technologies Annual Shareholders Meeting 05 May     16:30           Ecolab at Robert W. Baird Conf 05 May     16:30           Kilroy Realty Corp at Robert W. Baird Conf 05 May     16:30           Red Hat at Robert W. Baird Conf 05 May     16:30        Rocky Brands at Robert W. Baird Conf 05 May     17:00           Calgon Carbon Corp Annual Shareholders Meeting 05 May     17:15        LMI Aerospace at Wells Fargo Conf 05 May     17:15           RPM International at Wells Fargo Conf 05 May     17:15           Terex Corp at Wells Fargo Conf 05 May     17:15          Tower International at Wells Fargo Conf 05 May     17:40           Apartment Investment and Management Co at Robert W. Baird Conf 05 May     17:40        Dunkin' Brands at Robert W. Baird Conf 05 May     17:40        FARO Technologies at Robert W. Baird Conf 05 May     17:40        Power Solutions International at Robert W. Baird Conf 05 May     17:55          ADS Tactical at Wells Fargo Conf 05 May     17:55           Lennox International at Wells Fargo Conf 05 May     17:55           Sonoco Products Company at Wells Fargo Conf 05 May     17:55         TriMas Corp at Wells Fargo Conf 05 May     18:00            Knowles Corp Annual Shareholders Meeting 05 May     18:00           Nordstrom Annual Shareholders Meeting 05 May     18:15         Ignite Restaurant at Robert W. Baird Conf 05 May     18:15            La Quinta Holdings at Robert W. Baird Conf 05 May     18:15           Quanta Services at Robert W. Baird Conf 05 May     18:15        Xoom Corp at Robert W. Baird Conf 05 May     18:30           L-3 Communications Holdings Annual Shareholders Meeting 05 May     18:35           BorgWarner at Wells Fargo Conf 05 May     18:35           Crown Holdings at Wells Fargo Conf 05 May     18:35             Ryder System at Wells Fargo Conf 05 May     18:35           Stanley Black & Decker at Wells Fargo Conf 05 May     18:50           Armada Hoffler Properties at Robert W. Baird Conf 05 May     18:50        Hub at Robert W. Baird Conf 05 May     18:50           Krispy Kreme Doughnuts at Robert W. Baird Conf 05 May     19:00            Delek US Holdings Annual Shareholders Meeting 05 May     19:15           AK Steel Holding Corp at Wells Fargo Conf 05 May     19:15           Aptarat Wells Fargo Conf 05 May     19:15        US Ecology at Wells Fargo Conf 05 May     19:15           Watsco at Wells Fargo Conf 05 May     19:25        Constant Contact at Robert W. Baird Conf 05 May     19:25        GoPro at Robert W. Baird Conf 05 May     19:25        Plug Power at Robert W. Baird Conf 05 May     19:25        Stericycle at Robert W. Baird Conf 05 May     19:55           Myers Industries at Wells Fargo Conf 05 May     19:55           Olin Corp at Wells Fargo Conf 05 May     19:55           Ryerson Holding Corp at Wells Fargo Conf 05 May     19:55           TAL International at Wells Fargo Conf 05 May     20:00        Citrix Systems at Robert W. Baird Conf 05 May     20:00           Highwoods Properties at Robert W. Baird Conf 05 May     20:00           Neustar at Robert W. Baird Conf 05 May     20:50        NasdaqAkamai Technologies at Robert W. Baird Conf 05 May     21:00        East West Bancorp Annual Shareholders Meeting 05 May     21:00        IBERIABANK Corp Annual Shareholders Meeting 05 May     21:00           Plum Creek Timber Company Annual Shareholders Meeting      FOR ALL AMERICAN HOLIDAYS      FOR AN INDEX OF ALL DIARIES            If you have any questions or comments on the Corporate diary, please e-mail:     diaries@thomsonreuters.com   ",2015-04-28,BMY,"Tue Apr 28, 2015 | 9:18am EDT",DIARY-U.S. MEETINGS/WEEK AHEAD,http://www.reuters.com//article/diary-us-meetings-week-idUSL4N0XP5YC20150428?type=companyNews
141,"  April 28 Bristol-Myers Squibb Co  reported better than expected quarterly results, helped by cost cuts and a higher estimate of royalties owed the company from sales of its Abilify schizophrenia treatment.The U.S. drugmaker on Tuesday said it earned $1.19 billion, or 71 cents per share, in the first quarter. That compared with $937 million, or 56 cents per share, in the year-earlier period. Excluding special items, Bristol-Myers earned 71 cents per share, well above the average forecast of 51 cents per share, according to Thomson Reuters I/B/E/S. Results were helped by lower spending on marketing and advertising. Company sales rose 6 percent to $4.04 billion, about $200 million above Wall Street expectations. They would have risen 13 percent if not for the stronger dollar, which lowers the value of sales abroad. (Reporting by Ransdell Pierson)",2015-04-28,BMY,"Tue Apr 28, 2015 | 7:39am EDT","Bristol-Myers tops forecasts, helped by Abilify royalty adjustment",http://www.reuters.com//article/bristolmyers-results-idUSL1N0XO2TB20150428?type=companyNews
142,"  (Repeats Tuesday story with no changes to text.)By Ransdell Pierson and Bill BerkrotApril 28 Investors betting that Bristol-Myers Squibb will emerge as the leading player in a hot new class of cancer drugs hit the pause button on Tuesday as a rival therapy from Merck & Co showed much higher sales.Bristol shares fell as much as 2.7 percent and closed off 1 percent after reporting sales of Opdivo, a therapy that helps the immune system fight cancer, totaled $40 million in the first quarter of the year. That was below Wall Street forecasts of $50 million.Merck said its Keytruda treatment had quarterly sales of $83 million, topping Wall Street estimates of about $70 million, helped by early compassionate use patients converting to paying customers following approval.""When investors saw Opdivo's number was below Keytruda's, that caused concern,"" said John Boris, an analyst with Suntrust Robinson Humphrey. Merck shares closed up 5 percent, though the gains were mostly attributed to positive new safety data on its top-selling Januvia diabetes treatment.Boris and other industry analysts said the early sales data represent only the first skirmish in a long battle for market share between Bristol-Myers and Merck. Some expect both drugs will eventually generate billions of dollars in annual sales, particularly if proven effective against other forms of cancer.In addition, excitement over Bristol-Myers' cancer treatments have pushed shares to trade at 28.5 times expected 2016 per share earnings, Boris said. That compares with a multiple of 15.1 for Merck and 17.6 for the pharmaceutical sector. ""Based on price per fundamentals, we like the value of Merck versus Bristol at the moment,"" said Les Funtleyder, healthcare portfolio manager for ESquared Asset Management, which currently holds Merck but not Bristol shares.Ori Hershkovitz, a managing partner at Nexthera Capital in New York, said Bristol-Myers is trading more like a high-flying biotech.""The minute biotech gets pummeled, Bristol bears the brunt,"" he said, noting biotech stocks have retreated sharply in recent weeks on fears they were overly inflated. EARLY ADVANTAGE Opdivo was approved in December to treat advanced melanoma. In March, it received clearance to treat a common form of lung cancer, giving Bristol an early-mover advantage in a much larger market.Keytruda has been approved for advanced melanoma since September and awaits regulatory approval in lung cancer.Both drugs work by blocking a protein called PD-1, helping the immune system recognize and destroy cancer cells. Roche Holding AG, AstraZeneca Plc and Pfizer Inc  are also developing similar treatments. Boris forecast Opdivo annual sales reaching $7 billion by 2020 and said Tuesday's weakness in Bristol shares represents a buying opportunity. Opdivo has been shown to prolong survival in melanoma and lung cancer, according to clinical trial data.Keytruda has not yet demonstrated a survival benefit but is expected to do so in coming trials. Boris predicted it will capture annual sales of $3.7 billion by 2020.Bristol Chief Scientific Officer Francis Cuss told analysts on Tuesday that strong data on Opdivo along with the U.S. approvals in lung cancer and melanoma and expected European approval ""really puts us in a very strong competitive position.""The company recently reported strong results from a combination of Opdivo and its older immunotherapy Yervoy in advanced melanoma. It plans to apply for approval of the combination therapy by mid-year.Merck head of global human health, Adam Schechter, told analysts that the market will be big enough to handle several competitors, ""so I don't think it should be looked at as one company versus the other.""Pfizer is racing to catch up with Merck and Bristol-Myers, by beginning late-stage trials this year of its PD-1 inhibitor and conducting trials of four other immuno-oncology drugs.PD-1 treatments ""will be the workhorses for the foreseeable future, but they will need to be added to standard therapies or to (other) immuno-oncology treatments,"" Pfizer Chief Executive Ian Read said in an interview. ""That's where the market will be, and we will be well positioned with those combination agents.""     (Reporting by Ransdell Pierson and Bill Berkrot, editing by Michele Gershberg and Andrew Hay)",2015-04-29,BMY,"Wed Apr 29, 2015 | 7:00am EDT",RPT-Strong Merck cancer drug sales upstage rival Bristol-Myers,http://www.reuters.com//article/bristolmyers-merck-cancer-idUSL1N0XP3O820150429?type=companyNews
143,"  (The following statement was released by the rating agency) CHICAGO, April 30 (Fitch) Fitch Ratings has assigned an 'A-' rating to  Bristol-Myers Squibb Co.'s (Bristol- Myers, Bristol, BMY) Euro Bond issuance.  The net proceeds from the issuance are expected to be used to fund, in part, the  redemption of the company's existing 2016 and 2022 senior unsecured Euro notes.  A full list of the company's ratings follows at the end of this press release. KEY RATING DRIVERS --Fitch expects Bristol-Myers to operate with leverage below 2.0 times (x)  following the divestiture of its diabetes business. Leverage at Dec. 31, 2014  was 2.1x.  --Fitch anticipates that continued market uptake of Bristol's medicines with  longer patent protection and the successful commercialization of key research  projects will help offset the effects of the patent expirations of Baraclude and  Abilify during 2015. --Bristol has made progress in advancing a number of late-stage pipeline  candidates that treat various cancers and hepatitis C, which will help  longer-term growth.  --Baraclude and Abilify patent expirations will be a headwind to sales and cash  flows in 2015. Nevertheless, Fitch does see meaningful operational improvement  in 2016 as new and established patent-protected drugs continue to gain traction  and patent expiries are more manageable.  --The sale of the company's diabetes business has reduced EBITDA and left  Bristol less diversified. However, Fitch believes the company will benefit from  its narrower strategic focus from gains in operational efficiency and research  productivity in the intermediate to long term.  --Fitch believes Bristol will use a cash deployment strategy that generally  preserves cash through 2015 by moderating its share repurchases. Leverage Expected to Generally Remain Below 2.0x Fitch expects that Bristol will generally operate with gross debt leverage  (total debt/EBITDA) below 2.0x during the forecast horizon. The company paid  down approximately $755 million in debt during the first quarter of 2014 and has  maintained profitability during the past 12 months.  Patent Protected Products Growing Bristol has a number of growth drivers for the intermediate term that will help  to mitigate the roughly 20% of sales at risk to patent expiries through the end  of 2016. The company's longer-dated patented products continue to generate solid  growth. Sprycel (chronic myeloid leukemia), Yervoy (metastatic melanoma) and  Orencia (rheumatoid arthiritis) are generating strong double-digit growth as  favorable clinical outcomes drive increased utilization. Eliquis (blood clots)  revenues have increased eight-fold over the prior year due to positive clinical  data and improved formulary positioning.  Pipeline Progress Bristol-Myers has made meaningful progress with its late-stage pipeline during  the past year, during which it has advanced treatments for cancer and hepatitis  C through its pipeline. Opdivo/nivolumab (cancer) has had numerous positive  developments, including FDA approval in December 2014 to treat skin cancer.  Moderate Impact from Patent Losses in 2015 - 2016 A second wave of drug patent expirations occurs in 2015 - 2016 when Baraclude  and Abilify lose market exclusivity in the U.S. The maturing medicines account  for roughly 20% of total revenues. The patent expiration of Baraclude in the  U.S. is immaterial, although the expected loss of exclusivity in international  markets in October 2016 poses a moderate challenge, as its international sales  account for roughly 8% of total firm sales.  Expected strong performance of Yervoy and Eliquis and continued growth of core  blockbuster medicines, notably Sprycel, Reyataz, and Orencia, should provide  support during the 2015 -2016 patent expiry period. As such, the negative effect  on sales growth and operating margin should be more moderate than what Bristol  experienced during 2012 when Plavix lost most of its sales because of generic  competition after its U.S. patent expired.  Sharpened Strategic Focus In its effort to narrow its strategic focus, Bristol-Myers sold its diabetes  business to AstraZeneca in the February 2014. Fitch believes, over the long  term, the benefits of an increased strategic focus (improved operational  efficiencies and research productivity) will offset the negative effect of  divestiture-related decrease in product portfolio diversification. Bristol received $2.7 billion cash at closing and will receive $800 million in  potential approval milestones and sales performance milestones of potentially  $600 million payable in 2020. The company will also receive specified royalties  on the diabetes' business net worldwide sales through 2025. Soft Near-Term FCF Fitch forecasts relatively soft annual free cash flow (FCF; cash from operations  less dividends and capital expenditures) generation of roughly 500 million to  $700 million during 2014 -2015, mainly the result of top-line pressure from  patent expiries and the loss of contribution from the diabetes franchise. Steady  improvements should follow in 2016 and beyond as new products, recently-launched  and to-be-launched, gain traction. FCF in the latest 12-month (LTM) period ended  Dec. 31, 2014 was $224 million, compared to $699 million in prior year's LTM  period. Cash Preservation through Patent Cliff Fitch believes that Bristol will deploy cash in a relatively conservative manner  throughout 2015. While Fitch expects that Bristol will continue to support its  dividend, the company will likely lean towards cash preservation over  significant share repurchases. During the LTM period ended Dec. 31, 2014, share  repurchases declined and issuances actually exceeded purchases with net proceeds  of $288 million compared to net issuances of $131 million in the prior year  period. KEY ASSUMPTIONS: Fitch's key assumptions for Bristol-Myer's 'A-'/Stable Outlook include: --Modest revenue decline during 2015, primarily driven by the negative effect of  foreign exchange movement and the patent expiries of Abilify and Baraclude; --Established products such as Orencia, Yervoy and Eliquis as well as recently  introduced Opdivo should mitigate some of the headwinds to top-line growth; --EBITDA margin to increase to 25%-26% as mix improves with newer product growth  and ongoing efforts to rein in costs yield savings; --Annual FCF (cash flow from operations minus capital expenditures minus  dividends) to decline to roughly $500 - $600 million during 2015; --Leverage to trend slightly below 2.0x during 2015. RATING SENSITIVITIES Positive: While Fitch does not anticipate a positive rating action in the near  term, future developments that may, individually or collectively, lead to such  an action include: Given the anticipated operational pressure from expiring drug patents through  2016, Fitch would consider a positive rating action if it believes gross debt  leverage will be maintained below 1.7x and FCF will remain positive through the  forecast period. Drivers of operational improvement that would support a  positive revision include strong demand for new therapeutics, as well as  successful commercialization of promising oral Hepatitis C treatments and the  potential first-in-class oncology drug, Opdivo/nivolumumab.  Negative: Future developments that may, individually or collectively, lead to a  negative rating action include: Ratings pressure would result if the company is not successful in mitigating the  negative effects in 2015 - 2016 of the Abilify, Sustiva, and Baraclude patent  expirations. A negative Rating Outlook or a one-notch downgrade could follow a  sustained increase in total debt leverage to greater than 2.0x together with  significant FCF contraction resulting from margin compression and incremental  borrowings. Fitch currently rates Bristol-Myers Squibb as follows: --IDR 'A-'; --Senior unsecured debt 'A-'; --Bank loan 'A-'; --Short-term IDR 'F2'; --Commercial paper 'F2'. The Rating Outlook is Stable. Contact: Primary Analyst Bob Kirby, CFA Director +1-312-368-3147 Fitch Ratings, Inc.  70 West Madison Street Chicago, IL 60602 Secondary Analyst Jacob Bostwick Director +1-312-368-3169 Committee Chairperson Jason Pompei     Senior Director +1-312-368-3210 Media Relations: Alyssa Castelli, New York, Tel: +1 (212) 908 0540, Email:  alyssa.castelli@fitchratings.com; Elizabeth Fogerty, New York, Tel: +1 (212) 908  0526, Email: elizabeth.fogerty@fitchratings.com. Additional information is available at 'www.fitchratings.com'.  Applicable Criteria and Related Research: --'Corporate Rating Methodology' (May 2014); --'Pharmaceuticals: Ratings Navigator Companion' (November 2014); --'Global Pharmaceutical R&D Pipeline - Approvals Accelerating' (February 2015). Applicable Criteria and Related Research:  Corporate Rating Methodology - Including Short-Term Ratings and Parent and  Subsidiary Linkage here Pharmaceuticals: Ratings Navigator Companihere Global Pharmaceutical R&D Pipeline (Approvals Accelerating) here Additional Disclosure  Solicitation Status  here ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:  here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF  CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE.   ",2015-04-30,BMY,"Thu Apr 30, 2015 | 10:14am EDT",Fitch Rates Bristol-Myers Squibb's Euro Bond Issuance 'A-',http://www.reuters.com//article/idUSFit92134820150430?type=companyNews
144,"  FRANKFURT, April 30 Bayer brushed off concern that its stroke prevention pill Xarelto may be losing market share to rival Bristol-Myers Squibb's Eliquis in the United States.The German drugmaker told analysts during a conference call on Thursday that Eliquis was taking business from warfarin and other drugs, but not from Xarelto. It also raised its forecast for Xarelto's 2015 sales growth to 30 percent from 20 percent.  Bayer earlier lifted its targets for full-year earnings and sales as it benefited from strong overseas currencies.     (Reporting by Maria Sheahan; Additional reporting by Nadine Schimroszik; Editing by Arno Schuetze)",2015-04-30,BMY,"Thu Apr 30, 2015 | 9:15am EDT",Bayer says Xarelto isn't losing U.S. market share to Eliquis,http://www.reuters.com//article/bayer-results-xarelto-idUSL5N0XR49K20150430?type=companyNews
145,"  Thomson Reuters April 30, 2015 - Corporate Meetings for US companies for Week ahead.         S&P 500 Earnings - MONTH AHEAD     Dividends                            Non S&P 500 - Weekly             Federal Reserve events               ConferenceCall/Webcast - Weekly  Meetings - Weekly                                Xtra users can see more details on conference calls & webcasts by hovering your mouse  over the RIC, right click, no click on Related Co Data, now click on Co Events.                      - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - DATE       GMT      SYMBOL       EVENT TITLE  30 Apr     13:00        Altra Industrial Motion Corp Annual Shareholders Meeting 30 Apr     13:00        BroadSoft Annual Shareholders Meeting 30 Apr     13:00           Cobalt Energy Annual Shareholders Meeting 30 Apr     13:00           SCANA Corp Annual Shareholders Meeting 30 Apr     13:30           Energen Corp Annual Shareholders Meeting 30 Apr     13:30        RetailMeNot Annual Shareholders Meeting 30 Apr     22:00        Enterprise Financial Services Corp Annual Shareholders Meeting 30 Apr     12:00           American Axle & Manufacturing Annual Shareholders Meeting 30 Apr     12:00           Unisys Corp Annual Shareholders Meeting 30 Apr     12:30           Dana Holding Corp Annual Shareholders Meeting 30 Apr     14:00           Capital One Financial Corp Annual Shareholders Meeting 30 Apr     14:00        CenterState Banks Annual Shareholders Meeting 30 Apr     14:00           EMC Corp Annual Shareholders Meeting 30 Apr     14:00        Entegris Annual Shareholders Meeting 30 Apr     14:00           Fluor Corp Annual Shareholders Meeting 30 Apr     14:00           Mead Johnson Nutrition Co Annual Shareholders Meeting 30 Apr     14:00        MYR Group Annual Shareholders Meeting 30 Apr     14:00           Owens & Minor Annual Shareholders Meeting 30 Apr     14:00           Polaris Industries Annual Shareholders Meeting 30 Apr     14:00           South Jersey Industries Annual Shareholders Meeting 30 Apr     14:00       Southern Peru Copper Peru Branch Annual Shareholders Meeting 30 Apr     14:00           Vector Group Ltd Annual Shareholders Meeting 30 Apr     15:00        Bryn Mawr Bank Corp Annual Shareholders Meeting 30 Apr     15:00           Cincinnati Bell Annual Shareholders Meeting 30 Apr     15:00           Corning Annual Shareholders Meeting 30 Apr     15:00           Huntington Ingalls Industries Annual Shareholders Meeting 30 Apr     15:00           Kimberly-Clark Corp Annual Shareholders Meeting 30 Apr     15:00           Snap-On Annual Shareholders Meeting 30 Apr     15:00          Southern Copper Corp Annual Shareholders Meeting 30 Apr     15:00           Torchmark Corp Annual Shareholders Meeting 30 Apr     15:00           Valero Energy Corp Annual Shareholders Meeting 30 Apr     15:30           Hudson Valley Holding Corp Annual Shareholders Meeting 30 Apr     16:00        Enphase Energy Annual Shareholders Meeting 30 Apr     16:00        Kona Grill Annual Shareholders Meeting 30 Apr     16:30           HCP Annual Shareholders Meeting 30 Apr     17:00        EchoStar Corp Annual Shareholders Meeting 30 Apr     17:00        Entropic Special Meeting of Stockholders 30 Apr     17:00        Entropic Communications Annual Shareholders Meeting 30 Apr     17:00        Mobile Mini Annual Shareholders Meeting 30 Apr     17:30           Sunstone Hotel Investors Annual Shareholders Meeting 30 Apr     18:00      Itausa Investimentos Itau SA Annual Shareholders Meeting 30 Apr     18:00        Tessera Technologies Annual Shareholders Meeting 30 Apr     18:30          MSCI Annual Shareholders Meeting 30 Apr     19:00        Endurance Group Annual Shareholders Meeting 30 Apr     19:00           HCA Annual Shareholders Meeting 30 Apr     20:00           EOG Resources Annual Shareholders Meeting 30 Apr     20:00           Public Storage Annual Shareholders Meeting 30 Apr     20:00        WSFS Financial Corp Annual Shareholders Meeting 01 May     13:00        ArcBest Corp Annual Shareholders Meeting 01 May     13:00           CMS Energy Corp Annual Shareholders Meeting 01 May     13:00          Realogy Corp Annual Shareholders Meeting 01 May     13:00           Yum! Brands Annual Shareholders Meeting 01 May     13:30            Alcoa Annual Shareholders Meeting 01 May     13:30           Babcock & Wilcox Co Annual Shareholders Meeting 01 May     22:00        FormFactor Annual Shareholders Meeting 01 May                     Lindsay Corp at Gabelli Omaha Research Trip 01 May                  Rentrak Corp at Gabelli Omaha Research Trip 01 May                     Safeguard Scientifics at Gabelli Omaha Research Trip 01 May                    TD Ameritrade Holding Corp at Gabelli Omaha Research Trip 01 May                     Union Pacific Corp at Gabelli Omaha Research Trip 01 May                     Valmont Industries at Gabelli Omaha Research Trip 01 May                  Werner Enterprises at Gabelli Omaha Research Trip 01 May     12:30        Alnylam Pharmaceuticals Annual Shareholders Meeting 01 May     14:00        Lincoln Educational Services Corp Annual Shareholders Meeting 01 May     14:00        Olympic Steel Annual Shareholders Meeting 01 May     14:00         Pilgrims Pride Corp Annual Shareholders Meeting 01 May     14:00        Primoris Services Corp Annual Shareholders Meeting 01 May     14:00             Ryder System Annual Shareholders Meeting 01 May     14:00         Sprouts Farmers Market Annual Shareholders Meeting 01 May     14:00           Zoetis Annual Shareholders Meeting 01 May     14:30           Louisiana-Pacific Corp Annual Shareholders Meeting 01 May     15:00           Allegheny Technologies Annual Shareholders Meeting 01 May     15:00        eBay Annual Shareholders Meeting 01 May     15:00         Magnetek Annual Shareholder Meeting 01 May     15:00           Teleflex Annual Shareholders Meeting 01 May     15:30           Occidental Petroleum Corp Annual Shareholders Meeting 01 May     15:30           RLJ Lodging Trust Annual Shareholders Meeting 01 May     16:00        Huron Consulting Group Annual Shareholders Meeting 01 May     17:30        CommScope Holding Company Annual Shareholders Meeting 01 May     18:00        Hawaiian Telcom Holdco Annual Shareholders Meeting 01 May     07:00           Rowan Companies PLC Annual Shareholders Meeting 02 May     13:30        Cincinnati Financial Corp Annual Shareholders Meeting 02 May     20:45          Berkshire Hathaway Annual Shareholders Meeting 04 May     13:00          Tumi Annual Shareholders Meeting 04 May     13:30        Hancock Holding Co at Gulf South Bank Conf 04 May     13:30          Textura Corp Annual Shareholders Meeting 04 May     14:00           Aflac Annual Shareholders Meeting 04 May     14:00           Agree Realty Corp Annual Shareholders Meeting 04 May     14:00        Consolidated Communications Annual Shareholders Meeting 04 May     14:00        Exone Co Annual Shareholders Meeting 04 May     14:00           Masco Corp Annual Shareholders Meeting 04 May     14:00        MKS Instruments Annual Shareholders Meeting 04 May     14:00           Oasis Petroleum Annual Shareholders Meeting 04 May     14:00          STAG Industrial Annual Shareholders Meeting 04 May     14:10        First Financial Bankshares at Gulf South Bank Conf 04 May     14:30        Dot Hill Systems Corp Annual Shareholders Meeting 04 May     14:50        Bank of The Ozarks at Gulf South Bank Conf 04 May     15:00        CyrusOne Annual Shareholders Meeting 04 May     15:00           Eli Lilly and Co Annual Shareholders Meeting 04 May     16:00           Clearwater Paper Corp Annual Shareholders Meeting 04 May     16:00         Potlatch Corp Annual Shareholders Meeting 04 May     17:00           Excel Trust Annual Shareholders Meeting 04 May     17:00           PG&E Corp. and Pacific Gas & Electric Co Shareholder Meeting 04 May     18:00           QTS Realty Trust Annual Shareholders Meeting 04 May     18:05           Noble Energy at Credit Suisse Conf Tour 04 May     18:30         LKQ Corp Annual Shareholders Meeting 04 May     18:30           Peabody Energy Corp Annual Shareholders Meeting 04 May     19:30        First Merchants Corp Annual Shareholders Meeting 04 May     20:00           CBL & Associates Properties Annual Shareholders Meeting 04 May     20:00           E. W. Scripps Co Annual Shareholders Meeting 04 May     20:00        State Bank Financial Corp at Gulf South Bank Conf 04 May     20:00           Stillwater Mining Co Annual Shareholders Meeting 04 May     20:05           Chevron Corp at Credit Suisse Conf Tour 04 May     20:40           Halliburton Co at Credit Suisse Conf Tour 05 May     13:00        Bravo Brio Restaurant Group Annual Shareholders Meeting 05 May     13:00           Citizens Financial Group Annual Shareholders Meeting 05 May     13:00           DiamondRock Hospitality Co Annual Shareholders Meeting 05 May     13:00           FMC Technologies at Credit Suisse Conf Tour 05 May     13:00          Hubbell Annual Shareholders Meeting 05 May     13:00        Lumos Networks Corp Annual Shareholders Meeting 05 May     13:00           M/I Homes Annual Shareholders Meeting 05 May     13:00          NRG Yield Annual Shareholders Meeting 05 May     13:00         Orchids Paper Products Co at Taglich Brothers Conf 05 May     13:00           Ramco-Gershenson Properties Trust Annual Shareholders Meeting 05 May     13:00           Sturm Ruger & Co Annual Shareholders Meeting 05 May     13:15           Brady Corp at Wells FargoConf 05 May     13:15            Curtiss-Wright Corp at Wells FargoConf 05 May     13:15           PulteGroup at Wells FargoConf 05 May     13:30        Adobe Systems at Robert W. Baird & Co. Conf 05 May     13:30            Franklin Covey Co at Robert W. Baird & Co. Conf 05 May     13:30        Habit Restaurants at Robert W. Baird & Co. Conf 05 May     13:30        Houston Wire & Cable Co Annual Shareholders Meeting 05 May     13:30        Kraft Foods Group Annual Shareholders Meeting 05 May     13:30        Meridian Bioscience at Robert W. Baird & Co. Conf 05 May     13:30        PostRock Energy Corp Annual Shareholders Meeting 05 May     13:30           Superior Industries Annual Shareholders Meeting 05 May     13:30           West Pharmaceutical Services Annual Shareholders Meeting 05 May     13:35        Air Industries Group at Taglich Brothers Conf 05 May     13:55           Caterpillar at Wells FargoConf 05 May     13:55           Dow Chemical Co at Wells FargoConf 05 May     13:55        Stock Building Supply at Wells FargoConf 05 May     22:00          LifeLock Annual Shareholders Meeting 05 May                  Asure Software at Credit Suisse Ideas Conf 05 May                  First Cash Financial Services at Credit Suisse Ideas Conf 05 May                     Gap at Credit Suisse Ideas Conf 05 May                     LTC Properties at Mizuho Securities Corporate Access Day 05 May                  Nordson Corp at Wells FargoConf 05 May                  TESARO at Mizuho Securities Healthcare Corporate Access Day 05 May                  TESARO at Citi Midwest Healthcare Access Day 05 May     12:00           Albemarle Corp Annual Shareholders Meeting 05 May     12:00           Penske Automotive Group Annual Shareholders Meeting 05 May     12:00        Strayer Education Annual Shareholders Meeting 05 May     12:00           Zimmer Annual Shareholders Meeting 05 May     12:30           Charles River Laboratories Annual Shareholders Meeting 05 May     12:30           Entercom Communications Corp Annual Shareholders Meeting 05 May     12:30           Gamco Investors Annual Shareholders Meeting 05 May     12:35           Ametek at Wells FargoConf 05 May     12:35           Harman Industries at Wells FargoConf 05 May     12:35           Rockwell Collins at Wells FargoConf 05 May     12:35           Tenneco at Wells FargoConf 05 May     14:00        Abraxas Petroleum Corp Annual Shareholders Meeting 05 May     14:00           Alon USA Energy Annual Shareholders Meeting 05 May     14:00        Argo Group Ltd Annual Shareholders Meeting 05 May     14:00           Baxter Annual Shareholders Meeting 05 May     14:00           Bristol-Myers Squibb Co Annual Shareholders Meeting 05 May     14:00        Capella Education Co Annual Shareholders Meeting 05 May     14:00        Fulton Financial Corp Annual Shareholders Meeting 05 May     14:00           Kimco Realty Corp Annual Shareholders Meeting 05 May     14:00           Manitowoc Company Annual Shareholders Meeting 05 May     14:00        NBT Bancorp Annual Shareholders Meeting 05 May     14:00        Progress Software Corp Annual Shareholders Meeting 05 May     14:00        Varonis Systems Annual Shareholders Meeting 05 May     14:00        VSE Corp. Annual Meeting of Stockholders 05 May     14:00           ZAIS Financial Corp Annual Shareholders Meeting 05 May     14:10        Apricus Biosciences at the Taglich Brothers 12th Annual Conf 05 May     14:10        Apricus Biosciences at Taglich Brothers Conf 05 May     14:10        Blackbaud at Robert W. Baird & Co. Conf 05 May     14:10        Littelfuse at Robert W. Baird & Co. Conf 05 May     14:10        Paychex at Robert W. Baird & Co. Conf 05 May     14:10           United Parcel Service at Robert W. Baird & Co. Conf 05 May     14:30        Horsehead Holding Corp Annual Shareholders Meeting 05 May     14:35           Ball Corp at Wells FargoConf 05 May     14:35           Eastman Chemical Co at Wells FargoConf 05 May     14:35           Hovnanian Enterprises at Wells FargoConf 05 May     14:35        PACCAR at Wells FargoConf 05 May     14:45        Exlservice at Robert W. Baird & Co. Conf 05 May     14:45        Gentex Corp at Robert W. Baird & Co. Conf 05 May     14:45          Store Capital Corp at Robert W. Baird & Co. Conf 05 May     14:45          Zoe's Kitchen at Robert W. Baird & Co. Conf 05 May     15:00           Boston Scientific Corp Annual Shareholders Meeting 05 May     15:00            Celanese Corp at Barclays Chemical ROC Stars Conf 05 May     15:00           Cousins Properties Annual Shareholders Meeting 05 May     15:00           Great Plains Energy Annual Shareholders Meeting 05 May     15:00           Leggett & Platt Annual Shareholders Meeting 05 May     15:00        NIC Annual Shareholders Meeting 05 May     15:00           Oceaneering at Credit Suisse Conf Tour 05 May     15:00        O'Reilly Automotive Annual Shareholders Meeting 05 May     15:00        Raptor Pharmaceutical Corp Annual Shareholders Meeting 05 May     15:00        Sigma-Aldrich Corp Annual Shareholders Meeting 05 May     15:00        Thoratec Corp Annual Shareholders Meeting 05 May     15:00        Tractor Supply Co Annual Shareholders Meeting 05 May     15:15           AAR Corp at Wells FargoConf 05 May     15:15           FLY Leasing Ltd at Wells FargoConf 05 May     15:15           Huntsman Corp at Wells FargoConf 05 May     15:15            Owens Corning at Wells FargoConf 05 May     15:15        Sito Mobile Ltd at Taglich Brothers Conf 05 May     15:20        Broadcom Corp at Robert W. Baird & Co. Conf 05 May     15:20           Chipotle Mexican Grill at Robert W. Baird & Co. Conf 05 May     15:20        EnerNOC at Robert W. Baird & Co. Conf 05 May     15:20        Forward Air Corp at Robert W. Baird & Co. Conf 05 May     15:30           HNI Corp Annual Shareholders Meeting 05 May     15:30           NVR Annual Shareholders Meeting 05 May     15:30        Quidel Corp Annual Shareholders Meeting 05 May     15:35           Helix Energy Solutions Group at Credit Suisse Conf Tour 05 May     15:55        Buffalo Wild Wings at Robert W. Baird & Co. Conf 05 May     15:55            DeVry Education Group at Robert W. Baird & Co. Conf 05 May     15:55           Pebblebrook Hotel Trust at Robert W. Baird & Co. Conf 05 May     15:55         Silicon Graphics Corp at Robert W. Baird & Co. Conf 05 May     16:00           Goodrich Petroleum Corp Annual Shareholders Meeting 05 May     16:00           Nuverra Environmental Solutions Annual Shareholders Meeting 05 May     16:00          Paycom Software Annual Shareholders Meeting 05 May     16:00           TETRA Technologies Annual Shareholders Meeting 05 May     16:30           Ecolab at Robert W. Baird & Co. Conf 05 May     16:30           Kilroy Realty Corp at Robert W. Baird & Co. Conf 05 May     16:30           Red Hat at Robert W. Baird & Co. Conf 05 May     16:30        Rocky Brands at Robert W. Baird & Co. Conf 05 May     17:00           Calgon Carbon Corp Annual Shareholders Meeting 05 May     17:15        LMI Aerospace at Wells FargoConf 05 May     17:15           RPM at Wells FargoConf 05 May     17:15           Terex Corp at Wells FargoConf 05 May     17:15          Tower at Wells FargoConf 05 May     17:40           Apartment and Management Co at Robert W. Baird & Co. Conf 05 May     17:40        Dunkin' Brands Group at Robert W. Baird & Co. Conf 05 May     17:40        FARO Technologies at Robert W. Baird & Co. Conf 05 May     17:40        Power Solutions at Robert W. Baird & Co. Conf 05 May     17:55          ADS Tactical at Wells FargoConf 05 May     17:55           Lennox at Wells FargoConf 05 May     17:55           Sonoco Products Company at Wells FargoConf 05 May     17:55         TriMas Corp at Wells FargoConf 05 May     18:00            Knowles Corp Annual Shareholders Meeting 05 May     18:00           Nordstrom Annual Shareholders Meeting 05 May     18:15         Ignite Restaurant Group at Robert W. Baird & Co. Conf 05 May     18:15            La Quinta at Robert W. Baird & Co. Conf 05 May     18:15           Quanta Services at Robert W. Baird & Co. Conf 05 May     18:15        Xoom Corp at Robert W. Baird & Co. Conf 05 May     18:30        Bridgeline Digital at Taglich Brothers Conf 05 May     18:30           L-3 Communications Annual Shareholders Meeting 05 May     18:35           BorgWarner at Wells FargoConf 05 May     18:35           Crown at Wells FargoConf 05 May     18:35           Greenbrier Company at Wells FargoConf 05 May     18:35             Ryder System at Wells FargoConf 05 May     18:35           Stanley Black & Decker at Wells FargoConf 05 May     18:50           Armada Hoffler Properties at Robert W. Baird & Co. Conf 05 May     18:50        Hub Group at Robert W. Baird & Co. Conf 05 May     18:50           Krispy Kreme Doughnuts at Robert W. Baird & Co. Conf 05 May     19:00            Delek US Annual Shareholders Meeting 05 May     19:00        Overstock com Annual Shareholders Meeting 05 May     19:05       Intellinetics at Taglich Brothers Conf 05 May     19:15           AK Steel Holding Corp at Wells FargoConf 05 May     19:15           Aptargroup at Wells FargoConf 05 May     19:15        US Ecology at Wells FargoConf 05 May     19:15           Watsco at Wells FargoConf 05 May     19:25        Constant Contact at Robert W. Baird & Co. Conf 05 May     19:25        GoPro at Robert W. Baird & Co. Conf 05 May     19:25        Plug Power at Robert W. Baird & Co. Conf 05 May     19:25        Stericycle at Robert W. Baird & Co. Conf 05 May     19:55           Myers Industries at Wells FargoConf 05 May     19:55           Olin Corp at Wells FargoConf 05 May     19:55           Ryerson Holding Corp at Wells FargoConf 05 May     19:55           TAL Group at Wells FargoConf 05 May     20:00        Citrix Systems at Robert W. Baird & Co. Conf 05 May     20:00           Highwoods Properties at Robert W. Baird & Co. Conf 05 May     20:00           Neustar at Robert W. Baird & Co. Conf 05 May     20:50        NasdaqAkamai Technologies at Robert W. Baird & Co. Conf 05 May     21:00        East West Bancorp Annual Shareholders Meeting 05 May     21:00        IBERIABANK Corp Annual Shareholders Meeting 05 May     21:00           Plum Creek Timber Company Annual Shareholders Meeting 06 May     13:00           Aaron's Annual Shareholders Meeting 06 May     13:00           Avon Products Annual Shareholders Meeting 06 May     13:00           Brown & Brown Annual Shareholders Meeting 06 May     13:00          Colony Capital Annual Shareholders Meeting 06 May     13:00             Dominion Resources Annual Shareholders Meeting 06 May     13:00        Express Scripts Holding Co Annual Shareholders Meeting 06 May     13:00            General Dynamics Corp Annual Shareholders Meeting 06 May     13:00           Independence Contract Drilling Annual Shareholders Meeting 06 May     13:00          Kemper Corp Annual Shareholders Meeting 06 May     13:00           Knoll Annual Shareholders Meeting 06 May     13:00        NASDAQ OMX Group Annual Shareholders Meeting 06 May     13:00           PepsiCo Annual Shareholders Meeting 06 May     13:00            Philip Morris Annual Shareholders Meeting 06 May     13:00        Snyder's-Lance Annual Shareholders Meeting 06 May     13:00           W&T Offshore Annual Shareholders Meeting 06 May     13:10        ImmunoGen at Credit Suisse Antibody Day 06 May     13:15            Headwaters at Wells FargoConf 06 May     13:15           IDEX Corp at Wells FargoConf 06 May     13:20           Aetna at Deutsche Bank Health Care Conf 06 May     13:20           Boston Scientific Corp at Deutsche Bank Health Care Conf 06 May     13:20        Ligand Pharmaceuticals at Deutsche Bank Health Care Conf 06 May     13:20        Seattle Genetics at Deutsche Bank Health Care Conf 06 May     13:30        Fastenal Co at Robert W. Baird & Co. Conf 06 May     13:30          Opower at Robert W. Baird & Co. Conf 06 May     13:30           Rackspace Hosting Annual Shareholders Meeting 06 May     13:35          ChannelAdvisor Corp at Robert W. Baird & Co. Conf 06 May     13:35          Micron Technology at Robert W. Baird & Co. Conf 06 May     13:45        OncoMed Pharmaceuticals at Credit Suisse Antibody Day 06 May     13:55        Gentex Corp at Wells FargoConf 06 May     13:55           M/I Homes at Wells FargoConf 06 May     13:55        Manitex at Wells FargoConf 06 May     22:00          WageWorks Annual Shareholders Meeting 06 May     10:45           Freescale Semiconductor Ltd Annual Shareholders Meeting 06 May                     Manitowoc Company at Wells FargoConf 06 May                  RTI Surgical at Deutsche Bank Health Care Conf 06 May                     Schlumberger NV at Sandford C Bernstein Energy Conf 06 May                     United Technologies Corp at Wells FargoConf 06 May                     Vulcan Materials Co at Wells FargoConf 06 May                     Waste Connections at Houlihan Lokey Global Industrials Conf 06 May     11:30          Chemtura Corp at Houlihan Lokey Global Industrials Conf 06 May     12:00        Alexion Pharmaceuticals at Deutsche Bank Health Care Conf 06 May     12:00           Chicago Bridge & Iron Company NV Annual Shareholders Meeting 06 May     12:00           CNO Financial Group Annual Shareholders Meeting 06 May     12:00           Dun & Bradstreet Corp Annual Shareholders Meeting 06 May     12:00        Kite Pharma at Credit Suisse Antibody Day 06 May     12:00        Magellan Health at Deutsche Bank Health Care Conf 06 May     12:00           ResMed at Deutsche Bank Health Care Conf 06 May     12:00           Universal Health Services at Deutsche Bank Health Care Conf 06 May     12:30           Quaker Chemical Corp Annual Shareholders Meeting 06 May     12:30           Regal Entertainment Group Annual Shareholders Meeting 06 May     12:30          Triangle Capital Corp Annual Shareholders Meeting 06 May     12:35           CAI at Wells FargoConf 06 May     12:35           Cummins at Wells FargoConf 06 May     12:35           Meritage Homes Corp at Wells FargoConf 06 May     12:35           Textron at Wells FargoConf 06 May     12:35        XOMA Corp at Credit Suisse Antibody Day 06 May     12:40        AMAG Pharmaceuticals at Deutsche Bank Health Care Conf 06 May     12:40           Halyard Health at Deutsche Bank Health Care Conf 06 May     12:40        TG Therapeutics at Deutsche Bank Health Care Conf 06 May     14:00          Anthem at Deutsche Bank Health Care Conf 06 May     14:00           Aptargroup Annual Shareholders Meeting 06 May     14:00           Bank of America Corp Annual Shareholders Meeting 06 May     14:00        Brightcove Annual Shareholders Meeting 06 May     14:00            Brunswick Corp Annual Shareholders at Deutsche Bank Conf 06 May     14:00           Compass Minerals Annual Shareholders Meeting 06 May     14:00           CONSOL Energy Annual Shareholders Meeting 06 May     14:00           CSX Corp Annual Shareholders Meeting 06 May     14:00        DexCom at Deutsche Bank Health Care Conf 06 May     14:00           Federal Realty Trust Annual Shareholders Meeting 06 May     14:00        Financial Institutions Annual Shareholders Meeting 06 May     14:00           Hess Corp Annual Shareholders Meeting 06 May     14:00           Hilton Worldwide Annual Shareholders Meeting 06 May     14:00        IDEXX Laboratories Annual Shareholders Meeting 06 May     14:00        Innospec Annual Shareholders Meeting 06 May     14:00           Flavors & Fragrances Annual Shareholders Meeting 06 May     14:00          Materion Corp Annual Shareholders Meeting 06 May     14:00           MBIA Annual Shareholders Meeting 06 May     14:00           New York Times Co Annual Shareholders Meeting 06 May     14:00        OceanFirst Financial Corp Annual Shareholders Meeting 06 May     14:00           Phillips 66 Annual Shareholders Meeting 06 May     14:00        Pool Corp Annual Shareholders Meeting 06 May     14:00        PTC Therapeutics at Deutsche Bank Health Care Conf 06 May     14:00        Sears Corp Annual Shareholders Meeting 06 May     14:00          TimkenSteel Corp Annual Shareholders Meeting 06 May     14:00           United Rentals Annual Shareholders Meeting 06 May     14:10        Enphase Energy at Robert W. Baird & Co. Conf 06 May     14:10         Fairchild Semiconductor at Robert W. Baird & Co. Conf 06 May     14:10           RPM at Robert W. Baird & Co. Conf 06 May     14:20        MacroGenics at Credit Suisse Antibody Day 06 May     14:30            Air Lease Corp Annual Shareholders Meeting 06 May     14:30           Hatteras Financial Corp Annual Shareholders Meeting 06 May     14:30          National Bank Corp Annual Shareholders Meeting 06 May     14:35            Celanese Corp at Wells FargoConf 06 May     14:35           Titan at Wells FargoConf 06 May     14:35           Trinity Industries at Wells FargoConf 06 May     14:40        Biomarin Pharmaceutical at Deutsche Bank Health Care Conf 06 May     14:40           Bristol-Myers Squibb Co at Deutsche Bank Health Care Conf 06 May     14:40        Fate Therapeutics at Deutsche Bank Health Care Conf 06 May     14:45           Accenture PLC at Robert W. Baird & Co. Conf 06 May     14:45           Charles River Laboratories at Robert W. Baird & Co. Conf 06 May     14:45        Chuy's at Robert W. Baird & Co. Conf 06 May     14:45           W W Grainger at Robert W. Baird & Co. Conf 06 May     14:55        Merrimack Pharmaceuticals at Credit Suisse Antibody Day 06 May     15:00           Ametek Annual Shareholders Meeting 06 May     15:00        Halozyme Therapeutics Annual Shareholders Meeting 06 May     15:00       Kelly Services Annual Shareholders Meeting 06 May     15:15           Commercial Metals Co at Wells FargoConf 06 May     15:15           Regal Beloit Corp at Wells FargoConf 06 May     15:15          Taylor Morrison Home Corp at Wells FargoConf 06 May     15:15           Westlake Chemical Corp at Wells FargoConf 06 May     15:20        athenahealth at Robert W. Baird & Co. Conf 06 May     15:20        Biogen at Deutsche Bank Health Care Conf 06 May     15:20           Humana at Deutsche Bank Health Care Conf 06 May     15:20        Kirkland's at Robert W. Baird & Co. Conf 06 May     15:20        MiMedx Group at Deutsche Bank Health Care Conf 06 May     15:20             Pandora Media at Robert W. Baird & Co. Conf 06 May     15:20        Qualys at Robert W. Baird & Co. Conf 06 May     15:20        Regulus Therapeutics at Deutsche Bank Health Care Conf 06 May     15:55        Abraxas Petroleum Corp at Robert W. Baird & Co. Conf 06 May     15:55        Exact Sciences Corp at Robert W. Baird & Co. Conf 06 May     15:55        Fortinet at Robert W. Baird & Co. Conf 06 May     15:55            Praxair at Robert W. Baird & Co. Conf 06 May     16:00           Carlisle Companies Annual Shareholders Meeting 06 May     16:00           FMC Technologies Annual Shareholders Meeting 06 May     16:00            Halcon Resources Corp Annual Shareholders Meeting 06 May     16:00           Hospira Annual Shareholders Meeting 06 May     16:00          Imperva Annual Shareholders Meeting 06 May     16:00        Thomson Reuters Corp Annual Shareholders Meeting 06 May     16:00           Unit Corp Annual Shareholders Meeting 06 May     16:05        Prothena Corp. PLC at Credit Suisse Antibody Day 06 May     16:30        Altera Corp at Robert W. Baird & Co. Conf 06 May     16:30           Deluxe Corp at Robert W. Baird & Co. Conf 06 May     16:30           GNC at Robert W. Baird & Co. Conf 06 May     16:30        Shutterfly at Robert W. Baird & Co. Conf 06 May     16:50        Acadia Healthcare Company at Deutsche Bank Health Care Conf 06 May     16:50           AmerisourceBergen Corp at Deutsche Bank Health Care Conf 06 May     16:50        Dicerna Pharmaceuticals at Deutsche Bank Health Care Conf 06 May     16:50        Meridian Bioscience at Deutsche Bank Health Care Conf 06 May     17:00          Artisan Partners Asset Management Annual Shareholders Meeting 06 May     17:00           Molina Healthcare Annual Shareholders Meeting 06 May     17:00           Plantronics Annual Shareholders Meeting 06 May     17:00          USANA Health Sciences Annual Shareholders Meeting 06 May     17:00        Gilead Sciences Annual Shareholders Meeting 06 May     17:00           Portland General Electric Co Annual Shareholders Meeting 06 May     17:15        Alder Biopharmaceuticals at Credit Suisse Antibody Day 06 May     17:15           Applied Industrial Technologies at Wells FargoConf 06 May     17:15          Hubbell at Wells FargoConf 06 May     17:15           PPG Industries at Wells FargoConf 06 May     17:15           XPO Logistics at Wells FargoConf 06 May     17:30        Heritage Financial Corp Annual Shareholders Meeting 06 May     17:30           Mallinckrodt Plc at Deutsche Bank Health Care Conf 06 May     17:30           Ormat Technologies Annual Shareholders Meeting 06 May     17:40            Mistras Group at Robert W. Baird & Co. Conf 06 May     17:40         Texas Instruments at Robert W. Baird & Co. Conf 06 May     17:40         Tile Shop at Robert W. Baird & Co. Conf 06 May     17:50           Emergent BioSolutions at Credit Suisse Antibody Day 06 May     17:55           Belden at Wells FargoConf 06 May     17:55           Monsanto Co at Wells FargoConf 06 May     18:00           Invesco Mortgage Capital Annual Shareholders Meeting 06 May     18:00          Murphy USA Annual Shareholders Meeting 06 May     18:10        Antares Pharma at Deutsche Bank Health Care Conf 06 May     18:10        Computer Programs and Systems at Deutsche Bank Health Care Conf 06 May     18:10        Integra LifeSciences Corp at Deutsche Bank Health Care Conf 06 May     18:10        TESARO at Deutsche Bank Health Care Conf 06 May     18:10           Universal American Corp at Deutsche Bank Health Care Conf 06 May     18:15        PCTEL at Robert W. Baird & Co. Conf 06 May     18:15        Potbelly Corp at Robert W. Baird & Co. Conf 06 May     18:15          Roadrunner Transportation Systems at Robert W. Baird & Co. Conf 06 May     18:15           Southwestern Energy Co at Robert W. Baird & Co. Conf 06 May     18:25        Seattle Genetics at Credit Suisse Antibody Day 06 May     18:35           Aircastle Ltd at Wells FargoConf 06 May     18:35           MRC Global at Wells FargoConf 06 May     18:35           PolyOne Corp at Wells FargoConf 06 May     18:35            Sensata Technologies Holding NV at Wells FargoConf 06 May     18:50          AbbVie at Deutsche Bank Health Care Conf 06 May     18:50        Conmed Corp at Deutsche Bank Health Care Conf 06 May     18:50        Ehealth at Deutsche Bank Health Care Conf 06 May     18:50          Emerge Energy Services LP at Robert W. Baird & Co. Conf 06 May     18:50           Insperity at Robert W. Baird & Co. Conf 06 May     18:50            Knowles Corp at Robert W. Baird & Co. Conf 06 May     19:00        Five Prime Therapeutics at Credit Suisse Antibody Day 06 May     19:00        Sandy Spring Bancorp Annual Shareholders Meeting 06 May     19:00           Six Flags Entertainment Corp Annual Shareholders Meeting 06 May     19:15           Actuant Corp at Wells FargoConf 06 May     19:15           Navistar Corp at Wells FargoConf 06 May     19:15            Reliance Steel and Aluminum Co at Wells FargoConf 06 May     19:25           Aptargroup at Robert W. Baird & Co. Conf 06 May     19:25            Drew Industries at Robert W. Baird & Co. Conf 06 May     19:25          Extended Stay America at Robert W. Baird & Co. Conf 06 May     19:25           SolarWinds at Robert W. Baird & Co. Conf 06 May     19:30        Endologix at Deutsche Bank Health Care Conf 06 May     19:30          IGI Laboratories at Deutsche Bank Health Care Conf 06 May     19:30        United Therapeutics Corp at Deutsche Bank Health Care Conf 06 May     19:30        Verastem at Deutsche Bank Health Care Conf 06 May     19:35        Xencor at Credit Suisse Antibody Day 06 May     19:55          Delphi Automotive PLC at Wells FargoConf 06 May     08:00          AG Mortgage Trust Annual Shareholders Meeting 06 May     20:00         LKQ Corp at Robert W. Baird & Co. Conf 06 May     20:00        Noodles & Co Annual Shareholders Meeting 06 May     20:00          PowerSecure at Robert W. Baird & Co. Conf 06 May     20:00           PulteGroup Annual Shareholders Meeting 06 May     20:00           Snap-On at Robert W. Baird & Co. Conf 06 May     20:00          Starwood Waypoint Residential Trust Annual Shareholders Meeting 06 May     20:00        Tetra Tech at Robert W. Baird & Co. Conf 06 May     20:10        Alnylam Pharmaceuticals at Deutsche Bank Health Care Conf 06 May     20:10           Cambrex Corp at Deutsche Bank Health Care Conf 06 May     20:10          ExamWorks Group at Deutsche Bank Health Care Conf 06 May     20:10        Inteliquent at Deutsche Bank Health Care Conf 06 May     20:10        Radius Health at Deutsche Bank Health Care Conf 06 May     20:10        Tandem Diabetes Care at Deutsche Bank Health Care Conf 06 May     20:50        Aegerion Pharmaceuticals at Deutsche Bank Health Care Conf 06 May     20:50        Dyax Corp at Deutsche Bank Health Care Conf 06 May     21:30        Alexion Pharmaceuticals Annual Shareholders Meeting 07 May     13:00           Assurant Annual Shareholders Meeting 07 May     13:00           Cohen & Steers Annual Shareholders Meeting 07 May     13:00           CVS Health Corp Annual Shareholders Meeting 07 May     13:00           Dover Corp Annual Shareholders Meeting 07 May     13:00           LaSalle Hotel Properties Annual Shareholders Meeting 07 May     13:00           National Health Investors Annual Shareholders Meeting 07 May     13:00           NRG Energy Annual Shareholders Meeting 07 May     13:00           Och-Ziff Capital Management Group Annual Shareholders Meeting 07 May     13:00           P H Glatfelter Co Annual Shareholders Meeting 07 May     13:00        Preferred Apartment Communities Annual Shareholders Meeting 07 May     13:00             Quintiles Transnational Annual Shareholders Meeting 07 May     13:00           Reynolds American Annual Shareholders Meeting 07 May     13:00           Sotheby's Annual Shareholders Meeting 07 May     13:00           Tenet Healthcare Corp Annual Shareholders Meeting 07 May     13:00           Tesoro Corp Annual Shareholders Meeting 07 May     13:00          Tesoro Logistics LP Annual Shareholders Meeting 07 May     13:00          U.S. Silica Annual Shareholders Meeting 07 May     13:00           W. R. Grace & Co Annual Shareholders Meeting 07 May     13:20        Celgene Corp at Deutsche Bank Health Care Conf 07 May     13:20        Cerulean Pharma at Deutsche Bank Health Care Conf 07 May     13:20           Community Health Systems at Deutsche Bank Health Care Conf 07 May     13:20           Hill-Rom at Deutsche Bank Health Care Conf 07 May     13:30           Ashford Hospitality Prime at Robert W. Baird & Co. Conf 07 May     13:30           Ashford Hospitality Trust at Robert W. Baird & Co. Conf 07 May     13:30           Corporate Office Properties Trust Annual Shareholders Meeting 07 May     13:30           Furmanite Corp Annual Shareholders Meeting 07 May     13:30            MEDNAX Annual Shareholders Meeting 07 May     13:30        Mobile Mini at Robert W. Baird & Co. Conf 07 May     13:30           Polaris Industries at Robert W. Baird & Co. Conf 07 May     13:30           St. Jude Medical Annual Shareholders Meeting 07 May     13:30            Verizon Communications Annual Shareholders Meeting 07 May     13:35           Wolverine World Wide at Robert W. Baird & Co. Conf 07 May     22:00           Alaska Air Group Annual Shareholders Meeting 07 May                     Boardwalk Pipeline Partners LP at Mitsubishi UFJ Oil & Gas Conf 07 May                     Enterprise Products Partners LP at Mitsubishi Conf 07 May                     EQT Midstream Partners LP at Mitsubishi UFJ Oil & Gas Conf 07 May                  Garmin Ltd at RBC Capital Markets Day 07 May                     Kinder Morgan at Mitsubishi UFJ Oil & Gas Conf 07 May                  National Instruments Corp at Robert W. Baird & Co. Conf 07 May                  NetScout Systems at RBC Capital Markets Day 07 May                     Plains All American Pipeline LP at Mitsubishi Conf 07 May                     Plantronics at Deutsche Bank Health Care Conf 07 May                     Spectra Energy Partners LP at Mitsubishi UFJ Oil & Gas Conf 07 May     12:00        Achillion Pharmaceuticals at Deutsche Bank Health Care Conf 07 May     12:00        Amgen at Deutsche Bank Health Care Conf 07 May     12:00           Carter's Annual Shareholders Meeting 07 May     12:00           DTE Energy Co Annual Shareholders Meeting 07 May     12:00           Mettler-Toledo Annual Shareholders Meeting 07 May     12:00           Select Medical Corp at Deutsche Bank Health Care Conf 07 May     12:00        STAAR Surgical Company at Deutsche Bank Health Care Conf 07 May     12:00           United Parcel Service Annual Shareholders Meeting 07 May     12:30          Chemtura Corp Annual Shareholders Meeting 07 May     12:30        E*TRADE Financial Corp Annual Shareholders Meeting 07 May     12:30           Huntsman Corp Annual Shareholders Meeting 07 May     12:40          Adeptus Health at Deutsche Bank Health Care Conf 07 May     12:40        bluebird bio at Deutsche Bank Health Care Conf 07 May     12:40            Cigna Corp at Deutsche Bank Health Care Conf 07 May     14:00           American Campus Communities Annual Shareholders Meeting 07 May     14:00        athenahealth at Deutsche Bank Health Care Conf 07 May     14:00           Bemis Company Annual Shareholders Meeting 07 May     14:00        Buffalo Wild Wings Annual Shareholders Meeting 07 May     14:00            Curtiss-Wright Corp Annual Shareholders Meeting 07 May     14:00           Duke Energy Corp Annual Shareholders Meeting 07 May     14:00           EP Energy Corp Annual Shareholders Meeting 07 May     14:00            First Industrial Realty Trust Annual Shareholders Meeting 07 May     14:00           HCA at Deutsche Bank Health Care Conf 07 May     14:00           Health Care REIT Annual Shareholders Meeting 07 May     14:00        Heritage-Crystal Clean Annual Shareholders Meeting 07 May     14:00        Incyte Corp at Deutsche Bank Health Care Conf 07 May     14:00           Johnson & Johnson at Deutsche Bank Health Care Conf 07 May     14:00           Koppers Annual Shareholders Meeting 07 May     14:00         Old National Bancorp Annual Shareholders Meeting 07 May     14:00        Ophthotech Corp at Deutsche Bank Health Care Conf 07 May     14:00           Parker Drilling Co Annual Shareholders Meeting 07 May     14:00           Penn Virginia Corp Annual Shareholders Meeting 07 May     14:00           SunCoke Energy Annual Shareholders Meeting 07 May     14:00        Tech Data Corp at GTDC Investor Conf 07 May     14:00        Thompson Creek Metals Company Annual Shareholders Meeting 07 May     14:00           Timken Co Annual Shareholders Meeting 07 May     14:00           Weight Watchers Annual Shareholders Meeting 07 May     14:10            Brunswick Corp at Robert W. Baird & Co. Conf 07 May     14:10           Hilton Worldwide at Robert W. Baird & Co. Conf 07 May     14:10        Renewable Energy Group at Robert W. Baird & Co. Conf 07 May     14:30           Hexcel Corp Annual Shareholders Meeting 07 May     14:30        Web.com Group Annual Shareholders Meeting 07 May     14:40        Acorda Therapeutics at Deutsche Bank Health Care Conf 07 May     14:40           Chemed Corp at Deutsche Bank Health Care Conf 07 May     14:40        Henry Schein at Deutsche Bank Health Care Conf 07 May     14:40        NxStage Medical at Deutsche Bank Health Care Conf 07 May     14:45            Hersha Hospitality Trust at Robert W. Baird & Co. Conf 07 May     14:45           KAR Auction Services at Robert W. Baird & Co. Conf 07 May     14:50        Tech Data Corp at GTDC Investor Conf - Panel Discussion by CFO 07 May     15:00        Advanced Energy Industries Annual Shareholders Meeting 07 May     15:00           Archer Daniels Midland Co Annual Shareholders Meeting 07 May     15:00           Comstock Resources Annual Shareholders Meeting 07 May     15:00           Covanta Holding Corp Annual Shareholders Meeting 07 May     15:00           Ecolab Annual Shareholders Meeting 07 May     15:00        Gibraltar Industries Annual Shareholders Meeting 07 May     15:00        Gladstone Commercial Corp Annual Shareholders Meeting 07 May     15:00           Helix Energy Solutions Group Annual Shareholders Meeting 07 May     15:00        LDR Holding Corp Annual Shareholders Meeting 07 May     15:00        ManTech Corp Annual Shareholders Meeting 07 May     15:00           Mueller Industries Annual Shareholders Meeting 07 May     15:00           Ryman Hospitality Properties Annual Shareholders Meeting 07 May     15:00           Wisconsin Energy Corp Annual Shareholders Meeting 07 May     15:15           Avista Corp Annual Shareholders Meeting 07 May     15:20         Avis Budget Group at Robert W. Baird & Co. Conf 07 May     15:20           Harman Industries at Robert W. Baird & Co. Conf 07 May     15:20        Neurocrine Biosciences at Deutsche Bank Health Care Conf 07 May     15:20        SolarCity Corp at Robert W. Baird & Co. Conf 07 May     15:20        TherapeuticsMD at Deutsche Bank Health Care Conf 07 May     15:20            Workiva at Robert W. Baird & Co. Conf 07 May     15:30           Eastman Chemical Co Annual Shareholders Meeting 07 May     15:55        ANSYS at Robert W. Baird & Co. Conf 07 May     15:55           Rockwell Automation at Robert W. Baird & Co. Conf 07 May     15:55           Summit Hotel Properties at Robert W. Baird & Co. Conf 07 May     15:55           Winnebago Industries at Robert W. Baird & Co. Conf 07 May     16:00           Church & Dwight Co Annual Shareholders Meeting 07 May     16:00        FEI Co Annual Shareholders Meeting 07 May     16:00           HealthSouth Corp Annual Shareholders Meeting 07 May     16:00        PMC-Sierra Annual Shareholders Meeting 07 May     16:00          Re/Max Annual Shareholders Meeting 07 May     16:30           Alliant Energy Corp Annual Shareholders Meeting 07 May     16:30        Cognex Corp at Robert W. Baird & Co. Conf 07 May     16:30          Hannon Armstrong Sustainable at Robert W. Baird & Co. Conf 07 May     16:30             Hyatt Hotels Corp at Robert W. Baird & Co. Conf 07 May     16:30          Servicemaster Global at Robert W. Baird & Co. Conf 07 May     16:50        Acceleron Pharma at Deutsche Bank Health Care Conf 07 May     16:50        BioDelivery Sciences at Deutsche Bank Health Care Conf 07 May     16:50          Catalent at Deutsche Bank Health Care Conf 07 May     16:50        Isis Pharmaceuticals at Deutsche Bank Health Care Conf 07 May     16:50        Xencor at Deutsche Bank Health Care Conf 07 May     17:00           Health Net Annual Shareholders Meeting 07 May     17:00        Infinera Corp Annual Shareholders Meeting 07 May     17:00        Marchex Annual Shareholders Meeting 07 May     17:00           Southwest Gas Corp Annual Shareholders Meeting 07 May     17:30           American Homes 4 Rent Annual Shareholders Meeting 07 May     17:30        Coherus BioSciences at Deutsche Bank Health Care Conf 07 May     17:30        Golden Star Resources Ltd Annual Shareholders Meeting 07 May     17:30        Infinity Pharmaceuticals at Deutsche Bank Health Care Conf 07 May     17:40        AMAG Pharmaceuticals at Robert W. Baird & Co. Conf 07 May     17:40           Starwood Hotels & Resorts at Robert W. Baird & Co. Conf 07 May     17:40           Thor Industries at Robert W. Baird & Co. Conf 07 May     18:00           Alexandria Real Estate Equities Annual Shareholders Meeting 07 May     18:00        C.H. Robinson Worldwide Annual Shareholders Meeting 07 May     18:00           California Resources Corp Annual Shareholders Meeting 07 May     18:00           Kinder Morgan Annual Shareholders Meeting 07 May     18:00           Symetra Financial Corp Annual Shareholders Meeting 07 May     18:10        Abiomed at Deutsche Bank Health Care Conf 07 May     18:10        Anacor Pharmaceuticals at Deutsche Bank Health Care Conf 07 May     18:10           Capital Senior Living Corp at Deutsche Bank Health Care Conf 07 May     18:10        Enanta Pharmaceuticals at Deutsche Bank Health Care Conf 07 May     18:10          Puma Biotechnology at Deutsche Bank Health Care Conf 07 May     18:15          Chesapeake Lodging Trust at Robert W. Baird & Co. Conf 07 May     18:15           PerkinElmer at Robert W. Baird & Co. Conf 07 May     18:15           VF Corp at Robert W. Baird & Co. Conf 07 May     18:50        Arrowhead Research Corp at Deutsche Bank Health Care Conf 07 May     18:50        Momenta Pharmaceuticals at Deutsche Bank Health Care Conf 07 May     18:50        Sagent Pharmaceuticals at Deutsche Bank Health Care Conf 07 May     19:00           Danaher Corp Annual Shareholders Meeting 07 May     19:00           RLI Corp Annual Shareholders Meeting 07 May     08:00      Aquila SA Annual Shareholders Meeting 07 May     08:00      Aquila SA Extraordinary Shareholders Meeting 07 May     20:00        Fox Factory Holding Corp Annual Shareholders Meeting 07 May     20:00           Kansas City Southern Annual Shareholders Meeting     FOR ALL AMERICAN HOLIDAYS      FOR AN INDEX OF ALL DIARIES            If you have any questions or comments on the Corporate diary, please e-mail:     diaries@thomsonreuters.com   ",2015-04-30,BMY,"Thu Apr 30, 2015 | 8:25am EDT",DIARY-U.S. MEETINGS/WEEK AHEAD,http://www.reuters.com//article/diary-us-meetings-week-idUSL4N0XR6A320150430?type=companyNews
146,"   By Lawrence Hurley | WASHINGTON  WASHINGTON The U.S. Supreme Court on Monday brought to an end Bristol-Myers Squibb Co's attempt to revive patent protection for its Baraclude treatment for hepatitis B.The high court declined to hear Bristol-Myers' challenge to an appeals court ruling in favor of generic rival Teva Pharmaceutical Industries Ltd, which had successfully challenged the patent. In a June 2014 ruling, the U.S. Court of Appeals for the Federal Circuit upheld a federal district court's finding that the patent was invalid.Teva announced last September that it was launching its generic version of the drug. The case is Bristol-Myers v. Teva, U.S. Supreme Court, No. 14-886.  (Reporting by Lawrence Hurley; Editing by Will Dunham)",2015-05-04,BMY,"Mon May 4, 2015 | 9:55am EDT",U.S. top court rejects hepatitis B drug patent case,http://www.reuters.com//article/us-usa-court-hepatitis-idUSKBN0NP18Z20150504?type=companyNews
147,"   By Lawrence Hurley | WASHINGTON  WASHINGTON May 4 The U.S. Supreme Court on Monday brought to an end Bristol-Myers Squibb Co's  attempt to revive patent protection for its Baraclude treatment for hepatitis B.The high court declined to hear Bristol-Myers' challenge to an appeals court ruling in favor of generic rival Teva Pharmaceutical Industries Ltd, which had successfully challenged the patent. In a June 2014 ruling, the U.S. Court of Appeals for the Federal Circuit upheld a federal district court's finding that the patent was invalid. Teva announced last September that it was launching its generic version of the drug. The case is Bristol-Myers v. Teva, U.S. Supreme Court, No. 14-886.   (Reporting by Lawrence Hurley; Editing by Will Dunham)",2015-05-04,BMY,"Mon May 4, 2015 | 9:40am EDT",U.S. top court rejects hepatitis B drug patent case,http://www.reuters.com//article/usa-court-hepatitis-idUSL1N0XS1LE20150504?type=companyNews
148,"   By Brendan Pierson  A federal judge in New York has thrown out, for the second time, a lawsuit accusing Mylan Laboratories Ltd of breaching an agreement with Bristol-Myers Squibb Co to distribute an AIDS drug in developing countries, after being ordered by an appellate court to reconsider. U.S. District Judge Paul Engelmayer, who originally dismissed the lawsuit in 2013, said Wednesday that Bristol-Myers had failed to state a viable case even after the 2nd U.S. Circuit Court of Appeals gave it another chance last October. The decision was another victory for Wilson Sonsini Goodrich & Rosati, which represented Mylan.  To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/1Ji4wkO",2015-05-14,BMY,"Thu May 14, 2015 | 3:59pm EDT","Bristol-Myers' suit over drug distribution deal dismissed, again",http://www.reuters.com//article/health-aids-idUSL1N0Y52PX20150514?type=companyNews
149,"  European regulators have recommended approval of Merck & Co Inc's immune system-boosting cancer drug Keytruda, following a similar green light last month for Bristol-Myers Squibb Co's rival product Opdivo.Merck's drug, also known as pembrolizumab, was endorsed on Friday by the European Medicines Agency (EMA) for the treatment of melanoma.Both Keytruda and Opdivo are already approved in the United States.The EMA said Keytruda was recommended for use on its own for the treatment of advanced melanoma, the most aggressive type of skin cancer, in both first-line and previously treated patients. (bit.ly/1FrWjYm) Keytruda and Opdivo belong to a highly promising new class of medicines called PD-1 inhibitors that block a mechanism tumors use to hide from the immune system. It is expected to be one of the most commercially successful new drugs to reach major markets this year.  Although Keytruda is still waiting for final regulatory approval in Europe, some patients in Britain are receiving it through a new early-access scheme, under which highly promising new drugs are made available free of charge ahead of formal licensing. Friday's positive European opinion on Keytruda is an intermediary step on the drug's path to market, since it now has to be sent to the European Commission for formal adoption. After that, decisions on price and reimbursement will taken by individual governments around Europe.  (Reporting by Ben Hirschler in London and Esha Vaish in Bengaluru; Editing by Sriraj Kalluvila)",2015-05-22,BMY,"Fri May 22, 2015 | 7:28am EDT",Merck follows Bristol with EU green light for immune cancer drug,http://www.reuters.com//article/us-health-cancer-merck-co-idUSKBN0O71AL20150522?type=companyNews
150,"  May 22 European regulators have recommended approval of Merck & Co Inc's immune system-boosting cancer drug Keytruda, following a similar green light last month for Bristol-Myers Squibb Co's rival product Opdivo.Merck's drug, also known as pembrolizumab, was endorsed on Friday by the European Medicines Agency (EMA) for the treatment of melanoma.Both Keytruda and Opdivo are already approved in the United States. The EMA said Keytruda was recommended for use on its own for the treatment of advanced melanoma, the most aggressive type of skin cancer, in both first-line and previously treated patients. (bit.ly/1FrWjYm) Keytruda and Opdivo belong to a highly promising new class of medicines called PD-1 inhibitors that block a mechanism tumours use to hide from the immune system. It is expected to be one of the most commercially successful new drugs to reach major markets this year. Although Keytruda is still waiting for final regulatory approval in Europe, some patients in Britain are receiving it through a new early-access scheme, under which highly promising new drugs are made available free of charge ahead of formal licensing.Friday's positive European opinion on Keytruda is an intermediary step on the drug's path to market, since it now has to be sent to the European Commission for formal adoption. After that, decisions on price and reimbursement will taken by individual governments around Europe.   (Reporting by Ben Hirschler in London and Esha Vaish in Bengaluru; Editing by Sriraj Kalluvila)",2015-05-22,BMY,"Fri May 22, 2015 | 7:22am EDT",Merck follows Bristol with EU green light for immune cancer drug,http://www.reuters.com//article/health-cancer-merck-co-idUSL3N0YD3VV20150522?type=companyNews
151,"   By Deena Beasley and Bill Berkrot  New data to be released this weekend should help deepen the understanding of how broadly new drugs that unleash the body's immune system to fight cancer can be used.Results from key clinical trials will be presented starting Friday in Chicago at the annual meeting of the American Society of Clinical Oncology. These will include studies aimed at defining ahead of time which patients are likely to benefit from the costly drugs. At the forefront will be rival drugs from Bristol-Myers Squibb Co and Merck and Co designed to block a protein known as Programmed Death receptor (PD-1) that is used by tumors to evade the body's natural defenses.""It's going to be an important meeting to get some more (details) on the PD-1 and PD-L1 drugs,"" said Morningstar analyst Damien Conover. Bristol's Opdivo, or nivolumab, was approved by the U.S. Food and Drug Administration in December to treat advanced melanoma. In March, it also received clearance to treat a form of lung cancer, giving Bristol an early advantage in the much larger market. Merck's Keytruda, or pembrolizumab, has been approved for advanced melanoma since September and is awaiting regulatory approval in lung cancer treatment. First-quarter sales of both drugs surprised Wall Street, with Keytruda sales reaching $83 million, compared to $40 million for Opdivo, suggesting an early advantage for Merck in what many expect will be a years-long battle for market share.  Other drugmakers working on similar treatments include Roche Holding AG, AstraZeneca Plc and Pfizer Inc. Many industry experts expect the entire class will eventually generate billions of dollars in annual sales, particularly if proven effective against other forms of cancer.On Friday, the ASCO conference will feature studies looking at Opdivos use against advanced liver cancer and non-squamous, non-small cell lung cancer (NSCLC), the most common form of lung cancer. Results will also be presented from a trial of Keytruda in head and neck cancer.  ""Bristol's in a really good position,"" said Leerink Partners analyst Seamus Fernandez. ""My expectation is that they're going to be and will continue to be the leader in the lung cancer space."" Lung cancer, the most common cancer worldwide, is the largest cause of cancer deaths in the United States. At the same time, he said, Merck may bolster its argument that Keytruda has proven the broadest possible use to date, with ""clear activity in 13 different tumor types.Other data points that will be closely watched by oncologists and investors include whether the level of PD-1 protein in a tumor can predict how well the new immunotherapies will work. Earlier this month, Roche said that a mid-stage trial of its experimental immunotherapy, MPDL3280A, showed it doubled the likelihood of survival for lung cancer patients with the highest levels PD-L1.  A separate trial of Merck's Keytruda to be released at ASCO was designed to see whether a higher number of genetic mutations in a tumor can lead to better results in treating colorectal and other cancers.Doctors at the meeting will also hear more on the potential for combining different types of immunotherapies to make them more effective, as well as the high costs associated with multiple treatment regimens. Treatment with Opdivo or Keytruda alone in the United States, for example, costs about $12,500 per month, or $150,000 a year.""Really the name of the game is having overall survival data in your label,"" said Suntrust Robinson Humphrey analyst John Boris.  (Reporting by Deena Beasley in Los Angeles and Bill Berkrot in New York; Editing by Diane Craft)",2015-05-28,BMY,"Thu May 28, 2015 | 7:16am EDT","New drugs from Bristol, Merck at forefront of cancer meeting",http://www.reuters.com//article/us-cancer-asco-immunotherapies-idUSKBN0OD18L20150528?type=companyNews
152,"   By Brendan Pierson  Otsuka Pharmaceutical Co Ltd has lost a lawsuit challenging the U.S. Food and Drug Administration's decision to allow generic versions of the company's antipsychotic drug Abilify.At the end of April, the FDA approved applications to make  Abilify by several generic drugmakers, including Teva Pharmaceutical Industries Ltd, which immediately announced it would launch its own version.Otsuka sued the FDA saying it had an exclusive right to make Abilify until 2021 because the drug was designated an ""orphan drug,"" one that treats a rare condition, when it was approved for pediatric Tourette's syndrome.U.S. District Judge George Hazel denied Otsuka's motion for a preliminary order blocking generic Abilify the day after the FDA approved it, and issued a final ruling against Otsuka on Wednesday.             The FDA gives several years of exclusivity to orphan drugs in order to encourage companies to work on them since they might otherwise not be profitable given their high costs to develop.Hazel said Abilify has non-pediatric uses, which are not protected by orphan-drug status, allowing generic versions to go ahead. The drug is approved to treat schizophrenia and bipolar disorder, and lost patent protection for those uses in April. Otsuka may still appeal. A spokesman said the was reviewing Wednesday's decision and considering its options.Abilify, which is sold by Bristol-Myers Squibb Co in the United States, brought in sales of $554 million in the first quarter.  (Reporting By Brendan Pierson in New York; Editing by Ted Botha and Alan Crosby)",2015-05-28,BMY,"Thu May 28, 2015 | 1:54pm EDT",Otsuka loses lawsuit challenging FDA approval of generic Abilify,http://www.reuters.com//article/us-otsuka-abilify-idUSKBN0OD29420150528?type=companyNews
153,"  (Adds comment from Otsuka in paragraph 7.)By Brendan PiersonMay 28 Otsuka Pharmaceutical Co Ltd has lost a lawsuit challenging the U.S. Food and Drug Administration's decision to allow generic versions of the company's antipsychotic drug Abilify.At the end of April, the FDA approved applications to make  Abilify by several generic drugmakers, including Teva Pharmaceutical Industries Ltd, which immediately announced it would launch its own version. Otsuka sued the FDA saying it had an exclusive right to make Abilify until 2021 because the drug was designated an ""orphan drug,"" one that treats a rare condition, when it was approved for pediatric Tourette's syndrome.U.S. District Judge George Hazel denied Otsuka's motion for a preliminary order blocking generic Abilify the day after the FDA approved it, and issued a final ruling against Otsuka on Wednesday. The FDA gives several years of exclusivity to orphan drugs in order to encourage companies to work on them since they might otherwise not be profitable given their high costs to develop. Hazel said Abilify has non-pediatric uses, which are not protected by orphan-drug status, allowing generic versions to go ahead. The drug is approved to treat schizophrenia and bipolar disorder, and lost patent protection for those uses in April.Otsuka may still appeal. A spokesman said the was reviewing Wednesday's decision and considering its options.Abilify, which is sold by Bristol-Myers Squibb Co in the United States, brought in sales of $554 million in the first quarter.    (Reporting By Brendan Pierson in New York; Editing by Ted Botha and Alan Crosby)",2015-05-28,BMY,"Thu May 28, 2015 | 1:34pm EDT",UPDATE 1-Otsuka loses lawsuit challenging FDA approval of generic Abilify,http://www.reuters.com//article/otsuka-abilify-idUSL1N0YJ1RO20150528?type=companyNews
154,"   By Brendan Pierson  May 28 Otsuka Pharmaceutical Co Ltd has lost a lawsuit challenging the U.S. Food and Drug Administration's decision to allow generic versions of the company's antipsychotic drug Abilify.At the end of April, the FDA approved applications to make  Abilify by several generic drugmakers, including Teva Pharmaceutical Industries Ltd, which immediately announced it would launch its own version.Otsuka sued the FDA in March saying it had an exclusive right to make Abilify until 2021 because the drug was designated an ""orphan drug,"" one that treats a rare condition, when it was approved for pediatric Tourette's syndrome. The FDA gives several years of exclusivity to orphan drugs in order to encourage companies to develop them, since they might otherwise not be profitable. U.S. District Judge George Hazel denied Otsuka's motion for a preliminary order blocking generic Abilify the day after the FDA approved it, and issued a final ruling against Otsuka on Wednesday.Hazel said Abilify has non-pediatric uses, which are not protected by orphan-drug status, allowing generic versions to go ahead. The drug is approved to treat schizophrenia and bipolar disorder, and lost patent protection for those uses in April. Otsuka, which did not immediately reply to a request for comment, may still appeal Wednesday's decision.Abilify, which is sold by Bristol-Myers Squibb Co in the United States, brought in sales of $554 million in the first quarter.    (Reporting By Brendan Pierson in New York; Editing by Ted Botha and Alan Crosby)",2015-05-28,BMY,"Thu May 28, 2015 | 12:42pm EDT",Otsuka loses lawsuit challenging FDA approval of generic Abilify,http://www.reuters.com//article/otsuka-abilify-idUSL1N0YJ1GN20150528?type=companyNews
155,"   By Deena Beasley | Chicago  Chicago Bristol-Myers Squibb Co's drug, Opdivo, improved survival in a trial of patients with the most common form of lung cancer, but it did not work in patients who tested negative for a specific protein in their tumors, leading to a nearly 7 percent sell-off in the company's shares on Friday.The Phase III trial found that Opdivo, part of a new class of drugs that harness the immune system to fight cancer, reduced by 27 percent the risk of death from advanced non-squamous non-small cell lung cancer (NSCLC), compared with chemotherapy. The benefit reached 60 percent for patients with the highest levels of the PD-L1 protein.""Opdivo did not work in PD-L1 negative patients,"" said Amit Roy, an analyst at research group Foveal. ""That is nearly half of the non-squamous patients.""He said many investors had expected that the drug might be effective regardless of PD-L1 levels, but the results indicate regulators would likely restrict usage to patients who test positive for the protein.The Bristol drug was approved by U.S. regulators in December to treat advanced melanoma and competes with Keytruda from Merck & Co Inc. The current approvals for both drugs do not require testing patients for PD-L1.Investors have been keeping a close eye on Opdivo's performance in lung cancer, the most common form of the disease worldwide, and a far larger market. Opdivo was cleared in March to treat the less-common squamous type of NSCLC. Between 85 percent and 90 percent of all lung cancers are NSCLC, and more than two-thirds of those are the non-squamous type, according to the American Cancer Society. Bristol shares fell $4.55, or 6.6 percent, to close at $64.60 on the New York Stock Exchange.This latest trial, presented at the annual meeting of the American Society of Clinical Oncology, involved 582 previously treated patients with non-squamous NSCLC.""This marks the end of the chemotherapy era in second-line treatment of lung cancer,"" said Fouad Namouni, who oversees Opdivo development at Bristol-Myers. He said the company is talking with the Food and Drug Administration about applying to expand approval for Opdivo, or nivolumab, to include advanced non-squamous NSCLC. Bristol is also studying Opdivo on its own and in combination with another immunotherapy called Yervoy as an initial treatment for lung cancer.The trial results showed median overall survival of 12.2 months for the Opdivo group compared with 9.4 months for patients treated with docetaxel. For the subgroup of patients with high levels of PD-L1, which is used by tumors to evade the body's defenses, median survival exceeded 17 months with Opdivo, compared with 9 months for chemotherapy patients.One in 10 Opdivo patients in the trial experienced serious side effects, compared with more than half of patients in the chemotherapy group. Roy said eventual use of rival immunotherapy drugs being developed by Roche Holding AG, AstraZeneca Plc and Pfizer Inc will also likely be restricted based on biomarker levels.The ASCO conference also featured results from an early-stage study of Opdivo showing that 19 percent of patients with advanced liver cancer responded to the antibody with tumor shrinkage of more than 30 percent.Researchers said that compares with a response rate of just 2 percent for Nexavar, the only currently approved systemic treatment for advanced liver cancer. Nexavar is produced by subsidiaries of Bayer AG and Amgen Inc (Editing by Andre Grenon)",2015-05-29,BMY,"Fri May 29, 2015 | 4:39pm EDT",Bristol's Opdivo cuts risk of lung cancer death for some,http://www.reuters.com//article/us-cancer-asco-bristol-opdivo-idUSKBN0OE2BB20150529?type=companyNews
156,"  (Adds analyst comment, share price)By Deena BeasleyChicago May 29 Bristol-Myers Squibb Co's  drug, Opdivo, improved survival in a trial of patients with the most common form of lung cancer, but it did not work in patients who tested negative for a specific protein in their tumors, leading to a nearly 7 percent sell-off in the company's shares on Friday.The Phase III trial found that Opdivo, part of a new class of drugs that harness the immune system to fight cancer, reduced by 27 percent the risk of death from advanced non-squamous non-small cell lung cancer (NSCLC), compared with chemotherapy. The benefit reached 60 percent for patients with the highest levels of the PD-L1 protein.""Opdivo did not work in PD-L1 negative patients,"" said Amit Roy, an analyst at research group Foveal. ""That is nearly half of the non-squamous patients.""He said many investors had expected that the drug might be effective regardless of PD-L1 levels, but the results indicate regulators would likely restrict usage to patients who test positive for the protein. The Bristol drug was approved by U.S. regulators in December to treat advanced melanoma and competes with Keytruda from Merck & Co Inc. The current approvals for both drugs do not require testing patients for PD-L1.Investors have been keeping a close eye on Opdivo's performance in lung cancer, the most common form of the disease worldwide, and a far larger market. Opdivo was cleared in March to treat the less-common squamous type of NSCLC. Between 85 percent and 90 percent of all lung cancers are NSCLC, and more than two-thirds of those are the non-squamous type, according to the American Cancer Society.Bristol shares fell $4.55, or 6.6 percent, to close at $64.60 on the New York Stock Exchange. This latest trial, presented at the annual meeting of the American Society of Clinical Oncology, involved 582 previously treated patients with non-squamous NSCLC.""This marks the end of the chemotherapy era in second-line treatment of lung cancer,"" said Fouad Namouni, who oversees Opdivo development at Bristol-Myers.He said the company is talking with the Food and Drug Administration about applying to expand approval for Opdivo, or nivolumab, to include advanced non-squamous NSCLC. Bristol is also studying Opdivo on its own and in combination with another immunotherapy called Yervoy as an initial treatment for lung cancer. The trial results showed median overall survival of 12.2 months for the Opdivo group compared with 9.4 months for patients treated with docetaxel. For the subgroup of patients with high levels of PD-L1, which is used by tumors to evade the body's defenses, median survival exceeded 17 months with Opdivo, compared with 9 months for chemotherapy patients.One in 10 Opdivo patients in the trial experienced serious side effects, compared with more than half of patients in the chemotherapy group.Roy said eventual use of rival immunotherapy drugs being developed by Roche Holding AG, AstraZeneca Plc  and Pfizer Inc will also likely be restricted based on biomarker levels.The ASCO conference also featured results from an early-stage study of Opdivo showing that 19 percent of patients with advanced liver cancer responded to the antibody with tumor shrinkage of more than 30 percent.Researchers said that compares with a response rate of just 2 percent for Nexavar, the only currently approved systemic treatment for advanced liver cancer. Nexavar is produced by subsidiaries of Bayer AG and Amgen Inc    (Editing by Andre Grenon)",2015-05-29,BMY,"Fri May 29, 2015 | 4:38pm EDT",UPDATE 1-Bristol's Opdivo cuts risk of lung cancer death for some,http://www.reuters.com//article/cancer-asco-bristol-opdivo-idUSL1N0YK29N20150529?type=companyNews
157,"   By Caroline Humer | (Reuters) - NEW YORK  NEW YORK May 29 Bristol-Myers Squibb  has sued a top cancer immunotherapy executive for violating confidentiality and non-compete agreements after he left for direct competitor AstraZeneca, court documents show.The suit, filed in Delaware's Court of Chancery late on Thursday, said that David Berman violated agreements that prevented him from using confidential and trade secret information when he accepted a job at AstraZeneca, which is also developing treatments that use the immune system to fight cancer.Berman, who worked at Bristol for 10 years on immunotherapy-based cancer drugs, including Yervoy and the recently launched Opdivo, also broke non-compete agreements that were part of incentive pay packages, Bristol said.The company said that Berman had agreed not to work at a competitor on related business for 12 months. Berman, who was responsible for clinical development of Bristol's early stage immuno-oncology medicines and was connected to the clinical development of its entire immuno-oncology portfolio, resigned in writing on May 26, saying that he was headed to AstraZeneca's oncology division, according to the court documents. He had told his supervisor on May 20 of his plans to leave, the documents said.He was the leader on research and development of Bristol-Myers immunotherapy cancer treatments and had access to non-public information about the company's drug pipeline strategies, the documents said. Berman, who held the title of vice president and leader of Bristol's Immuno-oncology Exploratory Development Team, was not immediately reachable by phone or through his LinkedIn social media account. Documents identified him as living in Princeton, New Jersey.AstraZeneca declined to comment. According to the suit, Bristol and AstraZeneca are directly competing on the development of treatments based on the receptor proteins found on T-cells and in particular, the programmed death receptor, commonly referred to as PD-1.Bristol has asked the court to prevent Berman from working for AstraZeneca for twelve months and to prevent him from using the company's confidential information at any time.Bristol-Myers spokeswoman Laura Hortas said in a statement that the company ""is committed to protecting the confidentiality of proprietary information about its leading immuno-oncology portfolio and business.""(Reporting by Caroline Humer, additional reporting by Sharon Begley; editing by Diane Craft)   nL1N0YK1H2",2015-05-29,BMY,"Fri May 29, 2015 | 3:04pm EDT",Bristol-Myers sues immunotherapy exec who left for AstraZeneca,http://www.reuters.com//article/bristol-myers-astrazeneca-court-idUSL1N0YK1XB20150529?type=companyNews
158,"   By Caroline Humer | NEW YORK  NEW YORK Bristol-Myers Squibb has sued a top cancer immunotherapy executive for violating confidentiality and non-compete agreements after he left for direct competitor AstraZeneca, court documents show. The suit, filed in Delaware's Court of Chancery late on Thursday, said that David Berman violated agreements that prevented him from using confidential and trade secret information when he accepted a job at AstraZeneca, which is also developing treatments that use the immune system to fight cancer.Berman, who worked at Bristol for 10 years on immunotherapy-based cancer drugs, including Yervoy and the recently launched Opdivo, also broke non-compete agreements that were part of incentive pay packages, Bristol said.The company said that Berman had agreed not to work at a competitor on related business for 12 months.Berman, who was responsible for clinical development of Bristol's early stage immuno-oncology medicines and was connected to the clinical development of its entire immuno-oncology portfolio, resigned in writing on May 26, saying that he was headed to AstraZeneca's oncology division, according to the court documents. He had told his supervisor on May 20 of his plans to leave, the documents said. He was the leader on research and development of Bristol-Myers immunotherapy cancer treatments and had access to non-public information about the company's drug pipeline strategies, the documents said.Berman, who held the title of vice president and leader of Bristol's Immuno-oncology Exploratory Development Team, was not immediately reachable by phone or through his LinkedIn social media account. Documents identified him as living in Princeton, New Jersey. AstraZeneca declined to comment.    According to the suit, Bristol and AstraZeneca are directly competing on the development of treatments based on the receptor proteins found on T-cells and in particular, the programmed death receptor, commonly referred to as PD-1.Bristol has asked the court to prevent Berman from working for AstraZeneca for twelve months and to prevent him from using the company's confidential information at any time. Bristol-Myers spokeswoman Laura Hortas said in a statement that the company ""is committed to protecting the confidentiality of proprietary information about its leading immuno-oncology portfolio and business."" (Reporting by Caroline Humer, additional reporting by Sharon Begley; editing by Diane Craft)",2015-05-29,BMY,"Fri May 29, 2015 | 3:02pm EDT",Bristol-Myers sues immunotherapy exec who left for AstraZeneca,http://www.reuters.com//article/us-bristol-myers-astrazeneca-court-idUSKBN0OE2DV20150529?type=companyNews
159,"   By Caroline Humer | NEW YORK  NEW YORK May 29 Bristol-Myers Squibb  has sued a top cancer immunotherapy executive for violating confidentiality and non-compete agreements after he left for direct competitor AstraZeneca, court documents show.The suit, filed in Delaware's Court of Chancery late on Thursday, said that David Berman violated agreements that prevented him from using confidential and trade secret information when he accepted a job at AstraZeneca, which is also developing treatments that use the immune system to fight cancer.Berman, who worked at Bristol for 10 years on immunotherapy-based cancer drugs, including Yervoy and the recently launched Opdivo, also broke non-compete agreements that were part of incentive pay packages, Bristol said.The company said that Berman had agreed not to work at a competitor on related business for 12 months. Berman, who was responsible for clinical development of Bristol's early stage immuno-oncology medicines and was connected to the clinical development of its entire immuno-oncology portfolio, resigned in writing on May 26, saying that he was headed to AstraZeneca's oncology division, according to the court documents. He had told his supervisor on May 20 of his plans to leave, the documents said.He was the leader on research and development of Bristol-Myers immunotherapy cancer treatments and had access to non-public information about the company's drug pipeline strategies, the documents said. Berman, who held the title of vice president and leader of Bristol's Immuno-oncology Exploratory Development Team, was not immediately reachable by phone or through his LinkedIn social media account. Documents identified him as living in Princeton, New Jersey.AstraZeneca declined to comment. According to the suit, Bristol and AstraZeneca are directly competing on the development of treatments based on the receptor proteins found on T-cells and in particular, the programmed death receptor, commonly referred to as PD-1.Bristol has asked the court to prevent Berman from working for AstraZeneca for twelve months and to prevent him from using the company's confidential information at any time.Bristol-Myers spokeswoman Laura Hortas said in a statement that the company ""is committed to protecting the confidentiality of proprietary information about its leading immuno-oncology portfolio and business.""(Reporting by Caroline Humer, additional reporting by Sharon Begley; editing by Diane Craft)",2015-05-29,BMY,"Fri May 29, 2015 | 2:57pm EDT",Bristol-Myers sues immunotherapy exec who left for AstraZeneca,http://www.reuters.com//article/bristol-myers-astrazeneca-court-idUSL1N0YK1H220150529?type=companyNews
160,"  Editor: Steve Orlofsky 1 646 223 6200Global Picture Desk: +65 6870 3775Global Graphics Desk: +65 6870 3595(All times GMT / ET)Receive this schedule by email:mediaexpress.reuters.comTOP STORIES Intel close to deal to buy Altera for $16 bln -sourcesIntel Corp has resumed talks to buy programmable-chip maker Altera Corp and is close to a $16 billion deal, people familiar with the matter say, paving way for the third mega semiconductor-chip deal this year. (ALTERA-M&A/INTEL (UPDATE 2), moved, by Greg Roumeliotis and Liana B. Baker, 210 words)U.S. economy shrank in 1t qtr; dollar hit corporate profitsWASHINGTON - The U.S. economy contracted in the first quarter as it buckled under the weight of unusually heavy snowfalls and a resurgent dollar, but activity has rebounded modestly. (USA-ECONOMY/ (WRAPUP 4), moved, by Lucia Mutikani, 830 words)U.S. sues to block merger of Steris Corp, Synergy HealthWASHINGTON - The U.S. Federal Trade Commission files a lawsuit to stop the $1.9 billion merger of medical technology provider Steris Corp and British sterilization services provider Synergy Health Plc. (SYNERGYHEALTH-STERIS CORP/FTC (UPDATE 1), moved, by Diane Bartz, 320 words) Vanguard ties help Wellington buck weak trend in active fundsBOSTON - While many U.S. asset managers that focus on stock picking are getting squeezed by low-cost passive rivals, Wellington Management is prospering, leveraging decades-long ties to Vanguard Group that allow it charge management fees that are less than a third of the category average. (WELLINGTON-FUNDS/, moved, By Ross Kerber, 610 words)Bristol's Opdivo reduces risk of death from common lung cancerCHICAGO - Bristol-Myers Squibb Co's drug Opdivo improved survival for patients with the most common form of lung cancer, nearly doubling it for those with high levels of a specific protein in their tumors compared with chemotherapy, according to clinical trial results. (CANCER-ASCO/BRISTOL-OPDIVO, moved, by Deena Beasley, 480 words)MARKETS Wall St slips on weak economic dataU.S. stocks are lower as weak GDP and consumer sentiment data add to investor concerns about the strength of the economy. (MARKETS-STOCKS/USA (UPDATE 5), updated throughout the say, 400 words) + See also:- MARKETS-GLOBAL/ (WRAPUP 7), updated throughout the day, 400 words- MARKETS-OIL/ (UPDATE 7), updated throughout the day, 400 wordsINVESTING Investors find big upside in small U.S. death services companiesNEW YORK - Companies that provide funerals and other end-of-life services stand to benefit from what boils down to a macabre version of high demand as members of the U.S. baby boom generation approach their seventies. (USA-STOCKS/FUNERALS, moved, by Ryan Vlastelica, 510 words) Apps turn bedroom traders into star stock-pickersLONDON - The spread of smartphones has revolutionized trading for those who believe more in the wisdom of their peers than that of fee-charging fund managers (MARKETS-STOCKS/COPYCAT, moved, by Atul Prakash, 860 words)ECONOMY Canada economy contracts by most in 6 years in first quarterCanada's economy contracted the most in nearly six years in the first quarter, with business investment and exports falling as the country grappled with a slump in oil prices. (CANADA-ECONOMY/GDP (UPDATE 3), moved, by Leah Schnurr, 550 words)COMPANIES Equinix to buy TelecityGroup for $3.6 bln, Interxion deal endedLONDON/NEW YORK - U.S. data center company Equinix Inc will buy British peer TelecityGroup in a deal worth $3.6 billion that would also end  Telecity's pursuit of a smaller European rival. (TELECITY-M&A/EQUINIX (UPDATE 2), moved, by Sarah Young and Liana B. Baker, 380 words)AstraZeneca and Lilly to test new cancer drug combinationLONDON - AstraZeneca and Eli Lilly are to combine two of their cancer drugs in a new clinical trial against solid tumors in the latest sign that such cocktails may be the way forward in fighting the disease. (ASTRAZENECA-ELI LILLY/CANCER, moved, 220 words)ALSO IN THE NEWS Financial regulator says Vatican bank needs more reformVATICAN CITY - The Vatican bank has made good progress in transparency but needs more changes to consolidate anti-money laundering reforms, the Holy See's financial regulator says in its annual report. (VATICAN-BANK/, moved, by Philip Pullella, 425 words)",2015-05-29,BMY,"Fri May 29, 2015 | 2:42pm EDT",Reuters Business News Schedule at 1830 GMT/2:30 PM ET,http://www.reuters.com//article/business-news-schedule-at-1830-gmt-idUSL1N0YK1UG20150529?type=companyNews
161,"   By Deena Beasley  Chicago May 29 Bristol-Myers Squibb Co's  drug, Opdivo, improved survival for patients with the most common form of lung cancer, nearly doubling survival for those with high levels of a specific protein in their tumors compared with chemotherapy, according to clinical trial results presented on Friday.The trial found that Opdivo, part of a new class of drugs that harness the immune system to fight cancer, reduced by 27 percent the risk of death from advanced non-squamous non-small cell lung cancer (NSCLC), compared with chemotherapy. The benefit reached 60 percent for patients with the highest levels of the PD-L1 protein.The Bristol drug was approved by U.S. regulators in December to treat advanced melanoma and competes with Keytruda from Merck & Co Inc. Investors have been keeping a close eye on Opdivo's performance in lung cancer, the most common form of the disease worldwide, and a far larger market. Opdivo was cleared in March to treat the less-common squamous type of NSCLC. Between 85 percent and 90 percent of all lung cancers are NSCLC, and more than two-thirds of those are the non-squamous type, according to the American Cancer Society.This latest trial, presented at the annual meeting of the American Society of Clinical Oncology, involved 582 previously treated patients with non-squamous NSCLC. ""This marks the end of the chemotherapy era in second-line treatment of lung cancer,"" said Fouad Namouni, who oversees Opdivo development at Bristol-Myers.He said the company is talking with the Food and Drug Administration about applying to expand approval for Opdivo, or nivolumab, to include advanced non-squamous NSCLC. Bristol is also studying Opdivo on its own and in combination with another immunotherapy called Yervoy as an initial treatment for lung cancer. The trial results showed median overall survival of 12.2 months for the Opdivo group compared with 9.4 months for patients treated with docetaxel. For the subgroup of patients with high levels of PD-L1, which is used by tumors to evade the body's defenses, median survival exceeded 17 months with Opdivo, compared with 9 months for chemotherapy patients.""While nivolumab appears to be more potent against this most common lung cancer, it is important to note that it is also far easier on patients compared to the standard second-line treatment,"" said Dr. Luis Paz-Ares, a professor of medicine at Hospital Universitario 12 de Octubre in Madrid, and the study's lead author. One in 10 Opdivo patients in the trial experienced serious side effects, compared with more than half of patients in the chemotherapy group.The ASCO conference also featured results from an early-stage study of Opdivo showing that 19 percent of patients with advanced liver cancer responded to the antibody with tumor shrinkage of more than 30 percent.Researchers said that compares with a response rate of just 2 percent for Nexavar, the only currently approved systemic treatment for advanced liver cancer. Nexavar is produced by subsidiaries of Bayer AG and Amgen Inc(Editing by Andre Grenon)",2015-05-29,BMY,"Fri May 29, 2015 | 2:00pm EDT",Bristol's Opdivo reduces risk of death from common lung cancer,http://www.reuters.com//article/cancer-asco-bristol-opdivo-idUSL1N0YJ1RU20150529?type=companyNews
162,  June 2 Genmab says:* Gains license to antibody panel targeting CD19 * It is an exclusive license from Bristol-Myers Squibb * Will make a one-time $4 mln licensing payment to Bristol-Myers Squibb upon execution of license * Other financial terms of agreement were not disclosed  Source text for Eikon:  Further company coverage:    (Reporting By Teis Jensen),2015-06-02,BMY,"Tue Jun 2, 2015 | 1:20am EDT",BRIEF-Genmab gains license to antibody panel targeting CD19,http://www.reuters.com//article/idUSFWN0YN05420150602?type=companyNews
163,"  MOSCOW, June 5 Russian food retailer Dixy  plans to buy a controlling stake in spirits and tobacco chain Bristol in the second half of 2015, Dixy Chief Financial Officer Fedor Rybasov said on Friday.Dixy already owns 33 percent of Russian company Bristol's shares. It bought a 31.8 percent stake in May for 1.78 billion roubles ($32 million) from Russian tobacco distributor Megapolis, increasing its interest from 1.2 percent.""We are going to buy the Bristol retail chain, a controlling stake, in the second part (of the year), pretty much soon, in the next couple of months,"" Rybasov told a conference call.He added that in connection with the acquisition the company's total debt could rise by between 6 billion and 8 billion roubles this year although the company did not have a specific target as to how much new debt it would raise. The Bristol chain comprises more than 1,400 stores in some 400 Russian cities. It generated 7.7 billion roubles in revenues last year, according to Renaissance Capital. Dixy Chief Executive Ilya Yakubson told Reuters the acquisition of Bristol, which also sells food, would allow it to expand in a smaller store format of 100-120 square metres.""That is the type of a neighbourhood convenience store which comes in the stead of kiosks, pavilions, etc. A small shop which sells everything you may need to buy quickly,"" Yakubson said on the sidelines of a retail conference on Thursday. Dixy Group and Megapolis are both controlled by Russia's  Mercury Group of businessmen Igor Kesaev and Sergei Katsiev.($1 = 56.1750 roubles)   (Reporting by Maria Kiselyova and Olga Sichkar; Editing by Elizabeth Piper and Mark Potter)",2015-06-05,BMY,"Fri Jun 5, 2015 | 8:16am EDT",Russia's Dixy plans to buy control of Bristol chain in H2,http://www.reuters.com//article/russia-dixy-group-bristol-idUSL5N0YR1WZ20150605?type=companyNews
164,"  Bristol-Myers Squibb said on Thursday that it would stop efforts to find new antiviral drugs and cut 100 related jobs. The company said it will also discontinue its Hepatitis B and HIV early programs.Bristol-Myers said already marketed products and its ongoing clinical programs in virology would not be hit by the decision. The company is seeking U.S. approval for its experimental hepatitis C drug, daclatasvir.The compound is already approved in the European Union to treat the same condition under the brand name Daklinza. The company said a research facility is expected to open in Cambridge, Massachusetts in 2018 and that the expansion of an R&D site in San Francisco Bay Area is likely to be completed by 2016. Bristol-Myers' stock was up marginally at $67.47 on the New York Stock Exchange.  (Reporting by Anjali Rao Koppala in Bengaluru; Editing by Sriraj Kalluvila)",2015-06-25,BMY,"Thu Jun 25, 2015 | 11:48am EDT",Bristol-Myers to stop new antiviral drug research,http://www.reuters.com//article/us-bristol-myers-r-d-idUSKBN0P525420150625?type=companyNews
165,"  June 25 Bristol-Myers Squibb said on Thursday that it would stop efforts to find new antiviral drugs and cut 100 related jobs.The company said it will also discontinue its Hepatitis B and HIV early programs.Bristol-Myers said already marketed products and its ongoing clinical programs in virology would not be hit by the decision. The company is seeking U.S. approval for its experimental hepatitis C drug, daclatasvir. The compound is already approved in the European Union to treat the same condition under the brand name Daklinza. The company said a research facility is expected to open in Cambridge, Massachusetts in 2018 and that the expansion of an R&D site in San Francisco Bay Area is likely to be completed by 2016.Bristol-Myers' stock was up marginally at $67.47 on the New York Stock Exchange.   (Reporting by Anjali Rao Koppala in Bengaluru; Editing by Sriraj Kalluvila)",2015-06-25,BMY,"Thu Jun 25, 2015 | 11:08am EDT",Bristol-Myers to stop new antiviral drug research,http://www.reuters.com//article/bristol-myers-rd-idUSL3N0ZB4KF20150625?type=companyNews
166,"  Bristol-Myers Squibb Co's Opdivo, a new oncology drug that makes cancer cells more susceptible to the immune system, on Monday won European approval to treat a form of lung cancer and was also found to be beneficial in patients with advanced kidney cancer.   Bristol-Myers shares rose 1.2 percent after the favorable separate announcements involving the drug, which is already approved in the United States to treat advanced squamous lung cancer and melanoma that has spread. The drug works by blocking receptors to PD-1, or programmed death-1, a protein cancer cells use to evade detection by the immune system.Clinical trials showed that patients with the squamous form of non small cell lung cancer taking Opdivo had almost twice the survival rate at one year as patients taking standard chemotherapy. Earlier on Monday, Bristol-Myers said a trial of Opdivo among patients with the most common form of kidney cancer was stopped after the drug was found to be effective.The study, Checkmate-025, was stopped after an independent data monitoring committee concluded that Opdivo provided a survival advantage over the standard treatment, everolimus, among patients with advanced kidney cancer.[ID:nL3N1003SK]  Wall Street expects Opdivo, also known by its chemical name nivolumab, to generate annual sales of more than $7 billion by 2020.    (Reporting by Ransdell Pierson; Editing by Dan Grebler)",2015-07-20,BMY,"Mon Jul 20, 2015 | 2:01pm EDT",Bristol-Myers cancer immunotherapy advances on two fronts,http://www.reuters.com//article/us-bristol-myers-cancer-lung-idUSKCN0PU1ZX20150720?type=companyNews
167,"  July 20 Bristol-Myers Squibb Co's  Opdivo, a new oncology drug that makes cancer cells more susceptible to the immune system, on Monday won European approval to treat a form of lung cancer and was also found to be beneficial in patients with advanced kidney cancer.Bristol-Myers shares rose 1.2 percent after the favorable separate announcements involving the drug, which is already approved in the United States to treat advanced squamous lung cancer and melanoma that has spread.The drug works by blocking receptors to PD-1, or programmed death-1, a protein cancer cells use to evade detection by the immune system. Clinical trials showed that patients with the squamous form of non small cell lung cancer taking Opdivo had almost twice the survival rate at one year as patients taking standard chemotherapy.Earlier on Monday, Bristol-Myers said a trial of Opdivo among patients with the most common form of kidney cancer was stopped after the drug was found to be effective. The study, Checkmate-025, was stopped after an independent data monitoring committee concluded that Opdivo provided a survival advantage over the standard treatment, everolimus, among patients with advanced kidney cancer. Wall Street expects Opdivo, also known by its chemical name nivolumab, to generate annual sales of more than $7 billion by 2020.(Reporting by Ransdell Pierson; Editing by Dan Grebler)",2015-07-20,BMY,"Mon Jul 20, 2015 | 1:44pm EDT",Bristol-Myers cancer immunotherapy advances on two fronts,http://www.reuters.com//article/bristol-myers-cancer-lung-idUSL1N1001E820150720?type=companyNews
168,"   By Brendan Pierson  A federal judge in Manhattan has rejected a last-ditch attempt by Bristol-Myers Squibb Co to save a lawsuit accusing Mylan Laboratories Ltd of breaching an agreement to distribute an AIDS drug in developing countries, refusing to reconsider his second order dismissing the case. U.S. District Judge Paul Engelmayer ruled on Monday that reviving the lawsuit, which has already been amended, dismissed, reinstated on appeal and dismissed again, would be ""effectively a fourth bite at the apple"" for Bristol-Myers.  To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/1LAYrAA",2015-07-21,BMY,"Tue Jul 21, 2015 | 4:22pm EDT",Bristol-Myers loses bid to revive drug distribution lawsuit,http://www.reuters.com//article/health-atazanavir-idUSL1N10127A20150721?type=companyNews
169,"   By Ransdell Pierson  Bristol-Myers Squibb Co on Thursday reported far better than expected quarterly results thanks largely to delayed reimbursement for two hepatitis C treatments in France and demand for other leading company medicines.Shares of the U.S. drugmaker, which raised its full-year profit forecast because of the strong second-quarter results, rose almost 3 percent in pre-market trading.The company said it lost $130 million, or 8 cents per share, in the period. That compared with a profit of $333 million, or 20 cents per share, in the year-earlier period.Excluding special items, including an $800 million research charge related to the company's recent purchase of Flexus Biosciences, Bristol-Myers earned 53 cents per share. That was well above the average analyst forecast of 36 cents per share, according to Thomson Reuters I/B/E/S.  Bristol-Myers noted in its earnings report that its approved Yervoy treatment for melanoma failed to prove effective in two studies of patients with advanced prostate cancer and newly diagnosed advanced small cell lung cancer, and that those studies were canceled. The company said no new safety concerns for the drug were seen in the studies.Yervoy sales slipped 8 percent to $296 million in the quarter, hurt by sales of newer melanoma treatments that also work by harnessing the immune system, including Bristol-Myers own Opdivo. Company revenue rose 7 percent to $4.16 billion, about $400 million more than Wall Street expected. Revenue would have risen 16 percent if not for the stronger dollar, which lowers the value of sales outside the United States.New hepatitis C treatments Daklinza and Sunvepra had combined sales of $479 million in the quarter, about $220 million above forecasts. A pricing agreement with the French government allowed Bristol-Myers to receive $170 million for previously unreimbursed sales of the medicines.  Results were also helped by demand for Opdivo, a new treatment for melanoma and lung cancer that works by removing a mechanism cancer cells use to evade detection by the immune system. It had sales of $122 million in the quarter.Bristol-Myers said it now expects full-year earnings of $1.70 to $1.80 per share, compared with its earlier view of $1.60 to $1.70. (Reporting by Ransdell Pierson; Editing by Chizu Nomiyama)",2015-07-23,BMY,"Thu Jul 23, 2015 | 8:21am EDT","Bristol beats forecasts, raises profit view, shares jump",http://www.reuters.com//article/us-bristol-myers-results-idUSKCN0PX1C520150723?type=companyNews
170,"  (Adds details on Yervoy setbacks, Bristol-Myers shares)By Ransdell PiersonJuly 23 Bristol-Myers Squibb Co on Thursday reported far better than expected quarterly results thanks largely to delayed reimbursement for two hepatitis C treatments in France and demand for other leading company medicines.Shares of the U.S. drugmaker, which raised its full-year profit forecast because of the strong second-quarter results, rose almost 3 percent in pre-market trading.The company said it lost $130 million, or 8 cents per share, in the period. That compared with a profit of $333 million, or 20 cents per share, in the year-earlier period. Excluding special items, including an $800 million research charge related to the company's recent purchase of Flexus Biosciences, Bristol-Myers earned 53 cents per share. That was well above the average analyst forecast of 36 cents per share, according to Thomson Reuters I/B/E/S.Bristol-Myers noted in its earnings report that its approved Yervoy treatment for melanoma failed to prove effective in two studies of patients with advanced prostate cancer and newly diagnosed advanced small cell lung cancer, and that those studies were cancelled. The company said no new safety concerns for the drug were seen in the studies. Yervoy sales slipped 8 percent to $296 million in the quarter, hurt by sales of newer melanoma treatments that also work by harnessing the immune system, including Bristol-Myers' own Opdivo.Company revenue rose 7 percent to $4.16 billion, about $400 million more than Wall Street expected. Revenue would have risen 16 percent if not for the stronger dollar, which lowers the value of sales outside the United States. New hepatitis C treatments Daklinza and Sunvepra had combined sales of $479 million in the quarter, about $220 million above forecasts. A pricing agreement with the French government allowed Bristol-Myers to receive $170 million for previously unreimbursed sales of the medicines.Results were also helped by demand for Opdivo, a new treatment for melanoma and lung cancer that works by removing a mechanism cancer cells use to evade detection by the immune system. It had sales of $122 million in the quarter.Bristol-Myers said it now expects full-year earnings of $1.70 to $1.80 per share, compared with its earlier view of $1.60 to $1.70.   (Reporting by Ransdell Pierson; Editing by Chizu Nomiyama)",2015-07-23,BMY,"Thu Jul 23, 2015 | 8:19am EDT","UPDATE 2-Bristol beats forecasts, raises profit view, shares jump",http://www.reuters.com//article/bristol-myers-results-idUSL1N1030UW20150723?type=companyNews
171,"  July 23 Bristol-Myers Squibb Co reported far better than expected quarterly results thanks largely to delayed reimbursement for two hepatitis C treatments in France and demand for other leading company medicines.The U.S. drugmaker, which raised its full-year profit forecast because of the strong second-quarter results, on Thursday said it lost $130 million, or 8 cents per share, in the period.  Excluding special items, including an $800 million research charge related to the company's recent purchase of Flexus Biosciences, Bristol-Myers earned 53 cents per share. That was well above the average analyst forecast of 36 cents per share, according to Thomson Reuters I/B/E/S.   (Reporting by Ransdell Pierson; Editing by Chizu Nomiyama) ",2015-07-23,BMY,"Thu Jul 23, 2015 | 7:38am EDT","Bristol-Myers beats forecasts, raises full-year profit view",http://www.reuters.com//article/bristol-myers-results-idUSL1N1022ZJ20150723?type=companyNews
172,"  The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus (HCV) infections.The regulator cleared AbbVie Inc's Technivie, which targets HCV genotype 4 infections, and Bristol-Myers Squibb Co's Daklinza, used to treat HCV genotype 3 infections.About 2.7 million Americans are infected with HCV, of which 10 percent are genotype 3. Genotype 4 is considered among the least common, according to the Centers for Disease Control and Prevention.Both treatments do not require the co-administration of older antivirals, the regulator said.The viral disease causes inflammation of the liver that can lead to diminished function or failure of the organ. Technivie comprises three drugs that are included in Viekira Pak, AbbVie's regimen for the most common form of HCV infection - genotype 1. (1.usa.gov/1gSuFvU)Technivie is the first regimen approved to safely and effectively treat genotype 4, while Daklinza is the first for genotype 3, the FDA said. The regulator has approved the use of Daklinza in combination with Gilead Sciences Inc's Sovaldi.  (1.usa.gov/1VFlkaX)Viekira Pak raked in sales of $231 million in the first quarter 2015, while Gilead's Sovaldi brought in $972 million in the same period. (The story corrects paragraph six to say Technivie ""comprises three drugs that are included in Viekira Pak"", not ""includes the same cocktail of drugs that comprise Viekira Pak"") (Reporting by Samantha Kareen Nair in Bengaluru; Editing by Kirti Pandey and Saumyadeb Chakrabarty)",2015-07-24,BMY,"Fri Jul 24, 2015 | 5:43pm EDT","AbbVie, Bristol-Myers get FDA nod for hep C treatments",http://www.reuters.com//article/us-abbvie-fda-idUSKCN0PY1WA20150724?type=companyNews
173,"  (Corrects paragraph 6 to say Technivie ""comprises three drugs that are included in Viekira Pak"", not ""includes the same cocktail of drugs that comprise Viekira Pak"")July 24 The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus (HCV) infections.The regulator cleared AbbVie Inc's Technivie, which targets HCV genotype 4 infections, and Bristol-Myers Squibb Co's  Daklinza, used to treat HCV genotype 3 infections.About 2.7 million Americans are infected with HCV, of which 10 percent are genotype 3. Genotype 4 is considered among the least common, according to the Centers for Disease Control and Prevention. Both treatments do not require the co-administration of older antivirals, the regulator said.The viral disease causes inflammation of the liver that can lead to diminished function or failure of the organ. Technivie comprises three drugs that are included in Viekira Pak, AbbVie's regimen for the most common form of HCV infection - genotype 1. (1.usa.gov/1gSuFvU) Technivie is the first regimen approved to safely and effectively treat genotype 4, while Daklinza is the first for genotype 3, the FDA said.The regulator has approved the use of Daklinza in combination with Gilead Sciences Inc's Sovaldi.  (1.usa.gov/1VFlkaX)Viekira Pak raked in sales of $231 million in the first quarter 2015, while Gilead's Sovaldi brought in $972 million in the same period.   (Reporting by Samantha Kareen Nair in Bengaluru; Editing by Kirti Pandey and Saumyadeb Chakrabarty)",2015-07-24,BMY,"Fri Jul 24, 2015 | 5:42pm EDT","CORRECTED-UPDATE 2-AbbVie, Bristol-Myers get FDA nod for hep C treatments",http://www.reuters.com//article/abbvie-fda-idUSL3N1045E120150724?type=companyNews
174,"  (Adds Investindustrial, Pleasant Lake Partners, Bristol-Myers Squibb; updates Fiat Chrysler, Berkshire Hathaway)Aug 31 The following bids, mergers, acquisitions and disposals were reported by 2030 GMT on Monday:** It would be ""unconscionable"" for Fiat Chrysler Automobiles (FCA) not to pursue a merger with rival General Motors and create a company that can generate $30 billion a year in cash, FCA chief Sergio Marchionne said in a newspaper interview.** Warren Buffett's Berkshire Hathaway Inc  disclosed a $4.48 billion stake in oil refiner Phillips 66 PSX.N, rebuilding a bet it had made in the energy industry before oil prices fell.** Japan's Suzuki Motor Corp said on Sunday it would buy back the 19.9 percent stake it sold to Volkswagen AG  after an international arbitration court ordered the German automaker to sell its holding. Their planned partnership soured with Japanese automaker accusing VW of seeking to control it and filing for arbitration in November 2011. VW's stake, acquired in January 2010 for 1.7 billion euros ($1.9 billion), was worth some $3.8 billion at Friday's closing price.** Italian private equity firm Investindustrial has been discussing for months with French luxury group Kering  a possible purchase of its Sergio Rossi shoe brand but a deal is still far away, a source close to the matter said on Monday. ** Chinese financial regulators encouraged listed firms on Monday to merge, offer cash dividends and buy back shares to support volatile stock markets, a joint statement from four government agencies on the market regulator's website showed.** Investment firm Pleasant Lake Partners LLC offered to buy analog chipmaker MagnaChip Semiconductor Corp in a deal valuing the South Korea-based company at about $346 million. ** Drugmaker Bristol-Myers Squibb said it bought rights to a mid-stage fibrosis drug and its privately held developer for up to $1.25 billion, boosting its pipeline for drugs that treat tissue scarring.** Ageas has agreed to sell its Hong Kong insurance unit to a China-based asset manager JD Capital for HK$10.7 billion ($1.4 billion), the Belgian insurer said in a statement on Sunday, exiting a business it acquired eight years ago.** German media Group Bertelsmann will consider raising its stake in book publisher Penguin Random House, it said on Monday, now that shares in the joint venture with Pearson could come on the market. ** Swiss flavours and fragrances group Givaudan  said on Monday it would buy Induchem Holding AG, in a move to strengthen its active cosmetic business.** German insurer Allianz SE has joined Borealis Infrastructure, which manages investments for Canada's Ontario Municipal Employees Retirement Systems, to explore a bid for London City Airport, a source familiar with the process said.** Finland's largest telecoms operator Elisa said on Monday that it opposed plans by its takeover target Anvia to go public and still aimed to increase its stake in its smaller rival.** Polish utilities are more likely to buy stakes in a special fund partly aimed at rescuing the mining industry than invest directly in troubled miner Kompania Weglowa, PAP news agency quoted the treasury minister as saying.** Kellogg's South African unit will urge competition authorities to block a proposed merger between rivals Pioneer Foods and Futurelife, regulators said on Monday.     (Compiled by Manish Parashar and Yashaswini Swamynathan in Bengaluru)",2015-08-31,BMY,"Mon Aug 31, 2015 | 4:36pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL4N11631N20150831?type=companyNews
175,"  Drugmaker Bristol-Myers Squibb said it bought rights to a mid-stage fibrosis drug and its privately held developer for up to $1.25 billion, boosting its pipeline for drugs that treat tissue scarring.The deal gives Bristol-Myers access to Promedior Inc's lead experimental drug, PRM-151, which is being tested to treat two types of fibrosis.PRM-151 is undergoing trials as a treatment for the lung condition, idiopathic pulmonary fibrosis, and a form of blood disorder called myelofibrosis.Myelofibrosis, a condition that affects the bone marrow, is classified as a rare disease by the U.S. National Institutes of Health.The only drug approved by the U.S. Food and Drug Administration to treat myelofibrosis is Incyte Corp's Jakafi, which raked in about $258 million in sales for the six months ended June 30. Bristol-Myers has four experimental fibrosis drugs in its pipeline, two of them in mid-stage and two in early studies.Promedior's mid-stage studies of its fibrosis drug are expected to begin in the next few weeks, Bristol-Myers said on Monday.  Lexington, Massachusetts-based Promedior is backed by healthcare investors including British drugmaker Shire Plc. Bristol-Myers said rights to buy Promedior could be exercised after the completion of either of the studies.  The deal includes an upfront cash payment of $150 million for the right to acquire Promedior.  Bristol-Myers' shares were little changed at $60.95 in early trading on the New York Stock Exchange.  (Reporting by Vidya L Nathan in Bengaluru; Editing by Sriraj Kalluvila)",2015-08-31,BMY,"Mon Aug 31, 2015 | 9:41am EDT",Bristol-Myers buys rights to acquire fibrosis drug developer,http://www.reuters.com//article/us-bristol-myers-deals-fibrosis-idUSKCN0R017Z20150831?type=companyNews
176,"  (Adds details, background)Aug 31 Drugmaker Bristol-Myers Squibb  said it bought rights to a mid-stage fibrosis drug and its privately held developer for up to $1.25 billion, boosting its pipeline for drugs that treat tissue scarring.The deal gives Bristol-Myers access to Promedior Inc's lead experimental drug, PRM-151, which is being tested to treat two types of fibrosis.PRM-151 is undergoing trials as a treatment for the lung condition, idiopathic pulmonary fibrosis, and a form of blood disorder called myelofibrosis.Myelofibrosis, a condition that affects the bone marrow, is classified as a rare disease by the U.S. National Institutes of Health. The only drug approved by the U.S. Food and Drug Administration to treat myelofibrosis is Incyte Corp's  Jakafi, which raked in about $258 million in sales for the six months ended June 30.Bristol-Myers has four experimental fibrosis drugs in its pipeline, two of them in mid-stage and two in early studies. Promedior's mid-stage studies of its fibrosis drug are expected to begin in the next few weeks, Bristol-Myers said on Monday.Lexington, Massachusetts-based Promedior is backed by healthcare investors including British drugmaker Shire Plc . Bristol-Myers said rights to buy Promedior could be exercised after the completion of either of the studies.The deal includes an upfront cash payment of $150 million for the right to acquire Promedior.Bristol-Myers' shares were little changed at $60.95 in early trading on the New York Stock Exchange.     (Reporting by Vidya L Nathan in Bengaluru; Editing by Sriraj Kalluvila)",2015-08-31,BMY,"Mon Aug 31, 2015 | 9:39am EDT",UPDATE 1-Bristol-Myers buys rights to acquire fibrosis drug developer,http://www.reuters.com//article/bristol-myers-deals-fibrosis-idUSL4N11642V20150831?type=companyNews
177,"  Aug 31 Drugmaker Bristol-Myers Squibb  said it would buy the worldwide rights to a mid-stage fibrosis drug from privately held Promedior Inc for up to $1.25 billion. Bristol-Myers said the deal, which includes a $150 million upfront payment, also gives it the right to buy the smaller developer.    (Reporting by Vidya L Nathan in Bengaluru; Editing by Sriraj Kalluvila)  ",2015-08-31,BMY,"Mon Aug 31, 2015 | 8:42am EDT",Bristol-Myers buys rights to fibrosis drug for up to $1.25 bln,http://www.reuters.com//article/bristol-myers-deals-fibrosis-idUSL4N11641T20150831?type=companyNews
178,"   By Ransdell Pierson  An early-stage study shows Bristol-Myers Squibb Co's Opdivo treatment can be safely and effectively paired with relatively low and infrequent dosages of the company's other immunotherapy, Yervoy, for patients with previously untreated lung cancer, researchers said on Monday.Opdivo, whose chemical name is nivolumab, is approved to treat advanced melanoma and the less-common squamous type of non-small cell lung cancer. In a recent late-stage study, it improved survival compared with chemotherapy in previously treated patients with the more common non-squamous form of lung cancer.To bolster the effectiveness of Opdivo, Bristol-Myers is testing it in combination with Yervoy, which is approved to treat melanoma and, like Opdivo, takes the brakes off the immune system.Company researchers on Monday released updated data from a Phase I study, called Check Mate-12, that involved 148 previously untreated patients with squamous and non-squamous lung cancer. It compared results of four available drug regimens that paired Opdivo and Yervoy.In melanoma studies, Opdivo's effectiveness has been greatly enhanced by adding Yervoy, but with a worrisome increase in side effects. Yervoy, typically taken in 3 milligram doses every three weeks for melanoma, in the lung cancer trial was given at a 1 milligram dose every six weeks in one arm of the study, and at 1 milligram every 12 weeks in another arm. It was taken with 3 milligram doses of Opdivo every two weeks, the way it is used against melanoma and previously treated squamous lung cancer.Some 39 percent of patients taking Opdivo plus Yervoy every 12 weeks saw some reduction in tumors, similar to the 31 percent reduction for those taking Yervoy every 6 weeks.Importantly, 10 percent or fewer of patients in the two arms dropped out of the study because of side effects, little different from those who have taken Opdivo alone in other study arms and half the dropout rate seen among patients that have taken Opdivo with chemotherapy. ""A well tolerated regimen has been achieved, with ability to maintain the additive benefit of (Yervoy)"" to Opdivo, Michael Giordano, head of Bristol-Myers' immuno-oncology program, said in an interview.Opdivo and a similar treatment from Merck & Co called Keytruda block a protein called PD-1 whose natural function is to put checks on the immune system. Wall Street expects such drugs to capture combined annual sales of over $20 billion by 2020.   Results of the study were released at the World Conference on Lung Cancer being held in Denver.  (Reporting by Ransdell Pierson; Editing by Richard Chang)",2015-09-07,BMY,"Mon Sep 7, 2015 | 12:56pm EDT",Bristol pairs Yervoy safely with Opdivo vs lung cancer,http://www.reuters.com//article/us-bristol-myers-cancer-opdivo-idUSKCN0R71W420150907?type=companyNews
179,"  * Opdivo survival 25 months vs 19.6 for Afinitor - study* Sets up drug to be used beyond melanoma and lung cancerBy Ben HirschlerSept 26 Bristol-Myers Squibb's  immunotherapy drug Opdivo extended kidney cancer survival rates by more than two years in a late-stage trial, setting it up to be used beyond melanoma and lung cancer.The U.S. company said in July the study was stopped early because its drug was more effective than Novartis'  established product Afinitor, but detailed results were only disclosed at the European Cancer Congress in Vienna on Saturday.The successful outcome means Opdivo is the first so-called immune checkpoint inhibitor drug to show an improvement in overall survival in patients with renal cell carcinoma (RCC), a common type of kidney cancer. Opdivo is already approved for melanoma and lung cancer, with most attention focused on the big lung cancer opportunity. But analysts noted that RCC prevalence was twice that of melanoma, pointing to significant commercial upside.Drugs like Opdivo work by targeting molecules that play an important role in the immune system's ability to recognise and attack tumours.Padmanee Sharma of the U.S. MD Anderson Cancer Center, one of the lead researchers on the study, said patients taking Opdivo had a median overall survival of 25 months as compared to 19.6 months for those taking Afinitor. A greater proportion of patients also had tumours that shrank in response to the Bristol drug than to the Novartis one, with an objective response rate of 25 percent for Opdivo against 5 percent for Afinitor.""The results are significant and clinically meaningful to patients and healthcare professionals alike,"" Sharma said. ""They are likely to change the treatment of patients with advanced kidney cancer, whose disease has progressed on prior treatment.""The findings were also published online in the New England Journal of Medicine. Michael Giordano, Bristol's head of oncology development, told Reuters the company was working towards filing Opdivo for approval in kidney cancer ""very quickly"" but he declined to give a precise date for submission to regulators.Analysts at Morgan Stanley believe Opdivo could be approved for the new use by early 2016 and the U.S. National Comprehensive Cancer Network might endorse its off-label in kidney cancer before the end of 2015.Bristol is also a testing a combination of Opdivo and its drug Yervoy as a first-line treatment for kidney cancer.Opdivo is a so-called PD-1 inhibitor that blocks a mechanism tumours use to hide from the immune system. It competes with Merck's Keytruda.AstraZeneca, Roche and other drugmakers are also developing similar drugs known as PD-L1 inhibitors.   (Editing by David Clarke, Greg Mahlich)",2015-09-25,BMY,"Fri Sep 25, 2015 | 6:00pm EDT",Bristol's Opdivo boosts kidney cancer survival beyond two years,http://www.reuters.com//article/health-cancer-bristol-idUSL5N11S42L20150925?type=companyNews
180,"   By Bill Berkrot and Vidya L Nathan  The U.S. Food and Drug Administration on Thursday approved the first combination of two drugs that help the immune system fight cancer, a therapy regimen that could cost $256,000 a year.Bristol-Myers Squibb Co said the FDA had given the green light to combine its immuno-oncology drugs Opdivo and Yervoy to treat advanced or inoperable melanoma, the deadliest form of skin cancer, in patients who do not have a mutation of a gene called BRAF.The approval sets the scene for many more such combinations of expensive treatments currently undergoing clinical trials by numerous drugmakers at a time when the soaring cost of prescription medicines have come under intense criticism from politicians, medical societies and patient advocacy groups alike.Merck & Co, for example, is testing its Opdivo rival, Keytruda, in combination with other cancer treatments in at least 10 studies.The accelerated approval was based on results of a trial in which far more patients responded to the combination than to Yervoy alone, and is contingent on Bristol-Myers replicating those results in a larger ongoing Phase III study. Four doses of the combination would cost $141,000, about 6 percent more than the cost of Yervoy alone. Those who respond to the combination would continue receiving Opdivo alone, bringing the cost for a year of treatment to $256,000, a Bristol-Myers spokeswoman told Reuters.Opdivo and Yervoy, bought separately, would cost about $295,000 for just under a year's treatment, according to calculations by cancer specialist Leonard Saltz.The drugs block mechanisms which cancer uses to keep the immune system from attacking tumors. Wall Street analysts forecast sales of immuno-oncology drugs exceeding $20 billion a year by 2020. In the trial that led to approval, 60 percent of combination patients experienced significant tumor shrinkage, including 17 percent who were cancer free, compared with an 11 percent response rate for Yervoy alone.The combination delayed worsening of the cancer for an average of 8.9 months, only four months longer than for Yervoy. Bristol does not yet have data available showing the combination helps patients live longer, likely critical to wide acceptance by doctors.Yervoy was approved in 2011 and Opdivo in late 2014. The two drugs had sales of $783 million in the first half of this year. There are about 11,000 U.S. patients with untreated advanced melanoma. Those without the BRAF gene mutation account for 55 percent to 60 percent of cases, Bristol said.The company is also testing the combination in kidney cancer and the far-larger lung cancer population.Bristol-Myers shares were last up 40 cents at $59.60 in early afternoon trading on the New York Stock Exchange. (Reporting by Bill Berkrot in New York and Vidya L Nathan in Bengaluru; editing by Kirti Pandey,  Savio D'Souza and G Crosse)",2015-10-01,BMY,"Thu Oct 1, 2015 | 12:50pm EDT",FDA approves costly Bristol-Myers drug combo for melanoma,http://www.reuters.com//article/us-bristol-myers-fda-idUSKCN0RV4B020151001?type=companyNews
181,"  * First-ever approval of immuno-oncology combination - company* Two-drug combination to cost $256,000 a year* Drugs separately cost $295,000 a year - cancer specialist   (Recasts; adds study details, patient population size)By Bill Berkrot and Vidya L NathanOct 1 The U.S. Food and Drug Administration on Thursday approved the first combination of two drugs that help the immune system fight cancer, a therapy regimen that could cost $256,000 a year.Bristol-Myers Squibb Co said the FDA had given the green light to combine its immuno-oncology drugs Opdivo and Yervoy to treat advanced or inoperable melanoma, the deadliest form of skin cancer, in patients who do not have a mutation of a gene called BRAF.The approval sets the scene for many more such combinations of expensive treatments currently undergoing clinical trials by numerous drugmakers at a time when the soaring cost of prescription medicines have come under intense criticism from politicians, medical societies and patient advocacy groups alike. Merck & Co, for example, is testing its Opdivo rival, Keytruda, in combination with other cancer treatments in at least 10 studies.The accelerated approval was based on results of a trial in which far more patients responded to the combination than to Yervoy alone, and is contingent on Bristol-Myers replicating those results in a larger ongoing Phase III study.Four doses of the combination would cost $141,000, about 6 percent more than the cost of Yervoy alone. Those who respond to the combination would continue receiving Opdivo alone, bringing the cost for a year of treatment to $256,000, a Bristol-Myers spokeswoman told Reuters. Opdivo and Yervoy, bought separately, would cost about $295,000 for just under a year's treatment, according to calculations by cancer specialist Leonard Saltz.The drugs block mechanisms which cancer uses to keep the immune system from attacking tumors. Wall Street analysts forecast sales of immuno-oncology drugs exceeding $20 billion a year by 2020.In the trial that led to approval, 60 percent of combination patients experienced significant tumor shrinkage, including 17 percent who were cancer free, compared with an 11 percent response rate for Yervoy alone. The combination delayed worsening of the cancer for an average of 8.9 months, only four months longer than for Yervoy. Bristol does not yet have data available showing the combination helps patients live longer, likely critical to wide acceptance by doctors.Yervoy was approved in 2011 and Opdivo in late 2014. The two drugs had sales of $783 million in the first half of this year.There are about 11,000 U.S. patients with untreated advanced melanoma. Those without the BRAF gene mutation account for 55 percent to 60 percent of cases, Bristol said.The company is also testing the combination in kidney cancer and the far-larger lung cancer population.Bristol-Myers shares were last up 40 cents at $59.60 in early afternoon trading on the New York Stock Exchange.   (Reporting by Bill Berkrot in New York and Vidya L Nathan in Bengaluru; editing by Kirti Pandey,  Savio D'Souza and G Crosse)",2015-10-01,BMY,"Thu Oct 1, 2015 | 12:47pm EDT",UPDATE 3-FDA approves costly Bristol-Myers drug combo for melanoma,http://www.reuters.com//article/bristol-myers-fda-idUSL3N1213HR20151001?type=companyNews
182,"  Oct 1 Drugmaker Bristol-Myers Squibb Co  said its combination of two treatments to treat a form of skin cancer was approved for marketing by the U.S. Food and Drug Administration. The company said the approval was based on a late-stage study that showed the two drugs, Opdivo and Yervoy, were better at treating skin cancer than Yervoy alone.    (Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D'Souza)  ",2015-10-01,BMY,"Thu Oct 1, 2015 | 7:13am EDT",FDA approves Bristol Myers' combination treatment for skin cancer,http://www.reuters.com//article/bristol-myers-fda-idUSL3N1213H820151001?type=companyNews
183,"  (Adds analyst comment, updates share prices)By Deena Beasley and Natalie GroverOct 2 The U.S. Food and Drug Administration on Friday approved Merck & Co Inc's immunotherapy, Keytruda, for patients with the most common form of lung cancer whose tumors produce a specific biological marker.The FDA approval for Keytruda in advanced non-small cell lung cancer is for patients whose tumors express PD-L1, a protein targeted by the drug, and includes a companion diagnostic, made by a unit of Agilent Technologies Inc, to measure those protein levels. A Merck spokeswoman said clinical trials found that 22 percent of patients with this type of cancer had PD-L1 scores of at least 50 percent.""The restricted label is generally in line with expectations and is likely to broaden over time as data from additional trials support Keytruda's efficacy in a larger patient population,"" JP Morgan analyst Chris Schott said in a research note.The FDA decision ""has the potential to transform the way that lung cancer is treated,"" Dr. Edward Garon, associate clinical professor at the University of California, Los Angeles and a lead investigator on Keytruda clinical trials, said in a statement. Merck said the price of Keytruda for health insurers and other payers is around $12,500 per month, or $150,000 a year.Keytruda and another similar treatment from Bristol-Myers Squibb Co called Opdivo are antibodies designed to block the interaction between PD-L1 and another protein, PD-1, whose natural function is to put checks on the immune system. By blocking the interaction, the drugs aim to enable the patient's own immune system to attack the cancer. Wall Street analysts expect cancer immunotherapies to earn combined annual sales of over $20 billion by 2020.Bristol's Opdivo is approved by the FDA to treat melanoma as well as squamous non-small cell lung cancer, a smaller subset of the disease, but without a requirement for protein testing.Keytruda, now approved for both squamous and non-squamous non-small cell lung cancer, is also approved to treat patients with advanced melanoma. (1.usa.gov/1P9wW3p) Lung cancer is the leading cause of cancer deaths in the United States with an estimated 221,000 new cases diagnosed and 158,000 deaths this year, according to the National Cancer Institute.Shares of Merck rose 1.6 percent, or 77 cents, to close at $50.14 Friday on the New York Stock Exchange, while shares of Bristol-Myers rose 3.6 percent, or $2.18, to close at $62.23.(Reporting by Natalie Grover in Bengaluru and Deena Beasley in Los Angeles; Editing by Bernadette Baum and Lisa Shumaker)",2015-10-02,BMY,"Fri Oct 2, 2015 | 4:19pm EDT",UPDATE 3-U.S. FDA expands approval of Merck's Keytruda to lung cancer,http://www.reuters.com//article/merck-co-fda-idUSL3N12235920151002?type=companyNews
184,"   By Bill Berkrot  The U.S. Food and Drug Administration on Friday expanded its approval of Bristol-Myers Squibb Co's immunotherapy drug Opdivo for patients with an additional form of advanced lung cancer.The agency said Opdivo may now be used in patients with non-squamous non-small cell lung cancer (NSCLC) whose disease has progressed during or after platinum-based chemotherapy.Opdivo, known chemically as nivolumab, was first approved to treat advanced melanoma, the deadliest form of skin cancer, and later for squamous non-small cell lung cancer.While the expanded approval was widely expected based on clinical trial data, the FDA announcement came about three months ahead of the agency's mid-January action data. Lung cancer has a far larger patient population than melanoma, with NSCLC accounting for up to 90 percent of all cases, and is seen as a more lucrative use for the new medicines like Opdivo that help the immune system fight the disease.Lung cancer is the leading cause of cancer death in the United States, with an estimated 221,200 new diagnoses and 158,040 deaths in 2015, the FDA said. The squamous cell variety accounts about 25 percent to 30 percent of NSCLC cases, with non-squamous accounting for about 45 percent to 60 percent. Squamous and non-squamous refers to the type of cells in which the cancer occurs, and they tend to be situated in different parts of the lung.Opdivo competes with an immunotherapy drug from Merck & Co called Keytruda. Bristol recently began a high-profile direct-to-consumer ad campaign for Opdivo in lung cancer, with commercials running on prime-time network television shows. Bristol-Myers shares were up 58 cents, or about 1 percent, at $61.09 on the New York Stock Exchange.  (Reporting by Bill Berkrot in New York; Additional reporting by Shailesh Kuber in Bengaluru; Editing by Leslie Adler)",2015-10-09,BMY,"Fri Oct 9, 2015 | 3:09pm EDT",FDA expands lung cancer approval for Bristol-Myers' drug,http://www.reuters.com//article/us-bristol-myers-fda-idUSKCN0S329B20151009?type=companyNews
185,"  (Adds approval details, patient population, background, share price, byline)By Bill BerkrotOct 9 The U.S. Food and Drug Administration on Friday expanded its approval of Bristol-Myers Squibb Co's  immunotherapy drug Opdivo for patients with an additional form of advanced lung cancer.The agency said Opdivo may now be used in patients with non-squamous non-small cell lung cancer (NSCLC) whose disease has progressed during or after platinum-based chemotherapy. Opdivo, known chemically as nivolumab, was first approved to treat advanced melanoma, the deadliest form of skin cancer, and later for squamous non-small cell lung cancer.While the expanded approval was widely expected based on clinical trial data, the FDA announcement came about three months ahead of the agency's mid-January action data. Lung cancer has a far larger patient population than melanoma, with NSCLC accounting for up to 90 percent of all cases, and is seen as a more lucrative use for the new medicines like Opdivo that help the immune system fight the disease.Lung cancer is the leading cause of cancer death in the United States, with an estimated 221,200 new diagnoses and 158,040 deaths in 2015, the FDA said. The squamous cell variety accounts about 25 percent to 30 percent of NSCLC cases, with non-squamous accounting for about 45 percent to 60 percent. Squamous and non-squamous refers to the type of cells in which the cancer occurs, and they tend to be situated in different parts of the lung.Opdivo competes with an immunotherapy drug from Merck & Co  called Keytruda. Bristol recently began a high-profile direct-to-consumer ad campaign for Opdivo in lung cancer, with commercials running on prime-time network television shows.Bristol-Myers shares were up 58 cents, or about 1 percent, at $61.09 on the New York Stock Exchange.    (Reporting by Bill Berkrot in New York; Additional reporting by Shailesh Kuber in Bengaluru; Editing by Leslie Adler)",2015-10-09,BMY,"Fri Oct 9, 2015 | 3:04pm EDT",UPDATE 1-FDA expands lung cancer approval for Bristol-Myers' drug,http://www.reuters.com//article/bristol-myers-fda-idUSL3N1294VD20151009?type=companyNews
186,  Oct 14 Innate Pharma SA :* Has received a $5 million milestone payment from Bristol-Myers Squibb as part of lirilumab licencing agreement* Payment was triggered by dosing of a first patient in a Phase II trial of lirilumab in combination with rituximab in patients with relapsed/ refractory or high-risk untreated Chronic Lymphocytic Leukemia * CEO expects that results will begin to be delivered in 2016 Source text for Eikon: Further company coverage:    (Gdynia Newsroom),2015-10-14,BMY,"Wed Oct 14, 2015 | 1:42am EDT",BRIEF-Innate Pharma receives development milestone payment from Bristol-Myers Squibb,http://www.reuters.com//article/idUSFWN12D00U20151014?type=companyNews
187,"  Bristol-Myers Squibb Co said on Thursday it agreed to exclusively license and collaborate with Five Prime Therapeutics Inc to develop and commercialize Five Prime's antibody program in the treatment of cancer.Five Prime will receive $350 million upfront and potential development and regulatory milestone payments, totaling $1.74 billion, for the program which includes the drug component codenamed FPA008. The drug component, which is in Phase 1 development, belongs to a new class of drugs called immunotherapies, designed to harness body's own immune system to fight cancer. The global deal includes additional double-digit royalties on future sales and an option to co-promote in the United States, the companies said in a statement. [nGNXVEPOXa]   (Reporting by Ismail Shakil in Bengaluru; Editing by Gopakumar Warrier)",2015-10-15,BMY,"Thu Oct 15, 2015 | 6:02am EDT","Bristol-Myers, Five Prime enter licensing deal of up to $1.74 billion",http://www.reuters.com//article/five-prime-bristol-myers-idUSKCN0S90WT20151015?type=companyNews
188,"  Oct 15 Bristol-Myers Squibb Co said on Thursday it agreed to exclusively license and collaborate with Five Prime Therapeutics Inc to develop and commercialize Five Prime's antibody program in the treatment of cancer.Five Prime will receive $350 million upfront and potential development and regulatory milestone payments, totaling $1.74 billion, for the program which includes the drug component codenamed FPA008. The drug component, which is in Phase 1 development, belongs to a new class of drugs called immunotherapies, designed to harness body's own immune system to fight cancer.  The global deal includes additional double-digit royalties on future sales and an option to co-promote in the United States, the companies said in a statement.    (Reporting by Ismail Shakil in Bengaluru; Editing by Gopakumar Warrier)",2015-10-15,BMY,"Thu Oct 15, 2015 | 5:17am EDT","Bristol-Myers, Five Prime enter licensing deal of up to $1.74 bln",http://www.reuters.com//article/five-prime-bristol-myers-idUSL3N12F3D420151015?type=companyNews
189,"  Bristol-Myers Squibb Co (BMY.N) on Tuesday reported better than expected quarterly earnings, fueled by surging sales of its recently approved Opdivo immuno-oncology drug, hepatitis C treatments and its Eliquis blood clot preventer.Company shares rose 1.9 percent in premarket trading.Bristol-Myers is considered the leader among drugmakers racing to develop a new wave of cancer treatments that harness the immune system, including Opdivo. This treatment was approved in December for advanced melanoma and was approved in March to treat the less-common squamous type of non-small cell lung cancer.    Sales of Opdivo reached $305 million the third quarter, about $65 million higher than Wall Street forecasts, putting it on track to become a blockbuster product. Like Merck & Co's (MRK.N) similar new Keytruda treatment, it works by blocking a protein called PD-1 that hides tumors from the immune system.     But sales of Yervoy, an older Bristol-Myers treatment for melanoma, fell 31 percent to $240 million, as doctors reached instead for more-potent Opdivo and Keytruda.   Eliquis, approved in 2012 to prevent blood clots among patients with an irregular heartbeat called atrial fibrillation, and also used to prevent clots in patients that have undergone orthopedic surgery, has seemingly caught fire as more doctors have become familiar with its impressive clinical trial data. Sales of the pill, meant to be a safer and more convenient  alternative to an older oral blood clot preventer called warfarin, more than doubled to $466 million in the quarter.     The company said it earned $706 million, or 42 cents per share, in the third quarter. That compared with $721 million, or 43 cents per share, in the year-earlier period.     Excluding special items, Bristol-Myers earned 39 cents per share. Analysts, on average, expected 35 cents per share, according to Thomson Reuters I/B/E/S.    Company revenue rose 4 percent to $4.07 billion, topping Wall Street forecasts of $3.86 billion.  Shares were trading at $65.75 in premarket trading, up from their closing price of $64.55 Monday on the New York Stock Exchange.   (Reporting by Ransdell Pierson; Editing by Chizu Nomiyama)",2015-10-27,BMY,"Tue Oct 27, 2015 | 7:40am EDT","Bristol cancer, clot drugs drive profit beat, shares rise",http://www.reuters.com//article/us-bristolmyers-results-idUSKCN0SL1A720151027?type=companyNews
190,"  (Adds details on product sales, company background, share prices)Oct 27 Bristol-Myers Squibb Co on Tuesday reported better than expected quarterly earnings, fueled by surging sales of its recently approved Opdivo immuno-oncology drug, hepatitis C treatments and its Eliquis blood clot preventer.Company shares rose 1.9 percent in premarket trading.Bristol-Myers is considered the leader among drugmakers racing to develop a new wave of cancer treatments that harness the immune system, including Opdivo. This treatment was approved in December for advanced melanoma and was approved in March to treat the less-common squamous type of non-small cell lung cancer. Sales of Opdivo reached $305 million the third quarter, about $65 million higher than Wall Street forecasts, putting it on track to become a blockbuster product. Like Merck & Co's  similar new Keytruda treatment, it works by blocking a protein called PD-1 that hides tumors from the immune system.But sales of Yervoy, an older Bristol-Myers treatment for melanoma, fell 31 percent to $240 million, as doctors reached instead for more-potent Opdivo and Keytruda. Eliquis, approved in 2012 to prevent blood clots among patients with an irregular heartbeat called atrial fibrillation, and also used to prevent clots in patients that have undergone orthopedic surgery, has seemingly caught fire as more doctors have become familiar with its impressive clinical trial data. Sales of the pill, meant to be a safer and more convenient  alternative to an older oral blood clot preventer called warfarin, more than doubled to $466 million in the quarter.The company said it earned $706 million, or 42 cents per share, in the third quarter. That compared with $721 million, or 43 cents per share, in the year-earlier period. Excluding special items, Bristol-Myers earned 39 cents per share. Analysts, on average, expected 35 cents per share, according to Thomson Reuters I/B/E/S.Company revenue rose 4 percent to $4.07 billion, topping Wall Street forecasts of $3.86 billion.Shares were trading at $65.75 in premarket trading, up from their closing price of $64.55 Monday on the New York Stock Exchange.   (Reporting by Ransdell Pierson; Editing by Chizu Nomiyama)",2015-10-27,BMY,"Tue Oct 27, 2015 | 7:39am EDT","UPDATE 1-Bristol cancer, clot drugs drive profit beat, shares rise",http://www.reuters.com//article/bristolmyers-results-idUSL1N12R0N520151027?type=companyNews
191,"  Oct 27 Bristol-Myers Squibb Co reported better than expected quarterly earnings, fueled by surging sales of its recently approved Opdivo immuno-oncology drug, hepatitis C treatments and its Eliquis blood clot preventer.The company said it earned $706 million, or 42 cents per share, in the third quarter. That compared with $721 million, or 43 cents per share, in the year-earlier period. Excluding special items, Bristol-Myers earned 39 cents per share. Analysts, on average, excepted 35 cents per share, according to Thomson Reuters I/B/E/S. Company revenue rose 4 percent to $4.07 billion, topping Wall Street forecasts of $3.86 billion. (Reporting by Ransdell Pierson; Editing by Chizu Nomiyama)",2015-10-27,BMY,"Tue Oct 27, 2015 | 7:10am EDT","Bristol beats forecasts as cancer, blood clot drugs deliver",http://www.reuters.com//article/bristolmyers-results-idUSASB0ACAT20151027?type=companyNews
192,"  The U.S. Food and Drug Administration expanded the use of Bristol-Myers Squibb Co's skin cancer drug, Yervoy, as an additional therapy for patients with late-stage melanoma.This approval extends Yervoy's use to patients with stage III melanoma, who have a high risk of recurrence after surgery, the agency said on Wednesday. Due to the potential for fatal adverse reactions and unusual severe side effects with Yervoy, the drug's label carries a boxed warning - reserved for the most serious of risks.Treatment for stage III patients has historically been challenging, with fewer options available. A diagnosis means that melanoma cells have been found in lymph nodes, and that the patient will require surgery. Yervoy, administered intravenously, was originally approved in 2011 to treat late-stage melanoma that cannot be removed by surgery. Melanoma is the most aggressive type of skin cancer, and  will lead to an estimated 73,870 new cases and 9,940 deaths this year, the National Cancer Institute estimates.       Yervoy blocks a molecule known as CTLA-4, which may play a role in slowing down or turning off the immune system, and affects its ability to fight off cancerous cells. The drug, known chemically as ipilimumab, raked in global sales of $240 million in the quarter ended Sept. 30, 2015.Bristol-Myers' stock was little changed on the New York Stock Exchange after the bell on Wednesday,      (Reporting by Samantha Kareen Nair and Natalie Grover in Bengaluru; Editing by Anil D'Silva and Christian Plumb)",2015-10-28,BMY,"Wed Oct 28, 2015 | 6:41pm EDT",FDA expands use of Bristol Myers' cancer drug Yervoy,http://www.reuters.com//article/us-bristol-myers-fda-idUSKCN0SM2VM20151028?type=companyNews
193,"  (Adds details, shares)Oct 28 The U.S. Food and Drug Administration expanded the use of Bristol-Myers Squibb Co's skin cancer drug, Yervoy, as an additional therapy for patients with late-stage melanoma.This approval extends Yervoy's use to patients with stage III melanoma, who have a high risk of recurrence after surgery, the agency said on Wednesday. (1.usa.gov/1N95rXl)Due to the potential for fatal adverse reactions and unusual severe side effects with Yervoy, the drug's label carries a boxed warning - reserved for the most serious of risks. Treatment for stage III patients has historically been challenging, with fewer options available. A diagnosis means that melanoma cells have been found in lymph nodes, and that the patient will require surgery.Yervoy, administered intravenously, was originally approved in 2011 to treat late-stage melanoma that cannot be removed by surgery. Melanoma is the most aggressive type of skin cancer, and  will lead to an estimated 73,870 new cases and 9,940 deaths this year, the National Cancer Institute estimates.Yervoy blocks a molecule known as CTLA-4, which may play a role in slowing down or turning off the immune system, and affects its ability to fight off cancerous cells. The drug, known chemically as ipilimumab, raked in global sales of $240 million in the quarter ended Sept. 30, 2015.Bristol-Myers' stock was little changed on the New York Stock Exchange after the bell on Wednesday,(Reporting by Samantha Kareen Nair and Natalie Grover in Bengaluru; Editing by Anil D'Silva and Christian Plumb)",2015-10-28,BMY,"Wed Oct 28, 2015 | 6:32pm EDT",UPDATE 1-FDA expands use of Bristol Myers' cancer drug Yervoy,http://www.reuters.com//article/bristol-myers-fda-idUSL3N12S60120151028?type=companyNews
194,"  (In Oct 27 item, in paragraph 9 corrects number of Ibrance patients to 15,000 from 50,000)By Bill Berkrot and Ransdell PiersonNEW YORK Oct 27 Growing sales of expensive new cancer drugs and other newer medicines propelled top U.S. drugmakers Pfizer Inc, Merck & Co and Bristol-Myers Squibb Co to stronger-than-expected third-quarter profits.The results, announced on Tuesday, demonstrate that the ""patent cliff"" that had been hurting earnings as huge-selling drugs like Pfizer's Lipitor and Bristol's Plavix went generic is now well behind these companies.Shares of all three rose as they also modestly raised their full-year forecasts.Merck's Keytruda and Bristol-Myers' Opdivo, both immunotherapies for advanced melanoma and lung cancer, and Pfizer's Ibrance for breast cancer are off to strong starts, with Wall Street forecasting eventual multibillion-dollar sales. Keytruda and Opdivo list for about $150,000 for a year of treatment, and Ibrance goes for about $118,000.In addition, blood clot and stroke preventer Eliquis, which Pfizer and Bristol share, has begun to take off and is on track for annual sales of nearly $2 billion. ""This is the best innovation-based new product cycle in these companies' storied histories,"" said Suntrust Robinson Humphrey analyst John Boris. ""Eliquis is just knocking the cover off the ball.""Merck and Bristol are testing their new immuno-oncology drugs in numerous combinations and in dozens of different types of cancer.Pfizer said it expected to introduce a drug from the same PD-1 class as Opdivo and Keytruda in 2017, with one or more additional launches each year through 2022. It plans to have 10 new immuno-oncology drugs in clinical testing by next year.The largest U.S. drugmaker said 15,000 U.S. patients had used Ibrance, which is awaiting European approval. It had sales of $230 million for the quarter. ""A whole slew of (future) blockbuster drugs are getting traction today,"" said Tony Scherrer, director of research at Smead Capital Management. ""The pipelines look great.""The three drugmakers all invest heavily in research and development, which led to the new medicines.That stands in stark contrast to the business model of Valeant Pharmaceuticals International, which is known for buying companies and slashing R&D. The Canadian company has come under fire for its business practices, which include sharply raising prices of the drugs it acquires. The high cost of prescription drugs has become a major topic of the current U.S. presidential campaign, with calls by candidates and others to rein in prices and out-of-pocket expenses to patients.Merck Chief Executive Officer Ken Frazier called the pricing discussions ""a lot of noise"" that he does not believe will tarnish the industry's reputation.Pfizer CEO Ian Read said he believed that higher co-pays demanded by insurers were more of a problem for patients than prices charged by drugmakers.""We must preserve the market-based system in the U.S. that enables us to develop breakthrough treatments and cures for patients,"" Read said.Bristol-Myers shares were up 2.5 percent at midday, while Pfizer rose 2.2 percent, and Merck gained 1.4 percent.(Reporting by Bill Berkrot; Editing by Lisa Von Ahn)",2015-10-28,BMY,"Wed Oct 28, 2015 | 11:04am EDT",CORRECTED-WRAPUP 1-Top U.S. drugmakers ride new products to strong results,http://www.reuters.com//article/pharmaceuticals-results-wrapup-1-pix-cor-idUSL1N12R1KO20151028?type=companyNews
195,"   By Vidya L Nathan  Bristol-Myers Squibb Co (BMY.N) said on Monday it bought privately held drug developer Cardioxyl Pharmaceuticals Inc in a deal worth up to $2.07 billion, to gain access to a heart failure treatment.Bristol-Myers said Cardioxyl's CXL-1427, which is in mid-stage studies, would add to its basket of heart treatments that include three experimental treatments in early- and mid-stage studies. At least 5.1 million Americans suffer from heart failure, for which there is no cure, according to the Centers for Disease Control and Prevention. CXL-1427 works by releasing the chemical compound nitroxyl and relaxing the heart muscle, helping it expand and improving blood flow, Bristol-Myers said in a statement. The company said it would pay up $300 million upfront and that it expected the deal to hurt full-year profit by 12 cents per share. Bristol-Myers shares closed at $65.95 on Friday.",2015-11-02,BMY,"Mon Nov 2, 2015 | 11:29am EST",Bristol-Myers buys private drugmaker to boost heart treatment pipeline,http://www.reuters.com//article/us-cardioxyl-m-a-bristol-myers-idUSKCN0SR1AU20151102?type=companyNews
196,"  (Adds details, shares)Nov 2 Bristol-Myers Squibb Co said on Monday it bought privately held drug developer Cardioxyl Pharmaceuticals Inc in a deal worth up to $2.07 billion, to gain access to a heart failure treatment.Bristol-Myers said Cardioxyl's CXL-1427, which is in mid-stage studies, would add to its basket of heart treatments that include three experimental treatments in early- and mid-stage studies. At least 5.1 million Americans suffer from heart failure, for which there is no cure, according to the Centers for Disease Control and Prevention. CXL-1427 works by releasing the chemical compound nitroxyl and relaxing the heart muscle, helping it expand and improving blood flow, Bristol-Myers said in a statement. The company said it would pay up $300 million upfront and that it expected the deal to hurt full-year profit by 12 cents per share.Bristol-Myers shares closed at $65.95 on Friday.   (Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D'Souza)",2015-11-02,BMY,"Mon Nov 2, 2015 | 7:31am EST",UPDATE 1-Bristol-Myers buys private drugmaker to boost heart treatment pipeline,http://www.reuters.com//article/cardioxyl-ma-bristol-myers-idUSL3N12X4C520151102?type=companyNews
197,"  Nov 2 Bristol-Myers Squibb Co said it would buy privately held drug developer Cardioxyl Pharmaceuticals Inc in a deal worth up to $2.07 billion, to gain access to a heart failure treatment. Bristol-Myers said on Monday it would pay up $300 million upfront and that it expected the deal to hurt full-year profit by 12 cents per share.    (Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D'Souza)  ",2015-11-02,BMY,"Mon Nov 2, 2015 | 7:07am EST",Bristol-Myers to buy private drugmaker for up to $2 bln,http://www.reuters.com//article/cardioxyl-ma-bristol-myers-idUSL3N12X4BG20151102?type=companyNews
198,"  (Adds Dixy comment, share price)MOSCOW Nov 13 Russia's competition watchdog FAS has blocked food retailer Dixy Group's bid to buy a controlling stake in tobacco and spirits chain Bristol.The statement from the regulator said Dixy had failed to provide requested materials that would allow FAS to reach a conclusion on whether the deal would damage competition. Dixy declined to comment on the FAS decision but said its board would meet soon to discuss further steps.The company, which owns 33 percent of Bristol, said in June it planned to gain control of the 1,400-store Russian chain by buying more shares from a company controlled by its own biggest shareholder. Some analysts have questioned the deal at a time when Dixy's revenue growth has slowed, hurt by subdued consumer sentiment against a backdrop of high inflation. Dixy Chief Executive Ilya Yakubson flagged in an interview at the Reuters Russia Investment Summit in September that the company might end up scrapping the deal.Its shares closed 1.5 percent higher on Friday against a 0.7 percent drop in the broader market index.   (Reporting by Olga Sichkar and Maria Kiselyova; Editing by David Goodman and David Clarke)",2015-11-13,BMY,"Fri Nov 13, 2015 | 12:23pm EST",UPDATE 1-Russian watchdog rejects retailer Dixy's plan to buy rival Bristol,http://www.reuters.com//article/bristol-ma-dixy-idUSL8N13855420151113?type=companyNews
199,"  (Recasts with company comments on Bristol investment, adds CEO comments on like-for-like sales in Q4 and view on 2016)By Maria KiselyovaMOSCOW Nov 20 Russian food retailer Dixy  said on Friday it could sell its 33 percent interest in tobacco and spirits chain Bristol after Russia's competition watchdog blocked its attempt to take a bigger stake.""There is a high chance that (our) current stake in Bristol project will be sold back to our controlling stakeholders,"" Chief Financial Officer Fedor Rybasov said.He added the board was expected to take a decision in two weeks' time and that there was ""a high chance"" that the sale would be done on the same terms as its acquisition.Russia's No.4 grocery chain by sales, which operates mostly small neighbourhood stores, said in June it planned to gain control of the 1,400-store Bristol after buying 31.8 percent from a firm controlled by its own biggest shareholder. Analysts questioned the deal at a time when Dixy's revenue growth slowed sharply, hurt by subdued consumer sentiment and intensified competition from the discount stores of X5  and Magnit .Dixy cut its 2015 sales growth forecast in August to 16-20 percent from 20-25 percent, saying it had been slow to react to a drop in consumer purchasing power.Chief Executive Ilya Yakubson told analysts on Friday Dixy was sticking to the guidance and expected like-for-like sales in the fourth quarter to grow after they fell 1.8 percent in July-September. He forecast 2016 to be ""much more positive"" than 2015 although said he would not give any guidance until March.INTO THE RED  Russia's competition watchdog FAS last week blocked Dixy's  plan to buy more Bristol shares, saying the firm had failed to provide requested materials.Dixy bought 31.8 percent of Bristol for 1.8 billion roubles  ($28 million) from its controlling shareholder, tobacco distributor Megapolis, in May, adding to the 1.2 percent it already owned.It had said it planned to borrow in order to buy more Bristol shares and by October its net debt had risen to around 36 billion roubles from 25 billion at the end of 2014.Dixy said on Friday a resulting spike in finance costs and a share in Bristol's net losses contributed to its net profit slipping into the red in the third quarter.It made a net loss of 843 million roubles ($13 million) after a profit a year ago, also due to a foreign exchange loss, while its core profit fell because of higher expansion costs.  ($1 = 64.8070 roubles)   (Additional reporting by Anastasia Teterevleva; Editing by Mark Potter and David Evans)",2015-11-20,BMY,"Fri Nov 20, 2015 | 9:13am EST",UPDATE 1-Russia's Dixy says likely to sell stake in rival Bristol,http://www.reuters.com//article/dixy-group-results-idUSL8N13F20720151120?type=companyNews
200,"  A United Nations-backed organization working to cut the price of HIV drugs said it had signed a deal with Bristol-Myers Squibb Co to allow generic versions of the company's hepatitis C drug to be sold in 112 low- and middle-income countries.The drug, Daklinza, is on the World Health Organization's list of essential medicines.Hepatitis C affects about 150 million people globally and kills around half a million each year, the World Health Organisation estimates.The Medicines Patent Pool said on Monday that Daklinza would now be available to nearly two-thirds of people affected by the disease in low- and middle-income countries. The list price in the United States for Daklinza is $63,000 for a 12-week regimen, or about $750 per day at wholesale costs, according to pharmacy benefits manager Express Scripts.Other drugs used to treat hepatitis C include Gilead Sciences' Sovaldi. A single Sovaldi pill costs $1,000 in the United States, according to Express Scripts. The deal with Bristol-Myers allows drugmakers anywhere in the world to develop generic versions of Daklinza. The Medicines Patent Pool had earlier signed a deal with Bristol-Myers for generic versions of its HIV treatment Reyataz. (Reporting by Vidya L Nathan in Bengaluru; Editing by Ted Kerr)",2015-11-23,BMY,"Mon Nov 23, 2015 | 9:23am EST",Bristol-Myers signs deal with U.N. group for generic hepatitis C drug,http://www.reuters.com//article/us-bristol-myers-hepatitis-idUSKBN0TC1GD20151123?type=companyNews
201,"  Bristol-Myers Squibb Co said the U.S. Food and Drug Administration had approved the expanded use of its cancer drug, Opdivo, to treat an additional form of advanced skin cancer.Opdivo, first approved in December 2014, raked in worldwide revenue of $467 million in the nine months ended Sept. 30.The drug has been approved for five other indications in the past 12 months. The company said on Tuesday the approval allows for the drug's use in patients with a previously untreated, advanced form of melanoma and is based on data from a late-stage study comparing the drug with chemotherapy. Opdivo, already in use in patients with forms of lung cancer and with advanced melanoma who have received treatment, belongs to a promising new class of drugs designed to help the body's immune system fight cancer by blocking a protein called programmed death receptor (PD-1). Wall Street expects such drugs to capture combined annual sales of over $20 billion by 2020.  (Reporting by Amrutha Penumudi in Bengaluru; Editing by Sriraj Kalluvila)",2015-11-24,BMY,"Tue Nov 24, 2015 | 7:33am EST",FDA approves expanded use of Bristol-Myers' skin cancer drug,http://www.reuters.com//article/us-bristol-myers-fda-idUSKBN0TD1EF20151124?type=companyNews
202,"  Nov 24 Bristol-Myers Squibb Co said the U.S. Food and Drug Administration had approved the expanded use of its cancer drug, Opdivo, to treat an additional form of advanced skin cancer.Opdivo, first approved in December 2014, raked in worldwide revenue of $467 million in the nine months ended Sept. 30.The drug has been approved for five other indications in the past 12 months. The company said on Tuesday the approval allows for the drug's use in patients with a previously untreated, advanced form of melanoma and is based on data from a late-stage study comparing the drug with chemotherapy. Opdivo, already in use in patients with forms of lung cancer and with advanced melanoma who have received treatment, belongs to a promising new class of drugs designed to help the body's immune system fight cancer by blocking a protein called programmed death receptor (PD-1). Wall Street expects such drugs to capture combined annual sales of over $20 billion by 2020.(Reporting by Amrutha Penumudi in Bengaluru; Editing by Sriraj Kalluvila)",2015-11-24,BMY,"Tue Nov 24, 2015 | 7:31am EST",FDA approves expanded use of Bristol-Myers' skin cancer drug,http://www.reuters.com//article/bristol-myers-fda-idUSL3N13J3EE20151124?type=companyNews
203,"  Bristol-Myers Squibb Co said the U.S. Food and Drug Administration declined to approve its immuno-oncology drug, Opdivo, for its expanded use to treat an additional type of advanced skin cancer.Bristol-Myers said it received a so-called complete response letter from the health regulator, which indicated the need for additional data in the BRAF mutated patient population.The regulator issues a complete response letter when a new or generic treatment cannot be approved in its current form. The FDA approved Opdivo as a single agent for the treatment of patients with BRAF V600 wild-type melanoma earlier this week, but on Friday declined the approval of the drug for treating BRAF V600 mutation positive metastatic melanoma. Opdivo, first approved in December 2014, raked in worldwide revenue of $467 million in the nine months ended Sept. 30. The drug has been approved for five other indications in the past 12 months.Metastatic melanoma is the least common skin cancer. It is also the most deadly because it spreads (metastasizes) quickly and easily to other parts of the body.  (Reporting by Anya George Tharakan in Bengaluru; Editing Siddharth Cavale and Anil D'Silva)",2015-11-27,BMY,"Fri Nov 27, 2015 | 5:10pm EST",FDA declines expanded approval for Bristol-Myers' Opdivo drug,http://www.reuters.com//article/us-bristol-myers-fda-idUSKBN0TG2G820151127?type=companyNews
204,"  The U.S. Food and Drug Administration said on Monday it had approved a drug to be sold by Bristol-Myers Squibb Co as a treatment for a form of blood cancer.The FDA said it approved the treatment, Empliciti, to be used in multiple myeloma patients in combination with Celgene Corp's Revlimid and common anti-inflammatory drug dexamethasone. The National Cancer Institute estimates there will be 26,850 new cases of multiple myeloma and 11,240 related deaths in the United States in 2015. Research has shown that combination treatments increase the time that multiple myeloma patients survive without the disease.The FDA said that Empliciti is the second immuno-oncology treatment for multiple myeloma to be approved, after Johnson & Johnson's Darzalex. Bristol-Myers and AbbVie Inc co-developed the drug, but Empliciti will be sold only by Bristol-Myers.The company is considered the leader among drugmakers racing to develop a new wave of cancer treatments that harness the immune system, including its recently approved immuno-oncology product Opdivo.  Opdivo was approved in December for advanced melanoma and was approved in March to treat the less-common squamous type of non-small cell lung cancer.Sales of Opdivo reached $305 million the latest quarter, putting it on track to become a blockbuster product.  Bristol-Myers shares were down about 1 percent at $67.22 on Monday morning on the New York Stock Exchange. (Reporting by Vidya L Nathan in Bengaluru; Editing by Ted Kerr)",2015-11-30,BMY,"Mon Nov 30, 2015 | 11:12am EST",FDA approves new Bristol-Myers treatment for multiple myeloma,http://www.reuters.com//article/us-bristol-myers-fda-idUSKBN0TJ1ZH20151130?type=companyNews
205,"  Nov 30 The U.S. Food and Drug Administration said on Monday it had approved a drug to be sold by Bristol-Myers Squibb Co as a treatment for a form of blood cancer.The FDA said it approved the treatment, Empliciti, to be used in multiple myeloma patients in combination with Celgene Corp's Revlimid and common anti-inflammatory drug dexamethasone. (1.usa.gov/1lpWQEo)The National Cancer Institute estimates there will be 26,850 new cases of multiple myeloma and 11,240 related deaths in the United States in 2015.Research has shown that combination treatments increase the time that multiple myeloma patients survive without the disease. The FDA said that Empliciti is the second immuno-oncology treatment for multiple myeloma to be approved, after Johnson & Johnson's Darzalex.Bristol-Myers and AbbVie Inc co-developed the drug, but Empliciti will be sold only by Bristol-Myers. The company is considered the leader among drugmakers racing to develop a new wave of cancer treatments that harness the immune system, including its recently approved immuno-oncology product Opdivo. Opdivo was approved in December for advanced melanoma and was approved in March to treat the less-common squamous type of non-small cell lung cancer.Sales of Opdivo reached $305 million the latest quarter, putting it on track to become a blockbuster product.Bristol-Myers shares were down about 1 percent at $67.22 on Monday morning on the New York Stock Exchange.   (Reporting by Vidya L Nathan in Bengaluru; Editing by Ted Kerr)",2015-11-30,BMY,"Mon Nov 30, 2015 | 11:02am EST",FDA approves new Bristol-Myers treatment for multiple myeloma,http://www.reuters.com//article/bristol-myers-fda-idUSL3N13P5JE20151130?type=companyNews
206,"  LONDON Dec 18 British pharmaceutical company GlaxoSmithKline said it would buy HIV drugs at different stages of development from U.S. rival Bristol-Myers Squibb  in a deal which would boost its ViiV Healthcare unit.GSK said it would pay an initial $317 million to buy the late stage assets of Bristol-Myers's HIV research assets and $33 million for the preclinical and discovery stage assets, with both deals subject to further payments of over $500 million dependent on commercial milestones. HIV treatment is one of the strongest parts of GSK's portfolio.  (Reporting by Sarah Young, Editing by Paul Sandle)",2015-12-18,BMY,"Fri Dec 18, 2015 | 2:15am EST",GSK to buy HIV drugs from Bristol-Myers Squibb,http://www.reuters.com//article/bristol-myers-ma-gsk-idUSASM0000RW20151218?type=companyNews
207,"   By Bill Berkrot | NEW YORK  NEW YORK Dec 23 A new class of blood thinners that competes with widely used warfarin should get a boost next year when an ""antidote"" that can reverse the medications' effects in an emergency is expected to enter the market, according to top U.S. heart doctors and investors.Xarelto, from Bayer AG and Johnson & Johnson , and Eliquis, sold by Bristol-Myers Squibb and Pfizer, were approved as safer and more convenient alternatives for preventing blood clots and strokes than warfarin.But there was one hitch: there was no way to quickly restore normal clotting for patients in need of emergency surgery or to stop a major bleeding episode, leading many doctors to hold off on prescribing the drugs.""It may be uncommon, but they're memorable when they happen,"" Dr. Charles Pollack, an emergency physician at Thomas Jefferson University Hospital in Philadelphia, said of major bleeding events.""We didn't have a specific reversal strategy for these drugs, and I think that left people feeling a bit insecure,"" added Pollack, who has done clinical work on a recently approved antidote to Boehringer Ingelheim's rival blood clot preventer Pradaxa.That is about to change.Small drugmaker Portola Pharmaceuticals this month applied for U.S. approval of a drug called andexanet alfa that rapidly reverses the effect of Xarelto and Eliquis. It is expected to enter the market in 2016.""It will make a big difference,"" said Dr. Mariell Jessup, a cardiologist at the University of Pennsylvania Medical Center. ""I have many physicians, particularly surgeons, who hate these drugs. They're frightened of them because they've had to deal with the consequences of somebody coming in with trauma,"" while using the new blood thinners.The new drugs cause fewer major bleeding episodes than warfarin and do not require dietary restrictions or constant monitoring as with the decades-old medicine. But major bleeding remains the most worrisome risk of all anti-coagulant therapy as it can be fatal or cause debilitating, long-term problems. Bristol-Myers reported $466 million in global third-quarter sales of Eliquis, which won U.S. approval at the end of 2012, about 18 months after Xarelto. J&J posted U.S. Xarelto sales of $461 million in the quarter, while Bayer reported about $509 million in international sales.There is still a lot of room to grow as warfarin, also prescribed under the brand name Coumadin, commands some 60 percent of the blood thinner market. Morningstar expects annual sales for Xarelto and Eliquis could reach $8 billion for each.PAYERS SEE VALUE  The treatments are about 70 times more expensive than pennies-a-day warfarin, according to Express Scripts Holding Co , the largest U.S. pharmacy benefits manager. But given the superior safety and convenience, Express Scripts said in a statement that ""the overall value is likely justified.""Health insurer Aetna Inc expects approval of the Portola drug to gradually increase use of Xarelto and Eliquis, said Edmund Pezalla, Aetna's national medical director for pharmaceutical policy and strategy.Xarelto and Eliquis are approved to treat patients with a type of irregular heartbeat called atrial fibrillation that significantly increases stroke risk, as well as to prevent blood clots following hip or knee replacement, and to treat deep vein thrombosis and pulmonary embolism.Paul Burton, vice president of medical affairs for Johnson & Johnson's Janssen unit, stressed Xarelto's safety but said availability of Portola's drug would enhance doctor comfort levels.The Xarelto partnership is seeking additional approved uses, with trials underway in patients with acute coronary syndrome, and for reduction of major adverse cardiovascular events in patients with heart failure or peripheral artery disease. Bristol and Pfizer have a direct-to-consumer television ad campaign to increase Eliquis awareness.""We believe that a reversal agent could be an important consideration for physicians when initiating Eliquis and switching appropriate patients from warfarin to Eliquis,"" Bristol and Pfizer said in a joint statement.Portola's reversal drug ""will certainly help sales. Anybody who was waiting on the sidelines will not be fence-sitting anymore,"" said Les Funtleyder, healthcare portfolio manager for E Squared Capital Management, which holds Pfizer shares.The drug would become Portola's first product on the market.Cowen and Co forecast $355 million in sales by 2020 for the antidote. Portola is also developing a drug to rival Xarelto and Eliquis.Duke University's Dr. Jerrold Levy predicted that all hospitals will stock the Portola antidote.""It increases the safety margin,"" Levy said.(Reporting by Bill Berkrot; Editing by Michele Gershberg and Will Dunham)",2015-12-23,BMY,"Wed Dec 23, 2015 | 7:00am EST",New blood thinner 'antidote' to help doctors move past warfarin,http://www.reuters.com//article/pharmaceuticals-bloodthinners-idUSL1N14A1YE20151223?type=companyNews
208,"  Jan 5 Oncodesign SA :* Oncodesign Biotechnology and Bristol-Myers Squibb  enter into strategic drug discovery collaboration * Goal of collaboration is to generate novel Nanocyclix based compounds for targets of interest to Bristol-Myers Squibb * Oncodesign will receive an upfront payment of $3 million and research, development and regulatory based milestone payments of up to $80 million per target * In addition, Oncodesign is eligible to receive tiered royalties and sales based milestones for each product resulting from collaboration  Source text for Eikon:  Further company coverage:    (Gdynia Newsroom)",2016-01-05,BMY,"Tue Jan 5, 2016 | 1:39am EST",BRIEF-Oncodesign and Bristol-Myers Squibb enter into strategic drug discovery collaboration,http://www.reuters.com//article/idUSFWN14O01D20160105?type=companyNews
209,"   By Ransdell Pierson  Bristol-Myers Squibb Co (BMY.N) on Thursday positioned itself as a potential earnings pacesetter in 2016, with a forecast of up to 19 percent growth that eclipses profit gains expected by most other large drugmakers.Bolstered by blistering sales of its Opdivo immuno-oncology drug and its Eliquis blood clot preventer, Bristol-Myers  expects earnings this year of $2.30 to $2.40 per share. It earned $2.01 per share last year.In contrast, Eli Lilly and Co (LLY.N) on Thursday predicted relatively flat 2016 earnings following strong gains last year, when sales of new cancer and diabetes drugs offset sharp declines in older medicines.Swiss rivals Roche Holding AG ROG.VX and Novartis AG NOVN.VX have also predicted flat 2016 earnings, while Johnson & Johnson (JNJ.N) expects growth of 3.6 percent to 6.2 percent, driven by sales of newer medicines.Merck & Co (MRK.N) and Pfizer Inc (PFE.N) have not yet provided 2016 earnings expectations, but Thomson Reuters I/B/E/S expects them next week to forecast growth of 4.2 percent and 8 percent, respectively.Bristol-Myers, whose $17 billion in annual sales are far below its industry peers, has downsized in recent years by selling off its diabetes drugs and cutting costs. ""They've made courageous decisions to streamline expenses, and their reduced revenue base will also fuel earnings growth,"" said Guggenheim Partners analyst Tony Butler.Ashtyn Evans, an analyst with Edward Jones, said she expects Opdivo eventually to generate annual sales of more than $8 billion.Half of Bristol-Myers' revenue will likely come from Opdivo and other cancer drugs by 2020, Evans said, allowing the company to generate average annual earnings growth in the 20 percent range for the next three to five years. ""Bristol is a lot different than it was just a few years ago,"" Evans said, citing its razor focus on potentially lucrative immuno-oncology drugs, while also developing cardiovascular and anti-inflammation medicines.Sales of Eliquis, which Bristol-Myers markets with Pfizer Inc (PFE.N), more than doubled to $602 million in the quarter.The pill was approved in 2012 to prevent blood clots among patients with an irregular heartbeat called atrial fibrillation. Growing numbers of doctors are prescribing it as a safer and more-effective alternative to longstanding oral therapy warfarin. Bristol's better-than-expected quarterly earnings were also due to soaring sales of Opdivo, a new treatment for melanoma, lung cancer and kidney cancer that is also being tested against other cancers. Sales of the injectable medicine, which was approved in late 2014 and works by taking the brakes off the immune system, jumped to $475 million.    The Princeton, New Jersey-based company said on Thursday it had halted a large trial of Opdivo after a monitoring committee concluded that head and neck cancer patients taking the drug survived longer than those taking standard chemotherapy.Analysts said Opdivo could pick up $1 billion in eventual sales for head and neck cancer, if it is approved for that indication. Earlier on Thursday, Roche spooked investors by forecasting stagnant 2016 earnings. Analysts cited concern that growth could slow for Roche's three big cancer treatments: Herceptin, Rituxan and Avastin.Novartis on Wednesday also forecast flat 2016 results, amid generic competition for its Gleevec leukemia drug and disappointing sales of new heart failure medicine, Entresto. (Reporting by Ransdell Pierson in New York; Editing by Matthew Lewis)",2016-01-28,BMY,"Thu Jan 28, 2016 | 4:45pm EST","Bristol-Myers set to lead earnings parade in 2016, beyond",http://www.reuters.com//article/us-usa-health-results-idUSKCN0V62X5?type=companyNews
210,"   By Ransdell Pierson  Bristol-Myers Squibb Co (BMY.N) on Thursday positioned itself as a potential earnings pacesetter in 2016, with a forecast of up to 19 percent growth that eclipses profit gains expected by most other large drugmakers.Bolstered by blistering sales of its Opdivo immuno-oncology drug and its Eliquis blood clot preventer, Bristol-Myers  expects earnings this year of $2.30 to $2.40 per share. It earned $2.01 per share last year.In contrast, Eli Lilly and Co (LLY.N) on Thursday predicted relatively flat 2016 earnings following strong gains last year, when sales of new cancer and diabetes drugs offset sharp declines in older medicines.Swiss rivals Roche Holding AG ROG.VX and Novartis AG NOVN.VX have also predicted flat 2016 earnings, while Johnson & Johnson (JNJ.N) expects growth of 3.6 percent to 6.2 percent, driven by sales of newer medicines.Merck & Co (MRK.N) and Pfizer Inc (PFE.N) have not yet provided 2016 earnings expectations, but Thomson Reuters I/B/E/S expects them next week to forecast growth of 4.2 percent and 8 percent, respectively.Bristol-Myers, whose $17 billion in annual sales are far below its industry peers, has downsized in recent years by selling off its diabetes drugs and cutting costs. ""They've made courageous decisions to streamline expenses, and their reduced revenue base will also fuel earnings growth,"" said Guggenheim Partners analyst Tony Butler.Ashtyn Evans, an analyst with Edward Jones, said she expects Opdivo eventually to generate annual sales of more than $8 billion.Half of Bristol-Myers' revenue will likely come from Opdivo and other cancer drugs by 2020, Evans said, allowing the company to generate average annual earnings growth in the 20 percent range for the next three to five years. ""Bristol is a lot different than it was just a few years ago,"" Evans said, citing its razor focus on potentially lucrative immuno-oncology drugs, while also developing cardiovascular and anti-inflammation medicines.Sales of Eliquis, which Bristol-Myers markets with Pfizer Inc (PFE.N), more than doubled to $602 million in the quarter.The pill was approved in 2012 to prevent blood clots among patients with an irregular heartbeat called atrial fibrillation. Growing numbers of doctors are prescribing it as a safer and more-effective alternative to longstanding oral therapy warfarin. Bristol's better-than-expected quarterly earnings were also due to soaring sales of Opdivo, a new treatment for melanoma, lung cancer and kidney cancer that is also being tested against other cancers. Sales of the injectable medicine, which was approved in late 2014 and works by taking the brakes off the immune system, jumped to $475 million.    The Princeton, New Jersey-based company said on Thursday it had halted a large trial of Opdivo after a monitoring committee concluded that head and neck cancer patients taking the drug survived longer than those taking standard chemotherapy.Analysts said Opdivo could pick up $1 billion in eventual sales for head and neck cancer, if it is approved for that indication. Earlier on Thursday, Roche spooked investors by forecasting stagnant 2016 earnings. Analysts cited concern that growth could slow for Roche's three big cancer treatments: Herceptin, Rituxan and Avastin.Novartis on Wednesday also forecast flat 2016 results, amid generic competition for its Gleevec leukemia drug and disappointing sales of new heart failure medicine, Entresto. (Reporting by Ransdell Pierson in New York; Editing by Matthew Lewis)",2016-01-28,BMY,"Thu Jan 28, 2016 | 4:45pm EST","WRAPUP 1-Bristol-Myers set to lead earnings parade in 2016, beyond",http://www.reuters.com//article/usa-health-results-idUSL2N15C2RZ?type=companyNews
211,"  Bristol-Myers Squibb Co (BMY.N) forecast 2016 earnings slightly above Wall Street estimates and said it had halted a large trial of its Opdivo immuno-oncology drug after an independent monitoring committee concluded it prolonged survival compared to standard therapy for head and neck cancer.   While the U.S. drugmaker posted a fourth-quarter net loss on Thursday, results were stronger than expected, due in part to robust sales of Opdivo and its Eliquis pill to prevent blood clots. The company's shares were up 3.3 percent at $63.75 in trading before the market opened.Bristol forecast 2016 earnings of $2.30 to $2.40 per share, excluding special items. Analysts on average had expected $2.29, according to Thomson Reuters I/B/E/S. The full-year outlook would reflect a gain of up to 19.4 percent from 2015 and make Bristol an earnings-growth pacesetter for the industry.     Sales of Eliquis, co-marketed with Pfizer Inc (PFE.N), more than doubled to $602 million in the fourth quarter. The pill was approved in 2012 to prevent blood clots among patients with an irregular heartbeat called atrial fibrillation. Its global sales had risen slowly until the past year, when far more doctors began prescribing it as a safer and more-effective alternative to longstanding oral therapy warfarin.    Bristol's results also benefited from gangbuster sales of Opdivo, a new treatment for melanoma and lung cancer that is also being tested against a range of other cancers. The injectable medicine, which works by taking the brakes off the immune system, generated sales of $475 million.Bristol said it lost $138 million, or 8 cents per share, in the fourth quarter, compared with a year-earlier profit of $13 million, or 1 cent per share. Excluding special items, including those from acquisitions of drugmakers Five Prime Therapeutics and Cardioxyl Pharmaceuticals Inc, Bristol earned 38 cents per share. Analysts on average expected 28 cents.  Revenue rose 1 percent to $4.29 billion, topping Wall Street forecasts of $4.15 billion. Sales would have risen 6 percent if not for the stronger dollar, which lowers the value of sales outside the United States. (Reporting by Ransdell Pierson; Editing by Bernadette Baum and Lisa Von Ahn)",2016-01-28,BMY,"Thu Jan 28, 2016 | 8:53am EST",Bristol-Myers forecasts 2016 profit above Wall Street estimates,http://www.reuters.com//article/us-bristol-myers-results-idUSKCN0V61GG?type=companyNews
212,"  Bristol-Myers Squibb Co (BMY.N) forecast 2016 earnings slightly above Wall Street estimates and said it had halted a large trial of its Opdivo immuno-oncology drug after an independent monitoring committee concluded it prolonged survival compared to standard therapy for head and neck cancer.   While the U.S. drugmaker posted a fourth-quarter net loss on Thursday, results were stronger than expected, due in part to robust sales of Opdivo and its Eliquis pill to prevent blood clots. The company's shares were up 3.3 percent at $63.75 in trading before the market opened.Bristol forecast 2016 earnings of $2.30 to $2.40 per share, excluding special items. Analysts on average had expected $2.29, according to Thomson Reuters I/B/E/S. The full-year outlook would reflect a gain of up to 19.4 percent from 2015 and make Bristol an earnings-growth pacesetter for the industry.     Sales of Eliquis, co-marketed with Pfizer Inc (PFE.N), more than doubled to $602 million in the fourth quarter. The pill was approved in 2012 to prevent blood clots among patients with an irregular heartbeat called atrial fibrillation. Its global sales had risen slowly until the past year, when far more doctors began prescribing it as a safer and more-effective alternative to longstanding oral therapy warfarin.    Bristol's results also benefited from gangbuster sales of Opdivo, a new treatment for melanoma and lung cancer that is also being tested against a range of other cancers. The injectable medicine, which works by taking the brakes off the immune system, generated sales of $475 million.Bristol said it lost $138 million, or 8 cents per share, in the fourth quarter, compared with a year-earlier profit of $13 million, or 1 cent per share. Excluding special items, including those from acquisitions of drugmakers Five Prime Therapeutics and Cardioxyl Pharmaceuticals Inc, Bristol earned 38 cents per share. Analysts on average expected 28 cents.  Revenue rose 1 percent to $4.29 billion, topping Wall Street forecasts of $4.15 billion. Sales would have risen 6 percent if not for the stronger dollar, which lowers the value of sales outside the United States. (Reporting by Ransdell Pierson; Editing by Bernadette Baum and Lisa Von Ahn)",2016-01-28,BMY,"Thu Jan 28, 2016 | 8:53am EST",UPDATE 2-Bristol-Myers forecasts 2016 profit above Wall Street estimates,http://www.reuters.com//article/bristol-myers-results-idUSL2N15C1AL?type=companyNews
213,"  (Corrects that Opdivo trial stopped after drug shown to prolong survival, not stopped after failing to prolong survival)Jan 28 Bristol-Myers Squibb Co  forecast 2016 earnings slightly above Wall Street estimates and said it had halted a large trial of its Opdivo immuno-oncology drug after an independent monitoring committee concluded it prolonged survival compared to standard therapy for head and neck cancer.While the U.S. drugmaker posted a fourth-quarter net loss on Thursday, results were stronger than expected, due in part to robust sales of Opdivo and its Eliquis pill to prevent blood clots.Bristol-Myers forecast 2016 earnings of $2.30 to $2.40 per share, excluding special items. Analysts on average had expected $2.29, according to Thomson Reuters I/B/E/S. The full-year outlook would reflect a gain of up to 19.4 percent from 2015 and make Bristol-Myers an earnings-growth pacesetter for the industry.Sales of Eliquis, co-marketed with Pfizer Inc, more than doubled to $602 million in the fourth quarter. The pill was approved in 2012 to prevent blood clots among patients with an irregular heartbeat called atrial fibrillation. Its global sales had risen slowly until the past year, when far more doctors began prescribing it as a safer and more-effective alternative to longstanding oral therapy warfarin. Bristol-Myers results also benefited from gangbuster sales of Opdivo, a new treatment for melanoma and lung cancer that is also being tested against a range of other cancers. The injectable medicine, which works by taking the brakes off the immune system, generated sales of $475 million. Bristol said it lost $138 million, or 8 cents per share, in the fourth quarter, compared with a year-earlier profit of $13 million, or 1 cent per share.Excluding special items, including those from acquisitions of drugmakers Five Prime Therapeutics and Cardioxyl Pharmaceuticals Inc, Bristol earned 38 cents per share. Analysts on average expected 28 cents.Revenue rose 1 percent to $4.29 billion, topping Wall Street forecasts of $4.15 billion. Sales would have risen 6 percent if not for the stronger dollar, which lowers the value of sales outside the United States.   (Reporting by Ransdell Pierson; Editing by Bernadette Baum and Lisa Von Ahn)",2016-01-28,BMY,"Thu Jan 28, 2016 | 7:58am EST",CORRECTED-UPDATE 1-Bristol-Myers forecasts 2016 profit above Wall Street estimates,http://www.reuters.com//article/bristol-myers-results-idUSL2N15C0UH?type=companyNews
214,"  (Fixes date to Jan 28 from 27.)Jan 28 Bristol-Myers Squibb Co reported better-than-expected quarterly results, helped by strong sales of its cancer treatments and its Eliquis pill to prevent blood clots, and predicted 2016 earnings slightly above Wall Street forecasts. Bristol-Myers said it lost $138 million, or 8 cents per share, in the fourth quarter. That compared with earnings of $13 million, or 1 cent per share, in the year-earlier period. Excluding special items, including those related to acquisitions of drugmakers Five Prime Therapeutics and Cardioxyl Pharmaceuticals Inc, Bristol-Myers earned 38 cents per share. Analysts, on average, expected 28 cents per share, according to Thomson Reuters I/B/E/S. (Reporting by Ransdell Pierson; Editing by Bernadette Baum)",2016-01-28,BMY,"Thu Jan 28, 2016 | 7:53am EST",REFILE-Bristol-Myers forecasts 2016 profit above Wall Street estimates,http://www.reuters.com//article/bristol-myers-results-idUSL2N15B3HI?type=companyNews
215,"  NEW YORK Shares of Bristol-Myers Squibb could rise 25 percent within a year because of its cancer-fighting drug Opdivo, which some analysts see generating $8 billion to $9 billion in annual sales in five years, Barron's said in its latest edition.The drug's success in thwarting a number of cancers, including lung, melanoma, renal cell carcinoma, and head and neck, provides a major opportunity for Bristol-Myers, the publication said.Bristol-Myers holds an 80 percent share of the fledgling immuno-oncology market, and even as competition increases with treatments, the company is expected to retain a 50 percent to 60 percent share, Barron's said. Bristol-Myers in late January forecast 2016 earnings that would represent a gain of almost 20 percent over last year, which would make the company the pharmaceutical industry's earnings-growth pacesetter, Reuters reported at the time.     (Reporting by Herbert Lash)",2016-02-14,BMY,"Sun Feb 14, 2016 | 1:13pm EST",Bristol-Myers shares could rise 25 percent on cancer drug: Barron's,http://www.reuters.com//article/us-bristol-myers-opdivo-barron-s-idUSKCN0VN0X3?type=companyNews
216,"  NEW YORK Shares of Bristol-Myers Squibb could rise 25 percent within a year because of its cancer-fighting drug Opdivo, which some analysts see generating $8 billion to $9 billion in annual sales in five years, Barron's said in its latest edition.The drug's success in thwarting a number of cancers, including lung, melanoma, renal cell carcinoma, and head and neck, provides a major opportunity for Bristol-Myers, the publication said.Bristol-Myers holds an 80 percent share of the fledgling immuno-oncology market, and even as competition increases with treatments, the company is expected to retain a 50 percent to 60 percent share, Barron's said. Bristol-Myers in late January forecast 2016 earnings that would represent a gain of almost 20 percent over last year, which would make the company the pharmaceutical industry's earnings-growth pacesetter, Reuters reported at the time.     (Reporting by Herbert Lash)",2016-02-14,BMY,"Sun Feb 14, 2016 | 1:13pm EST",Bristol-Myers shares could rise 25 pct on cancer drug-Barron's,http://www.reuters.com//article/bristol-myers-opdivo-barrons-idUSL2N15T0GO?type=companyNews
217,"  Feb 22 Glaxosmithkline Plc* ViiV completes transaction to acquire BMS assets* Completion of both transactions follows antitrust approval by relevant regulatory authorities in US, with integration process beginning immediately * ViiV healthcare acquired late-stage HIV research and development assets from Bristol-Myers Squibb for an initial upfront payment of $317 * GSK's global HIV business ViiV healthcare completes transactions to acquire Bristol-Myers Squibb's research and development HIV assets * ViiV healthcare also acquired Bristol-Myers Squibb's preclinical and discovery stage HIV research business for an upfront payment of $33 million  Source text for Eikon:  Further company coverage:",2016-02-22,BMY,"Mon Feb 22, 2016 | 10:58am EST",BRIEF-GSK's ViiV completes deal to buy Bristol-Myers Squibb's R&D HIV assets,http://www.reuters.com//article/idUSFWN16102I?type=companyNews
218,"  LONDON U.S. drugmaker Bristol-Myers Squibb said on Tuesday it had stopped ""certain initiatives"" in China, when asked by Reuters to comment on industry chatter it was curbing financial incentives for prescribing doctors.Payments to healthcare professionals in China are under intense scrutiny after GlaxoSmithKline was slapped with a record $490 million fine for bribery in 2014.Industry sources cited reports on Chinese social media that Bristol-Myers had announced a clampdown on the use of expenses and speaker fees for doctors.  Reuters could not immediately verify the reports but a company spokesman said in an emailed statement: ""Bristol-Myers Squibb has voluntarily stoppedcertaininitiativesin China as the company continues to review its activities and build upon its business model in China."" Last October, Bristol-Myers agreed to pay $14 million to settle U.S. Securities and Exchange claims its joint venture in China made cash payments and provided other benefits to healthcare providers in China in exchange for prescription sales.  (Reporting by Ben Hirschler; Editing by Martinne Geller)",2016-03-08,BMY,"Tue Mar 8, 2016 | 9:40am EST",Bristol-Myers Squibb says stops some initiatives in China,http://www.reuters.com//article/us-bristol-myers-china-idUSKCN0WA1UY?type=companyNews
219,"  LONDON U.S. drugmaker Bristol-Myers Squibb said on Tuesday it had stopped ""certain initiatives"" in China, when asked by Reuters to comment on industry chatter it was curbing financial incentives for prescribing doctors.Payments to healthcare professionals in China are under intense scrutiny after GlaxoSmithKline was slapped with a record $490 million fine for bribery in 2014.Industry sources cited reports on Chinese social media that Bristol-Myers had announced a clampdown on the use of expenses and speaker fees for doctors.  Reuters could not immediately verify the reports but a company spokesman said in an emailed statement: ""Bristol-Myers Squibb has voluntarily stoppedcertaininitiativesin China as the company continues to review its activities and build upon its business model in China."" Last October, Bristol-Myers agreed to pay $14 million to settle U.S. Securities and Exchange claims its joint venture in China made cash payments and provided other benefits to healthcare providers in China in exchange for prescription sales.  (Reporting by Ben Hirschler; Editing by Martinne Geller)",2016-03-08,BMY,"Tue Mar 8, 2016 | 9:40am EST",Bristol-Myers Squibb says stops some initiatives in China,http://www.reuters.com//article/bristol-myers-china-idUSL5N16G3FV?type=companyNews
220,"  March 23 Bristol-Myers Squibb Co* Myers Squibb to acquire Padlock Therapeutics, Inc* Myers Squibb Co - will acquire all of outstanding capital stock of Padlock, a private, Cambridge, Massachusetts-based biotechnology company * Myers Squibb co - gains full-rights to padlock's protein/peptidyl arginine deiminase (PAD) inhibitor discovery program * Says transaction has been approved by the boards of directors of both companies and by the stockholders of padlock * Myers - deal includes additional contingent consideration of up to $375 million upon achievement by Bristol-Myers Squibb of certain events* Myers Squibb Co - transaction includes upfront and near term contingent milestone payments of up to $225 million  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)",2016-03-23,BMY,"Wed Mar 23, 2016 | 7:07am EDT",BRIEF-Bristol-Myers Squibb to acquire Padlock Therapeutics Inc,http://www.reuters.com//article/idUSASC08HXD?type=companyNews
221,  April 20 Eiger Biopharmaceuticals Inc* Eiger biopharmaceuticals announces license of worldwide rights to pegylated interferon lambda-1a from bristol-myers squibb * Eiger plans to evaluate lambda as a potential monotherapy and combination treatment for chronic hdv infection  * Exclusive worldwide license from bristol-myers squibb involved an upfront payment and issuance of eiger common stock   Source text for Eikon:   Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780),2016-04-20,BMY,"Wed Apr 20, 2016 | 5:12pm EDT",BRIEF-Eiger Biopharmaceuticals says license of worldwide rights to Pegylated Interferon lambda-1a from Bristol-Myers Squibb,http://www.reuters.com//article/idUSFWN17N0ZO?type=companyNews
222,"  Bristol-Myers Squibb Co (BMY.N) ratcheted up its 2016 profit view after trouncing first-quarter sales and earnings forecasts on strong demand for its new Opdivo immuno-oncology drug and Eliquis blood clot preventer.The U.S. drugmaker, whose shares rose nearly 4 percent, said on Thursday that net income rose to $1.20 billion, or 71 cents per share, from $1.19 billion, or 71 cents a share, a year earlier.Excluding special items, including litigation costs, Bristol-Myers earned 74 cents per share, well above the analysts' average estimate of 65 cents compiled by Thomson Reuters I/B/E/S.Revenue rose 9 percent to $4.39 billion, beating Wall Street forecasts of $4.25 billion. It would have increased 11 percent if not for the strong dollar, which lowers the value of sales outside the United States.Based on the first-quarter results, Bristol-Myers said it expected full-year earnings of $2.50 to $2.60 per share. In January it had forecast $2.30 to $2.40.  The updated outlook would reflect earnings growth of up to 29 percent from last year.Sales of Opdivo, which works by taking the brakes off the immune system, soared 40 percent to $704 million in the quarter, putting them on track for nearly $3 billion this year. Approved in late 2014 to treat melanoma, Opdivo later won approvals to treat lung and kidney cancer and is being tested against a wide array of other types of cancer. The drug competes with Merck & Co's (MRK.N) Keytruda, a similar treatment that has gotten off to a far slower start since being approved in September 2014.But sales of Yervoy, another Bristol-Myers treatment for melanoma, fell 19 percent to $263 million as doctors opted instead for Opdivo and Keytruda, which are deemed less toxic.    Sales of Eliquis, used to prevent blood clots and strokes among patients with an irregular heartbeat called atrial fibrillation, more than doubled to $734 million. The pill, sold in partnership with Pfizer Inc (PFE.N), is taking flight as growing numbers of doctors prescribe it as a safer and more-convenient alternative to longtime generic treatment warfarin. Shares of Bristol-Myers were up 3.7 percent at $72.82 in afternoon trading. (Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)",2016-04-28,BMY,"Thu Apr 28, 2016 | 1:23pm EDT",Bristol raises 2016 forecast after earnings beat,http://www.reuters.com//article/us-bristolmyers-results-idUSKCN0XP1HT?type=companyNews
223,"  Bristol-Myers Squibb Co (BMY.N) ratcheted up its 2016 profit view after trouncing first-quarter sales and earnings forecasts on strong demand for its new Opdivo immuno-oncology drug and Eliquis blood clot preventer.The U.S. drugmaker, whose shares rose nearly 4 percent, said on Thursday that net income rose to $1.20 billion, or 71 cents per share, from $1.19 billion, or 71 cents a share, a year earlier.Excluding special items, including litigation costs, Bristol-Myers earned 74 cents per share, well above the analysts' average estimate of 65 cents compiled by Thomson Reuters I/B/E/S.Revenue rose 9 percent to $4.39 billion, beating Wall Street forecasts of $4.25 billion. It would have increased 11 percent if not for the strong dollar, which lowers the value of sales outside the United States.Based on the first-quarter results, Bristol-Myers said it expected full-year earnings of $2.50 to $2.60 per share. In January it had forecast $2.30 to $2.40.  The updated outlook would reflect earnings growth of up to 29 percent from last year.Sales of Opdivo, which works by taking the brakes off the immune system, soared 40 percent to $704 million in the quarter, putting them on track for nearly $3 billion this year. Approved in late 2014 to treat melanoma, Opdivo later won approvals to treat lung and kidney cancer and is being tested against a wide array of other types of cancer. The drug competes with Merck & Co's (MRK.N) Keytruda, a similar treatment that has gotten off to a far slower start since being approved in September 2014.But sales of Yervoy, another Bristol-Myers treatment for melanoma, fell 19 percent to $263 million as doctors opted instead for Opdivo and Keytruda, which are deemed less toxic.    Sales of Eliquis, used to prevent blood clots and strokes among patients with an irregular heartbeat called atrial fibrillation, more than doubled to $734 million. The pill, sold in partnership with Pfizer Inc (PFE.N), is taking flight as growing numbers of doctors prescribe it as a safer and more-convenient alternative to longtime generic treatment warfarin. Shares of Bristol-Myers were up 3.7 percent at $72.82 in afternoon trading. (Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)",2016-04-28,BMY,"Thu Apr 28, 2016 | 1:23pm EDT",UPDATE 3-Bristol raises 2016 forecast after earnings beat,http://www.reuters.com//article/bristolmyers-results-idUSL2N17V0H9?type=companyNews
224,"   By Joyce Lee | SEOUL  SEOUL Samsung Biologics Co Ltd, a contract manufacturer of biotech drugs for global pharmaceutical firms, said it was planning an IPO this year, an offering that analysts have estimated as being worth as much as $2.6 billion.The IPO is aimed at helping fund an ambitious expansion in production capacity to make it the world's largest contract manufacturer. It plans to pick advisers for the offering in May, amid a likely record year for Seoul IPOs.Founded in 2011, Samsung Biologics has the third-largest capacity among global contract manufacturers and counts Roche Holding AG (ROG.S) and Bristol-Myers Squibb Co (BMY.N) among its clients.Analysts have estimated the company's potential market value at 10 trillion won ($8.7 billion) or more, and the offering size at around 2-3 trillion won. Biotech drugs, which are complex molecules generated by living cells, accounted for seven of the world's ten best-selling drugs in 2015. The global market for biotech drugs is expected to grow to $278 billion in 2020, up 52 percent from 2015 levels, according to data provider Evaluate Pharma, as aging populations in many countries fuel demand for medicine.Samsung Biologics is 51 percent owned by Samsung C&T Corp (028260.KS), the de facto holding company of Samsung Group [SAGR.UL]. Samsung Electronics Co Ltd (028260.KS) is the second-largest shareholder with a 46.8 percent stake.  The company owns 91 percent of Samsung Bioepis Co Ltd, an unlisted developer of biosimilar drugs, or copies of biotech drugs.Seoul is expecting a bumper year in IPOs on a stocks revival and conglomerate needs to streamline structures, smooth paths toward management succession or ease debt burdens. Bankers expect this year's proceeds to be at least $10 billion, eclipsing 2010's high of $8.5 billion.Samsung Biologics last year said it would build an additional 180,000 liter plant, bringing combined investment in production lines for the 2011-2018 period to 2 trillion won.  (Reporting by Joyce Lee; Editing by Edwina Gibbs)",2016-04-28,BMY,"Wed Apr 27, 2016 | 9:56pm EDT","UPDATE 1-Samsung Biologics plans IPO this year, seen worth as much as $2.6 bln",http://www.reuters.com//article/samsung-biologics-ipo-idUSL3N17V03Y?type=companyNews
225,  May 11 Bristol-myers Squibb Co * Bristol-Myers squibb and abbvie announce european commission approval of empliciti(tm) (elotuzumab) for the treatment of multiple myeloma in adult patients who have received at least one prior therapy  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom; +1 646 223 8780; )  ,2016-05-11,BMY,"Wed May 11, 2016 | 3:02pm EDT",BRIEF-Bristol-Myers says European Commission approval of Empliciti for treatment of multiple myeloma,http://www.reuters.com//article/idUSFWN18818J?type=companyNews
226,"  May 11 Bristol-myers Squibb Co* European Commission Approves The First And Only Immuno-Oncology Combination, Bristol-Myers Squibb's Opdivo (Nivolumab) + Yervoy (Ipilimumab) Regimen, For Treatment Of Advanced Melanoma  * Bristol Myers Squibb Co - Opdivo + Yervoy Regimen Now Approved For Unresectable Or Metastatic Melanoma Patients, Regardless Of Braf Mutational Status  Source text for Eikon:  Further company coverage: ",2016-05-11,BMY,"Wed May 11, 2016 | 11:38am EDT",BRIEF-Bristol-Myers says EU advanced melanoma drug,http://www.reuters.com//article/idUSFWN18811U?type=companyNews
227,  May 12 Htg Molecular Diagnostics Inc* Htg will provide bristol-myers squibb access to its ngs-based htg edgeseq system * Companies will collaborate to develop tools for use for molecular profiling research for immuno-oncology  * Htg molecular diagnostics announces immuno-oncology research collaboration agreement with bristol-myers squibb  Source text for Eikon:  Further company coverage:    ),2016-05-12,BMY,"Thu May 12, 2016 | 4:10pm EDT",BRIEF-HTG Molecular diagnostics announces Immuno-oncology research collaboration agreement with Bristol-Myers Squibb,http://www.reuters.com//article/idUSASC08PBG?type=companyNews
228,"  May 17 Bristol-myers Squibb Co* Bristol-Myers Squibb opens expanded biologics facility  * $280 million project increases workforce, ""adds new capabilities""  Source text for Eikon:  Further company coverage: ",2016-05-17,BMY,"Tue May 17, 2016 | 1:23pm EDT",BRIEF-Bristol-Myers Squibb opens expanded biologics facility,http://www.reuters.com//article/idUSFWN18E0J0?type=companyNews
229,  May 18 Bristol-myers Squibb Co* Two-Year overall survival data from two pivotal opdivo (nivolumab) trials demonstrate sustained benefit in patients with advanced non-small cell lung cancer  * Treatment-Related adverse events occurred in 71% and 61% of opdivo -treated patients  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom +1-646-223-8780) ,2016-05-18,BMY,"Wed May 18, 2016 | 5:52pm EDT",BRIEF-Bristol-Myers Squibb presents two-year overall survival data on Opdivo,http://www.reuters.com//article/idUSFWN18F0PM?type=companyNews
230,"   By Ben Hirschler | LONDON  LONDON AstraZeneca Chief Executive Pascal Soriot is a big believer in science, and the biggest experiment of his career is the reinvention of the drugmaker. The $500 million corporate headquarters and research hub emerging amid cranes on the southern edge of the university town of Cambridge symbolizes his aim to create a science-led company with uniquely close ties to academia.For employees, these are uncomfortable times. Thousands of job have been cut globally at the company in the past three years, with more to come. Some staff are also reluctant to move to Cambridge, with its high house prices, from north-west England where the company has a strong presence dating from its time as part of the old ICI chemicals empire. Soriot, however, relishes the chance to shake things up by setting up home near world-renowned university labs - where he says the firm is better placed to hire the ""best of the best"" - while shrinking its operations to focus on core areas like cancer, respiratory and cardiovascular disease. ""In the past, we've had too much stability,"" the CEO said in an interview with Reuters that gives some of the clearest indications yet of the scale of the cultural change he intends to push through at the company.  ""We had people who never moved and turnover of 1 or 2 percent. That might sound good but it's actually not, because you don't have new ideas flowing through the place."" The stakes are high. Two years after spurning a $100 billion bid from Pfizer, AstraZeneca is going through the biggest ""cliff"" of patent expiries the drug industry has ever seen, wiping off more than half of its sales - or $17 billion - in 2011-2017.That has forced Soriot to seek new routes to profit and his overhaul of the company is now entering a pivotal phase, with make-or-break trial results and drug approvals due over the next 12 months, coinciding with the move to Cambridge. As with any experiment, the outcome of Soriot's reinvention is uncertain - and investors are divided. Neil Woodford of Woodford Investment Management, the seventh largest AstraZeneca shareholder, is convinced the company will re-emerge as a successful player focused on specialty drugs like cancer treatments rather than mass-market medicines. He has added to his stake recently. But Andy Smith, chief investment officer at fund manager Mann Bioinvest, says Soriot has yet to prove his plan will pay off. ""The big question hanging over his tenure is how close he can get to showing actual value from the pipeline, rather than promised value,"" he said.   'IMPLODING' No other pharmaceutical company has moved itself wholesale to an academic center. Soriot argues the move is already paying off for some 1,600 staff, nearly a quarter of its UK workforce, now in rented space around Cambridge who are liaising far more closely with academic researchers.""It is fundamentally changing the way we operate,"" said the 56-year-old, who trained as a veterinarian in France. Most of the staff will move into the new building from late 2017.Soriot said he had no choice but to overhaul AstraZeneca when he took over in October 2012, due to the patent ""cliff"".""The company was imploding,"" he said bluntly.His answer has been to invest in internal research and bolt-on acquisitions, including more than $7 billion of deals at the end of 2015, to rebuild the company's drug pipeline.     This includes cancer drugs that boost the immune system, which are the hottest area of drug research right now, although AstraZeneca also has high hopes for other approaches to fighting tumors.That makes oncology the area with the greatest potential to drive future sales at AstraZeneca, as the company grapples with a wave of patent expiries on older products, such as its cholesterol fighter Crestor and stomach acid pill Nexium.Investors are anxious for proof Soriot's prescription will work, since AstraZeneca shares are languishing 28 percent below the 55 pounds offered by Pfizer and earnings are expected to fall in 2016 and 2017.AstraZeneca has also had to cope recently with some senior executive departures, including the loss on Tuesday of its North America head to Novartis. At the height of the takeover battle, the company went public with a forecast that sales would rise by three-quarters to $45 billion by 2023 - a hostage to fortune, perhaps, but a target Soriot remains confident will be met. ""I might not be here to see if we achieve that in 2023 but people won't have to wait until then. If we succeed, the share price will reflect the value of the company much earlier than that,"" he said. ""I think it is going to take another 12 months and then hopefully we can show people what they want to see.""      STEPS FORWARD, BACK   So far, there have been some steps forward, like success with lung cancer drug Tagrisso and with good results for a new asthma drug.  But there have also been setbacks, including the loss of a fast-to-market opportunity for AstraZeneca's big immuno-oncology hope durvalumab. The latter has increased the pressure to prove that a combination treatment mixing durvalumab and tremelimumab can help in lung cancer, giving AstraZeneca a foothold in a market currently dominated by Bristol-Myers Squibb.""Pascal has played his hand well but now he's at the point where it gets harder,"" said one top executive at a rival company. ""He's going down to the valley floor on earnings and we don't know how the clinical data will play out to get the business up the other side.""    AstraZeneca has also used so-called externalization income from licensing out non-core products to underpin profits, leading to criticism over earnings quality from some analysts.  With R&D spending equivalent to 24 percent of sales, AstraZeneca's science budget exceeds the industry average. But Soriot aims to push selling, general and administrative expenses down to 30-32 percent from 35 percent. The CEO says investors need patience to see through a turnaround story that, with luck, will mirror the recovery Bristol-Myers, now the star of the pharma sector.""There will be a tipping point where people see a sufficient number of projects progressing positively and then they can see the future is bright."" (Editing by Pravin Char)",2016-05-18,BMY,"Wed May 18, 2016 | 2:45am EDT",Pascal Soriot's big experiment: reinventing AstraZeneca,http://www.reuters.com//article/us-astrazeneca-ceo-insight-idUSKCN0Y90LS?type=companyNews
231,"   By Ben Hirschler | LONDON  LONDON AstraZeneca Chief Executive Pascal Soriot is a big believer in science, and the biggest experiment of his career is the reinvention of the drugmaker. The $500 million corporate headquarters and research hub emerging amid cranes on the southern edge of the university town of Cambridge symbolizes his aim to create a science-led company with uniquely close ties to academia.For employees, these are uncomfortable times. Thousands of job have been cut globally at the company in the past three years, with more to come. Some staff are also reluctant to move to Cambridge, with its high house prices, from north-west England where the company has a strong presence dating from its time as part of the old ICI chemicals empire. Soriot, however, relishes the chance to shake things up by setting up home near world-renowned university labs - where he says the firm is better placed to hire the ""best of the best"" - while shrinking its operations to focus on core areas like cancer, respiratory and cardiovascular disease. ""In the past, we've had too much stability,"" the CEO said in an interview with Reuters that gives some of the clearest indications yet of the scale of the cultural change he intends to push through at the company.  ""We had people who never moved and turnover of 1 or 2 percent. That might sound good but it's actually not, because you don't have new ideas flowing through the place."" The stakes are high. Two years after spurning a $100 billion bid from Pfizer, AstraZeneca is going through the biggest ""cliff"" of patent expiries the drug industry has ever seen, wiping off more than half of its sales - or $17 billion - in 2011-2017.That has forced Soriot to seek new routes to profit and his overhaul of the company is now entering a pivotal phase, with make-or-break trial results and drug approvals due over the next 12 months, coinciding with the move to Cambridge. As with any experiment, the outcome of Soriot's reinvention is uncertain - and investors are divided. Neil Woodford of Woodford Investment Management, the seventh largest AstraZeneca shareholder, is convinced the company will re-emerge as a successful player focused on specialty drugs like cancer treatments rather than mass-market medicines. He has added to his stake recently. But Andy Smith, chief investment officer at fund manager Mann Bioinvest, says Soriot has yet to prove his plan will pay off. ""The big question hanging over his tenure is how close he can get to showing actual value from the pipeline, rather than promised value,"" he said.   'IMPLODING' No other pharmaceutical company has moved itself wholesale to an academic center. Soriot argues the move is already paying off for some 1,600 staff, nearly a quarter of its UK workforce, now in rented space around Cambridge who are liaising far more closely with academic researchers.""It is fundamentally changing the way we operate,"" said the 56-year-old, who trained as a veterinarian in France. Most of the staff will move into the new building from late 2017.Soriot said he had no choice but to overhaul AstraZeneca when he took over in October 2012, due to the patent ""cliff"".""The company was imploding,"" he said bluntly.His answer has been to invest in internal research and bolt-on acquisitions, including more than $7 billion of deals at the end of 2015, to rebuild the company's drug pipeline.     This includes cancer drugs that boost the immune system, which are the hottest area of drug research right now, although AstraZeneca also has high hopes for other approaches to fighting tumors.That makes oncology the area with the greatest potential to drive future sales at AstraZeneca, as the company grapples with a wave of patent expiries on older products, such as its cholesterol fighter Crestor and stomach acid pill Nexium.Investors are anxious for proof Soriot's prescription will work, since AstraZeneca shares are languishing 28 percent below the 55 pounds offered by Pfizer and earnings are expected to fall in 2016 and 2017.AstraZeneca has also had to cope recently with some senior executive departures, including the loss on Tuesday of its North America head to Novartis. At the height of the takeover battle, the company went public with a forecast that sales would rise by three-quarters to $45 billion by 2023 - a hostage to fortune, perhaps, but a target Soriot remains confident will be met. ""I might not be here to see if we achieve that in 2023 but people won't have to wait until then. If we succeed, the share price will reflect the value of the company much earlier than that,"" he said. ""I think it is going to take another 12 months and then hopefully we can show people what they want to see.""      STEPS FORWARD, BACK   So far, there have been some steps forward, like success with lung cancer drug Tagrisso and with good results for a new asthma drug.  But there have also been setbacks, including the loss of a fast-to-market opportunity for AstraZeneca's big immuno-oncology hope durvalumab. The latter has increased the pressure to prove that a combination treatment mixing durvalumab and tremelimumab can help in lung cancer, giving AstraZeneca a foothold in a market currently dominated by Bristol-Myers Squibb.""Pascal has played his hand well but now he's at the point where it gets harder,"" said one top executive at a rival company. ""He's going down to the valley floor on earnings and we don't know how the clinical data will play out to get the business up the other side.""    AstraZeneca has also used so-called externalization income from licensing out non-core products to underpin profits, leading to criticism over earnings quality from some analysts.  With R&D spending equivalent to 24 percent of sales, AstraZeneca's science budget exceeds the industry average. But Soriot aims to push selling, general and administrative expenses down to 30-32 percent from 35 percent. The CEO says investors need patience to see through a turnaround story that, with luck, will mirror the recovery Bristol-Myers, now the star of the pharma sector.""There will be a tipping point where people see a sufficient number of projects progressing positively and then they can see the future is bright."" (Editing by Pravin Char)",2016-05-18,BMY,"Wed May 18, 2016 | 2:45am EDT",INSIGHT-Pascal Soriot's big experiment: reinventing AstraZeneca,http://www.reuters.com//article/astrazeneca-ceo-idUSL5N18D3P1?type=companyNews
232,  May 19 Inovalon Holdings Inc : * Inovalon announces agreement with Bristol-Myers Squibb to focus on real world outcomes & value-based contracting initiatives  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)  ,2016-05-19,BMY,"Thu May 19, 2016 | 9:10am EDT",BRIEF-Inovalon Holdings announces agreement with Bristol-Myers Squibb,http://www.reuters.com//article/idUSFWN18G0H3?type=companyNews
233,  May 24 Bristol-myers Squibb Co* Myers squibb announces health canada's approval of daklinza in combination with sofosbuvir  * Says health canada's approval of daklinza  in treatment of chronic hepatitis c in adult patients  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ,2016-05-24,BMY,"Tue May 24, 2016 | 7:30am EDT",BRIEF-Bristol-Myers Squibb says Health Canada approved Daklinza in combination with Sofosbuvir,http://www.reuters.com//article/idUSFWN18L0BX?type=companyNews
234,"   By Jessica Dye  (Reuters) - The California Supreme Court is set to decide whether non- residents can sue pharmaceutical giant Bristol-Myers Squibb in its state courts, in an appeal that could clarify what presence companies must have in California in order to be sued there by out-of-state plaintiffs. The state high court will hear oral arguments June 2 in Bristol-Myers Squibb's bid to overturn a ruling that found California courts had jurisdiction to hear claims from non-California residents who said they were injured by the New York-based company's blood thinner Plavix. To read the full story on Westlaw Practitioner Insights, click here: bit.ly/1Ua9q4X",2016-05-31,BMY,"Tue May 31, 2016 | 7:17am EDT",Case to Watch: California to weigh jurisdiction for out-of-state plaintiffs,http://www.reuters.com//article/products-jurisdiction-appeal-idUSL1N18S09J?type=companyNews
235,  June 6 Bristol-Myers Squibb Co : * Bristol-Myers Squibb -long-term data from two trials evaluating opdivo and yervoy regimen in advanced melanoma continues to validate co's immuno-oncology combination approach  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)  ,2016-06-06,BMY,"Mon Jun 6, 2016 | 7:09am EDT","BRIEF-Bristol-Myers Squibb posts data from trials evaluating Opdivo, Yervoy regimen",http://www.reuters.com//article/idUSFWN18W02C?type=companyNews
236,  June 7 Bristol-Myers Squibb Co : * Declared a quarterly dividend of $0.38 per share on $0.10 par value common stock of corporation  Source text for Eikon:  Further company coverage:  ,2016-06-07,BMY,"Tue Jun 7, 2016 | 4:59pm EDT",BRIEF-Bristol-Myers Squibb declares qtrly dividend of $0.38/shr,http://www.reuters.com//article/idUSFWN18Z0KI?type=companyNews
237,"  June 7 Bristol-Myers Squibb Co :* Bristol-Myers Squibb and MD Anderson announce new research collaboration in immuno-oncology focused on lung cancer  * Bristol-Myers Squibb - collaboration to support Phase 1 and 2 clinical trials testing Opdivo as monotherapy, in combination with Yervoy, or with other agents  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ",2016-06-07,BMY,"Tue Jun 7, 2016 | 7:16am EDT","BRIEF-Bristol-Myers Squibb, MD Anderson announce new collaboration focused on lung cancer",http://www.reuters.com//article/idUSFWN18Z0B8?type=companyNews
238,  June 8 Bristol-myers Squibb Co : * Announces new rheumatoid arthritis research and real-world data at the annual European Congress Of Rheumatology (EULAR 2016)  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)  ,2016-06-08,BMY,"Wed Jun 8, 2016 | 8:05am EDT",BRIEF-Bristol-Myers Squibb announces new rheumatoid arthritis research,http://www.reuters.com//article/idUSFWN1900EO?type=companyNews
239,"  June 10 Bristol-Myers Squibb Co* Says Opdivo demonstrated objective response rate of 66.3% in classical Hodgkin lymphoma patients* Says primary endpoint of objective response rate (orr) per an independent radiologic review committee (irrc) was 66.3% * Says safety profile of Opdivo in checkmate -205 was consistent with previously reported data in this tumor type * Says Opdivo indicates benefit in heavily pre-treated classical Hodgkin lymphoma patients in phase 2, single-arm pivotal trial Source text for Eikon:Further company coverage:",2016-06-10,BMY,"Fri Jun 10, 2016 | 3:05am EDT",BRIEF-Bristol-Myers announces phase 2 data for Opdivo studies,http://www.reuters.com//article/idUSASC08TKG?type=companyNews
240,"  June 15 PeptiDream Inc :* Says it has earned a milestone for the dosing of a first patient in a clinical trial by its alliance partner, Bristol-Myers Squibb Company (BMS) * Says this is the first program to enter clinical testing out of the discovery collaboration between the two companies* Says the molecule being advanced in clinical testing was discovered by Bristol-Myers Squibb starting from an active lead macrocyclic compound identified by Peptidream using its PDPS technology and provided to BMS for further optimization  Source text in Japanese: goo.gl/GDOvVrFurther company Coverage:     (Beijing Headline News)",2016-06-15,BMY,"Wed Jun 15, 2016 | 2:48am EDT",BRIEF-PeptiDream achieves milestone for initiation of clinical development for bristol-myers squibb's first collaboration product candidate,http://www.reuters.com//article/idUSL4N1972FM?type=companyNews
241,"  June 27 Bristol Myers Squibb Co* Bristol Myers Squibb Co - intends to file marketing application with health authorities based on results from phase 2 study ca209-275, other data * Bristol Myers Squibb - to file marketing application with health authorities based on results from study -275 and other supporting data in coming months  * Bristol Myers Squibb's Opdivo (nivolumab) receives breakthrough therapy designation from U.S. Food and drug administration for advanced form of bladder cancer  Source text for Eikon:  Further company coverage: [ BMY.N]",2016-06-27,BMY,"Mon Jun 27, 2016 | 7:11am EDT",BRIEF-Bristol-Myers Squibb's Opdivo gets breakthrough therapy approval from FDA,http://www.reuters.com//article/idUSASC08VBI?type=companyNews
242,"  June 30 Bristol-myers Squibb Co* Bristol-Myers squibb and psioxus therapeutics announce immuno-oncology clinical collaboration to evaluate the combination of opdivo and enadenotucirev* Myers Squibb co says under terms of this agreement, bristol-myers squibb will make a one-time upfront payment of $10 million to psioxus * Myers Squibb Co - bristol-myers squibb will make a one-time upfront payment of $10 million to psioxus, and parties will share development costs* Says Psioxus will be responsible for conducting phase 1 study with patient recruitment expected to start in q3 of 2016 * Bristol-Myers squibb will have a time-limited right of exclusive negotiation for commercial rights to enadenotucirev * Myers - both Co's also investigating other immune system pathways in treatment of cancer including ctla-4, cd-137, kir, slamf7, pd-1, gitr, csf1r, ido and lag-3* Myers Squibb - Co's will work exclusively with each other on anti-pd-1/pd-l1 antagonist antibody and enadenotucirev combination regimens  Source text for Eikon:  Further company coverage:    )",2016-06-30,BMY,"Thu Jun 30, 2016 | 7:17am EDT","BRIEF-Bristol-Myers Squibb, Psioxus Therapeutics announce immuno-oncology clinical collaboration",http://www.reuters.com//article/idUSFWN19M0ME?type=companyNews
243,"   By Brendan Pierson  A federal appeals court revived a lawsuit by Bristol-Myers Squibb Co accusing Indian generic drug maker Mylan Laboratories Ltd of breaching an agreement to distribute a generic version of an AIDS drug in developing countries. A unanimous three-judge panel of the 2nd U.S. Circuit Court of Appeals on Thursday vacated a lower court order dismissing the lawsuit, which claims that Mylan caused the drug, atazanavir, to be sold in Venezuela, a country not included in the agreement.  To read the full story on Westlaw Practitioner Insights, click here: bit.ly/29axRVC",2016-07-01,BMY,"Fri Jul 1, 2016 | 8:53am EDT",Circuit revives Bristol-Myers lawsuit over AIDS drug distribution deal,http://www.reuters.com//article/health-atazanavir-idUSL1N19N0IS?type=companyNews
244,"  LONDON, July 5 Bristol-Myers Squibb's  immunotherapy drug Opdivo is not worth using on the state health service for treating kidney cancer, Britain's healthcare cost-effectiveness watchdog said on Tuesday.The draft decision from the National Institute for Health and Care Excellence (NICE) is a blow for the U.S. drugmaker, which has had mixed fortunes under a British system.  Opdivo is recommended by NICE for melanoma but not for lung cancer. Bristol-Myers said the latest NICE verdict highlighted the limitations of the current process for accessing first-in-class medicines on the country's National Health Service.   (Reporting by Ben Hirschler, editing by Louise Heavens) ",2016-07-05,BMY,"Tue Jul 5, 2016 | 9:51am EDT",UK cost agency rejects Bristol's Opdivo for kidney cancer,http://www.reuters.com//article/health-bristol-myers-britain-idUSL8N19R3EI?type=companyNews
245,  July 5 Bristol* Myers Squibb acquires Cormorant Pharmaceuticals* Myers Squibb Co - transaction includes upfront and near term contingent milestone payments of up to us $95 million * Myers Squibb co - company gains full-rights to cormorant's humax-il8 antibody program and lead asset humax-il8 in phase 1/2 development * Myers Squibb co - transaction includes upfront and near term contingent milestone payments of up to us $95 million * Myers Squibb co - transaction has been approved by boards of directors of both companies and by stockholders of cormorant* Myers Squibb co -  transaction includes additional contingent consideration of up to us $425 million upon achievement by co of certain milestones  Source text for Eikon:  Further company coverage:    ),2016-07-05,BMY,"Tue Jul 5, 2016 | 7:17am EDT",BRIEF-Bristol-Myers acquires Cormorant Pharmaceuticals,http://www.reuters.com//article/idUSASC08W0R?type=companyNews
246,"  July 18 Bristol-Myers Squibb Co:* Bristol-Myers Squibb announces regulatory updates for Opdivo (nivolumab) in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck  * Myers Squibb Co - projected FDA action date is November 11, 2016  for Opdivo  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ",2016-07-18,BMY,"Mon Jul 18, 2016 | 7:33am EDT","BRIEF-Bristol-Myers Squibb- U.S., EU regulators accept application to expand approval for cancer drug, Opdivo",http://www.reuters.com//article/idUSFWN1A409J?type=companyNews
247,"   By Carl O'Donnell  Some of the world's largest drug companies are taking out their checkbooks for acquisitions of smaller peers whose cancer drugs have the potential to cure not just patients, but corporate growth prospects as well.After decades in which progress meant extending life by weeks or months, new cancer treatments hold promise of adding years to patients' lives and billions of dollars in revenue to the companies that own them. Some of the most promising, known as immunotherapy, harness the body's own defense system to fight cancer.For many pharmaceutical companies, this wave of innovation couldn't have come at a better time. A generation of mainstay drugs have gone off patent, raising the stakes for companies vying for a foothold in the burgeoning oncology market.In recent months, executives at many big pharmaceutical companies have expressed interest in building cancer treatment portfolios through acquisitions.They range from well-established incumbents, such as Roche Holding AG and Amgen Inc, to relative outsiders, including Sanofi and Gilead, according to public statements from the companies and several sources familiar with the companies plans and who requested anonymity because they were not authorized to speak to the media.Amgen declined to comment. Roche, Sanofi and Gilead did not respond to requests to comment.Among the most logical acquisition targets are Incyte Corporation and Seattle Genetics, which have respective market capitalizations of about $16 billion and $6 billion, said Michael King, a biotechnology analyst at JMP Securities.Incyte's blood cancer drug, Jakafi, produced more than $600 million in sales last year. Seattle Genetic's lymphoma drug, ADCETRIS, earned revenues of nearly $450 million. Both companies declined to comment.The acquisition of promising cancer drugs is ""going to be a major theme in the life sciences sector for the next several years,"" said Kennen MacKay, a biotechnology analyst at Credit Suisse Group AG.MORE DEALS EXPECTED  Acquisitions of cancer drug companies accounted for about 20 percent of the $63 billion in pharmaceutical and biotech M&A announced this year, according to data from Thomson Reuters. Cancer deals accounted for a smaller share - 16 percent - of a larger pharmaceutical M&A pie during the first half of 2015.Deals involving cancer drugs are expected to rise in the second half of the year, as corporate boards of potential target companies begin to accept the lower valuations the sector has seen in recent months and become more open to deals.The Nasdaq Biotech Index, a common measure of life sciences companies' performance, has plunged more than 30 percent from 2015 highs, as political criticism of drug prices fueled investor concerns.Global spending on cancer drugs is on the rise and may reach $178 billion by 2020, up from $107 billion in 2015, according to market research firm IMS Health. About half of that will occur in the United States.That makes oncology medication to be one of the single biggest anticipated drivers of prescription drug revenue growth over the next five years, according to data from consultancy Ernst and Young. ""I think an uptick in activity is very likely,"" said Jeff Greene, global transactions leader for life sciences at EY. ""We have seen some big deals already, and we are likely to see even more, large and small, in the second half of this year.""  Recent deals include AbbVie Inc's $10 billion acquisition of lung cancer company Stemcentryx, Jazz Pharmaceuticals' $1.5 billion takeover of leukemia drug maker Celator Pharmaceuticals Inc, and Bristol-Myers Squibb Co's roughly $500 million acquisition of Cormorant Pharmaceuticals.More dealmaking is on the way. Earlier this month, Medivation Inc, a U.S. prostate cancer drug company with a market capitalization of $10 billion, said it would open its books to Sanofi SA as part of a sale process that sources said also has attracted Pfizer Inc and Celgene Corp.REFRESHING PORTFOLIOS For some, laying claim to a piece of the oncology sector's blockbuster growth could help offset the waning fortunes of mature drugs. For example, Sanofi's blockbuster diabetes drug, Lantus, will face heightened generic drug competition in December. Gilead faces increased pressure on its liver disease franchise, which makes up two-thirds of its revenues.Abbvie, which purchased two oncology companies in the past year, Pharmacyclics and Stemcentryx, is facing potential competition for its biggest drug, Humira, for arthritis. A U.S. Food and Drug Administration (FDA) panel recently recommended approval of an application by Amgen to sell a similar product.Best equipped to play a leading role are major pharmaceutical companies because bringing the new generation of cancer medicines under development to market requires scale and resources.""Oncology is a go-big-or-go-home category,"" said Brian Corvino, a life sciences consultant at Decision Resources Group. ""The amount of investment to develop and commercialize oncology drugs is massive and only becomes efficient at a certain scale.""The benefits of scale have only grown in recent years, as insurance companies increasingly have demanded drug makers justify prices in terms of the value they add to patient's health.A large player in oncology is better equipped to partner with health care providers to collect data on a drug's efficacy and argue the case to major insurers, Corvino said.From an acquirer's perspective, the most attractive targets are companies with drugs that are already generating some revenue and are treating diseases where competition is scant.""For players that are looking to build an oncology presence, you need to buy a company that already has a blockbuster out there,"" MacKay said.Companies whose drugs are still in development pose greater risk. Shares of Juno Therapeutics, for example, dropped about 30 percent earlier this month when the FDA placed a hold on a clinical trial for its main leukemia drug after two people died. The hold was later reversed and the stock partly recovered. (Reporting by Carl O'Donnell in New York; Editing by Greg Roumeliotis and Lisa Girion)",2016-07-19,BMY,"Tue Jul 19, 2016 | 1:08am EDT",Old pharma sees new profit cure in cancer drugs,http://www.reuters.com//article/us-oncology-m-a-idUSKCN0ZZ0BG?type=companyNews
248,"   By Carl O'Donnell  Some of the world's largest drug companies are taking out their checkbooks for acquisitions of smaller peers whose cancer drugs have the potential to cure not just patients, but corporate growth prospects as well.After decades in which progress meant extending life by weeks or months, new cancer treatments hold promise of adding years to patients' lives and billions of dollars in revenue to the companies that own them. Some of the most promising, known as immunotherapy, harness the body's own defense system to fight cancer.For many pharmaceutical companies, this wave of innovation couldn't have come at a better time. A generation of mainstay drugs have gone off patent, raising the stakes for companies vying for a foothold in the burgeoning oncology market.In recent months, executives at many big pharmaceutical companies have expressed interest in building cancer treatment portfolios through acquisitions.They range from well-established incumbents, such as Roche Holding AG and Amgen Inc, to relative outsiders, including Sanofi and Gilead, according to public statements from the companies and several sources familiar with the companies plans and who requested anonymity because they were not authorized to speak to the media.Amgen declined to comment. Roche, Sanofi and Gilead did not respond to requests to comment.Among the most logical acquisition targets are Incyte Corporation and Seattle Genetics, which have respective market capitalizations of about $16 billion and $6 billion, said Michael King, a biotechnology analyst at JMP Securities.Incyte's blood cancer drug, Jakafi, produced more than $600 million in sales last year. Seattle Genetic's lymphoma drug, ADCETRIS, earned revenues of nearly $450 million. Both companies declined to comment.The acquisition of promising cancer drugs is ""going to be a major theme in the life sciences sector for the next several years,"" said Kennen MacKay, a biotechnology analyst at Credit Suisse Group AG.MORE DEALS EXPECTED  Acquisitions of cancer drug companies accounted for about 20 percent of the $63 billion in pharmaceutical and biotech M&A announced this year, according to data from Thomson Reuters. Cancer deals accounted for a smaller share - 16 percent - of a larger pharmaceutical M&A pie during the first half of 2015.Deals involving cancer drugs are expected to rise in the second half of the year, as corporate boards of potential target companies begin to accept the lower valuations the sector has seen in recent months and become more open to deals.The Nasdaq Biotech Index, a common measure of life sciences companies' performance, has plunged more than 30 percent from 2015 highs, as political criticism of drug prices fueled investor concerns.Global spending on cancer drugs is on the rise and may reach $178 billion by 2020, up from $107 billion in 2015, according to market research firm IMS Health. About half of that will occur in the United States.That makes oncology medication to be one of the single biggest anticipated drivers of prescription drug revenue growth over the next five years, according to data from consultancy Ernst and Young. ""I think an uptick in activity is very likely,"" said Jeff Greene, global transactions leader for life sciences at EY. ""We have seen some big deals already, and we are likely to see even more, large and small, in the second half of this year.""  Recent deals include AbbVie Inc's $10 billion acquisition of lung cancer company Stemcentryx, Jazz Pharmaceuticals' $1.5 billion takeover of leukemia drug maker Celator Pharmaceuticals Inc, and Bristol-Myers Squibb Co's roughly $500 million acquisition of Cormorant Pharmaceuticals.More dealmaking is on the way. Earlier this month, Medivation Inc, a U.S. prostate cancer drug company with a market capitalization of $10 billion, said it would open its books to Sanofi SA as part of a sale process that sources said also has attracted Pfizer Inc and Celgene Corp.REFRESHING PORTFOLIOS For some, laying claim to a piece of the oncology sector's blockbuster growth could help offset the waning fortunes of mature drugs. For example, Sanofi's blockbuster diabetes drug, Lantus, will face heightened generic drug competition in December. Gilead faces increased pressure on its liver disease franchise, which makes up two-thirds of its revenues.Abbvie, which purchased two oncology companies in the past year, Pharmacyclics and Stemcentryx, is facing potential competition for its biggest drug, Humira, for arthritis. A U.S. Food and Drug Administration (FDA) panel recently recommended approval of an application by Amgen to sell a similar product.Best equipped to play a leading role are major pharmaceutical companies because bringing the new generation of cancer medicines under development to market requires scale and resources.""Oncology is a go-big-or-go-home category,"" said Brian Corvino, a life sciences consultant at Decision Resources Group. ""The amount of investment to develop and commercialize oncology drugs is massive and only becomes efficient at a certain scale.""The benefits of scale have only grown in recent years, as insurance companies increasingly have demanded drug makers justify prices in terms of the value they add to patient's health.A large player in oncology is better equipped to partner with health care providers to collect data on a drug's efficacy and argue the case to major insurers, Corvino said.From an acquirer's perspective, the most attractive targets are companies with drugs that are already generating some revenue and are treating diseases where competition is scant.""For players that are looking to build an oncology presence, you need to buy a company that already has a blockbuster out there,"" MacKay said.Companies whose drugs are still in development pose greater risk. Shares of Juno Therapeutics, for example, dropped about 30 percent earlier this month when the FDA placed a hold on a clinical trial for its main leukemia drug after two people died. The hold was later reversed and the stock partly recovered. (Reporting by Carl O'Donnell in New York; Editing by Greg Roumeliotis and Lisa Girion)",2016-07-19,BMY,"Tue Jul 19, 2016 | 1:08am EDT",DEALTALK-Old pharma sees new profit cure in cancer drugs,http://www.reuters.com//article/oncology-ma-idUSL1N19L1QP?type=companyNews
249,"  July 20 Bristol-Myers Squibb Co* Bristol-Myers Squibb announces availability of FDA-approved ORENCIA (abatacept) clickject(tm), a self-administered subcutaneous autoinjector, for adults with moderate to severe rheumatoid arthritis  * Myers Squibb Co - study, agree, met its co-primary endpoints  Source text for Eikon:  Further company coverage: ",2016-07-20,BMY,"Wed Jul 20, 2016 | 7:18am EDT","BRIEF-Bristol-Myers says FDA-approved ORENCIA, clickject available",http://www.reuters.com//article/idUSFWN1A60HW?type=companyNews
250,  July 26 Bristol-myers Squibb Co* Bristol-Myers squibb announces new research collaboration with janssen in immuno-oncology focused on lung cancer  * Myers squibb co - phase 2 clinical trial will evaluate tolerability and clinical activity of combination of these agents in nsclc patients  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ,2016-07-26,BMY,"Tue Jul 26, 2016 | 7:36am EDT",BRIEF-Bristol-Myers Squibb collaborates with Johnson and Johnson for lung cancer research,http://www.reuters.com//article/idUSFWN1AC0L2?type=companyNews
251,"  July 28 (Reuters) -* Bristol Myers Squibb - In May 2016, co sold the business comprising an alliance with Reckitt Benckiser Group including several OTC products sold primarily in Mexico and Brazil  * Bristol Myers Squibb - Reckitt exercised its option to acquire the business, including a manufacturing facility, for $317 million, resulting in a gain of $277 million  Source text: bit.ly/2acCZFh   (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780) ",2016-07-28,BMY,"Thu Jul 28, 2016 | 11:45am EDT",BRIEF-Bristol-Myers Says in May sold business comprising an alliance with Reckitt Benckiser,http://www.reuters.com//article/idUSFWN1AE1AS?type=companyNews
252,"   By Ransdell Pierson  Bristol-Myers Squibb Co reported disappointing second-quarter sales of its Yervoy melanoma treatment on Thursday, raising concerns about the long-term prospects for one of its most important cancer medicines and sending its shares lower. Sales of Yervoy, often used in combination with either Bristol-Myers' newer Opdivo immuno-therapy or with Merck & Co's similar Keytruda, fell 19 percent to $241 million.BMO Capital Markets analyst Alex Arfaei said Yervoy sales were about $50 million below Wall Street forecasts, as doctors used Optivo or Keytruda instead, as standalone treatments. All three medicines work by taking the brakes off the immune system.""Yervoy appears to be rapidly losing share to (Opdivo and Keytruda)"" outside the United States, Arfaei said in a research note.  The company's shares were down 1.8 percent at $75.09 in late morning trading. Company revenue jumped 17 percent to $4.87 billion, about $200 million above analyst predictions. Still, most of the unexpected sales gains came from hepatitis C medicines that are expected to soon lose ground to newer treatments.    Bristol-Myers' most important medicine is Opdivo, a so-called PD-1 inhibitor that is also approved to treat lung cancer and kidney cancer. Approved in late 2014, its sales hit $840 million in the quarter and is expected to keep growing by leaps and bounds despite competition from Merck's Keytruda.Bristol-Myers shares trade at about 23 times the company's expected 2017 per-share earnings, well above the approximate price-earnings ratio of 16 for its large rivals, based on optimism for widening use of Opdivo and Yervoy.  Strong growth was seen for Eliquis, a pill co-marketed by Pfizer Inc, which is used to prevent blood clots in patients with an irregular heartbeat called atrial fibrillation. Its sales soared 78 percent to $777 million, helped by clinical data that suggest it is safer and more effective than rival new oral therapies.Sales of Orencia, used to treat rheumatoid arthritis, rose 29 percent to $593 million, about $70 million above Wall Street forecasts. Bristol-Myers earned $1.17 billion, or 69 cents a share, compared with a loss of $130 million, or 8 cents a share, a year earlier, when it took a big acquisition-related charge. Excluding special items, Bristol-Myers earned 69 cents per share, exceeding the average analyst estimate of 67 cents, according to Thomson Reuters I/B/E/S.    Bristol-Myers said it now expects 2016 earnings of $2.55 to $2.65 per share, slightly higher than its earlier forecast of $2.50 to $2.60 per share.  (Reporting by Ransdell Pierson in New York; Editing by Bernadette Baum)",2016-07-28,BMY,"Thu Jul 28, 2016 | 11:24am EDT",Bristol-Myers shares hit by decline of Yervoy melanoma drug,http://www.reuters.com//article/us-bristolmyers-results-idUSKCN1081AS?type=companyNews
253,"   By Ransdell Pierson  Bristol-Myers Squibb Co reported disappointing second-quarter sales of its Yervoy melanoma treatment on Thursday, raising concerns about the long-term prospects for one of its most important cancer medicines and sending its shares lower. Sales of Yervoy, often used in combination with either Bristol-Myers' newer Opdivo immuno-therapy or with Merck & Co's similar Keytruda, fell 19 percent to $241 million.BMO Capital Markets analyst Alex Arfaei said Yervoy sales were about $50 million below Wall Street forecasts, as doctors used Optivo or Keytruda instead, as standalone treatments. All three medicines work by taking the brakes off the immune system.""Yervoy appears to be rapidly losing share to (Opdivo and Keytruda)"" outside the United States, Arfaei said in a research note.  The company's shares were down 1.8 percent at $75.09 in late morning trading. Company revenue jumped 17 percent to $4.87 billion, about $200 million above analyst predictions. Still, most of the unexpected sales gains came from hepatitis C medicines that are expected to soon lose ground to newer treatments.    Bristol-Myers' most important medicine is Opdivo, a so-called PD-1 inhibitor that is also approved to treat lung cancer and kidney cancer. Approved in late 2014, its sales hit $840 million in the quarter and is expected to keep growing by leaps and bounds despite competition from Merck's Keytruda.Bristol-Myers shares trade at about 23 times the company's expected 2017 per-share earnings, well above the approximate price-earnings ratio of 16 for its large rivals, based on optimism for widening use of Opdivo and Yervoy.  Strong growth was seen for Eliquis, a pill co-marketed by Pfizer Inc, which is used to prevent blood clots in patients with an irregular heartbeat called atrial fibrillation. Its sales soared 78 percent to $777 million, helped by clinical data that suggest it is safer and more effective than rival new oral therapies.Sales of Orencia, used to treat rheumatoid arthritis, rose 29 percent to $593 million, about $70 million above Wall Street forecasts. Bristol-Myers earned $1.17 billion, or 69 cents a share, compared with a loss of $130 million, or 8 cents a share, a year earlier, when it took a big acquisition-related charge. Excluding special items, Bristol-Myers earned 69 cents per share, exceeding the average analyst estimate of 67 cents, according to Thomson Reuters I/B/E/S.    Bristol-Myers said it now expects 2016 earnings of $2.55 to $2.65 per share, slightly higher than its earlier forecast of $2.50 to $2.60 per share.  (Reporting by Ransdell Pierson in New York; Editing by Bernadette Baum)",2016-07-28,BMY,"Thu Jul 28, 2016 | 11:24am EDT",UPDATE 3-Bristol-Myers shares hit by decline of Yervoy melanoma drug,http://www.reuters.com//article/bristolmyers-results-idUSL1N1AE0DS?type=companyNews
254,  July 28 Bristol-Myers Squibb Co :* Myers Squibb reports second quarter financial results* Qtrly Opdivo worldwide revenues $840 million versus $122 million last year* Qtrly Sprycel worldwide revenues $451 million versus $405 million last year * FY2016 earnings per share view $2.60 -- Thomson Reuters I/B/E/S * Q2 revenue $4.9 billion versus I/B/E/S view $4.65 billion* Q2 earnings per share view $0.67 -- Thomson Reuters I/B/E/S * Sees FY 2016 non-gaap earnings per share $2.55 to $2.65* Sees FY 2016 gaap earnings per share $2.43 to $2.53  Source text for Eikon:  Further company coverage:,2016-07-28,BMY,"Thu Jul 28, 2016 | 7:16am EDT",BRIEF-Bristol-Myers squibb reports Q2 non-gaap EPS $0.69,http://www.reuters.com//article/idUSASC08Z1E?type=companyNews
255,"  July 28 Bristol-Myers Squibb Co reported better than expected quarterly results, fueled by sales of its treatments for hepatitis C, cancer and blood clots, and slightly raised its full year profit forecast.The U.S. drugmaker said on Thursday it earned $1.17 billion in the second quarter, or 69 cents per share, compared with a loss of $130 million, or 8 cents per share, in the year ago quarter, when it took a big acquisition-related charge.  Excluding special items, Bristol-Myers earned 69 cents per share, topping the average analyst forecast of 67 cents, according to Thomson Reuters I/B/E/S.      (Reporting by Ransdell Pierson) ",2016-07-28,BMY,"Thu Jul 28, 2016 | 7:03am EDT","Bristol-Myers beats forecasts, as hepatitis, cancer drugs deliver",http://www.reuters.com//article/bristolmyers-results-idUSL1N1AD2GS?type=companyNews
256,"   By Ransdell Pierson  Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's rival medicine.Shares of Bristol-Myers fell almost 16 percent to $63.54 on Friday after the company announced failure of the late-stage trial. Shares of Merck gained 8.7 percent to $62.89. ""This is the worst-case scenario"" for Opdivo and Bristol-Myers, Leerink analyst Seamus Fernandez said in a research note. ""There appears to be no silver lining.""Opdivo had been considered the clear leader in a costly new class of medicines called checkpoint inhibitors that work by taking the brakes off the immune system. Its second-quarter sales of $840 million were more than double those of Merck's Keytruda. Opdivo won approval in March 2015 for treatment of patients with advanced non-small cell lung cancer who had previously failed to benefit from chemotherapy. Six months later, Keytruda received approval for a similar patient population. Meanwhile, both companies raced to complete large trials to see if their drugs, which each cost about $150,000 a year, would also benefit patients who had never previously been treated for the most common form of lung cancer. The trials compared the drugs against chemotherapy. ""Obviously the results of this trial are disappointing,"" Bristol-Myers Chief Executive Giovanni Caforio said in an interview, saying that the data suggests there is no role in the foreseeable future for Opdivo as a standalone medicine for previously untreated lung cancer.Patients in the Opdivo trial had tumors with low levels of PD-L1, a protein whose presence may help identify those most likely to benefit from checkpoint inhibitors. Those in the successful Merck trial, by contrast, were only enrolled if they were shown to have high levels of PD-L1 and represented a smaller percentage of the lung cancer population.Caforio said the best hope now for Opdivo in front-line treatment of lung cancer is combination therapy. The company is conducting a late-stage study with more than 2,000 patients in which Opdivo will be combined with Bristol-Myers' other approved immunotherapy, Yervoy. The data is expected by early 2018. ""That study will provide the definitive answer of the role of combination immunotherapy in the front-line lung cancer setting,"" he said.Data in June from a large clinical study showed Keytruda was effective in newly treated patients, not only in delaying progression of lung cancer symptoms but also in prolonging survival. The trial was stopped so that all patients could receive Keytruda.The data spurred hopes that U.S. regulators would soon expand approved use of the Merck drug. Complete data for the study has not yet been released.  Now that Bristol-Myers' drug has failed in that effort, Merck's medicine could have a better chance to catch up with Opdivo's far larger sales. Sanford Bernstein analyst Tim Anderson said Opdivo, Keytruda and similar drugs in development had been expected to capture peak annual combined sales of $10 billion to $15 billion from lung cancer, with Bristol-Myers winning the lion's share.""Today's news very much helps level the playing field and is a major boost for Merck,"" Anderson said in a research note.Opdivo and Keytruda are also approved to treat advanced melanoma and are being studied against a wide range of other types of cancer. (Additional reporting by Natalie Grover in Bengaluru; Editing by Bernard Orr and Leslie Adler)",2016-08-05,BMY,"Fri Aug 5, 2016 | 3:19pm EDT",Bristol-Myers' Opdivo fails lung cancer trial; shares plunge,http://www.reuters.com//article/us-bristol-myers-study-idUSKCN10G1GA?type=companyNews
257,"   By Ransdell Pierson  Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's rival medicine.Shares of Bristol-Myers fell almost 16 percent to $63.54 on Friday after the company announced failure of the late-stage trial. Shares of Merck gained 8.7 percent to $62.89. ""This is the worst-case scenario"" for Opdivo and Bristol-Myers, Leerink analyst Seamus Fernandez said in a research note. ""There appears to be no silver lining.""Opdivo had been considered the clear leader in a costly new class of medicines called checkpoint inhibitors that work by taking the brakes off the immune system. Its second-quarter sales of $840 million were more than double those of Merck's Keytruda. Opdivo won approval in March 2015 for treatment of patients with advanced non-small cell lung cancer who had previously failed to benefit from chemotherapy. Six months later, Keytruda received approval for a similar patient population. Meanwhile, both companies raced to complete large trials to see if their drugs, which each cost about $150,000 a year, would also benefit patients who had never previously been treated for the most common form of lung cancer. The trials compared the drugs against chemotherapy. ""Obviously the results of this trial are disappointing,"" Bristol-Myers Chief Executive Giovanni Caforio said in an interview, saying that the data suggests there is no role in the foreseeable future for Opdivo as a standalone medicine for previously untreated lung cancer.Patients in the Opdivo trial had tumors with low levels of PD-L1, a protein whose presence may help identify those most likely to benefit from checkpoint inhibitors. Those in the successful Merck trial, by contrast, were only enrolled if they were shown to have high levels of PD-L1 and represented a smaller percentage of the lung cancer population.Caforio said the best hope now for Opdivo in front-line treatment of lung cancer is combination therapy. The company is conducting a late-stage study with more than 2,000 patients in which Opdivo will be combined with Bristol-Myers' other approved immunotherapy, Yervoy. The data is expected by early 2018. ""That study will provide the definitive answer of the role of combination immunotherapy in the front-line lung cancer setting,"" he said.Data in June from a large clinical study showed Keytruda was effective in newly treated patients, not only in delaying progression of lung cancer symptoms but also in prolonging survival. The trial was stopped so that all patients could receive Keytruda.The data spurred hopes that U.S. regulators would soon expand approved use of the Merck drug. Complete data for the study has not yet been released.  Now that Bristol-Myers' drug has failed in that effort, Merck's medicine could have a better chance to catch up with Opdivo's far larger sales. Sanford Bernstein analyst Tim Anderson said Opdivo, Keytruda and similar drugs in development had been expected to capture peak annual combined sales of $10 billion to $15 billion from lung cancer, with Bristol-Myers winning the lion's share.""Today's news very much helps level the playing field and is a major boost for Merck,"" Anderson said in a research note.Opdivo and Keytruda are also approved to treat advanced melanoma and are being studied against a wide range of other types of cancer. (Additional reporting by Natalie Grover in Bengaluru; Editing by Bernard Orr and Leslie Adler)",2016-08-05,BMY,"Fri Aug 5, 2016 | 3:19pm EDT",UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge,http://www.reuters.com//article/bristol-myers-study-idUSL4N1AM1PC?type=companyNews
258,  Aug 5 Moody's on Bristol-Myers Squibb:* Moody's: Bristol's lung cancer trial result a major setback  * There is no impact on Bristol-Myers Squibb's A2/PRIME-1 ratings or stable rating outlook  Source text for Eikon:  Further company coverage: ,2016-08-05,BMY,"Fri Aug 5, 2016 | 2:03pm EDT",BRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setback,http://www.reuters.com//article/idUSFWN1AM1EB?type=companyNews
259,"   By Ben Hirschler | LONDON  LONDON AstraZeneca (AZN.L) shares hit a record high on Friday, breaching for the first time the 55 pounds a share level offered by Pfizer (PFE.N) in 2014 during the U.S. group's abortive $100 billion attempt to buy the drugmaker.The British firm's stock has been on a roll recently, helped by a falling pound and speculation that Switzerland's Novartis (NOVN.S) might be next to launch a bid. However, the shares were lifted to a high of 55.05 pounds by the misfortunes of Bristol-Myers Squibb (BMY.N).The failure of Bristol's immunotherapy drug Opdivo to slow disease progression in previously untreated patients with lung cancer as hoped was seen by investors as good news for rivals Merck & Co (MRK.N) and AstraZeneca. Analysts at Leerink, Jefferies and Deutsche Bank said the negative result with Opdivo increased the potential market opportunity for AstraZeneca's keenly watched combination of durvalumab and tremelimumab.Crucial clinical trial results with durvalumab, both on its own and in combination with tremelimumab, are due next year. Chief Executive Pascal Soriot believes AstraZeneca can become a major player in cancer drugs that bolster the immune system. And its ability to carve out billions of dollars in potential sales hinges not only on the effectiveness of its own products but on the competitive profile of rivals. Cancer is currently the hottest area of research across the drugs industry and some analysts believe this could make AstraZeneca a takeover target once again, with speculation turning last week to Novartis as a bidder.  (Editing by Dale Hudson)",2016-08-05,BMY,"Fri Aug 5, 2016 | 10:43am EDT","AstraZeneca hits 2014 Pfizer bid price, helped by Bristol's woes",http://www.reuters.com//article/us-astrazeneca-cancer-idUSKCN10G1L6?type=companyNews
260,"  Aug 5 Bristol-myers Squibb Co :* Bristol-Myers Squibb announces top-line results from checkmate -026, a phase 3 study of Opdivo (nivolumab) in treatment-nave patients with advanced non-small cell lung cancer * Bristol-Myers Squibb announces top-line results from checkmate -026, a phase 3 study of opdivo (nivolumab) in treatment-nave patients with advanced non-small cell lung cancer * Myers Squibb co - Opdivo did not meet trial primary endpoint of progression-free survival in patients expressing pd-l1  5% * Myers Squibb co - will complete a full evaluation of checkmate -026 data and work with investigators on future presentation of results  Source text for Eikon:  Further company coverage:",2016-08-05,BMY,"Fri Aug 5, 2016 | 8:55am EDT",BRIEF-Bristol-Myers' Opdivo fails late-stage study in patients with lung cancer,http://www.reuters.com//article/idUSASC0917R?type=companyNews
261,"  Aug 5 Bristol-Myers Squibb Co said its blockbuster immunotherapy, Opdivo, failed to improve survival in previously untreated patients with a form of lung cancer, without their disease progressing, in a late-stage study.Bristol-Myers' shares were down 20 percent at $60.00 in premarket trading. Shares of Merck & Co, which makes rival drug Keytruda, were up 11 percent at $64.60. The trial was testing Opdivo against chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).  Opdivo, first approved in late 2014, is already approved for use in NSCLC patients who have failed prior therapy, as well as forms of melanoma, kidney cancer and blood cancer.   (Reporting by Natalie Grover in Bengaluru; Editing by Maju Samuel)",2016-08-05,BMY,"Fri Aug 5, 2016 | 8:40am EDT",Bristol-Myers' Opdivo fails late-stage study in lung cancer patients,http://www.reuters.com//article/bristol-myers-study-idUSL4N1AM1NM?type=companyNews
262,  Aug 15 Aveo* Initiates Evaluation Of Tivozanib In Combination With Bristol Myers Squibb's Opdivo (nivolumab) in advanced renal cell carcinoma  * Phase 1/2 tinivo trial to commence at institut gustave roussy in paris  Source text for Eikon:  Further company coverage: ,2016-08-15,BMY,"Mon Aug 15, 2016 | 7:15am EDT",BRIEF-Aveo initiates evaluation of Tivozanib in combination with Bristol-Myers Squibb's opdivo in advanced renal cell carcinoma,http://www.reuters.com//article/idUSFWN1AW0BW?type=companyNews
263,  Sept 6 European Commission Approves Bristol  :* Myers Squibb's Orencia (Abatacept) for the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with Methotrexate  * Says approval allows for expanded marketing of Orencia in all 28 member states of EU  Source text for Eikon:  Further company coverage: ,2016-09-06,BMY,"Tue Sep 6, 2016 | 7:58am EDT",BRIEF-European Commission approves Bristol-Myers Squibb's Orencia (Abatacept),http://www.reuters.com//article/idUSFWN1BI01W?type=companyNews
264,"   By Brendan Pierson  New Mexico Attorney General Hector Balderas has sued Bristol-Myers Squibb Co and Sanofi SA's U.S. arm for overstating the effectiveness of and concealing the risks of their blood thinner Plavix. The lawsuit, filed Wednesday in state court in Santa Fe, is the latest in a slew of cases brought by patients and state attorneys general over the drug.  To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2cBrR5Q",2016-09-16,BMY,"Fri Sep 16, 2016 | 7:51am EDT","New Mexico AG sues Bristol-Myers, Sanofi over blood thinner",http://www.reuters.com//article/health-plavix-idUSL2N1BS0CU?type=companyNews
265,  Sept 20 Bristol-Myers Squibb Co :* European Medicines Agency validates Bristol Myers Squibb's type II variation application for Opdivo (nivolumab) in advanced form of bladder cancer  * Validation of application confirms submission is complete and begins EMA's centralized review process  Source text for Eikon:  Further company coverage: ,2016-09-20,BMY,"Tue Sep 20, 2016 | 8:17am EDT",BRIEF-Bristol-Myers says EMA validates type II variation application for Opdivo,http://www.reuters.com//article/idUSFWN1BW0AN?type=companyNews
266,"  Bristol-Myers Squibb Co said on Tuesday it would evaluate the use of its blockbuster cancer immunotherapy Opdivo in combination with an experimental drug from Nektar Therapeutics to treat multiple cancers.Opdivo, which competes with Merck & Co's Keytruda, belongs to a costly new class of medicines called PD-1 checkpoint inhibitors that work by taking the brakes off the immune system.The collaboration involves Nektar's NKTR-214, an experimental immuno-stimulatory therapy designed to increase the expression of PD-1 on immune cells. The trials will evaluate the potential for the combination to improve on the current standard-of-care to treat melanoma and cancers of the kidney, colorectal system, bladder and the most common form of lung cancer.Opdivo is already approved to treat advanced melanoma and lung cancer, and is being studied for other cancers.   (Reporting by Natalie Grover in Bengaluru; Editing by Ted Kerr)",2016-09-27,BMY,"Tue Sep 27, 2016 | 7:44am EDT",Bristol-Myers to test Opdivo with Nektar drug for several cancers,http://www.reuters.com//article/uk-bristol-myers-nektar-idUSKCN11X17M?type=companyNews
267,  Sept 27 Bristol-myers Squibb Co :* Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration to evaluate combination of Opdivo (nivolumab) and NKTR-214* Says Bristol-Myers Squibb and Nektar will equally share costs of combined therapy trials * Myers Squibb co - an initial dose-escalation trial is underway with Opdivo and NKTR-214 * Nektar will maintain its global commercial rights to NKTR-214 * Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration to evaluate combination of Opdivo (nivolumab) and NKTR-214  Source text for Eikon:  Further company coverage:,2016-09-27,BMY,"Tue Sep 27, 2016 | 7:10am EDT",BRIEF-Bristol-Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration,http://www.reuters.com//article/idUSFWN1C30BC?type=companyNews
268,"   By Ben Hirschler | COPENHAGEN  COPENHAGEN The failure of Bristol-Myers Squibb's blockbuster Opdivo immunotherapy in previously untreated lung cancer patients has opened up the market for AstraZeneca, its chief executive believes.""Suddenly, this trial news opens quite some opportunities for us, in both monotherapy and combination therapy,"" Chief Executive Pascal Soriot told Reuters on Saturday, in his first comments since the Opdivo trial flop in August.Soriot is in Copenhagen for the European Society for Medical Oncology congress, where he and his team will be scouring data from competitors to determine how best to fine-tune their own clinical work to maximize its chance of success.The timing has been fortuitous for the British drugmaker, which can now take advantage of the experience of its rivals.At stake is a chunk of a hugely promising new market for cancer treatments that fight tumors by boosting the immune system. Industry analysts forecast such drugs could eventually generate annual sales of $30 billion to $40 billion, with lung cancer seen as the biggest opportunity.Much of the clinical focus is on the best way to select patients likely to benefit from the new and expensive medicines, by using biomarkers to assess their tumors. While the Opdivo trial included patients with low levels of a protein called PD-L1, a separate trial found Merck's similar drug Keytruda worked well in a much smaller group of patients expressing at least 50 percent PD-L1. That gives AstraZeneca the opportunity to steer a path between its two rivals by refining the PD-L1 benchmarks used in its own keenly awaited clinical trial, known as MYSTIC, which is expected to report results early next year.""It gives us a chance to do what BMS was trying to do, but do it in a less risky manner, by expanding the population from the 50 percent PD-L1 cut-off to a bit broader,"" Soriot said.AstraZenecas rival to Opdivo and Keytruda is durvalumab, which is being tested on its own and with another immunotherapy called tremelimumab. The British company is currently planning to look at how well its treatment fares among patients with a 25 percent PD-L1 expression level or more, but it has the flexibility to amend this.Roche also has a rival immunotherapy called Tecentriq, which has proved effective in previously treated lung cancer patients, and the fact that AstraZeneca looks like being fourth to market has been viewed negatively by many investors.Soriot argues this ignores the fact his company has the potential to leap ahead in combination therapy, which could well become the main choice for most lung cancer patients.""We're coming from a place where everybody thought we were behind and we have a very good chance to play in both the monotherapy and combination segments,"" Soriot said. ""Even if BMS were to catch up with us in combination, there would still only be two companies with these regimens.""Currently, Bristol's competing immunotherapy combination is not expected to produce clinical trial results until 2018.Furthermore, AstraZeneca has another card up its sleeve in the form of a so-called priority review voucher from the U.S. Food and Drug Administration, which Soriot said could be used, if needed, to help it seek rapid approval.""Being first is definitely important,"" Soriot said. (Editing by Susan Thomas)",2016-10-08,BMY,"Sat Oct 8, 2016 | 10:51am EDT",Bristol drug flop opens big cancer opportunity: AstraZeneca CEO,http://www.reuters.com//article/us-health-cancer-astrazeneca-idUSKCN1280OL?type=companyNews
269,"   By Ben Hirschler | COPENHAGEN  COPENHAGEN Lung cancer patients on Roche's immune system-boosting drug Tecentriq lived on average 4.2 months longer than those taking chemotherapy in a pivotal study, pressuring Bristol-Myers Squibb's dominant position in the field.The trial involved second-line patients, who have already used chemotherapy, and it found the Roche drug worked even in people with low or no levels of a protein called PD-L1, which is often used to test suitability for immunotherapy.The study results were presented at the annual European Society of Medical Oncology congress on Sunday.Bristol's Opdivo is currently the only immunotherapy drug approved without a PD-L1 test for non-small cell lung cancer (NSCLC), the most common form of the disease. Merck & Co's Keytruda requires a test. That has favored Opdivo and fueled its sales, but the arrival of a rival with the same broad effectiveness now promises increased competition. U.S. regulators are due to decide whether to approve Tecentriq in lung cancer by Oct. 19. The Roche drug is already cleared for use in bladder cancer.Tecentriq, Opdivo and Keytruda are the first of a highly promising class of immunotherapy drugs that are revolutionizing cancer treatment and are tipped to generate huge sales. Lung cancer, the biggest cancer killer globally, is the top commercial opportunity.Analysts believe Tecentriq sales across all cancers will reach $4 billion in 2021, according to consensus figures compiled by Thomson Reuters. In the 1,225-patient Roche study, the mean survival for patients on Tecentriq was 13.8 months, which was 27 percent better than the 9.6 months seen among those on docetaxel chemotherapy.The benefit of the new drug was greatest in patients with high levels of PD-L1 but even in people with no PD-L1 expression there was still a significant improvement. Martin Reck of Germany's Lung Clinic Grosshansdorf said the findings suggested doctors had a problem if they planned to use a negative PD-L1 reading as a reason to exclude second-line NSCLC patients from treatment.Companies are also racing to prove that immunotherapy can help in first-line NSCLC, where it would replace chemotherapy as the initial drug given. Here, however, the idea of giving immunotherapy to all patients has proved problematic, as evidenced by the failure of a recent Bristol trial.Roche has eight late-stage Phase III lung studies under way evaluating Tecentriq alone or in combination with other treatments in patients with early and advanced stages of lung cancer. (Reporting by Ben Hirschler; Editing by Stephen Powell)",2016-10-09,BMY,"Sun Oct 9, 2016 | 2:21am EDT",Roche lung cancer drug success adds to pressure on Bristol,http://www.reuters.com//article/us-health-cancer-roche-idUSKCN12904S?type=companyNews
270,"  * Keytruda cuts risk of death 40 pct in big lung cancer study* Drug also improves outcomes when given with chemotherapyBy Ben HirschlerCOPENHAGEN, Oct 9 Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemotherapy.As a monotherapy, Keytruda halved the risk of disease progression and cut overall deaths by 40 percent compared to chemotherapy alone in pre-selected patients whose tumours had been tested using a biomarker.In contrast to rival Bristol-Myers Squibb, whose Opdivo drug failed to help such first-line patients, Keytruda was targeted at people who express high levels of a protein called PD-L1, which makes them more receptive to immunotherapy.U.S. regulators are expected to decide whether to approve Keytruda for first-line non-small cell lung cancer, the most common type, by Dec. 24. Merck had already said in June that Keytruda worked in the trial but the scale of the benefit was only disclosed at the annual European Society for Medical Oncology (ESMO) congress.The second trial, mixing Keytruda with chemotherapy, was much smaller but was notable because it was the first time that a combination of immunotherapy and chemotherapy has been shown to work in a randomised Phase II study.Many experts have been sceptical about this approach and investors' expectations, up until now, have been quite low.In the event, researchers reported that Merck's combination cut the risk of disease progression or death by 47 percent compared to chemotherapy alone after 10.6 months, while 55 percent of patients saw their tumours shrink versus 29 percent. Patients in this trial were not selected by PD-L1 expression but the study did find that those with higher PD-L1 had a higher response.Roger Perlmutter, Merck's head of research, said both trials suggested Keytruda could offer a broad array of patients meaningful improvement over standard platinum-based chemotherapy, which is now more than two decades old.Drugs like Keytruda and Opdivo work by taking the brakes off the immune system and allowing the body's natural killer cells to home in on tumours. They are expected to sell tens of billions of dollars in the years ahead, with lung cancer, the biggest cancer killer globally, viewed as the largest market.Results of Bristol's failed Opdivo trial, which included patients with tumours testing only 5 percent or higher for PD-L1 against the 50 percent cut-off used by Merck, were also presented at ESMO.These showed progression-free survival was 4.2 months with Opdivo and 5.9 months with chemotherapy, although the difference was not statistically significant. Overall survival was 14.4 months with Opdivo versus 13.2 months.The failure of Opdivo to work for ""all comers"" in lung cancer was first announced in August, without any details. It was a major setback for Bristol, wiping out around a quarter of the company's market value, and it has caused investors to rethink prospects for immunotherapy treatments.Many now believe that combination therapy is the way ahead, with Bristol and AstraZeneca working primarily on using two immunotherapies together, while Roche and Merck look at adding chemotherapy.Results of Merck's two trials were published online in the New England Journal of Medicine and the Lancet Oncology journal.   (Reporting by Ben Hirschler; Editing by Stephen Powell)",2016-10-09,BMY,"Sun Oct 9, 2016 | 2:15am EDT",Merck drug shines in lung cancer and also works with chemo,http://www.reuters.com//article/health-cancer-merck-co-idUSL5N1CE0J7?type=companyNews
271,"   By Ben Hirschler | COPENHAGEN  COPENHAGEN Lung cancer patients on Roche's immune system-boosting drug Tecentriq lived on average 4.2 months longer than those taking chemotherapy in a pivotal study, pressuring Bristol-Myers Squibb's dominant position in the field.The trial involved second-line patients, who have already used chemotherapy, and it found the Roche drug worked even in people with low or no levels of a protein called PD-L1, which is often used to test suitability for immunotherapy.The study results were presented at the annual European Society of Medical Oncology congress on Sunday.Bristol's Opdivo is currently the only immunotherapy drug approved without a PD-L1 test for non-small cell lung cancer (NSCLC), the most common form of the disease. Merck & Co's Keytruda requires a test. That has favored Opdivo and fueled its sales, but the arrival of a rival with the same broad effectiveness now promises increased competition. U.S. regulators are due to decide whether to approve Tecentriq in lung cancer by Oct. 19. The Roche drug is already cleared for use in bladder cancer.Tecentriq, Opdivo and Keytruda are the first of a highly promising class of immunotherapy drugs that are revolutionizing cancer treatment and are tipped to generate huge sales. Lung cancer, the biggest cancer killer globally, is the top commercial opportunity.Analysts believe Tecentriq sales across all cancers will reach $4 billion in 2021, according to consensus figures compiled by Thomson Reuters. In the 1,225-patient Roche study, the mean survival for patients on Tecentriq was 13.8 months, which was 27 percent better than the 9.6 months seen among those on docetaxel chemotherapy.The benefit of the new drug was greatest in patients with high levels of PD-L1 but even in people with no PD-L1 expression there was still a significant improvement. Martin Reck of Germany's Lung Clinic Grosshansdorf said the findings suggested doctors had a problem if they planned to use a negative PD-L1 reading as a reason to exclude second-line NSCLC patients from treatment.Companies are also racing to prove that immunotherapy can help in first-line NSCLC, where it would replace chemotherapy as the initial drug given. Here, however, the idea of giving immunotherapy to all patients has proved problematic, as evidenced by the failure of a recent Bristol trial.Roche has eight late-stage Phase III lung studies under way evaluating Tecentriq alone or in combination with other treatments in patients with early and advanced stages of lung cancer. (Reporting by Ben Hirschler; Editing by Stephen Powell)",2016-10-09,BMY,"Sun Oct 9, 2016 | 2:21am EDT",Roche lung cancer drug success adds to pressure on Bristol,http://www.reuters.com//article/health-cancer-roche-idUSL5N1CE06R?type=companyNews
272,"   By Ransdell Pierson and Bill Berkrot  New data is likely to prompt doctors to abandon Bristol-Myers Squibb's immunotherapy Opdivo in favor of Merck & Co's rival Keytruda in a large segment of the lucrative lung cancer market, analysts said on Monday.    The results of a closely watched clinical trial sent Bristol's shares plunging 10 percent.    The data, presented at a medical meeting on Sunday, showed that lung cancer patients fared worse on Opdivo than those on chemotherapy. Merck shares rose nearly 2 percent on strong benefits shown by Keytruda in a similar late-stage lung cancer study. Both trials tested the drugs that help the immune system to recognize and fight cancer as an initial treatment for advanced lung cancer. They are already approved for patients whose disease had progressed following chemotherapy, but approval as a so called first-line therapy could greatly increase the number of patients taking them.Opdivo had been considered the leader among the new class of medicines. It generated $840 million of sales in the second quarter, more than double those of Keytruda.The view of the rival drugs began to change in August, with the surprise announcement by Bristol-Myers that Opdivo had failed to best older chemotherapies in the Phase III trial.Details of the trial unveiled at the European Society for Medical Oncology meeting in Copenhagen only heightened those   concerns. Patients on Opdivo went 4.2 months before their disease worsened versus 5.9 months for those on chemo, although the difference was not deemed statistically significant.""This data represented a worst-case scenario for Opdivo,"" Sanford Bernstein analyst Tim Anderson said in a research note.  The Opdivo trial enrolled patients regardless of their tumor's level of PD-L1 expression, a protein targeted by the drug whose presence may help identify those most likely to benefit from treatment with the new medicines.Meanwhile, researchers reported that Keytruda halved the risk of disease progression in previously untreated patients, and cut overall deaths by 40 percent compared to chemotherapy.Patients in the Merck trial were only enrolled if they were shown to have high levels of PD-L1, a narrower segment of the lung cancer population than those in the Bristol-Myers study. ""Merck will completely 'own' the segment of first-line lung cancer patients who have high PD-L1 expression levels, and Bristol Myers will capture nothing really,"" Anderson said.Doctors are allowed to prescribe medicines for not yet approved uses, but analysts said they expect current off-label prescribing of Opdivo in first-line lung cancer to dry up now.In addition, competition in second-line lung cancer is soon expected to intensify with the anticipated approval of Roche's immunotherapy Tecentriq, which is now approved to treat bladder cancer. Both Keytruda and Tecentriq are given every three weeks, while Opdivo is administered every two weeks, which is seen as a convenience disadvantage.   ""The nearly inexplicable failure of (Opdivo) at every level of PD-L1 expression ... puts Merck in the driver's seat in first-line lung cancer for at least the next 12-18 months,"" said Leerink Partners analyst Seamus Fernandez.Calling the Keytruda data ""stunning, Fernandez said, ""We fully expect Merck to retain a significant place at the table long term.""   Bristol shares, which had already lost one quarter of their value since the initial trial data was disclosed in August, fell 10 percent $49.85, while Merck shares were up 1.7 percent at $63.84 after earlier rising more than 3 percent to a near 15-year high.Opdivo is also approved for advanced melanoma, kidney cancer and a type of Hodgkin lymphoma, while Keytruda is also approved for advanced melanoma, plus head and neck cancer. But lung cancer is considered by far the biggest market for cancer drugs. (Reporting by Ransdell Pierson and Bill Berkrot; Editing by Bernadette Baum and Cynthia Osterman)",2016-10-10,BMY,"Tue Oct 11, 2016 | 1:29am EDT",UPDATE 1-Bristol lung-cancer setback puts rival Merck drug in driver seat,http://www.reuters.com//article/bristolmyers-merck-stocks-idUSL1N1CG0XE?type=companyNews
273,"   By Ransdell Pierson and Bill Berkrot  New data is likely to prompt doctors to abandon Bristol-Myers Squibb's immunotherapy Opdivo in favor of Merck & Co's rival Keytruda in a large segment of the lucrative lung cancer market, analysts said on Monday.    The results of a closely watched clinical trial sent Bristol's shares plunging 10 percent.    The data, presented at a medical meeting on Sunday, showed that lung cancer patients fared worse on Opdivo than those on chemotherapy. Merck shares rose nearly 2 percent on strong benefits shown by Keytruda in a similar late-stage lung cancer study. Both trials tested the drugs that help the immune system to recognize and fight cancer as an initial treatment for advanced lung cancer. They are already approved for patients whose disease had progressed following chemotherapy, but approval as a so called first-line therapy could greatly increase the number of patients taking them.Opdivo had been considered the leader among the new class of medicines. It generated $840 million of sales in the second quarter, more than double those of Keytruda.The view of the rival drugs began to change in August, with the surprise announcement by Bristol-Myers that Opdivo had failed to best older chemotherapies in the Phase III trial.Details of the trial unveiled at the European Society for Medical Oncology meeting in Copenhagen only heightened those   concerns. Patients on Opdivo went 4.2 months before their disease worsened versus 5.9 months for those on chemo, although the difference was not deemed statistically significant.""This data represented a worst-case scenario for Opdivo,"" Sanford Bernstein analyst Tim Anderson said in a research note.  The Opdivo trial enrolled patients regardless of their tumor's level of PD-L1 expression, a protein targeted by the drug whose presence may help identify those most likely to benefit from treatment with the new medicines.Meanwhile, researchers reported that Keytruda halved the risk of disease progression in previously untreated patients, and cut overall deaths by 40 percent compared to chemotherapy.Patients in the Merck trial were only enrolled if they were shown to have high levels of PD-L1, a narrower segment of the lung cancer population than those in the Bristol-Myers study. ""Merck will completely 'own' the segment of first-line lung cancer patients who have high PD-L1 expression levels, and Bristol Myers will capture nothing really,"" Anderson said.Doctors are allowed to prescribe medicines for not yet approved uses, but analysts said they expect current off-label prescribing of Opdivo in first-line lung cancer to dry up now.In addition, competition in second-line lung cancer is soon expected to intensify with the anticipated approval of Roche's immunotherapy Tecentriq, which is now approved to treat bladder cancer. Both Keytruda and Tecentriq are given every three weeks, while Opdivo is administered every two weeks, which is seen as a convenience disadvantage.   ""The nearly inexplicable failure of (Opdivo) at every level of PD-L1 expression ... puts Merck in the driver's seat in first-line lung cancer for at least the next 12-18 months,"" said Leerink Partners analyst Seamus Fernandez.Calling the Keytruda data ""stunning, Fernandez said, ""We fully expect Merck to retain a significant place at the table long term.""   Bristol shares, which had already lost one quarter of their value since the initial trial data was disclosed in August, fell 10 percent $49.85, while Merck shares were up 1.7 percent at $63.84 after earlier rising more than 3 percent to a near 15-year high.Opdivo is also approved for advanced melanoma, kidney cancer and a type of Hodgkin lymphoma, while Keytruda is also approved for advanced melanoma, plus head and neck cancer. But lung cancer is considered by far the biggest market for cancer drugs. (Reporting by Ransdell Pierson and Bill Berkrot; Editing by Bernadette Baum and Cynthia Osterman)",2016-10-11,BMY,"Tue Oct 11, 2016 | 1:29am EDT",Bristol lung-cancer setback puts rival Merck drug in driver seat,http://www.reuters.com//article/us-bristolmyers-merck-stocks-idUSKCN12A1V6?type=companyNews
274,"  Oct 14 Bristol-Myers Squibb Co* Receives positive CHMP opinion for Opdivo (nivolumab) for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant and treatment with Brentuximab Vedot * Says CHMP decision based on overall response rate demonstrated by data from two trials, Checkmate -205 and Checkmate -039  * CHMP recommendation will now be reviewed by European commission  Source text for Eikon:  Further company coverage:",2016-10-14,BMY,"Fri Oct 14, 2016 | 7:09am EDT",BRIEF-Bristol-Myers receives positive CHMP opinion for Opdivo,http://www.reuters.com//article/idUSFWN1CK0BY?type=companyNews
275,"   By John Miller | ZURICH  ZURICH Roche said on Thursday strong sales of new medicines like cancer immunotherapy drug Tecentriq would help to sustain the company's growth as patents on older drugs start to expire.Chief Executive Severin Schwan is betting he can stay ahead of the sales erosion with new medicines that include five launched in 2016 alone.""That is an unprecedented number of launches of new medicines in a short period of time,"" Schwan said on a conference call after Roche reported third-quarter sales figures. ""Our product pipeline is developing very well.""The Swiss drugmaker's three established cancer blockbusters Rituxan, Herceptin and Avastin, which account for annual sales of nearly 20 billion Swiss francs ($21 billion), all face biosimilar competition by the end of the decade.But so far this year, Tecentriq has won approval for bladder and lung cancer, Alecensa for lung cancer, Cotellic for skin cancer and Venclaxta for chronic lymphocytic leukaemia. Roche's multiple sclerosis drug Ocrevus is slated for U.S. approval before the year is over. Tecentriq has brought in 77 million Swiss francs ($78 million) since its U.S. approval in May for bladder cancer. That revenue is due to accelerate after the U.S. Food and Drug Administration this week gave the a green light for the drug to be used against lung cancer. Analysts are counting on it, too, as revenue growth from broad-based cancer drug Avastin, Rituxan for blood cancer, and breast cancer therapy Herceptin begins to slow.All three missed analyst expectations in the third quarter, and Avastin in particular, which fell 3 percent in the third quarter, led by a decline in the United States.  Overall, quarterly sales at the world's biggest maker of cancer drugs rose 3 percent to 12.48 billion francs, missing the average estimate of 12.68 billion in a Reuters poll of analysts.""The momentum seems weakening in the haematology and breast cancer franchises in the U.S. and Japanese territories,"" Bruno Bulic, an analyst at Baader Helvea, said. ""We see the entry of Tecentriq coming timely."" He has a ""buy"" recommendation on Roche's shares.They fell 0.2 percent by 0930 GMT, in line with the decline of the European health care sector index. Schwan still expected Roche's 2016 sales to grow by a low- to mid-single digit percentage rate at constant exchange rates, with core earnings rising faster than sales. The company also confirmed its full-year outlook.He declined to comment on Novartis's efforts to sell its $14 billion stake in Roche, saying any disposal was a matter for his cross-town rival to resolve. Novartis Chief Executive Joe Jimenez has said he may sell the stake without demanding a premium.($1 = 0.9889 Swiss francs) (Editing by Michael Shields and Jane Merriman)",2016-10-20,BMY,"Thu Oct 20, 2016 | 10:53am EDT",UPDATE 2-Roche bets on new cancer drugs to offset patent expiries,http://www.reuters.com//article/roche-results-idUSL8N1CQ0PV?type=companyNews
276,"  Oct 25 Bristol-Myers Squibb Co :* New results presented for opdivo (nivolumab) demonstrate encouraging response rate in an expanded population of heavily pre-treated classical hodgkin lymphoma patients * Safety profile of opdivo consistent with reported data in tumor type, no new clinically meaningful safety signals identified  * says after a median follow-up of 8.8 months, opdivo demonstrated an objective response of 73% overall, median pfs of 11.2 months  Source text for Eikon:  Further company coverage:    (Bangalore.newsroom@thomsonreuters.com)",2016-10-25,BMY,"Tue Oct 25, 2016 | 8:16am EDT",BRIEF-Bristol-Myers presents new results for opdivo (nivolumab),http://www.reuters.com//article/idUSFWN1CV0V3?type=companyNews
277,"   By Ben Hirschler and Dipika Jain  Merck & Co has won U.S. approval to market its immunotherapy Keytruda for use in previously untreated lung cancer patients two months ahead of schedule, making it the only such drug cleared for first-line treatment. The green light from the Food and Drug Administration (FDA), announced by the U.S. drugmaker late on Monday, confirms Merck's leading position in the hot area of medicines that fight tumors by harnessing the body's immune system.Keytruda's latest approval is for treating first-line metastatic non-small cell lung cancer (NSCLC) in patients with high-levels of a protein called PD-L1, which makes them more receptive to immunotherapy.The FDA had set a target date of Dec. 24 for deciding on this new use. Expectations for Keytruda, which works by taking the brakes off the immune system, have been building since its success in treating selected untreated patients. Annual sales of the drug are now expected to reach $8.1 billion in 2021, according to consensus forecasts compiled by Thomson Reuters. Rival Bristol-Myers Squibb's drug Opdivo failed in a late-stage trial for the same indication. Bristol had tried to make Opdivo work irrespective of PD-L1 levels. In the event, it disappointed comprehensively in a major study. Keytruda and Opdivo, along with Roche's  rival immunotherapy Tecentriq, are already approved for lung cancer patients who have undergone previous chemotherapy.Keytruda had originally only been cleared in this second-line setting for patients with high PD-L1 levels but the FDA also expanded this on Monday to allow for treatment where PD-L1 expression is just 1 percent or more. Immunotherapy drugs are used additionally in melanoma, Hodgkin lymphoma and cancers of the bladder, kidney, head and neck, but lung cancer, the world's biggest cancer killer with an annual death toll of 1.6 million, is the biggest potential market.Although doctors are allowed to prescribe medicines for not yet approved uses, the FDA's first-line clearance of Keytruda could greatly increase the number of patients taking the drug.Leerink analyst Seamus Fernandez said the news should cement Merck's position as leader in the first-line lung cancer field for at least the next 12 to 18 months, after when the battle is likely to shift to new combination therapies. Only a quarter to a third of non-small cell lung cancer patients have tumors with at least 50 percent of cells producing PD-L1, making them suitable for first-line Keytruda, so around 70 percent of the market is still up for grabs.As a result, the race is now on between Merck, Bristol, Roche and AstraZeneca to find smart ways for combining treatments, either by adding chemotherapy or using two different immunotherapies in tandem.Merck's first-line approval was based on data from a late-stage study which showed Keytruda achieved superior progression-free and overall survival compared to chemotherapy in patients whose tumors expressed high levels of PD-L1. (Editing by Lisa Shumaker and Jane Merriman)",2016-10-25,BMY,"Tue Oct 25, 2016 | 7:48am EDT",Merck wins early U.S. approval for Keytruda in untreated lung cancer,http://www.reuters.com//article/us-merck-co-fda-idUSKCN12P06Q?type=companyNews
278,"   By Ben Hirschler and Dipika Jain  Merck & Co has won U.S. approval to market its immunotherapy Keytruda for use in previously untreated lung cancer patients two months ahead of schedule, making it the only such drug cleared for first-line treatment. The green light from the Food and Drug Administration (FDA), announced by the U.S. drugmaker late on Monday, confirms Merck's leading position in the hot area of medicines that fight tumors by harnessing the body's immune system.Keytruda's latest approval is for treating first-line metastatic non-small cell lung cancer (NSCLC) in patients with high-levels of a protein called PD-L1, which makes them more receptive to immunotherapy.The FDA had set a target date of Dec. 24 for deciding on this new use. Expectations for Keytruda, which works by taking the brakes off the immune system, have been building since its success in treating selected untreated patients. Annual sales of the drug are now expected to reach $8.1 billion in 2021, according to consensus forecasts compiled by Thomson Reuters. Rival Bristol-Myers Squibb's drug Opdivo failed in a late-stage trial for the same indication. Bristol had tried to make Opdivo work irrespective of PD-L1 levels. In the event, it disappointed comprehensively in a major study. Keytruda and Opdivo, along with Roche's  rival immunotherapy Tecentriq, are already approved for lung cancer patients who have undergone previous chemotherapy.Keytruda had originally only been cleared in this second-line setting for patients with high PD-L1 levels but the FDA also expanded this on Monday to allow for treatment where PD-L1 expression is just 1 percent or more. Immunotherapy drugs are used additionally in melanoma, Hodgkin lymphoma and cancers of the bladder, kidney, head and neck, but lung cancer, the world's biggest cancer killer with an annual death toll of 1.6 million, is the biggest potential market.Although doctors are allowed to prescribe medicines for not yet approved uses, the FDA's first-line clearance of Keytruda could greatly increase the number of patients taking the drug.Leerink analyst Seamus Fernandez said the news should cement Merck's position as leader in the first-line lung cancer field for at least the next 12 to 18 months, after when the battle is likely to shift to new combination therapies. Only a quarter to a third of non-small cell lung cancer patients have tumors with at least 50 percent of cells producing PD-L1, making them suitable for first-line Keytruda, so around 70 percent of the market is still up for grabs.As a result, the race is now on between Merck, Bristol, Roche and AstraZeneca to find smart ways for combining treatments, either by adding chemotherapy or using two different immunotherapies in tandem.Merck's first-line approval was based on data from a late-stage study which showed Keytruda achieved superior progression-free and overall survival compared to chemotherapy in patients whose tumors expressed high levels of PD-L1. (Editing by Lisa Shumaker and Jane Merriman)",2016-10-25,BMY,"Tue Oct 25, 2016 | 7:48am EDT",UPDATE 1-Merck wins early U.S. approval for Keytruda in untreated lung cancer,http://www.reuters.com//article/merck-co-fda-idUSL1N1CV09T?type=companyNews
279,"   By Ransdell Pierson  Bristol-Myers Squibb Co (BMY.N), whose high-profile Opdivo immunotherapy failed an important lung-cancer trial last summer, sharply raised its 2016 profit forecast after strong quarterly sales of other leading medicines.The U.S. drugmaker on Thursday predicted 2016 earnings of $2.80 to $2.90 a share, up from its previous forecast range of $2.55 to $2.65. Bristol-Myers, whose shares rose 5 percent in premarket trading, said it expects 2017 earnings of $2.85 to $3.05 per share.Sales of Opdivo, which treats melanoma and lung cancer, tripled to $920 million in the third quarter, but trailed forecasts by $27 million.    Opdivo had been considered the leader among a new class of cancer drugs called PD-1 inhibitors until August, when researchers said it failed to slow progression of symptoms in previously untreated patients with advanced lung cancer.Making matters worse for Opdivo, researchers earlier this month said Merck's rival Keytruda prolonged the life of similar patients, and on Monday, it became the first of new immunotherapy drugs approved in the United States for initial lung cancer treatment. The company said it authorized a new $3 billion share repurchase program, in addition to the $1.1 billion remaining under an authorization in 2012. And it predicted flat operating expenses through 2020, which analysts said should help profit margins.""We believe today's updates should begin to address Wall Street concerns on Bristol's near-term earnings outlook"" in the wake of Opdivo's setbacks, JP Morgan analyst Chris Schott said in a research note.Sales of Yervoy, an older melanoma treatment, jumped 19 percent to $285 million, $45 million above expectations, while sales of leukemia treatment Sprycel grew 15 percent to $472 million, $25 million above forecasts. Eliquis, used to prevent blood clots and partnered with Pfizer Inc (PFE.N), jumped 90 percent to $884 million, $71 million above expectations, helped by compelling clinical trial data.It was not immediately clear how much of an impact price increases had on sales of Bristol-Myers drugs. Bristol-Myers earned $1.2 billion, or 72 cents per share in the quarter, compared with $706 million, or 42 cents per share, a year ago. Revenue jumped 21 percent to $4.9 billion, about $200 million above forecasts.Excluding special items, it earned 77 cents per share, well above expectations of 65 cents per share, according to Thomson Reuters I/B/E/S.Despite Bristol-Myers' rally on Thursday, its shares have fallen 31 percent since the unfavorable Opdivo lung cancer data was reported on Aug. 5.   (Reporting by Ransdell Pierson; Editing by Bernadette Baum)",2016-10-27,BMY,"Thu Oct 27, 2016 | 9:18am EDT","UPDATE 3-Bristol hikes 2016 profit forecast as top drugs deliver, shares jump",http://www.reuters.com//article/bristol-myers-results-idUSL1N1CX0G7?type=companyNews
280,"   By Ransdell Pierson  Bristol-Myers Squibb Co (BMY.N), whose high-profile Opdivo immunotherapy failed an important lung-cancer trial last summer, sharply raised its 2016 profit forecast after strong quarterly sales of other leading medicines.The U.S. drugmaker on Thursday predicted 2016 earnings of $2.80 to $2.90 a share, up from its previous forecast range of $2.55 to $2.65. Bristol-Myers, whose shares rose 5 percent in premarket trading, said it expects 2017 earnings of $2.85 to $3.05 per share.Sales of Opdivo, which treats melanoma and lung cancer, tripled to $920 million in the third quarter, but trailed forecasts by $27 million.    Opdivo had been considered the leader among a new class of cancer drugs called PD-1 inhibitors until August, when researchers said it failed to slow progression of symptoms in previously untreated patients with advanced lung cancer.Making matters worse for Opdivo, researchers earlier this month said Merck's rival Keytruda prolonged the life of similar patients, and on Monday, it became the first of new immunotherapy drugs approved in the United States for initial lung cancer treatment. The company said it authorized a new $3 billion share repurchase program, in addition to the $1.1 billion remaining under an authorization in 2012. And it predicted flat operating expenses through 2020, which analysts said should help profit margins.""We believe today's updates should begin to address Wall Street concerns on Bristol's near-term earnings outlook"" in the wake of Opdivo's setbacks, JP Morgan analyst Chris Schott said in a research note.Sales of Yervoy, an older melanoma treatment, jumped 19 percent to $285 million, $45 million above expectations, while sales of leukemia treatment Sprycel grew 15 percent to $472 million, $25 million above forecasts. Eliquis, used to prevent blood clots and partnered with Pfizer Inc (PFE.N), jumped 90 percent to $884 million, $71 million above expectations, helped by compelling clinical trial data.It was not immediately clear how much of an impact price increases had on sales of Bristol-Myers drugs. Bristol-Myers earned $1.2 billion, or 72 cents per share in the quarter, compared with $706 million, or 42 cents per share, a year ago. Revenue jumped 21 percent to $4.9 billion, about $200 million above forecasts.Excluding special items, it earned 77 cents per share, well above expectations of 65 cents per share, according to Thomson Reuters I/B/E/S.Despite Bristol-Myers' rally on Thursday, its shares have fallen 31 percent since the unfavorable Opdivo lung cancer data was reported on Aug. 5.   (Reporting by Ransdell Pierson; Editing by Bernadette Baum)",2016-10-27,BMY,"Thu Oct 27, 2016 | 9:18am EDT","Bristol hikes 2016 profit forecast as top drugs deliver, shares jump",http://www.reuters.com//article/us-bristol-myers-results-idUSKCN12R1JG?type=companyNews
281,"  Oct 27 Bristol-myers Squibb Co* Bristol-Myers squibb reports third quarter financial results* Sees fy 2017 non-gaap earnings per share $2.85 to $3.05* Sees fy 2017 gaap earnings per share $2.47 to $2.67* Q3 non-gaap earnings per share $0.77* Q3 gaap earnings per share $0.72* Q3 revenue $4.9 billion versus i/b/e/s view $4.8 billion * Q3 earnings per share view $0.65 -- Thomson Reuters I/B/E/S* Raises fy 2016 non-gaap earnings per share view to $2.80 to $2.90* Raises fy 2016 gaap earnings per share view to $2.62 to $2.72 * Bristol-Myers squibb co - announces approval of $3 billion share repurchase authorization* Increases 2016 gaap and non-gaap eps guidance* Bristol-Myers squibb co - new repurchase authorization is incremental to current repurchase program, announced in june 2012 * Qtrly yervoy worldwide revenues $285 million versus $240 million* Bristol-Myers squibb co - qtrly opdivo worldwide revenues $920 million versus $305 million last year* Bristol-Myers squibb co - qtrly sprycel worldwide revenues $472 million versus $411 million last year* Fy2017 earnings per share view $2.91 -- Thomson Reuters I/B/E/S* Fy2016 earnings per share view $2.63 -- Thomson Reuters I/B/E/S* Sees worldwide revenues increasing in high-teens in 2016  Source text for Eikon:  Further company coverage:",2016-10-27,BMY,"Thu Oct 27, 2016 | 7:08am EDT",BRIEF-Bristol-Myers Squibb Q3 adjusted earnings $0.77/shr,http://www.reuters.com//article/idUSASC09DLO?type=companyNews
282,"  Oct 27 Bristol-Myers Squibb Co  sharply raised its 2016 profit forecast after surprisingly strong quarterly sales for a handful of its other leading prescription drugs.The U.S. drugmaker on Thursday predicted 2016 earnings of $2.80 to $2.90 per share, up from its previous view of $2.55 to $2.65. The new forecast would reflect earnings growth of as much as 44 percent from last year. Bristol-Myers said it expects 2017 earnings of $2.85 to $3.05 per share. Bristol-Myers said it earned $1.2 billion, or 72 cents per share in the third quarter, compared with $706 million, or 42 cents per share, in the year-ago period.  Excluding special items, it earned 77 cents per share. Industry analysts, on average, were expecting 65 cents per share, according to Thomson Reuters I/B/E/S.   (Reporting by Ransdell Pierson; Editing by Bernadette Baum)",2016-10-27,BMY,"Thu Oct 27, 2016 | 7:04am EDT",Bristol hikes 2016 forecast after top drugs deliver,http://www.reuters.com//article/bristol-myers-results-idUSL1N1CW2EW?type=companyNews
283,  Oct 31 Bristol-Myers Squibb Canada: * Bristol-Myers gets approval from Health Canada for Opdivo + Yervoy regimen for unresectable or metastatic melanoma  Source text for Eikon:  Further company coverage:  ,2016-10-31,BMY,"Mon Oct 31, 2016 | 1:49pm EDT",BRIEF-Bristol-Myers gets Health Canada approval for combination regimen for unresectable or metastatic melanoma,http://www.reuters.com//article/idUSFWN1D10ZQ?type=companyNews
284,"  ZURICH Roche is pressing ahead with two skin cancer trials that combine its immunotherapy Tecentriq with other drugs after early data showed the treatments were well-tolerated and effective in a small number of patients, the company said Monday.One study combined Tecentriq with Cotellic and Zelboraf in 30 patients with untreated BRAFV600 mutation-positive metastatic melanoma, the other Tecentriq with Cotellic for 10 patients with BRAF-wild-type and BRAF-mutant metastatic melanoma. Both now move into phase III late-stage pivotal trials.After winning approval for Tecentriq earlier this year, first for bladder cancer and more recently for lung cancer, Roche is now trying it with other drugs in hopes that new combinations will result in potent weapons against cancer. Of Roche's 50 immunotherapy trials underway, 40 are with different combinations of medicines. ""We are encouraged by these early results which demonstrate a high proportion of people responded to these investigational combination therapies,"" said Sandra Horning, Roche's chief medical officer, in a statement. Though the Roche studies are just getting off the ground, analysts said the news so far looks good. ""Even when the data they are presenting was taken from a sample of only a few patients, the efficacy without the use of any chemotherapy is certainly extraordinarily high,"" Zuercher Kantonalbank analyst Michael Nawrath wrote in a note to investors.Other companies, including Bristol-Myers Squibb, are also pursuing immunotherapy combinations. Roche shares rose 1.6 percent in early trading on Monday. They have lost almost 20 percent of their value this year, compared with the Stoxx Europe 600 Health Care index's 16.4 percent drop. (Reporting by John Miller, editing by Louise Heavens)",2016-11-07,BMY,"Mon Nov 7, 2016 | 4:06am EST",Roche advances skin cancer trials as part of combination therapy strategy,http://www.reuters.com//article/roche-trials-idUSL8N1D81NY?type=companyNews
285,"  Nov 9 Bristol-Myers Squibb :* Bristol-Myers Squibb and infinity pharmaceuticals announce clinical collaboration to evaluate Opdivo (nivolumab) in combination with IPI-549 in advanced solid tumors * Bristol-Myers Squibb - evaluation of IPI-549 as a monotherapy continuing, with combination portion of phase 1 study expected to begin this fall  * Bristol-Myers Squibb says study to evaluate potential of ipi-549 plus Opdivo to target immune-suppressive cells in tumor microenvironment  Source text for Eikon:  Further company coverage:",2016-11-09,BMY,"Wed Nov 9, 2016 | 7:50am EST","BRIEF-Bristol-Myers, Infinity Pharma to evaluate Opdivo with IPI-549 in advanced solid tumors",http://www.reuters.com//article/idUSFWN1DA0LI?type=companyNews
286,  Nov 10 Bristol-myers Squibb Co* Opdivo (nivolumab) demonstrates overall survival benefit in patients with unresectable advanced or recurrent gastric cancer in phase 3 study  * Bristol-Myers Squibb Co says Opdivo met primary endpoint of overall survival in phase 3 study  Source text for Eikon:  Further company coverage: ,2016-11-10,BMY,"Thu Nov 10, 2016 | 8:23am EST",BRIEF-Opdivo (nivolumab) demonstrates overall survival benefit in patients with unresectable advanced or recurrent gastric cancer in phase 3 study,http://www.reuters.com//article/idUSASC09HTD?type=companyNews
287,  Nov 10 Bristol-myers Squibb Co * Bristol-Myers Squibb and Pfizer to deliver 12 new Eliquis (apixaban) presentations at American Heart Association (AHA) scientific sessions 2016  Source text for Eikon:  Further company coverage:  ,2016-11-10,BMY,"Thu Nov 10, 2016 | 8:21am EST",BRIEF-Bristol-Myers Squibb and Pfizer to deliver 12 new Eliquis (apixaban) presentations at American Heart Association (AHA) scientific sessions 2016,http://www.reuters.com//article/idUSASC09HVU?type=companyNews
288,"  Bristol-Myers Squibb Co said on Thursday its blockbuster immunotherapy Opdivo helped patients with advanced stomach cancer live longer in a late-stage study, becoming the first drug of its kind to show a survival benefit in these patients.Opdivo met the main study goal of overall survival in patients who failed to respond to or are intolerant of standard chemotherapy, the company said.New York-based Bristol-Myer's shares inched up 1.1 percent to $56.90 in premarket trade.The trial was conducted by Bristol-Myers' partner, Japan's Ono Pharmaceutical Co Ltd in Japan, Korea and Taiwan, and compared the effect of Opdivo to a placebo.Stomach cancer, also known as gastric cancer, is the third leading cause of cancer-related death in the world, and kills more than 720,000 every year, Bristol-Myers said. Opdivo, like Merck & Co Inc's Keytruda, belongs to a new class of medicines called PD-1 inhibitors that help the immune system unmask hidden cancer cells.Both drugs have secured regulatory approval for several types of cancer, but lung cancer is considered by far the biggest market for cancer drugs.Opdivo and Keytruda are both used in previously-treated lung cancer patients, but Merck's supremacy in this class of drugs was confirmed when Keytruda last month won approval for untreated lung cancer patients, significantly expanding its addressable population. Swiss drugmaker Roche Holding AG's Tecentriq is another major immunotherapy that has only recently won approvals for multiple types of cancer.As competition heats up, Bristol-Myers has orchestrated a string of deals to strengthen its pipeline. On Wednesday, it announced a collaboration to test Opdivo in combination with an experimental drug from Infinity Pharmaceuticals Inc in patients with advanced solid tumors.Separately on Thursday, Bristol-Myers agreed to pay Japan's Nitto Denko Corp $100 million up front for the right to its early-stage drug for liver fibrosis due to incurable fatty liver disease NASH or hepatitis C. (Reporting by Natalie Grover in Bengaluru; Editing by Sai Sachin Ravikumar)",2016-11-10,BMY,"Thu Nov 10, 2016 | 8:15am EST",Bristol-Myers' Opdivo succeeds in key stomach cancer study,http://www.reuters.com//article/us-bristol-myers-study-idUSKBN1351GA?type=companyNews
289,"  Bristol-Myers Squibb Co said on Thursday its blockbuster immunotherapy Opdivo helped patients with advanced stomach cancer live longer in a late-stage study, becoming the first drug of its kind to show a survival benefit in these patients.Opdivo met the main study goal of overall survival in patients who failed to respond to or are intolerant of standard chemotherapy, the company said.New York-based Bristol-Myer's shares inched up 1.1 percent to $56.90 in premarket trade.The trial was conducted by Bristol-Myers' partner, Japan's Ono Pharmaceutical Co Ltd in Japan, Korea and Taiwan, and compared the effect of Opdivo to a placebo.Stomach cancer, also known as gastric cancer, is the third leading cause of cancer-related death in the world, and kills more than 720,000 every year, Bristol-Myers said. Opdivo, like Merck & Co Inc's Keytruda, belongs to a new class of medicines called PD-1 inhibitors that help the immune system unmask hidden cancer cells.Both drugs have secured regulatory approval for several types of cancer, but lung cancer is considered by far the biggest market for cancer drugs.Opdivo and Keytruda are both used in previously-treated lung cancer patients, but Merck's supremacy in this class of drugs was confirmed when Keytruda last month won approval for untreated lung cancer patients, significantly expanding its addressable population. Swiss drugmaker Roche Holding AG's Tecentriq is another major immunotherapy that has only recently won approvals for multiple types of cancer.As competition heats up, Bristol-Myers has orchestrated a string of deals to strengthen its pipeline. On Wednesday, it announced a collaboration to test Opdivo in combination with an experimental drug from Infinity Pharmaceuticals Inc in patients with advanced solid tumors.Separately on Thursday, Bristol-Myers agreed to pay Japan's Nitto Denko Corp $100 million up front for the right to its early-stage drug for liver fibrosis due to incurable fatty liver disease NASH or hepatitis C. (Reporting by Natalie Grover in Bengaluru; Editing by Sai Sachin Ravikumar)",2016-11-10,BMY,"Thu Nov 10, 2016 | 8:15am EST",UPDATE 2-Bristol-Myers' Opdivo succeeds in key stomach cancer study,http://www.reuters.com//article/bristol-myers-study-idUSL4N1DB4GR?type=companyNews
290,"  Nov 10 Bristol-Myers Squibb Co said on Thursday its blockbuster immunotherapy Opdivo helped patients with advanced stomach cancer live longer in a late-stage study.Opdivo met the study's main goal of overall survival, the company said.  The trial was conducted by Bristol-Myers' partner, Japan's Ono Pharmaceutical Co Ltd.   (Reporting by Natalie Grover in Bengaluru; Editing by Sai Sachin Ravikumar) ",2016-11-10,BMY,"Thu Nov 10, 2016 | 7:10am EST",Bristol-Myers' Opdivo immunotherapy succeeds in key stomach cancer study,http://www.reuters.com//article/bristol-myers-study-idUSL4N1DB4FT?type=companyNews
291,"  Bristol-Myers Squibb Co said on Thursday it agreed to pay Japan's Nitto Denko Corp $100 million up front for the right to its early-stage drug for liver fibrosis due to  fatty liver disease NASH or hepatitis C.Fibrotic diseases are characterized by inflammation and subsequent formation of excess collagen in an organ or tissue, compromising function, and culminating in organ failure.Under the deal, Nitto is eligible to receive clinical and regulatory milestone payments and royalties, and Bristol-Myers has the option to get exclusive licenses for Nitto's other experimental drugs for lung fibrosis and other organ fibrosis. Bristol-Myers has been sharpening its focus on fibrosis. In July 2015, it struck a collaboration with the Medical University of South Carolina, to better understand scleroderma, renal fibrosis and idiopathic pulmonary fibrosis. It also has the option to buy privately held Promedior Inc and Swedish biotechnology company Galecto Biotech, both of which are fibrosis drug developers.  (Reporting by Natalie Grover in Bengaluru; Editing by Saumyadeb Chakrabarty)",2016-11-10,BMY,"Thu Nov 10, 2016 | 7:02am EST",Bristol-Myers' deepens focus on fibrosis with Nitto deal,http://www.reuters.com//article/us-bristol-myers-nitto-denko-idUSKBN1351CG?type=companyNews
292,"  Bristol-Myers Squibb Co said on Thursday it agreed to pay Japan's Nitto Denko Corp $100 million up front for the right to its early-stage drug for liver fibrosis due to  fatty liver disease NASH or hepatitis C.Fibrotic diseases are characterized by inflammation and subsequent formation of excess collagen in an organ or tissue, compromising function, and culminating in organ failure.Under the deal, Nitto is eligible to receive clinical and regulatory milestone payments and royalties, and Bristol-Myers has the option to get exclusive licenses for Nitto's other experimental drugs for lung fibrosis and other organ fibrosis. Bristol-Myers has been sharpening its focus on fibrosis. In July 2015, it struck a collaboration with the Medical University of South Carolina, to better understand scleroderma, renal fibrosis and idiopathic pulmonary fibrosis. It also has the option to buy privately held Promedior Inc and Swedish biotechnology company Galecto Biotech, both of which are fibrosis drug developers.  (Reporting by Natalie Grover in Bengaluru; Editing by Saumyadeb Chakrabarty)",2016-11-10,BMY,"Thu Nov 10, 2016 | 7:02am EST",Bristol-Myers' deepens focus on fibrosis with Nitto deal,http://www.reuters.com//article/bristol-myers-nitto-denko-idUSL4N1DB4AS?type=companyNews
293,"  Nov 16 Bristol-Myers Squibb Co :* Bristol-Myers Squibb and Enterome announce immuno-oncology collaboration focused on microbiome-derived biomarkers,drug targets, bioactive molecules* Bristol-Myers Squibb - Bristol-Myers Squibb will be granted exclusive rights to intellectual property and therapies generated during collaboration * Bristol-Myers - Enterome eligible to receive preclinical,clinical milestone payments for each licensed therapeutic candidate plus royalties on net sale * Enterome will receive an upfront payment of $15 million for access to its technology plus research and development funding * Bristol-Myers - Enterome is eligible for additional milestone payments in relation to new diagnostic products discovered and developed during collaboration  Source text for Eikon:  Further company coverage:",2016-11-16,BMY,"Wed Nov 16, 2016 | 3:37am EST",BRIEF-Bristol-Myers Squibb and Enterome announce immuno-oncology collaboration,http://www.reuters.com//article/idUSFWN1DH0BN?type=companyNews
294,"  Japan's health ministry has set a 50 percent cut in the price of Opdivo, a costly immune system-boosting cancer drug produced by Bristol Myers Squibb Co and marketed in the country by Ono Pharmaceutical Co Ltd, Ono Pharmaceutical said.The halving of the price on Opdivo, approved in Japan for treating advanced melanoma, non-small cell lung cancer and kidney cancer, will take effect from February 1, 2017, Ono Pharmaceutical said in an emailed statement on Wednesday.Japan's government-run health system typically adjusts drug prices every two years, but Opdivo's high price tag raised costs so much that officials decided to intervene with the steep price  cut, according to local media reports and confirmed by Ono. The company said the new Japanese price for a 20 mg vial of Opdivo will be 75,100 yen, and 364,925 yen for the 100 mg vial. Its current annual list price is 35 million yen ($321,787), based on the volume of drug needed to treat an average-size patient for a year.Opdivo is part of a new class of cancer drugs designed to fight cancer by unleashing the body's own immune system to kill tumors. In the United States, Opdivo's average list price is $13,100 per month, or $157,200 per year, according to Bristol Myers. The company said the U.S. price of Opdivo, first approved in late 2014, was increased by 1.5 percent earlier this year.  (Reporting By Deena Beasley in Los Angeles; Editing by Muralikumar Anantharaman)",2016-11-17,BMY,"Wed Nov 16, 2016 | 11:21pm EST",UPDATE 1-Japan sets 50 pct price cut for Bristol Myers' Opdivo cancer drug,http://www.reuters.com//article/cancer-japan-opdivo-idUSL1N1DI06X?type=companyNews
295,"  LONDON Roche and Bristol-Myers Squibb on Thursday became the latest drugmakers to cut the price of cancer medicines in order to secure access to Britain's National Health Service.The National Institute for Health and Care Excellence (NICE) cost watchdog, which had rejected Roche's breast cancer treatment Perjeta in May, said a price discount now offered by the Swiss firm had helped win it a green light.Bristol's leukemia drug Sprycel was also recommended for routine use after the U.S. company offered a bigger discount. Sprycel was previously covered by the Cancer Drugs Fund (CDF), which was overhauled earlier this year. Out of nine CDF treatments that NICE has looked at so far, seven have been cleared for general use. The remainder are in the process of being reappraised. ""Sensible pricing and in some cases better data is helping to secure access to important cancer medicines as they move out of the old Cancer Drugs Fund,"" said NICE Chief Executive Andrew Dillon. Other international drugmakers including Novartis and Pfizer have also offered increased discounts in recent months. The exact size of all these discounts is commercially confidential.Roche's Perjeta is designed for use in combination with chemotherapy and Herceptin before breast cancer surgery, while Sprycel is used in certain types of chronic myeloid leukemia.         (Reporting by Ben Hirschler; Editing by Alexandra Hudson)",2016-11-17,BMY,"Wed Nov 16, 2016 | 7:14pm EST","Roche, Bristol-Myers cut cancer drug prices to win UK approval",http://www.reuters.com//article/us-britain-cancer-bristolmyers-roche-idUSKBN13C006?type=companyNews
296,"  LONDON Roche and Bristol-Myers Squibb on Thursday became the latest drugmakers to cut the price of cancer medicines in order to secure access to Britain's National Health Service.The National Institute for Health and Care Excellence (NICE) cost watchdog, which had rejected Roche's breast cancer treatment Perjeta in May, said a price discount now offered by the Swiss firm had helped win it a green light.Bristol's leukemia drug Sprycel was also recommended for routine use after the U.S. company offered a bigger discount. Sprycel was previously covered by the Cancer Drugs Fund (CDF), which was overhauled earlier this year. Out of nine CDF treatments that NICE has looked at so far, seven have been cleared for general use. The remainder are in the process of being reappraised. ""Sensible pricing and in some cases better data is helping to secure access to important cancer medicines as they move out of the old Cancer Drugs Fund,"" said NICE Chief Executive Andrew Dillon. Other international drugmakers including Novartis and Pfizer have also offered increased discounts in recent months. The exact size of all these discounts is commercially confidential.Roche's Perjeta is designed for use in combination with chemotherapy and Herceptin before breast cancer surgery, while Sprycel is used in certain types of chronic myeloid leukemia.         (Reporting by Ben Hirschler; Editing by Alexandra Hudson)",2016-11-17,BMY,"Wed Nov 16, 2016 | 7:14pm EST","Roche, Bristol-Myers cut cancer drug prices to win UK approval",http://www.reuters.com//article/britain-cancer-bristolmyers-roche-idUSL8N1DH2PG?type=companyNews
297,  Nov 22 Bristol-Myers Squibb Co :* European Commission approves Bristol-Myers Squibb's Opdivo (nivolumab) for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin  * Approval allows for expanded marketing of Opdivo in relapsed or refractory CHL in all 28 member states of EU  Source text for Eikon:  Further company coverage: ,2016-11-22,BMY,"Tue Nov 22, 2016 | 3:26pm EST",BRIEF-Bristol-Myers' Opdivo gets European Commission approval for relapsed or refractory CHL treatment,http://www.reuters.com//article/idUSFWN1DN0UM?type=companyNews
298,"  Nov 22 Quintiles Ims Holdings Inc : * Quintilesims forms new collaboration with Bristol-Myers Squibb, Lilly, Merck Kgaa, Darmstadt, Germany, and Pfizer to generate real world insights on usage of anti-cancer therapies across Europe  Source text for Eikon:  Further company coverage:  ",2016-11-22,BMY,"Tue Nov 22, 2016 | 8:07am EST","BRIEF-QuintilesIMS forms new Collaboration with Bristol-Myers Squibb, Lilly, Merck KGaA, Darmstadt, Germany, and Pfizer to generate real world insights on usage of anti-cancer therapies across Europe",http://www.reuters.com//article/idUSFWN1DN0L3?type=companyNews
299,"  LONDON Bristol-Myers Squibb's immunotherapy drug Opdivo has been approved in Europe for the treatment of classical Hodgkin lymphoma, a rare blood cancer, the U.S. company said on Wednesday.Opdivo is already approved for melanoma, lung cancer and kidney cancer.     (Reporting by Ben Hirschler. Editing by Jane Merriman)",2016-12-07,BMY,"Tue Dec 6, 2016 | 7:02pm EST",EU clears Bristol-Myers immunotherapy drug for blood cancer,http://www.reuters.com//article/us-bristol-myers-cancer-europe-idUSKBN13W003?type=companyNews
